0001104659-13-047737.txt : 20130607 0001104659-13-047737.hdr.sgml : 20130607 20130607163141 ACCESSION NUMBER: 0001104659-13-047737 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20130430 FILED AS OF DATE: 20130607 DATE AS OF CHANGE: 20130607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIO REFERENCE LABORATORIES INC CENTRAL INDEX KEY: 0000792641 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 222405059 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-15266 FILM NUMBER: 13901015 BUSINESS ADDRESS: STREET 1: 481 EDWARD H ROSS DR CITY: ELMWOOD PARK STATE: NJ ZIP: 07407-3118 BUSINESS PHONE: 2017912186 MAIL ADDRESS: STREET 1: 481 EDWARD H ROSS DRIVE CITY: ELMWOOD PARK STATE: NJ ZIP: 07407-3118 FORMER COMPANY: FORMER CONFORMED NAME: MED MOBILE INC DATE OF NAME CHANGE: 19891115 10-Q 1 a13-12932_110q.htm 10-Q

Table of Contents

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC  20549

 

FORM 10-Q

 

(Mark One)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the quarterly period ended April 30, 2013

 

Or

 

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                                  to

 

Commission File Number  000-15266

 

BIO-REFERENCE LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

 

NEW JERSEY

 

22-2405059

(State or other jurisdiction of incorporation or organization)

 

(IRS Employer Identification No.)

 

481 Edward H. Ross Drive, Elmwood Park, NJ

 

07407

(Address of principal executive offices)

 

(Zip Code)

 

(201) 791-2600

(Registrant’s telephone number, including area code)

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 

Yes  x  No  o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). 

  Yes  x  No  o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated file in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer o

 

Accelerated Filer x

 

 

 

Non-accelerated Filer o

 

Smaller reporting company o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  

Yes  o  No  x

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

Indicate the number of shares outstanding of the issuer’s common stock, as of the latest practicable date: 27,663,213 shares of Common Stock ($.01 par value) at June 3, 2013.

 

 

 



Table of Contents

 

BIO-REFERENCE LABORATORIES, INC.

 

FORM 10-Q

 

April 30, 2013

 

I N D E X

 

 

Page

 

 

 

PART I. FINANCIAL INFORMATION

 

 

 

Item 1.

Financial Statements

 

 

 

 

 

Consolidated Balance Sheets as of April 30, 2013 (unaudited) and October 31, 2012.

1

 

 

 

 

Consolidated Statements of Operations (unaudited) for the three months and six months ended April 30, 2013 and April 30, 2012

3

 

 

 

 

Consolidated Statements of Cash Flows (unaudited) for the six months ended April 30, 2013 and April 30, 2012

4

 

 

 

 

Notes to consolidated financial statements (unaudited)

6

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

10

 

 

 

Item 3

Quantitative and Qualitative Disclosures About Market Risk

15

 

 

 

Item 4.

Controls and Procedures

15

 

 

 

PART II. OTHER INFORMATION

16

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

16

 

 

 

Item 6.

Exhibits

16

 

 

 

Signatures

17

 

 

Certifications

18-21

 



Table of Contents

 

PART I — FINANCIAL INFORMATION

 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

 

CONSOLIDATED BALANCE SHEETS

[Dollars In Thousands Except Share and Per Share Data]

 

ASSETS

 

 

 

April 30,

 

October 31,

 

 

 

2013

 

2012

 

 

 

(Unaudited)

 

 

 

CURRENT ASSETS:

 

 

 

 

 

 

 

 

 

 

 

Cash and Cash Equivalents

 

$

25,538

 

$

25,143

 

Accounts Receivable - Net

 

176,438

 

153,247

 

Inventory

 

14,468

 

14,902

 

Other Current Assets

 

5,223

 

5,373

 

Deferred Tax Assets

 

27,446

 

24,912

 

TOTAL CURRENT ASSETS

 

249,113

 

223,577

 

 

 

 

 

 

 

PROPERTY AND EQUIPMENT - AT COST

 

113,861

 

102,701

 

LESS: Accumulated Depreciation

 

(58,727

)

(52,261

)

PROPERTY AND EQUIPMENT - NET

 

55,134

 

50,440

 

 

 

 

 

 

 

OTHER ASSETS:

 

 

 

 

 

Investments in Unconsolidated Affiliate

 

5,352

 

4,977

 

Deposits

 

1,001

 

956

 

Goodwill - Net

 

25,986

 

23,408

 

Intangible Assets - Net

 

10,912

 

6,323

 

Other Assets

 

1,115

 

866

 

Deferred Tax Asset

 

2,780

 

2,278

 

 

 

 

 

 

 

TOTAL OTHER ASSETS

 

47,146

 

38,808

 

 

 

 

 

 

 

TOTAL ASSETS

 

$

351,393

 

$

312,825

 

 

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

 

1



Table of Contents

 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

 

CONSOLIDATED BALANCE SHEETS

[Dollars In Thousands Except Share and Per Share Data]

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

April 30,

 

October 31,

 

 

 

2013

 

2012

 

 

 

(Unaudited)

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

Accounts Payable

 

$

46,746

 

$

41,288

 

Accrued Salaries and Commissions Payable

 

15,933

 

16,490

 

Accrued Taxes and Expenses

 

13,770

 

9,753

 

Other Short Term Acquisition Payable

 

1,296

 

0

 

Revolving Note Payable - Bank

 

9,377

 

0

 

Current Maturities of Long-Term Debt

 

479

 

464

 

Capital Lease Obligations - Short-Term Portion

 

4,424

 

3,957

 

TOTAL CURRENT LIABILITIES

 

92,025

 

71,952

 

 

 

 

 

 

 

LONG-TERM LIABILITIES

 

 

 

 

 

Capital Lease Obligations - Long-Term Portion

 

9,849

 

9,463

 

Long - Term Debt — Net of Current Portion

 

3,920

 

4,163

 

TOTAL LONG-TERM LIABILITIES

 

13,769

 

13,626

 

 

 

 

 

 

 

SHAREHOLDERS’ EQUITY

 

 

 

 

 

Preferred Stock $.10 Par Value; Authorized 1,666,667 shares, including 3,000 shares of Series A Junior Preferred Stock None Issued

 

0

 

0

 

Common Stock, $.01 Par Value; Authorized 35,000,000 shares:

 

 

 

 

 

Issued and Outstanding 27,651,813 and 27,707,382 at April 30, 2013 and at October 31, 2012, respectively

 

277

 

277

 

 

 

 

 

 

 

Additional Paid-In Capital

 

39,256

 

40,907

 

Retained Earnings

 

206,066

 

186,063

 

 

 

 

 

 

 

TOTAL SHAREHOLDERS’ EQUITY

 

245,599

 

227,247

 

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

 

$

351,393

 

$

312,825

 

 

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

 

2



Table of Contents

 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF OPERATIONS

[Dollars In Thousands Except Share and Per Share Data]

 

[UNAUDITED]

 

 

 

Three months ended

 

Six months ended

 

 

 

April 30,

 

April 30,

 

 

 

2013

 

2012

 

2013

 

2012

 

 

 

 

 

 

 

 

 

 

 

NET REVENUES:

 

$

176,452

 

$

151,443

 

$

337,709

 

$

290,236

 

 

 

 

 

 

 

 

 

 

 

COST OF SERVICES:

 

 

 

 

 

 

 

 

 

Depreciation and Amortization

 

3,777

 

3,265

 

7,316

 

6,274

 

Employee Related Expenses

 

41,824

 

36,811

 

81,883

 

71,250

 

Reagents and Laboratory Supplies

 

33,767

 

29,546

 

65,477

 

57,325

 

Other Cost of Services

 

16,408

 

14,287

 

31,435

 

27,735

 

TOTAL COST OF SERVICES

 

95,776

 

83,909

 

186,111

 

162,584

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT ON REVENUES

 

80,676

 

67,534

 

151,598

 

127,652

 

 

 

 

 

 

 

 

 

 

 

GENERAL AND ADMINISTRATIVE EXPENSES:

 

 

 

 

 

 

 

 

 

Depreciation and Amortization

 

983

 

881

 

1,892

 

1,723

 

General and Administrative Expenses

 

43,812

 

39,772

 

85,453

 

76,616

 

Bad Debt Expense

 

15,172

 

10,110

 

27,785

 

19,258

 

TOTAL GENERAL AND ADMINISTRATIVE EXPENSES

 

59,967

 

50,763

 

115,130

 

97,597

 

 

 

 

 

 

 

 

 

 

 

INCOME FROM OPERATIONS

 

20,709

 

16,771

 

36,468

 

30,055

 

 

 

 

 

 

 

 

 

 

 

OTHER (INCOME) EXPENSE:

 

 

 

 

 

 

 

 

 

Interest Expense

 

434

 

412

 

733

 

771

 

Interest Income

 

(24

)

(42

)

(59

)

(84

)

Other (Income) Expense

 

104

 

0

 

225

 

0

 

TOTAL OTHER (INCOME) EXPENSES - NET

 

514

 

370

 

899

 

687

 

 

 

 

 

 

 

 

 

 

 

INCOME BEFORE INCOME TAXES

 

20,195

 

16,401

 

35,569

 

29,368

 

Provision for Income Taxes

 

8,857

 

7,095

 

15,566

 

12,697

 

 

 

 

 

 

 

 

 

 

 

NET INCOME

 

$

11,338

 

$

9,306

 

$

20,003

 

$

16,671

 

 

 

 

 

 

 

 

 

 

 

NET INCOME PER COMMON SHARE - BASIC:

 

$

0.41

 

$

0.34

 

$

0.72

 

$

0.60

 

WEIGHTED AVERAGE NUMBER OF SHARES - BASIC:

 

27,698,146

 

27,684,715

 

27,707,241

 

27,786,216

 

 

 

 

 

 

 

 

 

 

 

NET INCOME PER COMMON SHARE - DILUTED:

 

$

0.41

 

$

0.33

 

$

0.72

 

$

0.60

 

WEIGHTED AVERAGE NUMBER OF SHARES - DILUTED:

 

27,879,448

 

27,877,697

 

27,891,431

 

27,960,069

 

 

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

 

3



Table of Contents

 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

[Dollars In Thousands Except Share and Per Share Data]

 

[UNAUDITED]

 

 

 

Six months ended

 

 

 

April 30,

 

 

 

2013

 

2012

 

OPERATING ACTIVITIES:

 

 

 

 

 

Net Income

 

$

20,003

 

$

16,671

 

Adjustments to Reconcile Net Income to Cash Provided by (Used for) Operating Activities:

 

 

 

 

 

Depreciation and Amortization

 

9,208

 

7,997

 

Deferred Income Tax (Benefit) Expense

 

(3,036

)

(2,243

)

Stock Based Compensation

 

290

 

290

 

(Gain) Loss on Disposal of Fixed Assets

 

125

 

343

 

Undistributed Equity Method (Income) Loss

 

225

 

0

 

Change in Assets and Liabilities, (Increase) Decrease in:

 

 

 

 

 

Accounts Receivable

 

(28,554

)

(2,773

)

Provision for Doubtful Accounts

 

5,363

 

3,371

 

Inventory

 

434

 

(836

)

Other Current Assets

 

150

 

(459

)

Other Assets

 

(249

)

(250

)

Deposits

 

(45

)

(60

)

Increase (Decrease) in:

 

 

 

 

 

Accounts Payable and Accrued Liabilities

 

8,918

 

1,599

 

 

 

 

 

 

 

NET CASH - OPERATING ACTIVITIES

 

12,832

 

23,650

 

 

 

 

 

 

 

INVESTING ACTIVITIES:

 

 

 

 

 

Acquisition of Equipment and Leasehold Improvements

 

(10,585

)

(9,667

)

Business Acquisitions and Related Costs

 

(6,837

)

(4,375

)

 

 

 

 

 

 

NET CASH - INVESTING ACTIVITIES

 

(17,422

)

(14,042

)

 

 

 

 

 

 

FINANCING ACTIVITIES:

 

 

 

 

 

Payments of Long-Term Debt

 

(228

)

(631

)

Payments of Capital Lease Obligations

 

(2,223

)

(1,666

)

Increase (Decrease) in Revolving Line of Credit

 

9,377

 

(4,469

)

Common Stock Repurchase

 

(2,030

)

(5,193

)

Proceeds from Exercise of Options

 

89

 

64

 

 

 

 

 

 

 

NET CASH - FINANCING ACTIVITIES

 

4,985

 

(11,895

)

 

 

 

 

 

 

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

 

395

 

(2,287

)

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIODS

 

25,143

 

22,013

 

 

 

 

 

 

 

CASH AND CASH EQUIVALENTS AT END OF PERIODS

 

$

25,538

 

$

19,726

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:

 

 

 

 

 

Cash paid during the period for:

 

 

 

 

 

Interest

 

$

656

 

$

761

 

Income Taxes

 

$

16,339

 

$

20,340

 

 

The Accompanying Notes are an Integral Part of These Consolidated Financial Statements.

 

4



Table of Contents

 

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

[Dollars In Thousands]

[UNAUDITED]

 

During the six-month periods ended April 30, 2013 and April 30, 2012, the Company entered into capital leases totaling $3,076 and $4,896, respectively.

 

During the six-month periods ended April 30, 2013 and April 30, 2012, the Company wrote-off approximately $2,501 and $1,478 of property and equipment that were mostly fully depreciated.

 

During the six-month periods ended April 30, 2013 and April 30, 2012, the Company recorded approximately $290 and $290 of stock based compensation expense, respectively, related to granting of stock options and stock to employees pursuant to existing agreements.

 

5



Table of Contents

 

BIO-REFERENCE LABORATORIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

[Dollars In Thousands Except Share and Per Share Data, Or Unless Otherwise Noted]

(UNAUDITED)

 

[1] Basis of Presentation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the instructions to Form 10-Q and, therefore, do not include all information and footnotes necessary for complete audited financial statements. However, in the opinion of the management of the Company, all adjustments necessary for a fair presentation of the financial position and operating results have been included in these statements. Interim results are not necessarily indicative of results for a full year. Reference is made to the October 31, 2012 audited consolidated financial statements of Bio-Reference Laboratories, Inc. contained in its Annual Report on Form 10-K for the year ended October 31, 2012.

 

The consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes for the year ended October 31, 2012 as filed with the Securities and Exchange Commission in the Company’s Annual Report on Form 10-K. Significant accounting policies followed by the Company are set forth in Note 2 to the Company’s 2012 Annual Report on Form 10-K.

 

[2] Fair Value Measurements.

 

As of April 30, 2013, the Company’s financial instruments primarily consist of cash, short-term trade receivables and payables for which their carrying amounts approximate fair values, and long term debt, for which based on the borrowing rates currently available to the Company for bank loans with similar terms and average maturities, its carrying amount approximates its fair value.

 

The Company has evaluated subsequent events through the date the financial statements are issued as evidenced by the date of filing of this report with the Securities and Exchange Commission. No such reportable events have occurred.

 

[3] Certain prior year amounts have been reclassified to conform to the current year presentation.  The Company adopted Accounting Standard Update (“ASU”) No. 2011-7: Health Care Entities (Topic 954) — Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities commencing with the current fiscal year, the first year such standard is required for the Company.  The adoption of this update did not have a material impact on the Company’s financial statements.

 

Although this update does not have a material impact on the Company’s financial statements as a whole, it requires that we adjust our presentation of our statement of operations along with prior periods presented in this report to maintain comparability.  As the result of this change in presentation, our “Net Revenues”, “Gross Profit on Revenues” and our “General and Administrative Expenses” would change while our “Operating Income”, “Net Income” and “Earnings per Share” will remain the same.  The presentation is adjusted for a portion of our “Bad Debt Expense” that is now reported in our Net Revenues as required under ASU No. 2011-7.

 

[4] Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.

 

Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts.  Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by Bio-Reference Laboratories, Inc. (“BRLI”) are to patients covered under a third party payor contract.  In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly; in the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI.  Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests.  Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups.  The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed.  This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.  The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.

 

6



Table of Contents

 

 

 

($)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

April 30,

 

April 30,

 

 

 

[Unaudited]

 

[Unaudited]

 

 

 

2013

 

2012

 

2013

 

2012

 

Gross Service Revenues

 

861,506

 

763,823

 

1,660,216

 

1,447,639

 

 

 

 

 

 

 

 

 

 

 

Contractual Adjustments and Discounts:

 

 

 

 

 

 

 

 

 

Medicare/Medicaid Portion

 

86,433

 

81,318

 

168,260

 

156,059

 

All Other Third Party Payors*

 

584,211

 

519,117

 

1,127,496

 

978,273

 

Total Contractual Adjustments and Discounts

 

670,644

 

600,435

 

1,295,756

 

1,134,332

 

Service Revenues Net of Contractual Adjustments and Discounts

 

190,862

 

163,388

 

364,460

 

313,307

 

Patient Service Revenue Provision for Bad Debts**

 

14,410

 

11,945

 

26,751

 

23,071

 

Net Revenues

 

176,452

 

151,443

 

337,709

 

290,236

 

 


* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

 

** Represents the amount of Bad Debt Expense that is now required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

 

When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience.  The remaining bad debt expense is presented as part of operating expenses.  The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.

 

BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.

 

[5] It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses; this represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information; in the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary. BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer’s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:

 

 

 

($)

 

 

 

[Unaudited]

 

 

 

 

 

April 30,

 

October 31,

 

 

 

2013

 

2012

 

 

 

 

 

 

 

Contractual Credits/Discounts

 

336,642

 

267,921

 

Doubtful Accounts

 

56,636

 

51,274

 

Total Allowance

 

393,278

 

319,195

 

 

7



Table of Contents

 

[6] The following disclosures present certain information on the Company’s intangible assets as of April 30, 2013 (Unaudited) and October 31, 2012. All intangible assets are being amortized over their estimated useful lives, as indicated below, with no estimated residual value.

 

April 30, 2013

 

 

 

Weighted-

 

 

 

 

 

Net of

 

 

 

Average

 

 

 

Accumulated

 

Accumulated

 

 

 

Amortization

 

 

 

Amortization

 

Amortization

 

Intangible Asset

 

Period

 

Cost ($)

 

($)

 

($)

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

8,739

 

2,680

 

6,059

 

Covenants Not-to-Compete

 

5

 

5,095

 

4,305

 

790

 

Patents and Licenses

 

17

 

5,297

 

1,234

 

4,063

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

19,131

 

8,219

 

10,912

 

 

October 31, 2012

 

 

 

Weighted-Average

 

 

 

 

 

Net of

 

 

 

Amortization

 

 

 

Accumulated

 

Accumulated

 

Intangible Asset

 

Period

 

Cost ($)

 

Amortization ($)

 

Amortization ($)

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

4,573

 

2,537

 

2,036

 

Covenants Not-to-Compete

 

5

 

4,305

 

4,257

 

48

 

Patents and Licenses

 

17

 

5,297

 

1,058

 

4,239

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

14,175

 

7,852

 

6,323

 

 

The aggregate intangible amortization expense for the three months ended April 30, 2013 and 2012 was $227 and $156, respectively.  The aggregate intangible amortization expense for the six-months ended April 30, 2013 and 2012 was $367 and $299, respectively.  The estimated intangible asset amortization expense for the fiscal year ending October 31, 2013 and for the four subsequent years is as follows:

 

October 31,

 

($)

 

2013

 

452

 

2014

 

917

 

2015

 

892

 

2016

 

875

 

2017

 

870

 

Thereafter

 

6,906

 

 

 

 

 

Total

 

10,912

 

 

[7] Revolving Note Payable - Bank

 

In October 2011, the Company entered into an amended revolving note payable loan agreement with PNC Bank, N.A.  The maximum amount of the credit line available to the Company pursuant to the loan agreement is the lesser of (i) $45,000 or (ii) 50% of the Company’s qualified accounts receivable, as defined in the agreement.  The amendment to the Loan and Security Agreement provides for an interest rate on advances to be subject, at the election of the Company, to either the bank’s base rate or the Eurodollar rate of interest plus, in certain instances, an additional interest percentage.  The additional interest percentage charge on bank’s base rate borrowings and on Eurodollar rate borrowings ranges from 1% to 4% and is determined based upon certain financial ratios achieved by the Company.  On April 30, 2013, the Company had elected to have all of the total advances outstanding to be subject to the bank’s base rate of interest of 3.5%.  The credit line is collateralized by substantially all of the Company’s assets. The line of credit is available through October 2016 and may be extended for annual periods by mutual consent thereafter.  The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures and fixed charge coverage, and the prohibition of the payment of cash dividends by the Company. As of April 30, 2013, the Company utilized $9,377 of the available credit under this revolving note payable loan agreement.

 

8



Table of Contents

 

[8] Long-Term Debt - Bank

 

In December 2010, the Company issued a seven-year term note for $5,408 at the rate of interest of 6.12% per annum for the financing of new equipment.  The note is payable in 84 equal monthly installments commencing on January 29, 2011 of $61 including principal and interest followed by a balloon payment of the principal and interest outstanding on the loan repayment date of  December 29, 2017.  The balance on this note as of April 30, 2013 is approximately $4,399.

 

[9] The provision for income taxes for the three months ended April 30, 2013 consists of a current tax provision of $12,114 and a deferred tax benefit of $3,257. The provision for income taxes for the six-months ended April 30, 2013 consists of a current tax provision of $18,601 and a deferred tax benefit of $3,035.The provision for income taxes for the three months ended April 30, 2012 consists of a current tax provision of $8,398 and a deferred tax benefit of $1,302.  The provision for income taxes for the six-months ended April 30, 2012 consists of a current tax provision of $14,940 and a deferred tax benefit of $2,243.  On April 30, 2013, the Company had a current deferred tax asset of $27,446 and a long-term deferred tax asset of $2,780 included in other assets.  On April 30, 2012, the Company had a current deferred tax asset of $23,438 included in other current assets and a long-term deferred tax asset of $2,357 included in other assets.

 

[10] ] On December 21, 2012, we entered into an agreement pursuant to which we agreed to purchase all of the authorized, issued and outstanding shares of Meridian Clinical Laboratory, Corp. ( “MCL”), a Florida corporation.  More information about MCL and the agreement may be found in the Form 8-K the Company filed on December 27, 2012.

 

On December 31, 2012, we entered into an agreement pursuant to which we agreed to purchase all of the authorized, issued and outstanding shares of Florida Clinical Laboratory, Inc. (“FCL”), a Florida corporation.  More information about FCL and the agreement may be found in the Form 8-K we filed on January 4, 2013.

 

The initial accounting for these two acquisitions is now complete. Accordingly Management updated its previously reported provisional amounts of the assets, liabilities and equity interests initially reported on its first quarter report on form 10-Q. The following table sets forth these final allocations.

 

 

 

($)

 

 

 

FCL

 

MCL

 

Totals:

 

 

 

 

 

 

 

 

 

Accounts Receivable

 

1,008

 

232

 

1,240

 

Autos

 

137

 

48

 

185

 

Medical Equipment

 

225

 

3

 

228

 

Computer Equipment

 

21

 

 

21

 

Leasehold Improvements

 

53

 

 

53

 

Other Non-Current Assets

 

3

 

 

3

 

Non-Compete Agreement

 

747

 

43

 

790

 

Deposits

 

 

2

 

2

 

Customer Relationships in Place

 

3,235

 

930

 

4,165

 

Goodwill

 

1,905

 

673

 

2,578

 

Accounts Payable

 

118

 

83

 

201

 

Long Term Debt (Auto-Loans)

 

200

 

0

 

200

 

Short Term Acquisition Payable

 

1,000

 

250

 

1,250

 

 

[11] Common Stock Repurchase

 

On November 11, 2011, the Company announced that its board of directors approved a Stock Repurchase Program authorizing the repurchase of up to 1,000,000 shares of its Common Stock at prevailing market prices over the period ending October 31, 2012.  That period was subsequently extended to the period ending October 31, 2013.  During the six-month period ended April 30, 2013, the Company repurchased 81,600 shares of its common stock at a cost of $2,030.  These repurchased shares have been recorded as canceled.

 

9



Table of Contents

 

Forward-Looking Statements

 

Statements included in this quarterly report on Form 10-Q (the “Quarterly Report”) that are not historical in nature, are intended to be, and are hereby identified as “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements may be identified by words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning and include, but are not limited to, statements about our expected future business and financial performance. Statements looking forward in time are included in this report pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks and uncertainties, many of which are beyond our ability to control, that may cause our actual results in future periods to be materially different from any future performance suggested herein.

 

Several factors could cause actual results to differ materially from those currently anticipated due to a number of factors in addition to those discussed under “Risk Factors” in our October 31, 2012 Form 10-K including:

 

Loss or suspension of a license or imposition of a fine or penalties under, or future changes in, the law or regulations of CLIA, or those of state laboratory licensing laws;

Failure to comply with HIPAA, which could negatively impact profitability and cash flows;

FDA regulation of Laboratory Developed Tests and clinical laboratories;

Failure to comply with federal and state anti-kickback laws;

Failure to maintain the security of patient-related information;

Failure to comply with the Federal Occupational Safety and Health Administration requirements and the recently passed Needlestick Safety and Prevention Act;

Failure to comply with federal and state laws and regulations related to submission of claims for our services;

Changes in regulation and policies, including increasing downward pressure on health care reimbursement;

Efforts by third-party payors to reduce utilization and reimbursement for clinical testing services;

Failure to timely or accurately bill for our services;

Our failure to integrate newly acquired businesses and the costs related to such integration;

Increased competition, including price competition;

Our ability to attract and retain experienced and qualified personnel;

Our failure to obtain and retain new clients and business partners, or a reduction in tests ordered or specimens submitted by existing clients;

Adverse litigation results; and

Failure to establish, and perform to, appropriate quality standards to assure that the highest level of quality is observed in the performance of our testing services.

 

Item 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

[Dollars In Thousands Except Per Share Data, Total Patient Data Or Unless Otherwise Noted]

 

Overview

 

We are a national clinical diagnostic laboratory located in northeastern New Jersey. We are a national laboratory in certain focused areas of laboratory testing and a full service laboratory in the New York super-region. We have developed a national reputation for our expertise in certain focused areas of clinical testing. GenPath, the name by which we are known for our cancer and oncology services, is recognized for the superior hematopathology services it provides throughout the country. Our Women’s Health initiative, through which we provide dedicated services for obstetrics and gynecology practices, including a unique, technically advanced multiplex process for identifying sexually transmitted infections, is also offered as GenPath.  Our regional footprint lies within the New York City metropolitan area and the surrounding areas of New Jersey and southern New York State as well eastern Pennsylvania and some areas of western Connecticut; we also provide services further into New York State, Pennsylvania, Delaware and Maryland. As a regional provider, we are a full-service laboratory that primarily services physician office practices.  Our drivers pick up samples and deliver reports and supplies; we provide sophisticated technical support, phlebotomy services or patient service centers where appropriate, and electronic communication services in many cases.

 

Physicians outside of this regional footprint send samples to our laboratory in order to take advantage of the expertise that we are able to provide in blood-based cancer pathology and associated diagnostics or to take advantage of the superior service, support and technologically advanced testing we offer in our Women’s Health initiative. These accounts frequently send routine testing to us as well in order to simplify their office workflow and to take advantage of our outstanding capability, service and support.  Our correctional healthcare services are used throughout the country at prisons and jails. The focused markets we serve on a national basis outside of our regional footprint do not require many of the logistical and other ancillary support services required as a full service laboratory on a regional basis.  Within our regional footprint, we provide all of the same services that we provide on a national basis as well as some regionally focused diagnostic services, such as histology and pathology support services, substance abuse testing, fertility testing, hemostasis testing, women’s health testing, and molecular diagnostics that are unavailable from many of our smaller regional competitors; some of the regional testing may be provided outside of physician offices in clinics or other bulk deliverers of healthcare.  In October 2012, we launched Laboratorio Buena Salud (“LBS”), the first national testing laboratory dedicated to serving Spanish-speaking populations in the United States on a Spanish language first basis.  All interactions with patients and physician offices are handled in Spanish unless otherwise requested by the patient or office without the need of choosing Spanish or English

 

Over the last few years, there have been fundamental changes in the laboratory services industry. In the 1990s, the industry was negatively impacted by the growth of managed care, increased government regulation, and investigations into fraud and abuse. These factors led to revenue and profit declines and industry consolidations, especially among commercial laboratories.  There are currently two national mega-laboratories and Bio-Reference Laboratories, together with some specialty laboratories and a few small laboratories in the US public markets.  There is one other Australian-based laboratory with significant presence in the US markets.  In addition to these publicly-traded commercial laboratories, there are numerous hospital outreach programs and smaller reference laboratories that compete for the commercial clinical laboratory business scattered throughout the country.  These clinical laboratories have had to improve efficiency, leverage economies of scale, comply with government regulations and other laws and develop more profitable approaches to pricing. Moreover, there has been a proliferation of technology advancements in clinical diagnostics over the last decade that has created significant opportunities for new testing and growth.

 

As a full service clinical laboratory, we are constantly looking for new technologies and new methodologies that will help us to grow. Since the turn of the century, our size alone has made us attractive to companies that are driving the advances in technology. We represent a significant opportunity for these companies to market their products with a nationally recognized specialty provider in our focused areas of specialty or in one of the major population centers of the world—the New York super-region. We have had several successful strategic relationships with such technology opportunities. In addition to new

 

10



Table of Contents

 

technology opportunities, we have an extremely seasoned and talented management staff that has been able to identify emerging laboratory markets that are under-served or under-utilized. We have recently developed programs for cardiology, histology and women’s health to go along with our existing hemostasis, hematopathology and correctional healthcare initiatives which have already been established and in which we have been increasing our market share for the past several years.  Over the past year, we launched several new, disruptive testing services.  OnkoMatch, an offering that has emerged as a result of our joint venture with Massachusetts General Hospital, provides tumor genotyping for solid tumor cancer patients at reasonable and affordable pricing.  Inherigen, our pre-natal carrier detection panel, provides broad-spectrum carrier detection of autosomal conditions that may affect child-bearing decisions.  GenCerv is an advanced test for identifying which HPV positive patients are likely to have cervical cancer.  StormPath is our virtual pathology solution that allows remote pathologists to use our technical laboratory capabilities and consult with our pathologists remotely in order to provide improved diagnostics.  We continually seek to offer innovative testing services that are clinically relevant and which improve patient care.

 

The Company believes that it has an outstanding sales and marketing team and has implemented an acquisition strategy based on seeking out opportunities to acquire new technologies, new techniques, new opportunities that will enhance our existing business rather than seeking to acquire laboratories for their underlying business.  Over the recent past we have made some strategic acquisitions based on this approach. Our philosophy regarding acquisitions is: we buy laboratories we consider to be synergistic and accretive. As we have explained in the past, we offer one stop shopping to physicians as a specialty lab. When we buy laboratories in other geographic areas that do not bring in specific technical expertise, we do so to better service our clients and to add growth in the area.

 

On December 21, 2012, we entered into an agreement pursuant to which we agreed to purchase all of the authorized, issued and outstanding shares of Meridian Clinical Laboratory, Corp. (“MCL”), a Florida corporation.  Information about MCL and the agreement may be found in the Form 8-K we filed with the Securities and Exchange Commission on December 21, 2012.  MCL is a small laboratory located in the heart of the South Florida Hispanic community and will serve as a base of operations for our Florida LBS program. This acquisition will be our Florida presence for LBS.

 

On December 31, 2012, we entered into an agreement pursuant to which we agreed to purchase all of the authorized, issued and outstanding shares of Florida Clinical Laboratory, Inc. (“FCL”), a Florida corporation.  Information about FCL and the agreement may be found in the Form 8-K we filed with the Securities and Exchange Commission on January 4, 2013.  FCL had excess capacity and a strong presence in an underserved area of testing in Florida; its facilities provide the Company with better capability in Florida while expanding our service into an underserved area for testing.

 

On April 27, 2012, we entered into an agreement pursuant to which we purchased preferred shares of IncellDx, Inc. (“IncellDx”), a Delaware corporation.  Information about IncellDx and the agreement may be found in the Current Report on Form 8-K we filed on May 1, 2012.  InCellDx developed a valuable test for more positively identifying the likelihood that a woman may have cervical cancer than HPV testing alone.  The Company has since introduced GenCerv based on the technology developed at InCellDx.

 

While we recognize that we are a clinical laboratory that processes samples, we also understand that we are an information company that needs to effectively communicate the results of our efforts back to healthcare providers. Laboratory results play a major role in the implementation of physician healthcare. Laboratory results are used to diagnose, monitor and classify health concerns. In many cases, laboratory results represent the confirming data in diagnosing complicated health issues. Since laboratory results play such an important role in routine physician care, we have developed informatics solutions that leverage our role in healthcare. We built a web-based solution to quickly, accurately, conveniently and competitively collect ordering information and deliver results.  That solution is called CareEvolve.  CareEvolve is a basic tool for our own operations. We license the technology to other laboratories throughout the country in order for them to more effectively compete against the national mega-laboratories. The laboratories licensing our technology are typically not our competitors since they are outside our regional footprint.

 

We have also created our PSIMedica business unit that has developed a Clinical Knowledge Management (CKM) System that takes data from enrollment, claims, pharmacy, laboratory results and any other available electronic source to provide both administrative and clinical analysis of a population. The system uses proprietary algorithms to cleanse and configure the data and transfer the resulting information into a healthcare data repository. Using advanced cube technology methodologies, the data can be analyzed from a myriad of views and from highly granular transactional detail to global trended overview. Events such as the Hurricane Katrina disaster in Louisiana and general pressures from the government have made development of an electronic medical record system and Pay-for Performance reimbursement priority goals in the healthcare industry. A large portion of an individual’s medical record consists of laboratory data and a key performance indicator in any Pay-for-Performance initiative is laboratory result data. Our CKM system is a mature, full functioning solution that will allow us to play a role in these important national initiatives.

 

To date, neither our PSIMedica business unit nor CareEvolve have produced significant independent revenues relative to the primary laboratory operations, but they are important tools that we offer in the ordinary course of our laboratory business operations.

 

Recent Events:

 

We adopted the Accounting Standard Update (“ASU”) No. 2011-07: Health Care Entities (Topic 954) — Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities commencing with the current fiscal year, the first year such standard is required for the Company, We believe this update will have no material impact on the Company’s financial statements.

 

Although this update does not have a material impact on the Company’s financial statements as a whole, this update requires that we adjust the presentation of our statement of operations along with prior periods presented in this report to maintain comparability.  As the result of this change in presentation, our “Net Revenues”, “Gross Profit on Revenues and our “General and Administrative Expenses” will change while our “Operating Income”, “Net Income” and “Earnings per Share” will remain the same.  The presentation is adjusted for a portion of our “Bad Debt Expense” that is now reported in our Net Revenues as required under ASU No. 2011-7.

 

Note [4] to our financial statements includes a table that shows the amount of Bad Debt expense relating to patient service revenue that was moved from the Selling and Administrative expense section of our statement of operations to the Net Revenue section.

 

Effective February 27, 2013, we announced that we will be offering NonInvasive PreNatal Testing (“NIPT”) through the Natera Panorama program.  NIPT is a substitute for invasive amniocentesisand CVS testing and reduces risks associated with the testing process itself.  We believe that offering an NIPT test enhances our Women’s Health program and helps us to be a more comprehensive solution for the Obstetrician office.

 

11



Table of Contents

 

Second Quarter Fiscal 2013 Compared to Second Quarter Fiscal 2012

 

The numbers in this comparison are affected by the change in presentation on our statement of operations as the result of the Company adopting ASU 2011-7 on November 1, 2012.  See discussion of ASU 2011-7 in the notes to our consolidated financial statements for more information.

 

NET REVENUES:

 

Net revenues for the three-month period ended April 30, 2013 were $176,452 as compared to $151,443 for the three-month period ended April 30, 2012.  This represents a 17% increase in net revenues. This increase is due to a 6% increase in patient counts and an increase in revenue per patient of 11% due to a shift in business to higher reimbursement esoteric testing, which continues to be the principal driver in increasing net revenue per patient. The number of patients serviced during the three-month period ended April 30, 2013 was 2,066, which was 6% greater when compared to the prior fiscal year’s corresponding three-month period.  This increase in patient counts is mainly due to the overall success of all our lines of business.  Net revenue per patient for the three-month period ended April 30, 2013 was $84.93 compared to net revenue per patient of $77.09 for the three-month period ended April 30, 2012, an increase of 11%.

 

Our revenues and patient counts could be adversely affected by a number of factors, including, but not limited, to an extended economic downturn in general or healthcare economic conditions, an unexpected reduction in reimbursement rates, increased market penetration by our competitors or a substantial adverse change in federal regulatory requirements governing our industry as well as a failure to continue the sizeable annual percentage increase in base business from significantly higher levels after 19 years of sustained growth.

 

Many provisions of Affordable Care Act (“ACA”) became effective January 1, 2013.  At this time we are not yet aware as to how this will affect our revenues.

 

COST OF SERVICES:

 

Cost of services increased from $83,909 for the three-month period ended April 30, 2012 to $95,776 for the three-month period ended April 30, 2013, an increase of 14%. This increase in cost of services is basically in line with the increase in net revenues.

 

GROSS PROFITS:

 

Gross profits increased from $67,534 for the three-month period ended April 30, 2012 to $80,676 for the three-month period ended April 30, 2013, an increase of 19%. Gross profit margin increased to 45% from 46%.

 

GENERAL AND ADMINISTRATIVE EXPENSES:

 

General and administrative expenses for the three-month period ending April 30, 2012 were $50,763 as compared to $59,967 for the quarter ended April 30, 2013, an increase of $9,204 or 18%. This increase is in line with the increase in net revenues.

 

INTEREST EXPENSE:

 

Interest expense increased to $434 during the three-month period ending April 30, 2013 from $412 during the three-month period ended April 30, 2012. This decrease is due to an increase in the utilization of our PNC Bank’s credit line.

 

NET INCOME:

 

We realized net income of $11,338 for the three-month period ended April 30, 2013, as compared to $9,306 for the three-month period ended April 30, 2012, an increase of 22%. Pre-tax income for the period ended April 30, 2012 was $16,401, compared to $20,195 for the three-month period ended April 30, 2013, an increase of 23%. The provision for income taxes increased to $8,857 for the three-month period ended April 30, 2013 from $7,095 for the period ended April 30, 2012.

 

Six Months 2013 Compared to Six Months 2012

 

NET REVENUES:

 

Net revenues for the six-month period ended April 30, 2013 were $337,709 as compared to $290,236 for the six-month period ended April 30, 2012. This represents a 16% increase in net revenues. This increase is due to a 7% increase in patient counts and an increase in revenue per patient of 9%.

 

The number of patients serviced during the six-month period ended April 30, 2013 was 4,038, which was 7% greater when compared to the prior fiscal year’s corresponding six-month period. Net revenue per patient for the six-month period ended April 30, 2012 was $76.50 compared to net revenue per patient for the six- month period ended April 30, 2013 of $83.07, an increase of 9%.

 

COST OF SERVICES:

 

Cost of services increased to $186,111 for the six-month period ended April 30, 2013 from $162,584 for the six-month period ended April 30, 2012. This represents a 14% increase in direct operating costs.  This increase in cost of services is basically in line with the increase in sales.

 

GROSS PROFITS:

 

Gross profits on net revenues increased to $151,598 for the six-month period ended April 30, 2013 from $127,652 for the six-month period ended April 30, 2012; an increase of 19%.  Gross profit margins increased to 45% from 44% for the six-month period ended April 30, 2013 compared to the corresponding six-month period ended April 30, 2012.  This is due to an increase in cost of services of 14% while net revenues increased 16%.

 

GENERAL AND ADMINISTRATIVE EXPENSES:

 

General and administrative expenses for the six-month period ended April 30, 2013 were $115,130 as compared to $97,597 for the six-month period ended April 30, 2012.  This represents an increase of 18%. This increase is 2% more than the increase in net revenues.  This increase is basically in line with the increase to our net revenues.

 

12



Table of Contents

 

INTEREST EXPENSE:

 

Interest expense decreased to $733 during the six-month period ending April 30, 2013 as compared to $771 during the six-month period ending April 30, 2012, a decrease of $38.  This decrease is due to primarily a decrease in our utilization of our PNC Bank credit line.

 

INCOME:

 

We realized net income of $20,003 or $0.72 per share for the six-month period ended April 30, 2013 as compared to $16,671 or $0.60 per share for the six-month period ended April 30, 2012, an increase of 20%.  Our operating income increased by 21% for the six-month period ended April 30, 2013 as compared to the six-month period ended April 30, 2012.  Pre-tax income for the period ended April 30, 2013 was $35,569 as compared to $29,368 for the period ended April 30, 2012, an increase of 21%. The provision for income taxes increased from $12,697 for the period ended April 30, 2012, to $15,566 (23%) for the current six-month period. Our effective tax rate increased from 43% to 44% due to an increase in our revenues earned in jurisdictions with higher tax rates.

 

LIQUIDITY AND CAPITAL RESOURCES:

 

Our working capital at April 30, 2013 was $157,088 as compared to $151,625 at October 31, 2012, an increase of 4%.  Our cash position increased by approximately $395 during the current period.  We increased our short-term debt by $15 and repaid $243 in existing debt. We had current liabilities of $92,025 at April 30, 2013. We generated $12,832 in cash from operations, compared to $23,650 for the quarter ended April 30, 2012, an overall decrease of $10,818 in cash generated from operations year over year.  The decrease is primarily due to slower cash collections.  These slower collections are, in the opinion of management, attributed in part to the expired “Grandfather Clause”, a rule that allowed us to bill Medicare directly for in hospital laboratory work that was performed on Medicare patients even though the patient was in the hospital at the time the service was rendered.  This exemption expired at the end of 2012 and starting in 2013 we were required to bill the hospital directly for such laboratory work instead of billing Medicare for it.  As a consequence of this change collection cycle has increased and in some cases prices may have decreased.  Another reason for slower collections is the change in the Blue Cross Blue Shield (“BCBS”) reimbursement practices whereby instead of billing BCBS for all of the laboratory services preformed nationwide on one bill we are now required to bill each local BCBS only for the services preformed based on the location where a patient’s sample was drawn.  This new practice, also effective in 2013, significantly increased the complexity of our BCBS billing and collection processes.  The company has since signed a number of local BCBS contracts and is presently diligently working on entering into such additional BCBS contracts.

 

Accounts receivable, net of allowance for doubtful accounts, totaled $176,438 at April 30, 2013, an increase of $23,191 or 15% from October 31, 2012. Cash collected during the three-month period ended April 30, 2013 increased 3% over the comparable prior year three-month period.

 

Credit risk with respect to accounts receivable is generally diversified due to the large number of patients and payers comprising our client base.  We have significant receivable balances with government payors and various insurance carriers.  Generally, we do not require collateral or other security to support customer receivables. However, we continually monitor and evaluate our client acceptance and collection procedures to minimize potential credit risks associated with our accounts receivable and establish an allowance for uncollectible accounts. As a consequence, we believe that our accounts receivable credit risk exposure beyond such allowance is not material.

 

A number of proposals for legislation continue to be under discussion that could substantially reduce Medicare and Medicaid reimbursements to clinical laboratories.  Depending upon the nature of any regulatory action, and the content of legislation, we could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on us. We are unable to predict, however, the extent of which such actions will be taken if at all.

 

Billing for laboratory services is complicated and we must bill various payors, such as the individual, the insurance company, the government (federal or state), the private company or the health clinic. Other factors that may complicate billing include:

 

Differences between fee schedules and actual reimbursement rates.

Incomplete or inaccurate billing information provided by physicians or clinics.

Disparity in coverage and information requirements.

Disputes with payors.

Internal and external compliance policies and procedures.

 

Significant costs are incurred as a result of our participation in government programs since billing and reimbursement for laboratory tests are subject to complex regulations. We perform the requested tests and report the results whether the billing information is correct or not or even missing. This adds to the complexity and slows the collection process and increases the aging of our accounts receivable (“A/R”). When patient invoices are not collected in a timely manner, the item is written off to the allowance. Days Sales Outstanding (“DSO”) for the period ended April 30, 2013 was 89 days, an increase of 1 day, or  about 1%, from the 88 days that we reported for the period ended April 30, 2012, computed under the new method taking into account the change in presentation for patient service revenue provision for bad debts.  Depending on the period in question, our actual collections represent between 98% and 102% of our net collectable revenues after giving effect to our DSO lag.

 

See Notes to our consolidated financial statements for the information on our short and long term debt.

 

We intend to expand our laboratory operations organically through marketing while also diversifying into related medical fields through acquisitions.  These acquisitions may involve cash, notes, common stock and/or combinations thereof.

 

Tabular Disclosure of Contractual Obligations

 

 

 

Next Four Years and
Thereafter ($)

 

FY 2013 ($)

 

Long-Term Debt

 

4,627

 

458

 

Capital Leases

 

5,395

 

1,200

 

Operating Leases

 

15,250

 

7,127

 

Purchase Obligations

 

91,073

 

23,758

 

Long-Term Liabilities under Employment and Consultant Contracts

 

16,961

 

4,982

 

 

Our cash balance at April 30, 2013 totaled $25,538 as compared to $25,143 at October 31, 2012.  We believe that our cash position, the anticipated cash generated from future operations and the availability of our credit line with PNC Bank will meet our anticipated cash needs for the next 12 months.

 

13



Table of Contents

 

Impact of Inflation

 

To date, inflation has not had a material effect on our operations.

 

Critical Accounting Policies

 

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods.

 

Accounting for Intangible and Other Long-Lived Assets

 

We evaluate the possible impairment of our long-lived assets, including intangible assets. We review the recoverability of our long-lived assets when events or changes in circumstances occur that indicate that the carrying value of the asset may not be recoverable.  Evaluation of possible impairment is based on our ability to recover the asset from the expected future pretax cash flows (undiscounted and without interest charges) of the related operations. If the expected undiscounted pretax cash flows are less than the carrying amount of such asset, an impairment loss is recognized for the difference between the estimated fair value and the carrying amount of the asset.

 

Accounting for Revenue

 

Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.

 

Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by Bio-Reference Laboratories, Inc. (“BRLI”) are to patients covered under a third party payor contract. In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly; in the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups. The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed. This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed. The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations

 

 

 

($)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

April 30,

 

April 30,

 

 

 

[Unaudited]

 

[Unaudited]

 

 

 

2013

 

2012

 

2013

 

2012

 

Gross Service Revenues

 

861,506

 

763,823

 

1,660,216

 

1,447,639

 

 

 

 

 

 

 

 

 

 

 

Contractual Adjustments and Discounts:

 

 

 

 

 

 

 

 

 

Medicare/Medicaid Portion

 

86,433

 

81,318

 

168,260

 

156,059

 

All Other Third Party Payors*

 

584,211

 

519,117

 

1,127,496

 

978,273

 

Total Contractual Adjustments and Discounts

 

670,644

 

600,435

 

1,295,756

 

1,134,332

 

Service Revenues Net of Contractual Adjustments and Discounts

 

190,862

 

163,388

 

364,460

 

313,307

 

Patient Service Revenue Provision for Bad Debts**

 

14,410

 

11,945

 

26,751

 

23,071

 

Net Revenues

 

176,452

 

151,443

 

337,709

 

290,236

 

 


* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

 

** Represents the amount of Bad Debt Expense that is now required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

 

When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience.  The remaining bad debt expense is presented as part of operating expenses.  The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.

 

BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under

 

14



Table of Contents

 

discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.

 

It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses; this represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information; in the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary. BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer’s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:

 

 

 

($)

 

 

 

[Unaudited]

 

 

 

 

 

April 30,

 

October 31,

 

 

 

2013

 

2012

 

 

 

 

 

 

 

Contractual Credits/Discounts

 

336,642

 

267,921

 

Doubtful Accounts

 

56,636

 

51,274

 

Total Allowance

 

393,278

 

319,195

 

 

Item 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK [Not in Thousands]

 

We do not invest in or trade instruments that are sensitive to market risk. We also do not have any material foreign operations or foreign sales so we have no exposure to foreign currency exchange rate risk.

 

We do have exposure to both rising and falling interest rates. At April 30, 2013, advances of approximately $9,377,000 under our Loan Agreement with PNC Bank were subject to interest charges at the bank’s then prime rate of 3.50%.

 

We estimate that our monthly cash interest expense at April 30, 2013 was approximately $122,000 and that a one percentage point increase or decrease in short-term rates would increase or decrease our monthly interest expense by approximately $19,000.

 

Item 4 — CONTROLS AND PROCEDURES

 

An evaluation was performed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, as to the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on that evaluation, our principal executive officer and our principal financial officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC forms and rules, and include controls and procedures designed to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosures.

 

There have been no changes in our internal control over financial reporting during the fiscal quarter ended April 30, 2013 that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

 

15



Table of Contents

 

BIO-REFERENCE LABORATORIES, INC.

PART II—OTHER INFORMATION

 

Item 2. — UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

The table below sets forth information regarding repurchases of our common stock by us during the quarter ended April 30, 2013:

 

Period

 

(a) Total Number
of Shares
Purchased

 

(b) Average
Price Paid per
Share

 

(c) Total Number of
Shares Purchased as
part of Publicly
Announced Plans or
Programs

 

(d) Maximum
Number of
Shares that May
Yet Be Purchased
Under the Plan

 

 

 

 

 

($)

 

 

 

 

 

Q2 Month #2 (3/07/2013 to 3/31/2013)

 

15,000

 

27.92

 

15,000

 

699,550

 

Q3 Month #3 (4/1/2013 to 4/30/2013)

 

66,600

 

24.20

 

66,600

 

632,950

 

Total

 

367,050

 

 

 

367,050

 

 

 

 


*** On November 11, 2011, we announced that our board of directors approved a Stock Repurchase Program authorizing the repurchase of up to 1,000,000 shares of our common stock at prevailing market prices over the period ending October 31, 2012 that was subsequently extended to the period ending October 31, 2013. 285,450 shares have been repurchased under the plan in prior fiscal year.

 

Item 6 — EXHIBITS

 

31.1        Certification of Chief Executive Officer

31.2        Certification of Chief Financial Officer

32.1        Certification Pursuant to 18 U.S.C. Section 1350 of Chief Executive Officer

32.2        Certification Pursuant to 18 U.S.C. Section 1350 of Chief Financial Officer

101         Interactive Data File

 

16



Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

BIO-REFERENCE LABORATORIES, INC.

 

(Registrant)

 

 

 

 

 

/S/ Marc D. Grodman M.D.

 

Marc D. Grodman, M.D.

 

President and Chief Executive Officer

 

 

 

 

 

/S/ Sam Singer

 

Sam Singer

 

Chief Financial and Accounting Officer

 

 

 

 

Date: June 7, 2013

 

 

17


EX-31.1 2 a13-12932_1ex31d1.htm EX-31.1

Exhibit 31.1

 

CHIEF EXECUTIVE OFFICER CERTIFICATION

 

I, Marc D. Grodman, certify that:

 

1. I have reviewed this report on Form 10-Q of Bio-Reference Laboratories, Inc. (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s second quarter) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

 

(a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

Dated: June 7, 2013

 

 

/S/ Marc D. Grodman M.D.

 

Marc D. Grodman

 

Chief Executive Officer

 

Principal Executive Officer

 

1


EX-31.2 3 a13-12932_1ex31d2.htm EX-31.2

Exhibit 31.2

 

CHIEF FINANCIAL OFFICER CERTIFICATION

 

I, Sam Singer, certify that:

 

1. I have reviewed this report on Form 10-Q of Bio-Reference Laboratories, Inc. (the “registrant”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a)                                 Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)                                 Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)                                  Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)                                 Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s second quarter ) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)                                 All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)                                 Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: June 7, 2013

 

 

/S/ Sam Singer

 

Sam Singer

 

Chief Financial Officer

 

Principal Financial and Accounting Officer.

 

1


EX-32.1 4 a13-12932_1ex32d1.htm EX-32.1

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Marc D. Grodman, Chief Executive Officer of Bio-Reference Laboratories, Inc. (the “registrant”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(a)                                 The Periodic Report on Form 10-Q of the registrant for the period ended April, 30 2013, which this certification accompanies (the “Periodic Report”), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

 

(b)                                 Based on my knowledge, the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the registrant.

 

 

Dated: June 7, 2013

 

 

/S/ Marc D. Grodman M.D.

 

Marc D. Grodman

 

Chief Executive Officer

 

Principal Executive Officer

 

1


EX-32.2 5 a13-12932_1ex32d2.htm EX-32.2

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

I, Sam Singer, Chief Financial Officer of Bio-Reference Laboratories, Inc. (the “registrant”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(a)                                 The Periodic Report on Form 10-Q of the registrant for the period ended April 30th 2013, which this certification accompanies (the “Periodic Report”), fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

 

(b)                                 Based on my knowledge, the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the registrant.

 

 

Dated: June 7, 2013

 

 

/S/ Sam Singer

 

Sam Singer

 

Chief Financial Officer

 

Principal Financial and Accounting Officer.

 

1


EX-101.INS 6 brli-20130430.xml XBRL INSTANCE DOCUMENT 0000792641 2012-11-01 2013-04-30 0000792641 2011-11-01 2012-04-30 0000792641 2013-02-01 2013-04-30 0000792641 2012-02-01 2012-04-30 0000792641 brli:AllowanceForContractualCreditsDiscountsMember 2012-10-31 0000792641 us-gaap:AllowanceForDoubtfulAccountsMember 2012-10-31 0000792641 2012-10-31 0000792641 brli:AllowanceForContractualCreditsDiscountsMember 2013-04-30 0000792641 us-gaap:AllowanceForDoubtfulAccountsMember 2013-04-30 0000792641 2013-04-30 0000792641 us-gaap:CustomerListsMember 2011-11-01 2012-10-31 0000792641 us-gaap:NoncompeteAgreementsMember 2011-11-01 2012-10-31 0000792641 brli:PatentsAndLicensesMember 2011-11-01 2012-10-31 0000792641 us-gaap:CustomerListsMember 2012-11-01 2013-04-30 0000792641 us-gaap:NoncompeteAgreementsMember 2012-11-01 2013-04-30 0000792641 brli:PatentsAndLicensesMember 2012-11-01 2013-04-30 0000792641 us-gaap:CustomerListsMember 2012-10-31 0000792641 us-gaap:NoncompeteAgreementsMember 2012-10-31 0000792641 brli:PatentsAndLicensesMember 2012-10-31 0000792641 us-gaap:CustomerListsMember 2013-04-30 0000792641 us-gaap:NoncompeteAgreementsMember 2013-04-30 0000792641 brli:PatentsAndLicensesMember 2013-04-30 0000792641 us-gaap:RevolvingCreditFacilityMember 2013-04-30 0000792641 us-gaap:RevolvingCreditFacilityMember brli:DebtInstrumentVariableRateBaseRateMember 2012-11-01 2013-04-30 0000792641 brli:DebtInstrumentVariableRateEurodollarMember us-gaap:RevolvingCreditFacilityMember 2012-11-01 2013-04-30 0000792641 us-gaap:RevolvingCreditFacilityMember brli:DebtInstrumentVariableRateBaseRateMember us-gaap:MinimumMember 2013-04-30 0000792641 us-gaap:RevolvingCreditFacilityMember brli:DebtInstrumentVariableRateBaseRateMember us-gaap:MaximumMember 2013-04-30 0000792641 brli:DebtInstrumentVariableRateEurodollarMember us-gaap:RevolvingCreditFacilityMember us-gaap:MinimumMember 2013-04-30 0000792641 us-gaap:RevolvingCreditFacilityMember brli:DebtInstrumentVariableRateEurodollarMember us-gaap:MaximumMember 2013-04-30 0000792641 us-gaap:RevolvingCreditFacilityMember brli:DebtInstrumentVariableRateBaseRateMember 2013-04-30 0000792641 us-gaap:MediumTermNotesMember 2010-12-01 2010-12-31 0000792641 us-gaap:MediumTermNotesMember 2013-04-30 0000792641 us-gaap:MediumTermNotesMember 2012-11-01 2013-04-30 0000792641 2012-04-30 0000792641 brli:FloridaClinicalLaboratoryIncMember 2012-12-31 0000792641 brli:MeridianClinicalLaboratoryCorporationMember 2012-12-21 0000792641 brli:FloridaClinicalLaboratoryIncMember us-gaap:LeaseholdImprovementsMember 2012-12-31 0000792641 us-gaap:LeaseholdImprovementsMember 2013-04-30 0000792641 brli:FloridaClinicalLaboratoryIncMember us-gaap:EquipmentMember 2012-12-31 0000792641 us-gaap:EquipmentMember 2013-04-30 0000792641 us-gaap:SeriesAPreferredStockMember 2012-10-31 0000792641 us-gaap:SeriesAPreferredStockMember 2013-04-30 0000792641 2013-06-03 0000792641 2011-10-31 0000792641 brli:FloridaClinicalLaboratoryIncMember us-gaap:AutomobilesMember 2012-12-31 0000792641 brli:FloridaClinicalLaboratoryIncMember us-gaap:ComputerEquipmentMember 2012-12-31 0000792641 brli:FloridaClinicalLaboratoryIncMember us-gaap:NoncompeteAgreementsMember 2012-12-31 0000792641 brli:FloridaClinicalLaboratoryIncMember us-gaap:CustomerRelationshipsMember 2012-12-31 0000792641 brli:MeridianClinicalLaboratoryCorporationMember us-gaap:AutomobilesMember 2012-12-21 0000792641 brli:MeridianClinicalLaboratoryCorporationMember us-gaap:EquipmentMember 2012-12-21 0000792641 brli:MeridianClinicalLaboratoryCorporationMember us-gaap:NoncompeteAgreementsMember 2012-12-21 0000792641 brli:MeridianClinicalLaboratoryCorporationMember us-gaap:CustomerRelationshipsMember 2012-12-21 0000792641 us-gaap:AutomobilesMember 2013-04-30 0000792641 us-gaap:ComputerEquipmentMember 2013-04-30 0000792641 us-gaap:CustomerRelationshipsMember 2013-04-30 0000792641 2011-11-11 iso4217:USD xbrli:shares xbrli:pure brli:Item iso4217:USD xbrli:shares <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">[1] Basis of Presentation</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the instructions to Form&#160;10-Q and, therefore, do not include all information and footnotes necessary for complete audited financial statements. However, in the opinion of the management of the Company, all adjustments necessary for a fair presentation of the financial position and operating results have been included in these statements. Interim results are not necessarily indicative of results for a full year. Reference is made to the October&#160;31, 2012 audited consolidated financial statements of Bio-Reference Laboratories,&#160;Inc. contained in its Annual Report on Form&#160;10-K for the year ended October&#160;31, 2012.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes for the year ended October&#160;31, 2012 as filed with the Securities and Exchange Commission in the Company&#8217;s Annual Report on Form&#160;10-K. Significant accounting policies followed by the Company are set forth in Note 2 to the Company&#8217;s 2012 Annual Report on Form&#160;10-K.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">[2] Fair Value Measurements.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">As of April&#160;30, 2013, the Company&#8217;s financial instruments primarily consist of cash, short-term trade receivables and payables for which their carrying amounts approximate fair values, and long term debt, for which based on the borrowing rates currently available to the Company for bank loans with similar terms and average maturities, its carrying amount approximates its fair value.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company has evaluated subsequent events through the date the financial statements are issued as evidenced by the date of filing of this report with the Securities and Exchange Commission. No such reportable events have occurred.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">[3] Certain prior year amounts have been reclassified to conform to the current year presentation.&#160; The Company adopted Accounting Standard Update (&#8220;ASU&#8221;) No.&#160;2011-7: Health Care Entities (Topic 954) &#8212; Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities commencing with the current fiscal year, the first year such standard is required for the Company.&#160; The adoption of this update did not have a material impact on the Company&#8217;s financial statements.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Although this update does not have a material impact on the Company&#8217;s financial statements as a whole, it requires that we adjust our presentation of our statement of operations along with prior periods presented in this report to maintain comparability.&#160; As the result of this change in presentation, our &#8220;Net Revenues&#8221;, &#8220;Gross Profit on Revenues&#8221; and our &#8220;General and Administrative Expenses&#8221; would change while our &#8220;Operating Income&#8221;, &#8220;Net Income&#8221; and &#8220;Earnings per Share&#8221; will remain the same.&#160; The presentation is adjusted for a portion of our &#8220;Bad Debt Expense&#8221; that is now reported in our Net Revenues as required under ASU No.&#160;2011-7.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">[4] Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts.&#160; Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by Bio-Reference Laboratories,&#160;Inc. (&#8220;BRLI&#8221;) are to patients covered under a third party payor contract.&#160; In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly; in the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI.&#160; Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests.&#160; Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups.&#160; The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed.&#160; This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.&#160; The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.</font></p> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p> <table style="text-align:left;WIDTH: 86.66%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="86%"> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 53.08%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="53%" colspan="7"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25.4%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="25%" colspan="3"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three&#160;Months&#160;Ended</font></b></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25.38%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="25%" colspan="3"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Six&#160;Months&#160;Ended</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="25%" colspan="3"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">April&#160;30,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25.38%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="25%" colspan="3"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">April&#160;30,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25.4%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="25%" colspan="3"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">[Unaudited]</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25.38%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="25%" colspan="3"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">[Unaudited]</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Gross Service Revenues</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">861,506</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">763,823</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,660,216</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,447,639</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Contractual Adjustments and Discounts:</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Medicare/Medicaid Portion</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">86,433</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">81,318</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">168,260</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">156,059</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">All Other Third Party Payors*</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">584,211</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">519,117</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,127,496</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">978,273</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total Contractual Adjustments and Discounts</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">670,644</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">600,435</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,295,756</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,134,332</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Service Revenues Net of Contractual Adjustments and Discounts</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">190,862</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">163,388</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">364,460</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">313,307</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Patient Service Revenue Provision for Bad Debts**</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">14,410</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">11,945</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">26,751</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">23,071</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net Revenues</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">176,452</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">151,443</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">337,709</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">290,236</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">** Represents the amount of Bad Debt Expense that is now required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No.&#160;2011-7.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience.&#160; The remaining bad debt expense is presented as part of operating expenses.&#160; The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">[5] It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses; this represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information; in the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary. BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer&#8217;s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <table style="text-align:left;WIDTH: 60%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1.5in;" border="0" cellspacing="0" cellpadding="0" width="60%"> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="50%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="44%" colspan="3"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="50%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">[Unaudited]</font></b></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="50%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">April&#160;30,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">October&#160;31,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="50%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="50%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="50%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Contractual Credits/Discounts</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">336,642</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">267,921</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="50%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Doubtful Accounts</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">56,636</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">51,274</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="50%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total Allowance</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">393,278</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">319,195</font></p></td></tr></table> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">[6] The following disclosures present certain information on the Company&#8217;s intangible assets as of April&#160;30, 2013 (Unaudited) and October&#160;31, 2012. All intangible assets are being amortized over their estimated useful lives, as indicated below, with no estimated residual value.</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in;"><u><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">April&#160;30, 2013</font></u></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="80%"> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted-</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Net&#160;of</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Average</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Accumulated</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Accumulated</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Amortization</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Amortization</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Amortization</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Intangible&#160;Asset</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Period</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Cost&#160;($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Customer Lists</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8,739</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,680</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6,059</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Covenants Not-to-Compete</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5,095</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,305</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">790</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Patents and Licenses</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">17</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5,297</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,234</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,063</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Totals</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">19,131</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8,219</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">10,912</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in;"><u><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">October&#160;31,&#160;2012</font></u></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="80%"> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted-Average</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Net&#160;of</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Amortization</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Accumulated</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Accumulated</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Intangible&#160;Asset</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Period</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Cost&#160;($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Amortization&#160;($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Amortization&#160;($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Customer Lists</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,573</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,537</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,036</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Covenants Not-to-Compete</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,305</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,257</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">48</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Patents and Licenses</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">17</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5,297</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,058</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,239</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Totals</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">14,175</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7,852</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6,323</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The aggregate intangible amortization expense for the three months ended April&#160;30, 2013 and 2012 was $227 and $156, respectively.&#160; The aggregate intangible amortization expense for the six-months ended April&#160;30, 2013 and 2012 was $367 and $299, respectively.&#160; The estimated intangible asset amortization expense for the fiscal year ending October&#160;31, 2013 and for the four subsequent years is as follows:</font></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;WIDTH: 40%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 2.25in;" border="0" cellspacing="0" cellpadding="0" width="40%"> <tr style="padding:0;"> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="61%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">October&#160;31,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="30%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2013</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">452</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2014</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">917</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2015</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">892</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2016</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">875</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2017</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">870</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Thereafter</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6,906</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><u><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Total</font></u></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">10,912</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">[7] <b>Revolving Note Payable - Bank</b></font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In October&#160;2011, the Company entered into an amended revolving note payable loan agreement with PNC Bank, N.A.&#160; The maximum amount of the credit line available to the Company pursuant to the loan agreement is the lesser of (i)&#160;$45,000 or (ii)&#160;50% of the Company&#8217;s qualified accounts receivable, as defined in the agreement.&#160; The amendment to the Loan and Security Agreement provides for an interest rate on advances to be subject, at the election of the Company, to either the bank&#8217;s base rate or the Eurodollar rate of interest plus, in certain instances, an additional interest percentage.&#160; The additional interest percentage charge on bank&#8217;s base rate borrowings and on Eurodollar rate borrowings ranges from 1% to 4% and is determined based upon certain financial ratios achieved by the Company.&#160; On April&#160;30, 2013, the Company had elected to have all of the total advances outstanding to be subject to the bank&#8217;s base rate of interest of 3.5%.&#160; The credit line is collateralized by substantially all of the Company&#8217;s assets. The line of credit is available through October&#160;2016 and may be extended for annual periods by mutual consent thereafter.&#160; The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures and fixed charge coverage, and the prohibition of the payment of cash dividends by the Company. As of April&#160;30, 2013, the Company utilized $9,377 of the available credit under this revolving note payable loan agreement.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">[8] <b>Long-Term Debt - Bank</b></font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">In December&#160;2010, the Company issued a seven-year term note for $5,408 at the rate of interest of 6.12% per annum for the financing of new equipment.&#160; The note is payable in 84 equal monthly installments commencing on January&#160;29, 2011 of $61 including principal and interest followed by a balloon payment of the principal and interest outstanding on the loan repayment date of&#160; December&#160;29, 2017.&#160; The balance on this note as of April&#160;30, 2013 is approximately $4,399.</font></p> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">[9] The provision for income taxes for the three months ended April&#160;30, 2013 consists of a current tax provision of $12,114 and a deferred tax benefit of $3,257. The provision for income taxes for the six-months ended April&#160;30, 2013 consists of a current tax provision of $18,601 and a deferred tax benefit of $3,035.The provision for income taxes for the three months ended April&#160;30, 2012 consists of a current tax provision of $8,398 and a deferred tax benefit of $1,302.&#160; The provision for income taxes for the six-months ended April&#160;30, 2012 consists of a current tax provision of $14,940 and a deferred tax benefit of $2,243.&#160; On April&#160;30, 2013, the Company had a current deferred tax asset of $27,446 and a long-term deferred tax asset of $2,780 included in other assets.&#160; On April&#160;30, 2012, the Company had a current deferred tax asset of $23,438 included in other current assets and a long-term deferred tax asset of $2,357 included in other assets.</font> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">[10] ] On December&#160;21, 2012, we entered into an agreement pursuant to which we agreed to purchase all of the authorized, issued and outstanding shares of Meridian Clinical Laboratory,&#160;Corp. ( &#8220;MCL&#8221;), a Florida corporation.&#160; More information about MCL and the agreement may be found in the Form&#160;8-K the Company filed on December&#160;27, 2012.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">On December&#160;31, 2012, we entered into an agreement pursuant to which we agreed to purchase all of the authorized, issued and outstanding shares of Florida Clinical Laboratory,&#160;Inc. (&#8220;FCL&#8221;), a Florida corporation.&#160; More information about FCL and the agreement may be found in the Form&#160;8-K we filed on January&#160;4, 2013.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The initial accounting for these two acquisitions is now complete. Accordingly Management updated its previously reported provisional amounts of the assets, liabilities and equity interests initially reported on its first quarter report on form 10-Q. The following table sets forth these final allocations.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <table style="text-align:left;WIDTH: 80%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="80%"> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.28%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="51%" colspan="5"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">FCL</font></b></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">MCL</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Totals:</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accounts Receivable</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,008</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">232</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,240</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Autos</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">137</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">48</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">185</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Medical Equipment</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">225</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">228</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Computer Equipment</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">21</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">21</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Leasehold Improvements</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">53</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">53</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other Non-Current Assets</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Non-Compete Agreement</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">747</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">43</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">790</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Deposits</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Customer Relationships in Place</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,235</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">930</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,165</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Goodwill</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,905</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">673</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,578</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accounts Payable</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">118</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">83</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">201</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long Term Debt (Auto-Loans)</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">200</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">200</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Short Term Acquisition Payable</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,000</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">250</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,250</font></p></td></tr></table> </div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p> <table style="text-align:left;WIDTH: 86.66%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.5in;" border="0" cellspacing="0" cellpadding="0" width="86%"> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 53.08%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="53%" colspan="7"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25.4%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="25%" colspan="3"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Three&#160;Months&#160;Ended</font></b></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25.38%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="25%" colspan="3"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Six&#160;Months&#160;Ended</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25.4%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="25%" colspan="3"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">April&#160;30,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25.38%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="25%" colspan="3"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">April&#160;30,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25.4%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="25%" colspan="3"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">[Unaudited]</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 25.38%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="25%" colspan="3"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">[Unaudited]</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Gross Service Revenues</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">861,506</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">763,823</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,660,216</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,447,639</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Contractual Adjustments and Discounts:</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Medicare/Medicaid Portion</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">86,433</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">81,318</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">168,260</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">156,059</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">All Other Third Party Payors*</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">584,211</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">519,117</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,127,496</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">978,273</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total Contractual Adjustments and Discounts</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">670,644</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">600,435</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,295,756</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,134,332</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Service Revenues Net of Contractual Adjustments and Discounts</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">190,862</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">163,388</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">364,460</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">313,307</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Patient Service Revenue Provision for Bad Debts**</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">14,410</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">11,945</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">26,751</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">23,071</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 43.46%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="43%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Net Revenues</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.56%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">176,452</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">151,443</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">337,709</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 11.54%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="11%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">290,236</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.</font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">** Represents the amount of Bad Debt Expense that is now required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No.&#160;2011-7.</font></p> </div> 800 1660216000 1447639000 861506000 763823000 168260000 156059000 86433000 81318000 1127496000 978273000 584211000 519117000 1295756000 1134332000 670644000 600435000 364460000 313307000 190862000 163388000 26751000 23071000 14410000 11945000 337709000 290236000 176452000 151443000 <div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <table style="text-align:left;TEXT-ALIGN: left; WIDTH: 342px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 1.5in;" border="0" cellspacing="0" cellpadding="0" width="342"> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="50%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.04%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="44%" colspan="3"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="50%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">[Unaudited]</font></b></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="50%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">April&#160;30,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">October&#160;31,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="50%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="50%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="50%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Contractual Credits/Discounts</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">336,642</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">267,921</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="50%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Doubtful Accounts</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">56,636</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">51,274</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 50.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="50%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Total Allowance</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">393,278</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 4.16%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="4%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 19.94%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="19%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">319,195</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.64%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table></div> 267921000 51274000 319195000 336642000 56636000 393278000 <div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in;"><u><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">April&#160;30, 2013</font></u></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;TEXT-ALIGN: left; WIDTH: 710px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="710"> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted-</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Net&#160;of</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Average</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Accumulated</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Accumulated</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Amortization</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Amortization</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Amortization</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Intangible&#160;Asset</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Period</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Cost&#160;($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Customer Lists</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8,739</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,680</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6,059</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Covenants Not-to-Compete</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5,095</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,305</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">790</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Patents and Licenses</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">17</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5,297</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,234</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,063</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Totals</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">19,131</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">8,219</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 14.96%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="14%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">10,912</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.2%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr></table> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.75in;"><u><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">October&#160;31,&#160;2012</font></u></p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;TEXT-ALIGN: left; WIDTH: 704px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="704"> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Weighted-Average</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Net&#160;of</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Amortization</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Accumulated</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Accumulated</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Intangible&#160;Asset</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Period</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Cost&#160;($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Amortization&#160;($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Amortization&#160;($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Customer Lists</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">20</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,573</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,537</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,036</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Covenants Not-to-Compete</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,305</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,257</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">48</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Patents and Licenses</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">17</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5,297</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,058</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,239</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 26.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="26%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Totals</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">14,175</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">7,852</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6,323</font></p></td></tr></table></div> <div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <table style="text-align:left;WIDTH: 40%; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 2.25in;" border="0" cellspacing="0" cellpadding="0" width="40%"> <tr style="padding:0;"> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="61%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">October&#160;31,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="30%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;"> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2013</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">452</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2014</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">917</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2015</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">892</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2016</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">875</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="top" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2017</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">870</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Thereafter</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6,906</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 61.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="top" width="61%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><u><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Total</font></u></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 6.26%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="6%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 30%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="30%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">10,912</font></p></td></tr></table> </div> P20Y P5Y P17Y P20Y P5Y P17Y 4573000 4305000 5297000 14175000 8739000 5095000 5297000 19131000 2537000 4257000 1058000 7852000 2680000 4305000 1234000 8219000 2036000 48000 4239000 6323000 6059000 790000 4063000 10912000 0 0 0 0 0 0 0 0 367000 299000 452000 917000 892000 875000 870000 6906000 10912000 45000000 0.50 base rate Eurodollar rate 0.01 0.04 0.01 0.04 0.035 9377000 P7Y 5408000 0.0612 84 61000 4399000 12114000 3257000 18601000 -3036000 8398000 1302000 14940000 -2243000 27446000 23438000 2780000 2357000 2 1008000 232000 1240000 53000 53000 225000 228000 1905000 673000 2578000 118000 83000 201000 25143000 153247000 14902000 5373000 24912000 223577000 102701000 52261000 50440000 249113000 55134000 4977000 956000 23408000 6323000 866000 2278000 38808000 312825000 351393000 47146000 41288000 16490000 9753000 9377000 464000 3957000 71952000 92025000 9463000 4163000 13626000 13769000 277000 40907000 186063000 227247000 312825000 351393000 245599000 1666667 1666667 0 0 0.01 0.01 35000000 35000000 27651813 27651813 27707382 27707382 3000 3000 36811000 71250000 29546000 57325000 14287000 27735000 83909000 162584000 67534000 127652000 881000 1723000 39772000 76616000 10110000 19258000 50763000 97597000 16771000 30055000 412000 771000 -42000 -84000 -370000 -687000 16401000 29368000 7095000 12697000 9306000 16671000 0.34 0.60 0.33 0.60 27684715 27877697 27786216 27960069 95776000 80676000 59967000 20709000 -514000 20195000 11338000 186111000 151598000 115130000 36468000 -899000 35569000 20003000 -104000 7997000 290000 -343000 -225000 2773000 3371000 836000 459000 250000 -60000 1599000 23650000 12832000 9667000 4375000 -14042000 -17422000 631000 1666000 4469000 5193000 64000 -11895000 4985000 -2287000 761000 20340000 4896000 1478000 395000 BIO REFERENCE LABORATORIES INC 0000792641 10-Q 2013-04-30 false --10-31 Yes Accelerated Filer 2013 Q2 27663213 <div style="font-size:10.0pt;font-family:Times New Roman;FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <table style="text-align:left;TEXT-ALIGN: left; WIDTH: 603px; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 0.75in;" border="0" cellspacing="0" cellpadding="0" width="603"> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 51.28%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="51%" colspan="5"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">($)</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">FCL</font></b></p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">MCL</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Totals:</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accounts Receivable</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,008</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">232</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,240</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Autos</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">137</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">48</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">185</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Medical Equipment</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">225</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">228</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Computer Equipment</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">21</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">21</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Leasehold Improvements</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">53</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">53</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other Non-Current Assets</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Non-Compete Agreement</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">747</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">43</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">790</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Deposits</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">&#8212;</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Customer Relationships in Place</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">3,235</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">930</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">4,165</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Goodwill</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,905</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">673</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,578</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Accounts Payable</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">118</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">83</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">201</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Long Term Debt (Auto-Loans)</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">200</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">0</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">200</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.24%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td></tr> <tr style="padding:0;PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 44.36%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="44%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Short Term Acquisition Payable</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,000</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">250</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 3.12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="3%"> <p style="MARGIN: 0in 0in 0pt;">&#160;</p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 15.02%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="15%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,250</font></p></td></tr></table></div> 156000 227000 0 0 25538000 19726000 22013000 290000 176438000 14468000 5223000 113861000 58727000 5352000 1001000 25986000 10912000 1115000 46746000 15933000 13770000 479000 4424000 9849000 3920000 0 277000 39256000 206066000 41824000 81883000 33767000 65477000 16408000 31435000 983000 1892000 43812000 85453000 15172000 27785000 434000 733000 -24000 -59000 0 -225000 0 8857000 15566000 0.41 0.72 27698146 27707241 0.41 0.72 27879448 27891431 9208000 290000 -125000 0 28554000 5363000 -434000 -150000 249000 -45000 8918000 10585000 6837000 228000 2223000 -9377000 2030000 89000 656000 16339000 3076000 2501000 290000 137000 21000 747000 3235000 200000 1000000 48000 3000 43000 2000 930000 0 250000 185000 21000 3000 790000 2000 4165000 200000 1250000 3000 <div style="font-size:10.0pt;font-family:Times New Roman;FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">[11] <b>Common Stock Repurchase</b></font></p> <p style="MARGIN: 0in 0in 0pt 0.5in;">&#160;</p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">On November&#160;11, 2011, the Company announced that its board of directors approved a Stock Repurchase Program authorizing the repurchase of up to 1,000,000 shares of its Common Stock at prevailing market prices over the period ending October&#160;31, 2012.&#160; That period was subsequently extended to the period ending October&#160;31, 2013.&#160; During the six-month period ended April&#160;30, 2013, the Company repurchased 81,600 shares of its common stock at a cost of $2,030.&#160; These repurchased shares have been recorded as canceled.</font></p></div> 1000000 81600 2030000 1296000 0.10 0.10 3265000 6274000 3777000 7316000 0 EX-101.SCH 7 brli-20130430.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0010 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0015 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0020 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0030 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1010 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 1020 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 1030 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 1040 - Disclosure - Accounting for Revenues link:presentationLink link:calculationLink link:definitionLink 1050 - Disclosure - Accounting for Accounts Receivable link:presentationLink link:calculationLink link:definitionLink 1060 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 1070 - Disclosure - Revolving Note Payable - Bank link:presentationLink link:calculationLink link:definitionLink 1080 - Disclosure - Long-Term Debt - Bank link:presentationLink link:calculationLink link:definitionLink 1090 - Disclosure - Provision for Income Taxes link:presentationLink link:calculationLink link:definitionLink 1100 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 1110 - Disclosure - Common Stock Repurchase link:presentationLink link:calculationLink link:definitionLink 3040 - Disclosure - Accounting for Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 3050 - Disclosure - Accounting for Accounts Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 3060 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 3100 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 4040 - Disclosure - Accounting for Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 4050 - Disclosure - Accounting for Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 4060 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 4061 - Disclosure - Intangible Assets (Details) (Calc 2) link:presentationLink link:calculationLink link:definitionLink 4070 - Disclosure - Revolving Note Payable - Bank (Details) link:presentationLink link:calculationLink link:definitionLink 4080 - Disclosure - Long-Term Debt - Bank (Details) link:presentationLink link:calculationLink link:definitionLink 4090 - Disclosure - Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 4100 - Disclosure - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 4110 - Disclosure - Common Stock Repurchase (Details) link:presentationLink link:calculationLink link:definitionLink 8000 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 8010 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 8020 - Disclosure - Accounting Standards Update link:presentationLink link:calculationLink link:definitionLink 8030 - Disclosure - Presentation Other Information link:presentationLink link:calculationLink link:definitionLink 8040 - Disclosure - Other Income link:presentationLink link:calculationLink link:definitionLink 8050 - Disclosure - Laboratory Inspection and Reference fees link:presentationLink link:calculationLink link:definitionLink 8060 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 8070 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 8080 - Disclosure - Other Income (Details) link:presentationLink link:calculationLink link:definitionLink 8090 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 8100 - Disclosure - Laboratory Inspection and Reference fees (Details) link:presentationLink link:calculationLink link:definitionLink 8110 - Disclosure - Reclassification of Prior Year Amounts link:presentationLink link:calculationLink link:definitionLink 8120 - Disclosure - Acquisitions (Details 3) link:presentationLink link:calculationLink link:definitionLink 8130 - Disclosure - Acquisitions (Details 2) link:presentationLink link:calculationLink link:definitionLink 8140 - Disclosure - Long-Term Debt - Bank (Tables) link:presentationLink link:calculationLink link:definitionLink 8150 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) link:presentationLink link:calculationLink link:definitionLink 8160 - Disclosure - Selected Quarterly Financial Data (Details) link:presentationLink link:calculationLink link:definitionLink 8170 - Disclosure - Investment in IncellDx link:presentationLink link:calculationLink link:definitionLink 8180 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 8190 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 8200 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 8210 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 8220 - Disclosure - Employee Benefit Plan (Details) link:presentationLink link:calculationLink link:definitionLink 8230 - Disclosure - Health Insurance Plan (Details) link:presentationLink link:calculationLink link:definitionLink 8240 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 8250 - Disclosure - Significant Risks and Uncertainties (Details) link:presentationLink link:calculationLink link:definitionLink 8260 - Disclosure - Capital Transactions link:presentationLink link:calculationLink link:definitionLink 8270 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 8280 - Disclosure - Stock Options and Warrants link:presentationLink link:calculationLink link:definitionLink 8290 - Disclosure - Employment Contracts and Consulting Agreements link:presentationLink link:calculationLink link:definitionLink 8300 - Disclosure - Capitalized Lease Obligations link:presentationLink link:calculationLink link:definitionLink 8310 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 8320 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 8330 - Disclosure - Insurance link:presentationLink link:calculationLink link:definitionLink 8340 - Disclosure - Significant Risks and Uncertainties link:presentationLink link:calculationLink link:definitionLink 8350 - Disclosure - Insurance (Details) link:presentationLink link:calculationLink link:definitionLink 8360 - Disclosure - Health Insurance Plan link:presentationLink link:calculationLink link:definitionLink 8370 - Disclosure - Employee Benefit Plan link:presentationLink link:calculationLink link:definitionLink 8380 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 8390 - Disclosure - Selected Quarterly Financial Data [Unaudited] link:presentationLink link:calculationLink link:definitionLink 8400 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS link:presentationLink link:calculationLink link:definitionLink 8410 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 8420 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 8430 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 8440 - Disclosure - Revolving Note Payable - Bank (Tables) link:presentationLink link:calculationLink link:definitionLink 8450 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 8460 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 8470 - Disclosure - Stock Options and Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 8480 - Disclosure - Employment Contracts and Consulting Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 8490 - Disclosure - Capitalized Lease Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 8500 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 8510 - Disclosure - Selected Quarterly Financial Data [Unaudited] (Tables) link:presentationLink link:calculationLink link:definitionLink 8520 - Disclosure - Organization and Business (Details) link:presentationLink link:calculationLink link:definitionLink 8530 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 8540 - Disclosure - Summary of Significant Accounting Policies (Details 2) link:presentationLink link:calculationLink link:definitionLink 8550 - Disclosure - Summary of Significant Accounting Policies (Details 3) link:presentationLink link:calculationLink link:definitionLink 8560 - Disclosure - Summary of Significant Accounting Policies (Details 4) link:presentationLink link:calculationLink link:definitionLink 8570 - Disclosure - Summary of Significant Accounting Policies (Details 5) link:presentationLink link:calculationLink link:definitionLink 8580 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 8590 - Disclosure - Capitalized Lease Obligations (Details) (Calc 2) link:presentationLink link:calculationLink link:definitionLink 8600 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 8610 - Disclosure - Income Taxes (Details) (Calc 2) link:presentationLink link:calculationLink link:definitionLink 8620 - Disclosure - Capital Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 8630 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 8640 - Disclosure - Stock Options and Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 8650 - Disclosure - Stock Options and Warrants (Details 2) link:presentationLink link:calculationLink link:definitionLink 8660 - Disclosure - Employment Contracts and Consulting Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 8670 - Disclosure - Capitalized Lease Obligations (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 brli-20130430_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 9 brli-20130430_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Business Acquisition Purchase Price Allocation Current Liabilities Loans Payable Short Term Acquisition Payable Represents the amount of acquisition cost of a business combination allocated to the current portion of loans payable of the acquired entity. Percentage of Reportable Segment Assets to Total Assets Percentage of assets to consolidated assets Percentage of reportable segment assets to total assets. Percentage of reportable segment revenue to total revenue. Percentage of Reportable Segment Revenue to Total Revenue Percentage of net revenue to consolidated net revenues Percentage of Reportable Segment Income to Total Income Percentage of net income to consolidated net income Percentage of reportable segment net income to total net income. Share Based Compensation Arrangement by Share Based Payment Award Options Exercise Period after Termination due to Retirement Period within which options must be exercised by the optionee after termination of his employment due to retirement Represents the period within which options must be exercised by the optione under the stock incentive plan after termination of his employment due to retirement. Share Based Compensation Arrangement by Share Based Payment Award Options Exercise Period after Termination due to Disability or Death Period within which options must be exercised by the optionee after termination of employment due to disability or death Represents the period within which options must be exercised under the stock incentive plan after termination of employment due disability or death. Share Based Compensation Arrangement by Share Based Payment Award Percentage of Exercise Price of Option for Which Loan or Guaranty May be Provided Percentage of exercise price of option for which the Board (or a Stock Option Committee) in its sole discretion, cause the company to lend money or guaranty any obligation Represents the percentage of exercise price of an option for which the Board (or a Stock Option Committee) in its sole discretion, cause the entity to lend money to or guaranty any obligation of an employee for the purpose of enabling such employee to exercise an award granted under the stock incentive plan. $2.76 to $2.76 Represents exercise price range one. Exercise Price Range One [Member] Represents exercise price range two. $3.60 to $3.60 Exercise Price Range Two [Member] Exercise Price Range Three [Member] $6.57 to $6.57 Represents exercise price range three. Amendment Description Exercise Price Range Four [Member] $7.25 to $7.25 Represents exercise price range four. Amendment Flag Exercise Price Range Five [Member] $7.41 to $7.67 Represents exercise price range five. Exercise Price Range Six [Member] $9.12 to $9.13 Represents exercise price range six. Exercise Price Range Seven [Member] $17.50 to $17.50 Represents the exercise price range seven. Excess commercial insurance coverage over the primary limits Represent the additional coverage over the primary limits under the excess commercial insurance arrangement. Excess Commercial Insurance Additional Coverage Over Primary Limits Excess Umbrella Insurance Annual Coverage Limit Excess umbrella coverage Represent the annual coverage limit provided by the excess umbrella insurance arrangement. Concentration Risk, Credit Risk Uninsured Amount Cash and certificate of deposit balances at financial institutions in excess of the federally insured limits Represents the credit risk associated with the amount of cash and deposits, as of the balance sheet date, that is not insured by the Federal Deposit Insurance Corporation. Self Funded Health Insurance Plan, Initial Payment for Covered Medical Expenses Per Person Initial amount the entity pays for covered medical expenses per person each year Represents the initial amount that the entity pays for covered medical expenses per person each year under the limited self-funded health insurance plan. Maximum amount per person, covered by the third party insurance carrier for any excess Represents the maximum amount per person, which is covered by the third party insurance carrier in case if the claim exceeds the amount covered under the limited self-funded health insurance plan. Self Funded Health Insurance Plan, Third Party Insurance Coverage Per Person Self Funded Health Insurance Plan, Third Party Insurance Coverage Aggregate Maximum amount in the aggregate, covered by the third party insurance carrier for any excess Represents the maximum amount in the aggregate, which is covered by the third party insurance carrier in case if the claims exceeds the amount covered under the limited self-funded health insurance plan. Self Funded Health Insurance Plan, Health Insurance Premium Expenses Health insurance premium expenses Represents the amount of health insurance premium expenses under the limited self-funded health insurance plan. Represents the medical expenses incurred by the entity during the reporting period for uninsured employees. Uninsured Employee Medical Expenses Uninsured employee medical expenses Self Funded Health Insurance Plan, Employee Contribution Employee contributions for limited health insurance plan Represents the amount contributed by an employee during the period under the limited self-funded health insurance plan. Defined Contribution Plan, Age of Employees Covered Age requirement for employees to participate in the Plan Represents the age of employees to be eligible to participate in the defined contribution plan. Defined Contribution Plan, Requisite Service Period Requisite service period Represents the estimated period over which an employee is required to provide service to be eligible to participate in the defined contribution plan. Defined Contribution Plan, Maximum Annual Contributions Per Employee Percent Contribution by participants (as a percent) Represents the maximum percentage of gross pay that the employee may contribute to a defined contribution plan. Deferred Income Tax Expense Benefit Allowance for Doubtful Accounts Net benefit in allowance for bad debts Represents the amount of deferred income tax expense (benefit) arising from deductible temporary differences from the allowance for doubtful accounts. Current Fiscal Year End Date Deferred Income Tax Expense Benefit Depreciation and Amortization Benefit from depreciation and amortization Represents the amount of deferred income tax expense (benefit) attributable to deductible temporary differences from property, plant, and equipment. Benefit in certain accrued expenses Represents the amount of deferred tax expense (benefit) attributable to deductible temporary differences from accrued liabilities. Deferred Income Tax Expense Benefit Accrued Liabilities Depreciation expense on assets under capital leases Amount of depreciation related to assets under capital lease. Depreciation Related to Assets Under Capital Lease Schedule of Employment Contracts and Consulting Agreements [Table] Tabular disclosure detailing information related to employment contracts and consulting agreements, including, but not limited to, aggregate future minimum commitment under the employment contracts and agreements. Represents the allowance established for contractual credits or discounts. Allowance for Contractual Credits and Discounts [Member] Contractual Credits/Discounts Preferred stock, shares authorized The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws and including Series A Junior Preferred Stock. Preferred Stock, Shares Authorized, Including Series A Junior Preferred Stock, Authorized shares, including Series A Junior Preferred Stock Bad Debt Expense Bad Debt Expense This element represents the amount of bad debt expense for the reporting period. TOTAL GENERAL AND ADMINISTRATIVE EXPENSES Total General and Administrative Expense This element represents the total general and administrative expenses including depreciation, amortization and bad debt expense. Cash paid during the period for: Cash Paid [Abstract] Write Off of Furniture and Equipment Write-off of furniture and equipment This element represents the value of furniture and equipment written off that were fully depreciated. Write-off of property and equipment Write Off of Property and Equipment Represents the value of property and equipment written off that were fully depreciated. Document Period End Date Cash paid to Prior Owners This element represents the cash paid to prior owners of GeneDx after achieving certain targets. Awards to Prior Owners in Cash Write-off of property Write Off of Property This element represents the value of properties written off that were fully depreciated. Write Off of Intangible Assets This element represents the value of intangible assets written off that were fully amortized. Write-off of Intangible Assets Equipment with an initial cost Initial Cost of Equipment Represents gross amount of equipment as of the date of the statement of financial position. Presentation Other Information Presentation Other Information Presentation Other Information [Text Block] This element represents the disclosure of presentation of other information of the reporting company. Reclassification of Prior Year Amounts Disclosure [Text Block] Reclassification of Prior Year Amounts This element represents the disclosure of reclassification of prior year amounts. Accounting for Revenues This element represents the disclosure of revenue recognition. Revenue Recognition Disclosure [Text Block] Laboratory Inspection and Reference fees Refund Received Related to Dispute over Laboratory Inspection and Reference Fees Amount of refund received relating to the dispute over laboratory inspection and reference fees Represents the amount of refund received from New York State Department of Health relating to dispute over the state's laboratory inspection and reference fees. Expense Amount Incurred Excluded from Refund Received Amount of expense incurred in pursuit of refund claim Represents the amount of expenses incurred in pursuit of the refund claim. Net Amount of Refund Net amount of refund Represents the net amount of refund after deducting expenses incurred in pursuit of the refund claim. Laboratory Inspection and Reference Fees Disclosure [Text Block] Laboratory Inspection and Reference fees The entire disclosure for laboratory inspection and reference fees. Fractional Share Adjustments (in shares) This element represents the number of shares issued during the period as a result of fractional share adjustments. Stock Issued, During, the Period, Shares, Fractional Shares Adjustments Series A Senior Preferred Stock This element represents series A senior preferred stock member. Series A Senior Preferred Stock [Member] Deferred Compensation Deferred Compensation [Member] Represents the information about deferred compensation arrangements (such as stock or unit options and share or unit awards) that are equity-based payments with individual employees. Employment Contracts and Consulting Agreements Employment Contracts and Consulting Agreements Disclosure [Text Block] Employment Contracts and Consulting Agreements Disclosure for employment contracts and consulting agreements. The disclosure may provide parties to agreement and term of the agreement. Litigation Health Insurance Plan Health Insurance Plan Disclosure [Text Block] Health Insurance Plan Disclosure in respect of limited self-funded health insurance plan of the reporting entity for its employees. Document and Entity Information Schedule of Net Service Revenues [Table Text Block] Schedule of adjustments made to gross service revenues to arrive at net revenues Tabular disclosure of adjustments made to gross service revenues to arrive at net revenues. Contractual Adjustments and Discounts [Abstract] Contractual Adjustments and Discounts: Contractual Adjustments and Discounts Medicare Medicaid Portion Medicare/Medicaid Portion Represents the contractual adjustments and discounts related to amounts billed to medicare and medicaid. Contractual Adjustments and Discounts All Other Third Party Payors Represents the contractual adjustments and discounts related to amounts billed to third parties other than medicare and medicaid, or direct billed. All Other Third Party Payors Contractual Adjustments and Discounts Total Contractual Adjustments and Discounts Represents the total contractual adjustments and discounts to be deducted from gross service revenue. Allowance for Contractual Credits Discounts [Member] Contractual Credits/Discounts Represents the allowance related to contractual credits and discounts. Patents and Licenses [Member] Patents and Licenses Represents the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law and also includes rights under a license arrangement. Automobiles [Member] Autos Lenetix Medical Screening Laboratory Inc [Member] Lenetix Represents Lenetix Medical Screening Laboratory, Inc. which was acquired by the entity. Represents the amount of purchase price held back by the entity to insure the accuracy of the seller's representations and to protect itself from any claims based on the operations of the laboratory prior to closing. Business Acquisition Cost of Acquired Entity Amount Hold Back Purchase price hold-back Accounting Standards Update Accounting Changes and Error Corrections [Text Block] Genetics Center Inc [Member] GCI Represents information pertaining to Genetics centre, Inc. Term loan Represents the term loan from PNC Bank. Term Loan [Member] Debt Instrument, Variable Rate Base [Axis] The alternative reference rates that may be used to calculate the variable interest rate of the debt instrument. Debt Instrument, Variable Rate Base [Domain] Identification of the reference rate that is used to calculate the variable interest rate of the debt instrument. Eurodollar rate Represents the Eurodollar rate used to calculate the variable rate of the debt instrument. Debt Instrument, Variable Rate Eurodollar [Member] Debt Instrument, Maturity Term Term of debt Represents the term of the debt instrument. Debt Instrument Number of Equal Periodic Payments Number of equal monthly installments Represents the number of equal periodic payments payable by the entity. Sales Tax Refund Claim Resolved Sales tax refund claim resolved Represents the amount of sales tax refund claim successfully resolved with New Jersey Division of Taxation by the entity. Amount of Interest Included in Sales Tax Refund Claim Resolved Interest amount included in sales tax refund claim resolved Represents the amount of interest included in sales tax refund claim resolved. Expenses Excluded from Sales Tax Refund Claim Resolved Expenses excluded from sales tax refund claim resolved Represents the amount of expenses excluded from sales tax refund claim resolved. Sales Tax Refund Claim Resolved Net Amount Net amount of sales tax refund claim resolved Represents the sales tax refund claim recognized in earnings, net of expenses. Number of Distinct Payors Included in All Other Third Party and Direct Payors Number of distinct payors included in all other third party and Direct Represents the number of distinct payors included in all other third party payors and direct payors. Revenue Recognition Percentage of Contractual Adjustments and Discounts to Gross Revenues Percent of Contractual Adjustments and Discounts to Gross Revenues Represents the percentage of contractual adjustments and discounts to gross revenues. Debt Instrument, Variable Rate Base Rate [Member] Bank's base rate Represents the bank's base rate used to calculate the variable rate of the debt instrument. Line of Credit Facility Maximum Borrowing Capacity as Percentage of Accounts Receivable The percentage of qualified accounts receivable that serves as a limit to the maximum borrowing capacity under the credit facility. Maximum credit line available as percentage of accounts receivable Debt Instrument, Reference Rate Variable rate of interest (as a percent) As of the balance sheet date, the effective reference rate for the variable rate of the debt instrument. IncellDx Inc[Member] IncellDx Represents IncellDx, Inc., an equity method investee of the entity. Equity Method Investment, Additional Investment Committed Amount of note signed for purchase of additional shares and warrants Represents the amount committed by the entity for the purchase of additional shares and warrants. Tabular disclosure of any allowance and reserve accounts. Schedule of amounts for contractual credits and doubtful accounts Schedule of Valuation and Qualifying Accounts [Table Text Block] Genedx Inc [Member] Represents information pertaining to GeneDX, Inc. GeneDx, Inc. Meridian Clinical Laboratory Corporation [Member] MCL Represents Meridian Clinical Laboratory, Corp., which was acquired by the entity. Florida Clinical Laboratory Inc [Member] FCL Represents Florida Clinical Laboratory, Inc., which was acquired by the entity. Summary of Significant Accounting Policies Equity Method Investment Additional Investment Amount of additional investment made under note signed for purchase of additional shares and warrants Represents the amount invested by the entity for the purchase of additional shares and warrants. Furniture Fixtures and Office and Computer Equipment [Member] Furniture, Fixtures and Office & Computer Equipment Represents information pertaining to equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. It also includes information pertaining to tangible personal property used in an office setting and long-lived depreciable assets that are used in the creation, maintenance and utilization of information systems. Furniture, Fixtures and Office & Computer Equipment Entity Well-known Seasoned Issuer Line of Credit Disclosure [Text Block] Revolving Note Payable - Bank This element represent as Line of Credit Disclosure. Entity Voluntary Filers Line of Credit Facility, Maximum Borrowing Capacity Prior to Amendment Maximum credit availability prior to amendment Represents the amount of maximum borrowing capacity prior to amendment under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Entity Current Reporting Status Accounting Standards Update This element represents the number of highly compensated senior management employees of the entity. Number of Highly Compensated Senior Management Employees Number of highly compensated senior management employees Entity Filer Category Permanent differences and Other (as a percent) The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to permanent differences and other adjustments under enacted tax laws. Effective Income Tax Rate Reconciliation Permanent Differences and Other Entity Public Float Common Stock, Number of Votes Per Share Number of votes per share for holders of common stock Represents the number of votes entitled for each share of common stock. Entity Registrant Name Excess Commercial Insurance Coverage Per Incident Excess commercial insurance coverage per occurrence Represent the maximum coverage per excess commercial insurance claim provided by the insurance arrangement. Entity Central Index Key 2003 Plan Represents information pertaining to the 2003 employee incentive stock option plan. Employee Incentive Stock Option Plan 2003 [Member] Employee Incentive Stock Option Plan 2000 [Member] 2000 Plan Represents information pertaining to the 2000 employee incentive stock option plan. Shareholder with Minimum Specified Percentage of Stock [Member] Holder of 10% or more of the outstanding common stock Represents information pertaining to the holder of 10% or more of the outstanding common stock of the entity. Share based Compensation Arrangement by Share based Payment Award Minimum Specified Common Stock Percentage Minimum specified percentage of outstanding common stock for the holder of which the exercise price must be at least 110% of fair market value Represents the minimum specified percentage of outstanding common stock for the holder of which the exercise price must be a minimum specified percentage of the fair market value. Entity Common Stock, Shares Outstanding Share Based Compensation Arrangements by Share Based Payment Award Options Expiration Term Option term The period of time, from the grant date until the time at which the share-based option award expires. Share Based Compensation Arrangements by Share Based Payment Award Aggregate Fair Market Value of Common Stock with Respect to which Options are Exercisable for the First Time Aggregate fair market value of the common stock with respect to which options are exercisable for the first time by the grantee (in dollars) Represents the aggregate fair market value of the common stock with respect to which options are exercisable for the first time by the grantee under all of the employee stock option plans of the entity. Laboratory Testing Business [Member] Laboratory testing business Represents the laboratory testing business, a reportable segment of the entity. Lessee Leasing Arrangements, Operating Leases, Renewal Term Period of renewal options Term of the lessee's leasing arrangement renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Purchase Obligation, Purchases Regent supplies expenses Represents the amount of reagent supplies expensed during the period under a purchase obligation. Property [Member] Property Represents the long-lived, physical assets used to produce goods and services, excluding equipment. Current Income Tax [Policy Text Block] Current Income Taxes Disclosure of accounting policy for current income taxes. Deferred Income Tax [Policy Text Block] Deferred Income Taxes Disclosure of accounting policy for deferred income taxes. Other Income [Policy Text Block] Other Income Disclosure of accounting policy for all other income recognized by the entity not otherwise specified in the income statement. Goodwill [Abstract] Goodwill Sales Tax Refund Gross Amount of sales tax refund claim successfully resolved with New Jersey Division of Taxation Represents the amount of sales tax refund, including any interest thereon but excluding expenses incurred in pursuit of such refund claim. Other Income Restitution Payments Received Amount paid by Mr. Littleton for improper payments made to him by the company Represents the amount of restitution payments received by the entity in connection with a restitution agreement entered into with the former Vice President in sales. Sales Tax Refund Interest Amount Interest on sales tax refund Represents the amount of interest on sales tax refund. Sales Tax Refund Related Expenses Expenses incurred in pursuit of sales tax refund claim Represents the amount of expenses incurred by the entity in connection with sales tax refund claim. Net amount of sales tax refund Sales Tax Refund Amount Net Represents the amount of sales tax refund, including any interest thereon but net of any expenses incurred in pursuit of such refund claim. Refund Related to Dispute Over State Laboratory Inspection and Reference Fees Gross Refund received from New York State Department of Health, before expenses, related to the dispute over the state's Laboratory Inspection and Reference fees Represents the amount of refund related to the dispute over the state's laboratory inspection and reference fees before deducting any expenses incurred in pursuit of such claim. Expenses incurred in pursuit of refund claim related to dispute over the state's Laboratory Inspection and Reference fees Represents the amount of expenses incurred in pursuit of refund claim related to dispute over the state's laboratory inspection and reference fees. Refund Related to Dispute Over State Laboratory Inspection and Reference Fees Related Expenses Document Fiscal Year Focus Refund Related to Dispute Over State Laboratory Inspection and Reference Fees Net Net amount of refund related to the dispute over the state's Laboratory Inspection and Reference fees Represents the amount of refund related to the dispute over the state's laboratory inspection and reference fees, net of any expenses incurred in pursuit of such refund claim. Document Fiscal Period Focus Advertising Costs [Abstract] Advertising Costs Employment Contracts and Consulting Agreements [Line Items] Employment contracts and consulting agreements Represents the term of employment contracts and consulting agreements. Employment Contracts and Consulting Agreements Term Term of consulting agreement Employment Contracts and Consulting Agreements Bonuses and Commissions as Percentage of Collected Revenue Bonuses and commissions based on percentage of collected revenues (as a percent) Represents the percentage of bonuses and commissions based on collected revenues on accounts referred by or serviced by the employee or consultant under employment contracts and consulting agreements. Employment Contracts and Consulting Agreements Additional Number of Agreements Number of additional at-will employment and consulting agreements Represents the number of additional employment and consulting agreements, the entity has entered into. Employment Contracts and Consulting Agreements Annual Minimum Commitments Including under Additional Agreements not Subject to Termination Annual aggregate commitments under agreement Represents the annual aggregate minimum commitments, which have no termination dates, under the entity's employment and consulting agreements together with the commitments under additional agreements, which the entity has entered into. Equity Method Investment, Amount Allocated for Additional Investment Amount allocated for an additional investment Represents the amount allocated by the entity for an additional investment as on the balance sheet date. Sales Revenue Services Net Before Provision for Bad Debts Service Revenues Net of Contractual Adjustments and Discounts Represents the aggregate revenue during the period from services rendered in the normal course of business, before deducting provision for bad debts. Provision for Bad Debts of Sales Revenue Services Patient Service Revenue Provision for Bad Debts Represents the amount of the current period expense charged against operations, the offset which is generally to the allowance for bad debts for the purpose of reducing the receivables. Finite Lived Intangible Assets Future Amortization Expense Total Allocated Total The aggregate estimated amortization expense for succeeding fiscal years for intangible assets subject to amortization which have been allocated to an intangible asset group. Business Acquisition Purchase Price Allocation Deposits Deposits Amount of acquisition cost of a business combination allocated to deposits not separately disclosed. Document Type Accounts Receivable - Net Accounts Receivable, Net, Current Accounts Payable Accounts Payable, Current Accrued Income Taxes, Current Accrued Taxes and Expenses LESS: Accumulated Depreciation Less Accumulated Depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Acquired Finite-lived Intangible Asset, Residual Value Estimated residual value Additional Paid in Capital Additional Paid-In Capital Additional Paid-in Capital Additional Paid-in Capital [Member] Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to Reconcile Net Income to Cash Provided by (Used for) Operating Activities: Advertising Costs Advertising Expense Advertising Costs Advertising Costs, Policy [Policy Text Block] Compensation cost recognized (in dollars) Allocated Share-based Compensation Expense Allowance for Doubtful Accounts Allowance for Doubtful Accounts [Member] Doubtful Accounts Amortization of Intangible Assets Amortization expenses Amortization of Deferred Compensation Amortization of Deferred Charges Assets, Current [Abstract] CURRENT ASSETS: Assets [Abstract] ASSETS Assets, Noncurrent TOTAL OTHER ASSETS Assets, Current TOTAL CURRENT ASSETS Assets TOTAL ASSETS Assets, Fair Value Disclosure [Abstract] Assets: Assets, Noncurrent [Abstract] OTHER ASSETS: Accounts Payable Business Acquisition, Purchase Price Allocation, Current Liabilities, Accounts Payable Business Acquisition [Axis] Business Acquisition, Cost of Acquired Entity, Cash Paid Amount used in connection with purchase of operating assets Down payment Addition to goodwill resulting from acquisition Business Acquisition, Purchase Price Allocation, Goodwill Amount Goodwill Business Acquisition, Acquiree [Domain] Acquisitions Intangible assets Business Acquisition, Purchase Price Allocation, Amortizable Intangible Assets Accounts Receivable Business Acquisition, Purchase Price Allocation, Current Assets, Receivables Business Acquisition [Line Items] Acquisitions Purchase price Business Acquisition, Cost of Acquired Entity, Purchase Price Grand Total Long Term Debt (Auto-Loans) Business Acquisition, Purchase Price Allocation, Notes Payable and Long-term Debt Other Non-Current Assets Business Acquisition, Purchase Price Allocation, Other Noncurrent Assets Property, plant and equipment Business Acquisition, Purchase Price Allocation, Property, Plant and Equipment Business Combination Disclosure [Text Block] Acquisitions Capital Leases, Future Minimum Payments Due in Two Years 2014 Capital Leases, Future Minimum Payments Due in Five Years 2017 Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments Total Capital Leases, Balance Sheet, Assets by Major Class, Net Net Capital Leases, Future Minimum Payments Due Total Capital Leases, Lessee Balance Sheet, Assets by Major Class, Accumulated Depreciation Less: Accumulated Depreciation Capitalized Lease Obligations Capital Leases in Financial Statements of Lessor Disclosure [Text Block] Capital Lease Obligations Incurred Capital Leases Capital Leased Assets, Gross Totals Capital Leases, Future Minimum Payments Due in Three Years 2015 Capital Leases, Future Minimum Payments Due, Next Twelve Months 2013 Capital Leases, Future Minimum Payments Due Thereafter Thereafter Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments, Fiscal Year Maturity [Abstract] Future minimum rentals under capital leases Capitalized Lease Obligations Capital Leases in Financial Statements of Lessee Disclosure [Text Block] Capital Leases, Future Minimum Payments Due in Four Years 2016 Capital Leased Assets [Line Items] Assets under capital leases Capital Lease Obligations, Current Capital Lease Obligations - Short-Term Portion Capital Lease Obligations, Noncurrent Capital Lease Obligations - Long-Term Portion Capital Leases, Future Minimum Payments, Interest Included in Payments Less Interest Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIODS CASH AND CASH EQUIVALENTS AT END OF PERIODS Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, at Carrying Value [Abstract] Cash surrender value of officer's life insurance policies Cash Surrender Value, Fair Value Disclosure Cash surrender value of officer's life insurance policies (a component of Other Assets) Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Class of Stock [Domain] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies. COMMITMENTS AND CONTINGENCIES Common Stock Common Stock [Member] Common Stock, Shares, Outstanding Common Stock, Outstanding shares Common Stock, Value, Issued Common Stock, $.01 Par Value; Authorized 35,000,000 shares: Issued and Outstanding 27,651,813 and 27,707,382 at April 30, 2013 and at October 31, 2012, respectively Common Stock, Shares, Issued Common Stock, Issued shares Common Stock, Par or Stated Value Per Share Common Stock, Par Value (in dollars per share) Common Stock, Shares Authorized Common Stock, Authorized shares Employee Benefit Plan Computer Equipment Computer Equipment [Member] Significant Risks and Uncertainties Concentration Risk Disclosure [Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] 2014 Contractual Obligation, Due in Second Year 2017 Contractual Obligation, Due in Fifth Year Schedule of aggregate minimum commitment under employment contracts and agreements, excluding commissions or consumer price index increases Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] 2016 Contractual Obligation, Due in Fourth Year 2013 Contractual Obligation, Due in Next Twelve Months 2015 Contractual Obligation, Due in Third Year Thereafter Contractual Obligation, Due after Fifth Year Employees and Consultants Contractual Obligation, Fiscal Year Maturity [Abstract] Aggregate minimum commitment under these employment contracts and agreements, excluding commissions or consumer price index increases Total Contractual Obligation Total Depreciation and Amortization Cost of Services, Depreciation and Amortization Depreciation and Amortization Cost of Services, Depreciation Cost of Services, Direct Materials Reagents and Laboratory Supplies Cost of Services TOTAL COST OF SERVICES Cost of Services [Abstract] COST OF SERVICES: Credit Facility [Domain] Credit Facility [Axis] State & Local Current State and Local Tax Expense (Benefit) Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Current: Current tax provision Current Income Tax Expense (Benefit) Current Federal Tax Expense (Benefit) Federal Customer lists Customer Lists [Member] Customer Relationships in Place Customer Relationships [Member] Debt Instrument, Description of Variable Rate Basis Variable rate basis Debt Instrument [Line Items] Debt Long-term debt Schedule of Long-term Debt Instruments [Table] Frequency of principal payments Debt Instrument, Frequency of Periodic Payment Debt Disclosure [Abstract] Percentage of additional interest Debt Instrument, Basis Spread on Variable Rate Debt Instrument [Axis] Debt instrument amount Debt Instrument, Face Amount Debt Instrument, Name [Domain] Monthly installment including principal and interest Debt Instrument, Periodic Payment Debt Instrument, Increase, Additional Borrowings Debt issued Monthly principal payments Debt Instrument, Periodic Payment, Principal Prime rate (as a percent) Debt Instrument, Interest Rate at Period End Debt instrument interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Deferred Tax Assets, Property, Plant and Equipment Depreciation and amortization Title of Individual [Axis] Deferred Federal Income Tax Expense (Benefit) Federal Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred: Deferred Income Tax Expense (Benefit) Deferred Income Tax (Benefit) Expense Deferred tax provision (benefit) Deferred Income Tax Expense (Benefit) [Abstract] Net deferred tax benefit Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Asset - Net Deferred Tax Assets, Net [Abstract] Deferred Tax Asset: Deferred Tax Assets, Net of Valuation Allowance, Current Deferred Tax Assets Current deferred tax asset Current Deferred Tax Asset - Net Deferred State and Local Income Tax Expense (Benefit) State and Local Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts Bad Debt Allowance Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Accrued Expenses Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Deferred Tax Asset Long-term deferred tax asset Long Term Deferred Tax Asset - Net Entity's contribution under the Plan Defined Contribution Plan, Cost Recognized Deposits Assets, Noncurrent Deposits Depreciation, Depletion and Amortization, Nonproduction Depreciation and Amortization Depreciation, Depletion and Amortization Depreciation and Amortization Depreciation expense Depreciation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Options and Warrants Stock Options and Warrants Earnings Per Share, Diluted NET INCOME PER COMMON SHARE - DILUTED: (in dollars per share) Net Income Per Common Share, Diluted (in dollars per share) Net Income Per Share - Diluted (in dollars per share) Earnings Per Share, Basic NET INCOME PER COMMON SHARE - BASIC: (in dollars per share) Net Income Per Common Share, Basic (in dollars per share) Net Income Per Share - Basic (in dollars per share) Earnings Per Share Earnings Per Share [Text Block] Earnings Per Share Earnings Per Share, Policy [Policy Text Block] Earnings Per Share Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract] Reconciliation of income tax from continuing operations computed at the U.S. federal statutory tax rate to the company's effective income tax rate Effective Income Tax Rate, Continuing Operations Actual Rate (as a percent) Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate U.S. Federal Statutory Rate (as a percent) Effective Income Tax Rate Reconciliation, State and Local Income Taxes State and Local Taxes, Net of U.S. Federal Tax Benefit (as a percent) Employee-related Liabilities, Current Accrued Salaries and Commissions Payable Compensation cost, related tax benefit (in dollars) Employee Service Share-based Compensation, Tax Benefit from Compensation Expense Compensation cost Employee Service Share-based Compensation, Aggregate Disclosures [Abstract] Medical Equipment Equipment [Member] Equity Method Investments and Joint Ventures Disclosure [Text Block] Investment in IncellDx Asset recorded for the shares and warrants purchased Investments in Unconsolidated Affiliate Equity Method Investments Investment Equity Method Investment, Aggregate Cost Equity Component [Domain] Equity Method Investee, Name [Domain] Investment in IncellDx Total Estimate of Fair Value, Fair Value Disclosure [Member] Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Purchase of new equipment Fair Value of Assets Acquired Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Schedule of fair value measurements Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements. Fair Value Measurements Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value, Inputs, Level 3 [Member] Significant Unobservable Inputs, Level 3 Fair Value, Inputs, Level 1 [Member] Quoted Prices in Active Markets for Identical Assets/Liabilities, Level 1 Significant Other Observable Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Weighted-Average Amortization Period Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Assets, Major Class Name [Domain] 2017 Finite-Lived Intangible Assets, Amortization Expense, Year Five Cost Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets [Line Items] Intangible assets Other intangible assets 2015 Finite-Lived Intangible Assets, Amortization Expense, Year Three Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Estimated amortization expense related to intangible assets Finite-Lived Intangible Assets by Major Class [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five 2016 Finite-Lived Intangible Assets, Amortization Expense, Year Four Finite-Lived Intangible Assets, Amortization Expense, Year Two 2014 2013 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Net of Accumulated Amortization Net of Accumulated Amortization Finite-Lived Intangible Assets, Net Gain (Loss) on Sale of Property Plant Equipment (Gain) Loss on Disposal of Fixed Assets General and Administrative Expense General and Administrative Expenses General and Administrative Expense [Abstract] GENERAL AND ADMINISTRATIVE EXPENSES: Other Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Goodwill Goodwill - Net Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Intangible Assets Goodwill, Impaired, Accumulated Impairment Loss Goodwill accumulated amortization Gross Profit GROSS PROFIT ON REVENUES Gross Profit Impairment of Intangible Assets, Finite-lived Capitalized costs written off Recoverability and Impairment of Intangible Assets and Other Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] CONSOLIDATED STATEMENTS OF OPERATIONS Income Tax Disclosure [Text Block] Provision for Income Taxes Provision for Income Taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest INCOME BEFORE INCOME TAXES Undistributed Equity Method (Income) Loss Share of undistributed loss Income (Loss) from Equity Method Investments Share of undistributed loss Income Tax Expense (Benefit), Continuing Operations [Abstract] Provision for income taxes Income Tax Expense (Benefit) Provision for Income Taxes Provision for Income Taxes Income Taxes Paid Income Taxes Increase (Decrease) in Customer Deposits Deposits Increase (Decrease) in Other Current Assets Other Current Assets Increase (Decrease) in Accounts Receivable Accounts Receivable Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities Increase (Decrease) in Operating Capital [Abstract] Change in Assets and Liabilities, (Increase) Decrease in: Increase (Decrease) in Other Operating Assets Other Assets Increase (Decrease) in Inventories Inventory Increase (Decrease) in Operating Liabilities [Abstract] Increase (Decrease) in: Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity Effect of Dilutive Securities: Warrants/Options (in shares) Incremental Common Shares Attributable to Call Options and Warrants Insurance Insurance Disclosure [Text Block] Insurance Intangible Assets Disclosure [Text Block] Intangible Assets Intangible Assets, Net (Excluding Goodwill) Intangible Assets - Net Interest Expense Interest Expense Interest Paid Interest Inventory Inventory, Policy [Policy Text Block] Inventory, Net Inventory Investment Income, Interest Other (Income) Expense Long-term Debt, Type [Domain] Long-term Debt, Type [Axis] Labor and Related Expense Employee Related Expenses Leasehold Improvements [Member] Leasehold improvements Capitalized Lease Obligations Litigation Legal Matters and Contingencies [Text Block] Liabilities, Current TOTAL CURRENT LIABILITIES Contingent liability Liabilities Assumed Liabilities, Noncurrent TOTAL LONG-TERM LIABILITIES TOTAL LONG-TERM LIABILITIES Liabilities, Current [Abstract] CURRENT LIABILITIES: Liabilities, Noncurrent [Abstract] LONG-TERM LIABILITIES Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Maximum amount of the credit line available pursuant to the loan agreement Line of Credit Facility, Maximum Borrowing Capacity Revolving notes payable outstanding amount Line of Credit Facility, Amount Outstanding Line of Credit Facility, Increase (Decrease), Other, Net Increase (Decrease) in Revolving Line of Credit Line of Credit Facility [Line Items] Revolving note payable - Bank Line of Credit Facility [Table] Line of Credit, Current Revolving Note Payable - Bank Amount of credit utilized Accounting for Accounts Receivable Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Long-Term Debt - Bank Debt outstanding Long-term Debt Totals Principal repayment for each of the five succeeding fiscal years and thereafter Long-term Debt, Fiscal Year Maturity [Abstract] Long-Term Debt - Bank Long-term Debt [Text Block] Schedule of minimum purchase commitments Long-term Purchase Commitment [Table Text Block] 2015 Long-term Debt, Maturities, Repayments of Principal in Year Three 2014 Long-term Debt, Maturities, Repayments of Principal in Year Two 2016 Long-term Debt, Maturities, Repayments of Principal in Year Four 2013 Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months 2017 Long-term Debt, Maturities, Repayments of Principal in Year Five Long-term Debt, Current Maturities Current Maturities of Long-Term Debt Long-term Debt, Excluding Current Maturities Long - Term Debt - Net of Current Portion Long Term Acquisition Payable Loans Payable, Noncurrent Thereafter Long-term Debt, Maturities, Repayments of Principal after Year Five Professional liability insurance coverage Malpractice Insurance, Annual Coverage Limit Professional liability insurance coverage per occurrence Malpractice Insurance, Maximum Coverage Per Incident Mr. Richard Faherty Management [Member] Maximum Maximum [Member] Seven-year term note Medium-term Notes [Member] Minimum Minimum [Member] Valuation and qualifying accounts Movement in Valuation Allowances and Reserves [Roll Forward] Organization and Business Nature of Operations [Text Block] FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] NET CASH - OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities, Continuing Operations OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net Cash Provided by (Used in) Continuing Operations NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS NET CASH - INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net Income (Loss) Available to Common Stockholders, Basic NET INCOME Net Income Income Available to Common Stockholders (in dollars) NET CASH - FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities, Continuing Operations INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Recent Accounting Pronouncements Recent Accounting Pronouncements New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) Acquisition of certain assets Covenants Not-to-Compete Noncompete Agreements [Member] Non-Compete Agreement Number of reportable business segment Number of Reportable Segments Number of businesses acquired Number of Businesses Acquired Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Aggregate future minimum rental payments Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Total rental expenses for property and equipment Operating Leases, Rent Expense, Net Operating Income (Loss) INCOME FROM OPERATIONS 2015 Operating Leases, Future Minimum Payments, Due in Three Years 2014 Operating Leases, Future Minimum Payments, Due in Two Years 2013 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2016 Operating Leases, Future Minimum Payments, Due in Four Years 2017 Operating Leases, Future Minimum Payments, Due in Five Years Operating Leases Operating Leased Assets [Line Items] Totals Operating Leases, Future Minimum Payments Due Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Basis of Presentation Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Other Assets, Current Other Current Assets Other Income Other Income Other Income [Abstract] Other Assets, Noncurrent Other Assets Other Cost of Services Other Cost of Services Other Income and Other Expense Disclosure [Text Block] Other Income Other Nonoperating Expense Interest Income Other Short Term Acquisition Payable Other Loans Payable, Current Other Loans Payable, Long-term, Noncurrent Other Long Term Acquisition Payable Other Nonoperating Income (Expense) TOTAL OTHER (INCOME) EXPENSES - NET Other Nonoperating Income (Expense) [Abstract] OTHER (INCOME) EXPENSE: Common Stock Repurchase Payments for Repurchase of Common Stock Payments to Acquire Businesses, Net of Cash Acquired Business Acquisitions and Related Costs Acquisition of Intangible Assets Payments to Acquire Intangible Assets Payments to Acquire Productive Assets Acquisition of Equipment and Leasehold Improvements Employee Benefit Plan Pension and Other Postretirement Benefits Disclosure [Text Block] Plan Name [Domain] Plan Name [Axis] Preferred Stock, Value, Issued Preferred Stock $.10 Par Value; Authorized 1,666,667 shares, including 3,000 shares of Series A Junior Preferred Stock None Issued Preferred Stock, Shares Authorized Preferred Stock, Authorized shares Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred Stock, Issued shares Preferred Stock, Par or Stated Value Per Share Preferred Stock, Par Value (in dollars per share) Preferred stock, par value (in dollars per share) Reclassification of Prior Year Amounts Reclassifications Reclassification, Policy [Policy Text Block] Proceeds from Stock Options Exercised Proceeds from Exercise of Options Estimated useful lives Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Type [Domain] Property and Equipment Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Property, Plant and Equipment, Net PROPERTY AND EQUIPMENT - NET PROPERTY AND EQUIPMENT - NET Property and equipment Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Gross PROPERTY AND EQUIPMENT - AT COST Summary of property and equipment - at cost Property, Plant and Equipment [Table Text Block] Property, Plant and Equipment, Type [Axis] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Provision for Doubtful Accounts Provision for Doubtful Accounts 2013 Purchase Obligation, Due in Next Twelve Months Totals Purchase Obligation 2014 Purchase Obligation, Due in Second Year 2016 Purchase Obligation, Due in Fourth Year Minimum purchase commitments Purchase Obligation, Fiscal Year Maturity [Abstract] Purchase Obligation, Due after Fifth Year 2015 Purchase Obligation, Due in Third Year 2017 Purchase Obligation, Due in Fifth Year Selected Quarterly Financial Data [Unaudited] Quarterly Financial Information [Text Block] Selected Quarterly Financial Data [Unaudited] Range [Axis] Range [Domain] Accounting for Accounts Receivable Related Party Transactions Related Party Transactions Disclosure [Text Block] Related party transactions Related Party Transaction [Line Items] Related Party [Domain] Aircraft rentals Related Party Transaction, Expenses from Transactions with Related Party Related Party Transactions Related Party [Axis] Repayments of Long-term Debt Payments of Long-Term Debt Repayments of Long-term Capital Lease Obligations Payments of Capital Lease Obligations Retained Earnings (Accumulated Deficit) Retained Earnings Retained Earnings Retained Earnings [Member] Accounting for Revenues Accounting for Revenue Revenue Recognition, Policy [Policy Text Block] Revolving Credit Facility [Member] Revolving note payable - bank Significant Risks and Uncertainties Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Exercise price as a percentage of fair value of common stock Weighted Average, Exercise Price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Exercisable, Exercise Price (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Weighted Average, Remaining Life Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Schedule of estimated amortization expense related to remaining intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Sales Revenue, Services, Net NET REVENUES: Net Revenues Net Revenues Gross Service Revenues Sales Revenue, Services, Other Scenario, Unspecified [Domain] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of provision for income taxes Summary of employee incentive stock option plan transactions Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of basic and diluted net earnings per common share Schedule of principal repayment for each of the five succeeding fiscal years and thereafter Schedule of Maturities of Long-term Debt [Table Text Block] Schedule of aggregate future minimum rentals under capital leases Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] Schedule of assets under capital leases expiring in fiscal 2017 Schedule of Capital Leased Assets [Table Text Block] Schedule of reconciliation of income tax from continuing operations computed at the U.S. federal statutory tax rate to the Company's effective income tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Capital Leased Assets [Table] Schedule of aggregate future minimum rental payments on non cancelable operating leases (exclusive of several month to month leases) Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of provisional purchase price allocations Schedule of Purchase Price Allocation [Table Text Block] Schedule of quarterly financial data Schedule of Quarterly Financial Information [Table Text Block] Schedule of net deferred tax asset [liability] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of information on intangible assets Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Operating Leased Assets [Table] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Line Items] Equity method investment Equity Method Investee, Name [Axis] Summary of employee incentive stock option plan transactions by exercise price range Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Property, Plant and Equipment [Table] SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Organization and Business Segment Reporting Information [Line Items] Segment [Domain] Series A Junior Preferred Stock Series A Preferred Stock [Member] Share-based Compensation Stock Based Compensation Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Weighted Average Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Employee incentive stock options Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Outstanding options, eligible for exercise, weighted average exercise price (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Expired (in shares) Employee incentive stock option plan, additional disclosures Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Outstanding options, eligible for exercise (in shares) Shares Under Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Maximum aggregate shares of common stock authorized under the plan Exercisable, Shares Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options Exercise Price Range [Axis] Employee Incentive Stock Options Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at the end of the period (in dollars per share) Outstanding at the beginning of the period (in dollars per share) Weighted Average, Shares Outstanding Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options Exercise price range, low end of range (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Exercise price range, high end of range (in dollars per share) Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit Balance (in shares) Balance (in shares) Shares, Issued Revolving Note Payable - Bank Statement [Table] Scenario [Axis] Statement [Line Items] Statement Common Stock Repurchase CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY CONSOLIDATED STATEMENTS OF CASH FLOWS Business Segments [Axis] Equity Components [Axis] CONSOLIDATED BALANCE SHEETS Class of Stock [Axis] Stock Issued During Period, Shares, Period Increase (Decrease) Total Number of shares of common stock issued for employment or consulting services Stock Issued During Period, Shares, Issued for Services Stock Repurchased and Retired During Period, Value Cost of shares of common stock repurchased Common Stock Repurchased and Canceled Stock Repurchase Program, Number of Shares Authorized to be Repurchased Number of shares of common stock authorized to be repurchased Stock Issued for Acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Exercise of Options - Employees Stock Issued During Period, Value, Stock Options Exercised Stock Issued for Acquisition Stock Issued During Period, Value, Acquisitions Stock-based compensation expense Stock Granted During Period, Value, Share-based Compensation, Net of Forfeitures Stock Repurchased and Retired During Period, Shares Number of shares of common stock repurchased Common Stock Repurchased and Canceled (in shares) Stock Based Compensation (in shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Stock Based Compensation Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Stock Based Compensation Stock Issued During Period, Shares, New Issues Shares Issued to Prior Owners (in shares) Exercise of Options - Employees (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) SHAREHOLDERS' EQUITY Stockholders' Equity Attributable to Parent [Abstract] Balance Balance TOTAL SHAREHOLDERS' EQUITY Stockholders' Equity Attributable to Parent Common Stock Repurchase Stockholders' Equity Note, Stock Split, Conversion Ratio Stock split ratio Common Stock Repurchase Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity, Period Increase (Decrease) Total SUBSEQUENT EVENTS Subsequent Events [Text Block] SUBSEQUENT EVENTS Subsequent Event Type [Domain] Subsequent Event [Line Items] Subsequent events Subsequent Events Subsequent Events, Policy [Policy Text Block] Subsequent Event Type [Axis] Subsequent Event [Table] Subsequent events Subsequent Event [Member] Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Title of Individual with Relationship to Entity [Domain] Accounting for Contractual Credits and Doubtful Accounts Trade and Other Accounts Receivable, Policy [Policy Text Block] Automobiles and Aircraft Transportation Equipment [Member] Use of Estimates Use of Estimates, Policy [Policy Text Block] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves [Domain] Charged to Cost and Expenses Valuation Allowances and Reserves, Charged to Cost and Expense Balance at the End of a Period Valuation Allowances and Reserves, Balance Balance at the Beginning of a Period Total Allowance Deductions Charged to Valuation Allowance Accounts Valuation Allowances and Reserves, Deductions SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and qualifying accounts Allowances Allowances Valuation Allowances and Reserves Type [Axis] Vehicles Vehicles [Member] Weighted Average Number of Shares Outstanding, Basic WEIGHTED AVERAGE NUMBER OF SHARES - BASIC: (in shares) WEIGHTED AVERAGE NUMBER OF SHARES - DILUTED: (in shares) Weighted Average Common Shares Outstanding - Diluted (in shares) Weighted Average Diluted Common Shares Outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted EX-101.PRE 10 brli-20130430_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 11 brli-20130430_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT XML 12 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accounting for Revenues (Tables)
6 Months Ended
Apr. 30, 2013
Accounting for Revenues  
Schedule of adjustments made to gross service revenues to arrive at net revenues

 

 

 

 

($)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

April 30,

 

April 30,

 

 

 

[Unaudited]

 

[Unaudited]

 

 

 

2013

 

2012

 

2013

 

2012

 

Gross Service Revenues

 

861,506

 

763,823

 

1,660,216

 

1,447,639

 

 

 

 

 

 

 

 

 

 

 

Contractual Adjustments and Discounts:

 

 

 

 

 

 

 

 

 

Medicare/Medicaid Portion

 

86,433

 

81,318

 

168,260

 

156,059

 

All Other Third Party Payors*

 

584,211

 

519,117

 

1,127,496

 

978,273

 

Total Contractual Adjustments and Discounts

 

670,644

 

600,435

 

1,295,756

 

1,134,332

 

Service Revenues Net of Contractual Adjustments and Discounts

 

190,862

 

163,388

 

364,460

 

313,307

 

Patient Service Revenue Provision for Bad Debts**

 

14,410

 

11,945

 

26,751

 

23,071

 

Net Revenues

 

176,452

 

151,443

 

337,709

 

290,236

 

 

* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

 

** Represents the amount of Bad Debt Expense that is now required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

XML 13 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 6 Months Ended
Apr. 30, 2013
Apr. 30, 2012
Apr. 30, 2013
Apr. 30, 2012
CONSOLIDATED STATEMENTS OF OPERATIONS        
NET REVENUES: $ 176,452 $ 151,443 $ 337,709 $ 290,236
COST OF SERVICES:        
Depreciation and Amortization 3,777 3,265 7,316 6,274
Employee Related Expenses 41,824 36,811 81,883 71,250
Reagents and Laboratory Supplies 33,767 29,546 65,477 57,325
Other Cost of Services 16,408 14,287 31,435 27,735
TOTAL COST OF SERVICES 95,776 83,909 186,111 162,584
GROSS PROFIT ON REVENUES 80,676 67,534 151,598 127,652
GENERAL AND ADMINISTRATIVE EXPENSES:        
Depreciation and Amortization 983 881 1,892 1,723
General and Administrative Expenses 43,812 39,772 85,453 76,616
Bad Debt Expense 15,172 10,110 27,785 19,258
TOTAL GENERAL AND ADMINISTRATIVE EXPENSES 59,967 50,763 115,130 97,597
INCOME FROM OPERATIONS 20,709 16,771 36,468 30,055
OTHER (INCOME) EXPENSE:        
Interest Expense 434 412 733 771
Interest Income (24) (42) (59) (84)
Other (Income) Expense 104 0 225 0
TOTAL OTHER (INCOME) EXPENSES - NET 514 370 899 687
INCOME BEFORE INCOME TAXES 20,195 16,401 35,569 29,368
Provision for Income Taxes 8,857 7,095 15,566 12,697
NET INCOME $ 11,338 $ 9,306 $ 20,003 $ 16,671
NET INCOME PER COMMON SHARE - BASIC: (in dollars per share) $ 0.41 $ 0.34 $ 0.72 $ 0.60
WEIGHTED AVERAGE NUMBER OF SHARES - BASIC: (in shares) 27,698,146 27,684,715 27,707,241 27,786,216
NET INCOME PER COMMON SHARE - DILUTED: (in dollars per share) $ 0.41 $ 0.33 $ 0.72 $ 0.60
WEIGHTED AVERAGE NUMBER OF SHARES - DILUTED: (in shares) 27,879,448 27,877,697 27,891,431 27,960,069
XML 14 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accounting for Accounts Receivable
6 Months Ended
Apr. 30, 2013
Accounting for Accounts Receivable  
Accounting for Accounts Receivable

[5] It is typically the responsibility of the patient to pay for laboratory service bills. Most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or commercial insurance to pay all or a portion of their healthcare expenses; this represents the major portion of payment for all services provided by BRLI. In certain cases, the individual has no insurance or does not provide insurance information; in the remainder of the cases, BRLI is provided the third party billing information, usually by the referring physician, and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and coverage of specific tests. BRLI routinely reviews the reimbursement policies and subsequent payments and collection rates from these different types of payors. Contractual adjustments and discounts are recorded as reductions to gross service revenues and are collectively referred to as the contractual allowance. BRLI has not been required to record an adjustment in a subsequent period related to revenue recorded in a prior period which was material in nature. Aging of accounts receivable is monitored by billing personnel and follow-up activities including collection efforts are conducted as necessary. BRLI writes off receivables against the allowance for doubtful accounts when they are deemed uncollectible. For client billing, accounts are written off when all reasonable collection efforts prove to be unsuccessful. Patient accounts, where the patient is directly responsible for all or a remainder portion of the account after partial payment or denial by a third party payor, are written off after the normal dunning cycle has occurred, although these may be subsequently transferred to a third party collection agency after being written off. Third party payor accounts are written off when they exceed the payer’s timely filing limits. Accounts Receivable on the balance sheet is net of the following amounts for contractual credits and doubtful accounts:

 

 

 

($)

 

 

 

[Unaudited]

 

 

 

 

 

April 30,

 

October 31,

 

 

 

2013

 

2012

 

 

 

 

 

 

 

Contractual Credits/Discounts

 

336,642

 

267,921

 

Doubtful Accounts

 

56,636

 

51,274

 

Total Allowance

 

393,278

 

319,195

XML 15 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 16 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6
Revolving Note Payable - Bank (Details) (USD $)
In Thousands, unless otherwise specified
6 Months Ended 6 Months Ended
Apr. 30, 2013
Oct. 31, 2012
Apr. 30, 2013
Revolving note payable - bank
Apr. 30, 2013
Revolving note payable - bank
Bank's base rate
Apr. 30, 2013
Revolving note payable - bank
Bank's base rate
Minimum
Apr. 30, 2013
Revolving note payable - bank
Bank's base rate
Maximum
Apr. 30, 2013
Revolving note payable - bank
Eurodollar rate
Apr. 30, 2013
Revolving note payable - bank
Eurodollar rate
Minimum
Apr. 30, 2013
Revolving note payable - bank
Eurodollar rate
Maximum
Revolving note payable - Bank                  
Maximum amount of the credit line available pursuant to the loan agreement     $ 45,000            
Maximum credit line available as percentage of accounts receivable     50.00%            
Variable rate basis       base rate     Eurodollar rate    
Percentage of additional interest         1.00% 4.00%   1.00% 4.00%
Variable rate of interest (as a percent)       3.50%          
Amount of credit utilized $ 9,377 $ 0 $ 9,377            
XML 17 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accounting for Accounts Receivable (Tables)
6 Months Ended
Apr. 30, 2013
Accounting for Accounts Receivable  
Schedule of amounts for contractual credits and doubtful accounts

 

 

 

 

($)

 

 

 

[Unaudited]

 

 

 

 

 

April 30,

 

October 31,

 

 

 

2013

 

2012

 

 

 

 

 

 

 

Contractual Credits/Discounts

 

336,642

 

267,921

 

Doubtful Accounts

 

56,636

 

51,274

 

Total Allowance

 

393,278

 

319,195

 

XML 18 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
Acquisitions (Details) (USD $)
In Thousands, unless otherwise specified
6 Months Ended
Apr. 30, 2013
Item
Apr. 30, 2013
Autos
Apr. 30, 2013
Medical Equipment
Apr. 30, 2013
Computer Equipment
Apr. 30, 2013
Leasehold improvements
Apr. 30, 2013
Non-Compete Agreement
Apr. 30, 2013
Customer Relationships in Place
Dec. 31, 2012
FCL
Dec. 31, 2012
FCL
Autos
Dec. 31, 2012
FCL
Medical Equipment
Dec. 31, 2012
FCL
Computer Equipment
Dec. 31, 2012
FCL
Leasehold improvements
Dec. 31, 2012
FCL
Non-Compete Agreement
Dec. 31, 2012
FCL
Customer Relationships in Place
Dec. 21, 2012
MCL
Dec. 21, 2012
MCL
Autos
Dec. 21, 2012
MCL
Medical Equipment
Dec. 21, 2012
MCL
Non-Compete Agreement
Dec. 21, 2012
MCL
Customer Relationships in Place
Acquisitions                                      
Number of businesses acquired 2                                    
Acquisitions                                      
Accounts Receivable $ 1,240             $ 1,008             $ 232        
Property, plant and equipment   185 228 21 53       137 225 21 53       48 3    
Other Non-Current Assets 3             3                      
Intangible assets           790 4,165           747 3,235       43 930
Deposits 2                           2        
Goodwill 2,578             1,905             673        
Accounts Payable 201             118             83        
Long Term Debt (Auto-Loans) 200             200             0        
Short Term Acquisition Payable $ 1,250             $ 1,000             $ 250        
XML 19 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6
Provision for Income Taxes (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended
Apr. 30, 2013
Apr. 30, 2012
Apr. 30, 2013
Apr. 30, 2012
Oct. 31, 2012
Provision for Income Taxes          
Current tax provision $ 12,114 $ 8,398 $ 18,601 $ 14,940  
Deferred tax provision (benefit) 3,257 1,302 (3,036) (2,243)  
Current deferred tax asset 27,446 23,438 27,446 23,438 24,912
Long-term deferred tax asset $ 2,780 $ 2,357 $ 2,780 $ 2,357 $ 2,278
XML 20 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6
Long-Term Debt - Bank (Details) (Seven-year term note, USD $)
In Thousands, unless otherwise specified
1 Months Ended 6 Months Ended
Dec. 31, 2010
Apr. 30, 2013
Item
Seven-year term note
   
Long-term debt    
Term of debt 7 years  
Debt issued $ 5,408  
Debt instrument interest rate (as a percent)   6.12%
Number of equal monthly installments   84
Monthly installment including principal and interest   61
Debt outstanding   $ 4,399
XML 21 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Basis of Presentation
6 Months Ended
Apr. 30, 2013
Basis of Presentation  
Basis of Presentation

[1] Basis of Presentation

 

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the instructions to Form 10-Q and, therefore, do not include all information and footnotes necessary for complete audited financial statements. However, in the opinion of the management of the Company, all adjustments necessary for a fair presentation of the financial position and operating results have been included in these statements. Interim results are not necessarily indicative of results for a full year. Reference is made to the October 31, 2012 audited consolidated financial statements of Bio-Reference Laboratories, Inc. contained in its Annual Report on Form 10-K for the year ended October 31, 2012.

 

The consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes for the year ended October 31, 2012 as filed with the Securities and Exchange Commission in the Company’s Annual Report on Form 10-K. Significant accounting policies followed by the Company are set forth in Note 2 to the Company’s 2012 Annual Report on Form 10-K.

XML 22 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Recent Accounting Pronouncements
6 Months Ended
Apr. 30, 2013
Recent Accounting Pronouncements  
Recent Accounting Pronouncements

[3] Certain prior year amounts have been reclassified to conform to the current year presentation.  The Company adopted Accounting Standard Update (“ASU”) No. 2011-7: Health Care Entities (Topic 954) — Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities commencing with the current fiscal year, the first year such standard is required for the Company.  The adoption of this update did not have a material impact on the Company’s financial statements.

 

Although this update does not have a material impact on the Company’s financial statements as a whole, it requires that we adjust our presentation of our statement of operations along with prior periods presented in this report to maintain comparability.  As the result of this change in presentation, our “Net Revenues”, “Gross Profit on Revenues” and our “General and Administrative Expenses” would change while our “Operating Income”, “Net Income” and “Earnings per Share” will remain the same.  The presentation is adjusted for a portion of our “Bad Debt Expense” that is now reported in our Net Revenues as required under ASU No. 2011-7.

XML 23 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Intangible Assets
6 Months Ended
Apr. 30, 2013
Intangible Assets  
Intangible Assets

[6] The following disclosures present certain information on the Company’s intangible assets as of April 30, 2013 (Unaudited) and October 31, 2012. All intangible assets are being amortized over their estimated useful lives, as indicated below, with no estimated residual value.

 

April 30, 2013

 

 

 

Weighted-

 

 

 

 

 

Net of

 

 

 

Average

 

 

 

Accumulated

 

Accumulated

 

 

 

Amortization

 

 

 

Amortization

 

Amortization

 

Intangible Asset

 

Period

 

Cost ($)

 

($)

 

($)

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

8,739

 

2,680

 

6,059

 

Covenants Not-to-Compete

 

5

 

5,095

 

4,305

 

790

 

Patents and Licenses

 

17

 

5,297

 

1,234

 

4,063

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

19,131

 

8,219

 

10,912

 

 

October 31, 2012

 

 

 

Weighted-Average

 

 

 

 

 

Net of

 

 

 

Amortization

 

 

 

Accumulated

 

Accumulated

 

Intangible Asset

 

Period

 

Cost ($)

 

Amortization ($)

 

Amortization ($)

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

4,573

 

2,537

 

2,036

 

Covenants Not-to-Compete

 

5

 

4,305

 

4,257

 

48

 

Patents and Licenses

 

17

 

5,297

 

1,058

 

4,239

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

14,175

 

7,852

 

6,323

 

 

The aggregate intangible amortization expense for the three months ended April 30, 2013 and 2012 was $227 and $156, respectively.  The aggregate intangible amortization expense for the six-months ended April 30, 2013 and 2012 was $367 and $299, respectively.  The estimated intangible asset amortization expense for the fiscal year ending October 31, 2013 and for the four subsequent years is as follows:

 

October 31,

 

($)

 

2013

 

452

 

2014

 

917

 

2015

 

892

 

2016

 

875

 

2017

 

870

 

Thereafter

 

6,906

 

 

 

 

 

Total

 

10,912

 

XML 24 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accounting for Revenues
6 Months Ended
Apr. 30, 2013
Accounting for Revenues  
Accounting for Revenues

[4] Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis, urine analysis and genetic testing among others. Service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.

 

Service revenues before provision for bad debts are determined utilizing gross service revenues net of contractual adjustments and discounts.  Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by Bio-Reference Laboratories, Inc. (“BRLI”) are to patients covered under a third party payor contract.  In certain cases, the individual has no insurance or does not provide insurance information and in other cases tests are performed under contract to a professional organization (such as physicians, hospitals, and clinics) which reimburse BRLI directly; in the remainder of the cases, BRLI is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like BRLI.  Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests.  Estimated revenues are established based on a series of highly complex procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends. We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings due to the contractual adjustments and discounts and that our estimates remain sensitive to variances and changes within our payor groups.  The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed.  This calculation is routinely analyzed by BRLI on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.  The table below shows the adjustments made to gross service revenues to arrive at net revenues, the amount reported on our statement of operations.

 

 

 

($)

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

April 30,

 

April 30,

 

 

 

[Unaudited]

 

[Unaudited]

 

 

 

2013

 

2012

 

2013

 

2012

 

Gross Service Revenues

 

861,506

 

763,823

 

1,660,216

 

1,447,639

 

 

 

 

 

 

 

 

 

 

 

Contractual Adjustments and Discounts:

 

 

 

 

 

 

 

 

 

Medicare/Medicaid Portion

 

86,433

 

81,318

 

168,260

 

156,059

 

All Other Third Party Payors*

 

584,211

 

519,117

 

1,127,496

 

978,273

 

Total Contractual Adjustments and Discounts

 

670,644

 

600,435

 

1,295,756

 

1,134,332

 

Service Revenues Net of Contractual Adjustments and Discounts

 

190,862

 

163,388

 

364,460

 

313,307

 

Patient Service Revenue Provision for Bad Debts**

 

14,410

 

11,945

 

26,751

 

23,071

 

Net Revenues

 

176,452

 

151,443

 

337,709

 

290,236

 

 

* All Other Third Party and Direct Payors consists of almost eight hundred distinct payors, including commercial health insurers and administrators as well as professionally billed accounts such as physicians, hospitals, clinics and other direct billed accounts.

 

** Represents the amount of Bad Debt Expense that is now required to be presented as a deduction from patient service revenue (net of contractual allowances and discounts) pursuant to ASU No. 2011-7.

 

When new business is received by BRLI, service revenues net of contractual adjustments and discounts are calculated by reducing gross service revenues by the estimated contractual allowance. The Patient Service Revenue Provision for Bad Debts represents the amount of bad debt expense expected to occur on patient service revenue based upon our experience.  The remaining bad debt expense is presented as part of operating expenses.  The bad debt expense presented as part of operating expense represents the bad debt expense related to receivables from service revenues determined after taking into account our ability to collect on such revenue.

 

BRLI recognized the amounts in subsequent periods for actual allowances/discounts to gross service revenue; bad debt may have been adjusted over the same periods of time to maintain an accurate balance between net revenues and actual revenues. Management has reviewed the allowances/discounts recognized in subsequent periods and believes the amounts to be immaterial. A number of proposals for legislation or regulation continue to be under discussion which could have the effect of substantially reducing Medicare reimbursements for clinical laboratories or introducing cost sharing to beneficiaries. Depending upon the nature of regulatory action, if any, which is taken and the content of legislation, if any, which is adopted, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken.

XML 25 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6
Common Stock Repurchase (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
6 Months Ended
Apr. 30, 2013
Nov. 11, 2011
Common Stock Repurchase    
Number of shares of common stock authorized to be repurchased   1,000,000
Number of shares of common stock repurchased 81,600  
Cost of shares of common stock repurchased $ 2,030  
EXCEL 26 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]F8F(Y-38U9E\P8S=A7S0Y8F%?.64X,E]A9&-F M8F$X-#,Y-S`B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I% M>&-E;%=O#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D%C8V]U;G1I;F=?9F]R7T%C8V]U;G1S7U)E M8V5I=CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN M=&%N9VEB;&5?07-S971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K M#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%C8V]U;G1I;F=?9F]R7T%C8V]U;G1S7U)E M8V5I=C$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K M#I%>&-E;%=O#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E!R;W9I&5S7T1E=#PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%C<75I#I%>&-E;%=O M#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV M95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^0DE/(%)%1D5214Y#12!,04)/4D%43U))15,@ M24Y#/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^ M07!R(#,P+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@ M("`@("`\=&0@8VQA'0^,C`Q,SQS<&%N/CPO'0^43(\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!!'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$F5D(#,U M+#`P,"PP,#`@3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%SF5D(#$L-C8V+#8V-R!S:&%R97,L(&EN8VQU9&EN9R`S+#`P M,"!S:&%R97,@;V8@4V5R:65S($$@2G5N:6]R(%!R969E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F M8F(Y-38U9E\P8S=A7S0Y8F%?.64X,E]A9&-F8F$X-#,Y-S`-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9F)B.34V-69?,&,W85\T.6)A7SEE.#)? M861C9F)A.#0S.3'0O:'1M;#L@8VAAF5D('-H87)E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XX+#@U-SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&5D($%S2!-971H;V0@*$EN8V]M M92D@3&]S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$6UE;G1S(&]F($QO;F&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-BPS M,SD\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R M/ELQ72!"87-I6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0[)R!S:7IE/3-$,CY4:&4@86-C;VUP86YY:6YG('5N875D:71E9"!C M;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@:&%V92!B965N('!R M97!A2!F;W(@8V]M<&QE=&4@875D M:71E9"!F:6YA;F-I86P@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P M<'0[)R!S:7IE/3-$,CY4:&4@8V]N'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R M/ELR72!&86ER(%9A;'5E($UE87-U6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-) M6D4Z(#$P<'0[)R!S:7IE/3-$,CY!28C.#(Q-SMS(&9I;F%N8VEA;"!I;G-T&EM871E6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$ M,CY4:&4@0V]M<&%N>2!H87,@979A;'5A=&5D('-U8G-E<75E;G0@979E;G1S M('1H&-H86YG M92!#;VUM:7-S:6]N+B!.;R!S=6-H(')E<&]R=&%B;&4@979E;G1S(&AA=F4@ M;V-C=7)R960N/"]F;VYT/CPO<#X-"CPO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA6QE/3-$)V9O;G0M65A65A2XF(S$V,#L@5&AE(&%D;W!T:6]N(&]F M('1H:7,@=7!D871E(&1I9"!N;W0@:&%V92!A(&UA=&5R:6%L(&EM<&%C="!O M;B!T:&4@0V]M<&%N>28C.#(Q-SMS(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO M9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N M-6EN.R<^)B,Q-C`[/"]P/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D%L=&AO=6=H('1H M:7,@=7!D871E(&1O97,@;F]T(&AA=F4@82!M871E'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=B!S='EL93TS1"=F;VYT M+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CLG/@T* M/'`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`@=VED=&@],T0X-B4^ M#0H-"CQT6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#(N,R4[(%!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,R4[(%!! M1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0Q/E1H6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE/3-$ M<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0S+C0V)3L@4$%$1$E.1RU2 M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$-#,E/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$<&%D M9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0S+C0V)3L@4$%$1$E.1RU224=( M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$-#,E/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/EM5;F%U9&ET M961=/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,38E M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E M>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1) M3D'0@,7!T('-O;&ED.R!"3U)$15(M M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=. M.B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`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`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2 M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X- M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE M/3-$,CXX-C$L-3`V/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[ M(%!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C$L-C8P M+#(Q-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,R4[(%!! M1$1)3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!! M1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L-#0W+#8S M.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,38E.R!0041$ M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP M.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0S+C0V)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M-#,E/@T*/'`@6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$Q+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$ M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T* M/'`@6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#(N,R4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O M;G0@6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,R4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$Q+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!" M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO M6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DUE9&EC87)E+TUE9&EC86ED(%!O6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C4V)3L@ M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C@V+#0S,SPO9F]N=#X\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,R4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S M:7IE/3-$,CXQ-C@L,C8P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`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`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W M:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE M.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$Q+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C M8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4 M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C M0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ+#$R M-RPT.38\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$Q+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/ M54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52 M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$ M,CXY-S@L,C6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/E1O=&%L($-O;G1R86-T=6%L($%D:G5S=&UE;G1S(&%N9"!$ M:7-C;W5N=',\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0[)R!S:7IE/3-$,CXV-S`L-C0T/"]F;VYT/CPO<#X\+W1D/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO M;F4[(%!!1$1)3D6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4] M,T0R/C$L,CDU+#6QE M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$ M15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L,3,T+#,S,CPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,38E.R!0041$24Y'+5))1TA4.B`P:6X[ M(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#0S+C0V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/ M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4] M,T0R/C$V,RPS.#@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$Q+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!" M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@ M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S M:7IE/3-$,CXS-C0L-#8P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R M('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0S+C0V)3L@ M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$-#,E/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/DYE="!2 M979E;G5E6QE/3-$)T)/4D1%4BU" M3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!" M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@ M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S M:7IE/3-$,CXQ-S8L-#4R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$U,2PT-#,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B M;&4[($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ M(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XU-"4[(%!!1$1) M3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR M-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C4T M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!" M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@ M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR.3`L,C,V/"]F;VYT M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ M(#!I;B`P:6X@,'!T.R<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BHJ(%)E<')E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/E=H96X@ M;F5W(&)U'!E;G-E('!R97-E;G1E9"!A'!E M;G-E(')E<')E6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D)23$D@2!H M879E(&)E96X@861J=7-T960@;W9E2!I3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]F8F(Y-38U9E\P8S=A7S0Y8F%?.64X,E]A9&-F8F$X-#,Y M-S`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9F)B.34V-69?,&,W M85\T.6)A7SEE.#)?861C9F)A.#0S.3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`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`P<'0@,"XU M:6X[)SXF(S$V,#L\+W`^#0H\=&%B;&4@6QE/3-$ M<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4P+C$V)3L@4$%$1$E.1RU2 M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$-3`E/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N,38E.R!0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!" M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE M/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@ M;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU M;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T M('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/ M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3DE/@T*/'`@6QE M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4P+C$V)3L@4$%$1$E. M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$-3`E/@T*/'`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`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$Y+CDT)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(V-RPY,C$\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@ M,&EN(#!P="`Q,'!T.R<^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E M>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1) M3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C4Q+#(W M-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N-C0E.R!0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D M9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#4P+C$V)3L@4$%$1$E.1RU224=( M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN M.R<@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,Y,RPR-S@\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,Q.2PQ.34\+V9O;G0^/"]P M/CPO=&0^/"]T3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F8F(Y-38U9E\P8S=A7S0Y8F%?.64X M,E]A9&-F8F$X-#,Y-S`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M9F)B.34V-69?,&,W85\T.6)A7SEE.#)?861C9F)A.#0S.3'0O:'1M;#L@8VAA M6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CY;-ET@5&AE(&9O M;&QO=VEN9R!D:7-C;&]S=7)EF5D(&]V97(@=&AE:7(@97-T:6UA=&5D('5S969U;"!L M:79E6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R<^/'4^/&9O;G0@6QE/3-$<&%D9&EN9SHP.SX-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#(V+C4E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#(V+C4E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3DF%T:6]N/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#,N,24[(%!!1$1)3D6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0Q/D%M;W)T:7IA=&EO;CPO9F]N=#X\+V(^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/ M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5& M5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/ M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5& M5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU" M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#(V+C4E.R!0041$24Y'+5))1TA4.B`P:6X[($)/4D1%4BU43U`Z(&UE9&EU M;2!N;VYE.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/ M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,C8E/@T*/'`@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$T+CDV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@ M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+CDV)3L@4$%$1$E.1RU2 M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5)) M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,24[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!! M1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#(V+C4E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]5 M3D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D-U6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$T+CDV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C@L-S,Y/"]F M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)' M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P M<'0[)R!S:7IE/3-$,CXR+#8X,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#,N,24[(%!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#(V+C4E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D-O=F5N86YT M6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$T+CDV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y' M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@ M6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T M+CDV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C4L,#DU/"]F;VYT M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4 M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT+#,P-3PO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#,N,24[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+CDV)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C M;VQO6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$T+CDV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!" M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@ M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S M:7IE/3-$,CXQ+#(S-#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#,N,24[(%!!1$1)3D6QE/3-$)T)/ M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5& M5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C0L,#8S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+CDV)3L@4$%$1$E.1RU224=( M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,30E/@T*/'`@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$T+CDV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@ M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#,N,24[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!" M3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E M>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$T+CDV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E M969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-% M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ.2PQ,S$\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W M:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I=6T@ M;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P:6X[ M(%=)1%1(.B`Q-"XY-B4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494 M.B`P:6X[(%=)1%1(.B`Q-"XY-B4[(%!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XW-6EN.R<^/'4^/&9O M;G0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\=&%B;&4@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N M,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!! M1$1)3D6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(V+C(V)3L@4$%$1$E. M1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,C8E/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q M/D%M;W)T:7IA=&EO;CPO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)U!!1$1)3D6QE/3-$)U1% M6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0Q/D%C8W5M=6QA=&5D/"]F;VYT/CPO8CX\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`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`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C M;VQO6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4] M,T0R/C0L-36QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1) M3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR M+#`S-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0 M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN M9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(V+C(V)3L@4$%$1$E.1RU224=(5#H@ M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$ M,C8E/@T*/'`@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT+#,P-3PO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$ M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C0L,C4W/"]F;VYT/CPO<#X\+W1D M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P M=#L@34%21TE..B`P:6X@,&EN(#!P="`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`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=( M5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4 M.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N M93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I M;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI M9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N M,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@ M4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#(V+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C M8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)U!!1$1)3D6QE M/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@ M0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=( M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I M=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU4 M3U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0[)R!S:7IE/3-$,CXQ-"PQ-S4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T M(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$ M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@ M4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!& M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXV+#,R,SPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P:6X[ M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X\+W1R/CPO=&%B;&4^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@ M,'!T(#`N-6EN.R<^)B,Q-C`[/"]P/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/E1H92!A M9V=R96=A=&4@:6YT86YG:6)L92!A;6]R=&EZ871I;VX@97AP96YS92!F;W(@ M=&AE('1H"UM;VYT:',@96YD960@07!R:6PF(S$V,#LS,"P@,C`Q M,R!A;F0@,C`Q,B!W87,@)#,V-R!A;F0@)#(Y.2P@F%T M:6]N(&5X<&5N65A6QE M/3-$)W1E>'0M86QI9VXZ;&5F=#M724142#H@-#`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`C8V-E969F.R!"3U)$15(M5$]0.B!M M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E. M1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1'1O<"!W M:61T:#TS1#8Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@ M34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#,P)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5)) M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(] M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,P)3X-"CQP('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT M-3(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP M.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I9'1H/3-$-C$E M/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$ M)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T M.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,P)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C M;VQO6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4] M,T0R/C@Y,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-24[ M(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4] M,T0R/C(P,38\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXX-S4\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#8Q+C(V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!" M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO M6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@ M34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI M9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,P)3L@4$%$1$E.1RU2 M24=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5)) M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#,P)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!& M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXV+#DP-CPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!! M1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE. M.B`P:6X@,&EN(#!P="`Q,'!T.R<^/&(^/'4^/&9O;G0@F4],T0R/E1O=&%L/"]F;VYT/CPO=3X\ M+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C$P+#DQ,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#(N-24[(%!!1$1)3D7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6%B;&4@ M+2!"86YK/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\6%B;&4@+2!"86YK/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M6%B;&4@+2!"86YK M/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@ M,'!T(#`N-6EN.R<^)B,Q-C`[/"]P/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/DEN($]C M=&]B97(F(S$V,#LR,#$Q+"!T:&4@0V]M<&%N>2!E;G1E&EM=6T@86UO=6YT M(&]F('1H92!C2P@=&\@96ET M:&5R('1H92!B86YK)B,X,C$W.W,@8F%S92!R871E(&]R('1H92!%=7)O9&]L M;&%R(')A=&4@;V8@:6YT97)E2!T:&4@0V]M<&%N>2XF(S$V,#L@3VX@07!R M:6PF(S$V,#LS,"P@,C`Q,RP@=&AE($-O;7!A;GD@:&%D(&5L96-T960@=&\@ M:&%V92!A;&P@;V8@=&AE('1O=&%L(&%D=F%N8V5S(&]U='-T86YD:6YG('1O M(&)E('-U8FIE8W0@=&\@=&AE(&)A;FLF(S@R,3<['!E;F1I='5R97,@86YD(&9I>&5D(&-H87)G92!C;W9E2!T:&4@0V]M<&%N>2X@07,@;V8@07!R:6PF(S$V,#LS,"P@,C`Q,RP@ M=&AE($-O;7!A;GD@=71I;&EZ960@)#DL,S3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F8F(Y-38U9E\P8S=A7S0Y8F%? M.64X,E]A9&-F8F$X-#,Y-S`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO9F)B.34V-69?,&,W85\T.6)A7SEE.#)?861C9F)A.#0S.3'0O:'1M;#L@ M8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$3I4:6UE6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE M/3-$,CY;.%T@/&(^3&]N9RU497)M($1E8G0@+2!"86YK/"]B/CPO9F]N=#X\ M+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N-6EN.R<^ M)B,Q-C`[/"]P/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DEN($1E8V5M8F5R)B,Q-C`[ M,C`Q,"P@=&AE($-O;7!A;GD@:7-S=65D(&$@65A6UE;G0@;V8@=&AE('!R:6YC M:7!A;"!A;F0@:6YT97)E2`D-"PS.3DN/"]F;VYT/CPO M<#X-"CPO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&5S M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\&5S/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V9O;G0M&5S M(&9O"!P"!B96YE9FET(&]F("0S+#`S-2Y4:&4@<')O=FES:6]N(&9O"!P"!A2!H860@82!C=7)R96YT(&1E9F5R"!A'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/&1I M=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CLG/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/ELQ,%T@72!/;B!$96-E M;6)E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@ M,"XU:6X[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P M:6X@,'!T.R<^/&9O;G0@F5D+"!I2!B92!F;W5N9"!I;B!T:&4@1F]R;28C,38P.S@M2R!W92!F M:6QE9"!O;B!*86YU87)Y)B,Q-C`[-"P@,C`Q,RX\+V9O;G0^/"]P/@T*/'`@ M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SX\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-) M6D4Z(#$P<'0[)R!S:7IE/3-$,CY4:&4@:6YI=&EA;"!A8V-O=6YT:6YG(&9O M2!I;G1E6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0T M+C,V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#0E/@T*/'`@6QE M/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ M('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO M;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R!" M3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^#0H\<"!S='EL93TS1"=415A4 M+4%,24=..B!C96YT97([($U!4D=)3CH@,&EN(#!I;B`P<'0[)R!A;&EG;CTS M1&-E;G1E6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/DU#3#PO M9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0Q/E1O=&%L6QE/3-$)U!!1$1)3D6QE M/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q M,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@ M34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C$L M,#`X/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P M:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ,S<\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0[)R!S:7IE/3-$,CXT.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$U+C`R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$ M24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T* M/'`@6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4] M,T0R/C$X-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C0E M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE M/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0T+C,V)3L@4$%$1$E. M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/ M4#H@,&EN.R<@8F=C;VQO6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/ M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C(R-3PO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y' M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU2 M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@ M,&EN.R<@8F=C;VQO6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR,C@\+V9O;G0^/"]P M/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P M="`Q,'!T.R<^/&9O;G0@6QE/3-$)U!!1$1) M3D6QE/3-$ M)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-) M6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T* M/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@ M,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@ M8F=C;VQO6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C4S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C`R)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C M;VQO6QE/3-$)T9/3E0M1D%- M24Q9.B!4:6UEF4] M,T0R/C4S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/D]T:&5R($YO;BU#=7)R96YT($%S6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@ M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,34E/@T*/'`@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R M,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#0T+C,V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!& M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXW-#<\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT M,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$ M24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C`R)3L@4$%$ M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y' M+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T* M/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0T+C,V M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$-#0E/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@ M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,34E/@T*/'`@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/B8C.#(Q,CL\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$ M,CXR/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#0T+C,V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[ M)R!S:7IE/3-$,CXY,S`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT+#$V-3PO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C0E.R!0041$24Y'+5))1TA4 M.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#0T+C,V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y' M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#0E/@T*/'`@ M6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@ M4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N M/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L.3`U/"]F;VYT/CPO<#X\ M+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@ M34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/ M54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C$Q.#PO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y' M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU2 M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@ M,&EN.R<@8F=C;VQO6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C@S/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DQO;F<@5&5R M;2!$96)T("A!=71O+4QO86YS*3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y' M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@ M6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R M/C(P,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C`\+V9O;G0^/"]P/CPO M=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0[)R!S:7IE/3-$,CXR,#`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M24Y$ M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@ M6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@ M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR-3`\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0[)R!S:7IE/3-$,CXQ+#(U,#PO9F]N=#X\+W`^/"]T9#X\+W1R/CPO M=&%B;&4^#0H\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z,3`N,'!T.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CM&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SX\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CLG('-I>F4],T0R/D]N($YO=F5M8F5R)B,Q-C`[,3$L(#(P M,3$L('1H92!#;VUP86YY(&%N;F]U;F-E9"!T:&%T(&ET2!R97!U7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0M6QE/3-$)W1E M>'0M86QI9VXZ;&5F=#M724142#H@.#8N-C8E.R!"3U)$15(M0T],3$%04T4Z M(&-O;&QA<'-E.R!-05)'24XM3$5&5#H@,"XU:6X[)R!B;W)D97(],T0P(&-E M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0X-B4^#0H- M"CQT6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#(N,R4[(%!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,R4[(%!!1$1) M3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0Q/E1H6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M M(&YO;F4[(%!!1$1)3D6QE/3-$<&%D M9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0S+C0V)3L@4$%$1$E.1RU224=( M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$-#,E/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$<&%D9&EN M9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0S+C0V)3L@4$%$1$E.1RU224=(5#H@ M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$-#,E/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/EM5;F%U9&ET961= M/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,38E.R!0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@ M,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@,7!T('-O;&ED.R!"3U)$15(M4DE' M2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,B4^#0H\<"!S='EL93TS1"=415A4+4%,24=..B!C M96YT97([($U!4D=)3CH@,&EN(#!I;B`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`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/ M54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52 M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$ M,CXX-C$L-3`V/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!! M1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L-C8P+#(Q M-CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,R4[(%!!1$1) M3D6QE/3-$)T)/4D1%4BU"3U143TTZ M(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1) M3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L-#0W+#8S.3PO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,38E.R!0041$24Y' M+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#0S+C0V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0 M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#,E M/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$Q+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y' M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3$E/@T*/'`@ M6QE M/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#(N,R4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$ M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@ M6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,R4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$Q+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$ M)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DUE9&EC87)E+TUE9&EC86ED(%!O6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C4V)3L@4$%$ M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,3$E/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C@V+#0S,SPO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N,R4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE M/3-$,CXQ-C@L,C8P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`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`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$Q+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E M969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-% M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ+#$R-RPT M.38\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$Q+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5)) M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(] M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXY M-S@L,C6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/E1O=&%L($-O;G1R86-T=6%L($%D:G5S=&UE;G1S(&%N9"!$:7-C M;W5N=',\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!" M3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@ M;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)' M24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P M<'0[)R!S:7IE/3-$,CXV-S`L-C0T/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[ M(%!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R M/C$L,CDU+#6QE/3-$ M)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L,3,T+#,S,CPO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$N,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!! M1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#0S+C0V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R M/C$V,RPS.#@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$Q+C4T)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2 M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X- M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE M/3-$,CXS-C0L-#8P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T M>6QE/3-$<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0S+C0V)3L@4$%$ M1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$-#,E/@T*/'`@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/DYE="!2979E M;G5E6QE/3-$)T)/4D1%4BU"3U14 M3TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$Q+C4V)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+ M1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2 M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G M8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X- M"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE M/3-$,CXQ-S8L-#4R/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$U,2PT-#,\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[ M($)/4D1%4BU,1494.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I M;CL@4$%$1$E.1RU,1494.B`P:6X[(%=)1%1(.B`Q,2XU-"4[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,BXR-7!T M(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Q+C4T)3L@ M4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!"3U)$ M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N M93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H M=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR.3`L,C,V/"]F;VYT/CPO M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I M;B`P:6X@,'!T.R<^/&9O;G0@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/BHJ(%)E<')E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/B@D*3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$ M)W!A9&1I;F#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^ M#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N,38E.R!0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5& M5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE M9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D'0@ M,7!T('-O;&ED.R!"3U)$15(M4DE'2%0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3DE/@T*/'`@ M6QE/3-$)W!A9&1I;F#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@ M,'!X.R<^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N,38E.R!0041$24Y' M+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)U!!1$1)3D6QE/3-$)W!A9&1I;F#L@4$%$1$E.1RU224=(5#H@,'!X.R!0 M041$24Y'+51/4#H@,'!X.R<^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#0N M,38E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)T)/4D1%4BU" M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0Q/C(P,3(\+V9O;G0^/"]B/CPO<#X\+W1D/@T* M/'1D('-T>6QE/3-$)U!!1$1)3D#L@4$%$1$E. M1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N M;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1% M4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO M;F4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Y+CDT)3L@4$%$1$E.1RU2 M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@ M,&EN.R<@8F=C;VQO6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,S-BPV-#(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR-C6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$Y+CDT)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$Y)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0[)R!S:7IE/3-$,CXU-BPV,S8\+V9O;G0^/"]P/CPO=&0^#0H\=&0@ M6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R M/C,Y,RPR-S@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C,Q.2PQ.34\+V9O;G0^/"]P/CPO=&0^#0H\=&0@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)V9O;G0M6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S='EL M93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N-S5I;CLG/CQU/CQF;VYT('-T M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D%P6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^#0H\=&%B;&4@#L@0D]21$52+4-/3$Q!4%-% M.B!C;VQL87!S93L@34%21TE.+4Q%1E0Z(#`N-S5I;CLG(&)O6QE/3-$)W!A9&1I;F#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$ M24Y'+51/4#H@,'!X.R<^#0H\=&0@6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0Q/E=E:6=H=&5D+3PO9F]N=#X\+V(^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q M/DYE="8C,38P.V]F/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$N,B4[(%!!1$1)3D#L@4$%$1$E.1RU,1494 M.B`P<'@[(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#LG M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4 M.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E M;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/D%C8W5M=6QA M=&5D/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,24[ M(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ M(&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4] M,T0Q/D%C8W5M=6QA=&5D/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$N,B4[(%!!1$1)3D#L@4$%$1$E.1RU, M1494.B`P<'@[(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P M>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5)) M1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)U1%6%0M04Q) M1TXZ(&-E;G1E6QE/3-$)U!!1$1)3DF%T:6]N/"]F;VYT/CPO8CX\+W`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`P<'@[ M(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE M.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU" M3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[ M(%!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I M=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+CDV)3L@ M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@ M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX] M,T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,B4[ M(%!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D-U6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#$T+CDV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!" M04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO M6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R M/C@L-S,Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4 M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR+#8X,#PO9F]N=#X\+W`^/"]T9#X- M"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q% M1E0Z(#!I;CL@5TE$5$@Z(#,N,24[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I M;F#L@ M4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R M/C4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R M:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXU+#`Y-3PO9F]N=#X\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,24[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+CDV)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,30E/@T*/'`@6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/E!A M=&5N=',@86YD($QI8V5N6QE M/3-$)U!!1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD M;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$T+CDV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E M969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-% M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXU+#(Y-SPO M9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,24[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ('=I M;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[ M(%!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C$L,C,T M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F#L@4$%$ M1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$T+CDV)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,30E/@T*/'`@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N M93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$T+CDV)3L@4$%$1$E. M1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52 M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$T)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H M=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,24[(%!!1$1) M3D6QE/3-$)T)/4D1%4BU" M3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M(&YO;F4[ M(%!!1$1)3D6QE M/3-$)U!!1$1)3D#L@4$%$1$E. M1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE. M.B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]- M.B!W:6YD;W=T97AT(#(N,C5P="!D;W5B;&4[($)/4D1%4BU,1494.B!M961I M=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!I;CL@4$%$1$E.1RU,1494.B`P M:6X[(%=)1%1(.B`Q-"XY-B4[(%!!1$1)3D6QE/3-$)U!!1$1) M3D6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C@L,C$Y/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$ M)U!!1$1)3D6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$P+#DQ,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$N,B4[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^#0H\<"!S='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T(#`N-S5I M;CLG/CQU/CQF;VYT('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]C=&]B97(F(S$V M,#LS,2PF(S$V,#LR,#$R/"]F;VYT/CPO=3X\+W`^#0H\<"!S='EL93TS1"=- M05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE M/3-$)W1E>'0M86QI9VXZ;&5F=#M415A4+4%,24=..B!L969T.R!724142#H@ M-S`T<'@[($)/4D1%4BU#3TQ,05!313H@8V]L;&%P#L@4$%$1$E.1RU,1494.B`P<'@[(%!! M1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3DF%T:6]N/"]F;VYT/CPO8CX\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!!1$1)3D6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)U!! M1$1)3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5&5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/DEN M=&%N9VEB;&4F(S$V,#M!6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E M6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0Q/E!E M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0Q/D-O6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$ M)T)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D M:75M(&YO;F4[(%!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52 M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I M=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$ M1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]2 M1$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R M:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0 M041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N M;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E. M1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE M/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52 M+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN M.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I M=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#XF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$ M24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0041$24Y'+5))1TA4.B`P M:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F#L@4$%$1$E.1RU2 M24=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@6QE/3-$)U1%6%0M24Y$ M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@ M6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C(P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1) M3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR M+#4S-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0 M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$ M1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y' M+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(L,#,V/"]F;VYT/CPO<#X\+W1D/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$ M,CXT+#,P-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E M.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C0L,C4W/"]F;VYT M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D#L@ M4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/E!A=&5N=',@86YD($QI8V5N6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5)) M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(] M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXU M+#(Y-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0 M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5)) M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(] M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ M+#`U.#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0 M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!W:6YD;W=T97AT(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$ M.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5)) M1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(] M,T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT M+#(S.3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/ M5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C8E.R!0 M041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P M<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I M;F#L@ M4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@ M6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN M(#!P="`Q,'!T.R<^)B,Q-C`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`C8V-E M969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-% M149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ-"PQ-S4\ M+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ('=I;F1O=W1E>'0@,BXR-7!T(&1O=6)L93L@0D]21$52+4Q%1E0Z(&UE M9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/ M54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52 M+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L M;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$U)3X-"CQP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$ M,CXV+#,R,SPO9F]N=#X\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/"]D:78^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$F%T:6]N(&5X<&5N6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^#0H\<"!S M='EL93TS1"=-05)'24XZ(#!I;B`P:6X@,'!T.R<^)B,Q-C`[/"]P/@T*/'1A M8FQE('-T>6QE/3-$)W1E>'0M86QI9VXZ;&5F=#M724142#H@-#`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`C8V-E969F.R!"3U)$ M15(M5$]0.B!M961I=6T@;F]N93L@0D]21$52+5))1TA4.B!M961I=6T@;F]N M93L@4$%$1$E.1RU43U`Z(#!I;CLG(&)G8V]L;W(],T0C0T-%149&('9A;&EG M;CTS1'1O<"!W:61T:#TS1#8Q)3X-"CQP('-T>6QE/3-$)U1%6%0M24Y$14Y4 M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@0D]21$52+4Q% M1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,P)3L@4$%$1$E.1RU224=(5#H@,&EN.R!" M04-+1U)/54Y$.B`C8V-E969F.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@ M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG M(&)G8V]L;W(],T0C0T-%149&('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,P M)3X-"CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I M;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S M:7IE/3-$,CXT-3(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN M(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$ M<&%D9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8Q+C(V)3L@4$%$1$E.1RU2 M24=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$=&]P('=I M9'1H/3-$-C$E/@T*/'`@6QE/3-$)U!! M1$1)3D6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN M(#!P="`Q,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,P)3L@4$%$1$E.1RU2 M24=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@ M,&EN.R<@8F=C;VQO6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C@Y,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#(N-24[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(P,38\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T M.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@ M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXX M-S4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$<&%D M9&EN9SHP.SX-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#8Q+C(V)3L@4$%$1$E.1RU224=( M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN M.R<@8F=C;VQO6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4 M.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^ M/"]T9#X-"CQT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B!W:6YD;W=T97AT M(#%P="!S;VQI9#L@0D]21$52+4Q%1E0Z(&UE9&EU;2!N;VYE.R!0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,P)3L@ M4$%$1$E.1RU224=(5#H@,&EN.R!"3U)$15(M5$]0.B!M961I=6T@;F]N93L@ M0D]21$52+5))1TA4.B!M961I=6T@;F]N93L@4$%$1$E.1RU43U`Z(#!I;CLG M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,P)3X-"CQP('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXV+#DP-CPO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#(N-24[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!! M1$1)3D6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!"3U)$15(M3$5&5#H@;65D:75M M(&YO;F4[(%!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P M=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&(^/'4^/&9O;G0@F4],T0R/E1O=&%L/"]F M;VYT/CPO=3X\+V(^/"]P/CPO=&0^#0H\=&0@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$P+#DQ,CPO9F]N=#X\+W`^/"]T9#X\+W1R/CPO M=&%B;&4^#0H\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$)V9O;G0M6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0@,"XU:6X[)SXF(S$V,#L\+W`^ M#0H\=&%B;&4@#L@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S M93L@34%21TE.+4Q%1E0Z(#`N-S5I;CLG(&)O6QE/3-$)W!A9&1I;F#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@ M,'!X.R<^#0H\=&0@6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF M(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@ M,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y' M+5))1TA4.B`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`@6QE/3-$ M)U1%6%0M04Q)1TXZ(&-E;G1E6QE/3-$)T)/ M4D1%4BU"3U143TTZ('=I;F1O=W1E>'0@,7!T('-O;&ED.R!"3U)$15(M3$5& M5#H@;65D:75M(&YO;F4[(%!!1$1)3D6QE/3-$)W!A9&1I;F#L@4$%$ M1$E.1RU224=(5#H@,'!X.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P M="`Q,'!T.R<^)B,Q-C`[/"]P/CPO=&0^#0H\=&0@#L@4$%$1$E.1RU43U`Z M(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9 M.B!4:6UEF4],T0R M/D%C8V]U;G1S(%)E8V5I=F%B;&4\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXQ+#`P.#PO9F]N M=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5)) M1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=( M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN M.R<@8F=C;VQO6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C(S,CPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E M9F8[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$U+C`R)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E M969F.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L,C0P/"]F;VYT/CPO M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@ M,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,34E/@T*/'`@6QE/3-$ M)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$S-SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/ M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C0X M/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V M,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN M.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=( M5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/4#H@,&EN M.R<@8F=C;VQO6QE/3-$)T9/ M3E0M1D%-24Q9.B!4:6UEF4],T0R/C(R-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[($)!0TM'4D]53D0Z("-C8V5E M9F8[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@ M,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F M.R!0041$24Y'+51/4#H@,&EN.R<@8F=C;VQO6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C,\+V9O;G0^/"]P/CPO=&0^ M#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@ M,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E, M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$ M,CXR,C@\+V9O;G0^/"]P/CPO=&0^#0H\=&0@#L@4$%$1$E.1RU,1494.B`P<'@[ M(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/D-O;7!U M=&5R($5Q=6EP;65N=#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0 M041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z M(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@ M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C(Q/"]F M;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\ M+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0 M041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C`R)3L@4$%$1$E.1RU224=( M5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,34E/@T*/'`@6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(Q/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T>6QE M/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!- M05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z M(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D/@T*/'1D M('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1) M3D#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE M/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D]T:&5R($YO;BU# M=7)R96YT($%S6QE/3-$)TU! M4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL M93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@ M5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@ M,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE MF4],T0R/C,\+V9O M;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4 M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXF(S@R,3([/"]F;VYT/CPO<#X\+W1D M/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X\+W1R/@T* M/'1R('-T>6QE/3-$)W!A9&1I;F#L@4$%$1$E.1RU224=(5#H@,'!X.R!0041$24Y' M+51/4#H@,'!X.R<^#0H\=&0@6QE/3-$)U1%6%0M24Y$14Y4.B`M,3!P=#L@34%2 M1TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX] M,T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXW.3`\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!! M1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/D1E<&]S:71S/"]F;VYT/CPO M<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0 M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E M/@T*/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C(\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR/"]F;VYT M/CPO<#X\+W1D/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE M/3-$,CXY,S`\+V9O;G0^/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\ M9F]N="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!& M3TY4+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXT+#$V-3PO9F]N=#X\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$N,C0E.R!0041$24Y'+5))1TA4.B`P:6X[ M($)!0TM'4D]53D0Z("-C8V5E9F8[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W!A9&1I;F#L@4$%$1$E.1RU224=(5#H@,'!X M.R!0041$24Y'+51/4#H@,'!X.R<^#0H\=&0@6QE/3-$)U1%6%0M24Y$ M14Y4.B`M,3!P=#L@34%21TE..B`P:6X@,&EN(#!P="`Q,'!T.R<^/&9O;G0@ M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ M(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[ M)R!S:7IE/3-$,CXQ+#DP-3PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$ M)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S M='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I M;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/ M4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/C8W M,SPO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$ M24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=)3CH@,&EN(#!I M;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U+C`R M)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN.R<@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C(L-36QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$ M)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XZ(#!I;B`P M:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0[)R!S:7IE M/3-$,CXR,#$\+V9O;G0^/"]P/CPO=&0^#0H\=&0@#L@4$%$1$E.1RU,1494.B`P M<'@[(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T* M/'1D('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T9/3E0M1D%-24Q9.B!4 M:6UEF4],T0R/DQO M;F<@5&5R;2!$96)T("A!=71O+4QO86YS*3PO9F]N=#X\+W`^/"]T9#X-"CQT M9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z M(#!I;CL@5TE$5$@Z(#,N,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1) M3D6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T M9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y' M+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0 M041$24Y'+51/4#H@,&EN.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E M/@T*/'`@6QE/3-$)T9/3E0M M1D%-24Q9.B!4:6UEF4],T0R/C(P,#PO9F]N=#X\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$ M24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#,N M,3(E.R!0041$24Y'+5))1TA4.B`P:6X[(%!!1$1)3D6QE/3-$)TU!4D=) M3CH@,&EN(#!I;B`P<'0[)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS M1"=0041$24Y'+4)/5%1/33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$ M5$@Z(#$U)3L@4$%$1$E.1RU224=(5#H@,&EN.R!0041$24Y'+51/4#H@,&EN M.R<@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,34E/@T*/'`@6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C`\+V9O;G0^ M/"]P/CPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!-05)'24XZ(#!I;B`P:6X@,'!T.R<@86QI9VX],T1R:6=H=#X\9F]N M="!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4 M+5-)6D4Z(#$P<'0[)R!S:7IE/3-$,CXR,#`\+V9O;G0^/"]P/CPO=&0^#0H\ M=&0@#L@4$%$1$E.1RU,1494.B`P<'@[(%!!1$1)3D#L@4$%$1$E.1RU43U`Z(#!P>#LG/@T*/'1D('-T>6QE/3-$)U!!1$1)3D6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/E-H;W)T(%1E6QE/3-$)TU!4D=)3CH@,&EN(#!I;B`P<'0[ M)SXF(S$V,#L\+W`^/"]T9#X-"CQT9"!S='EL93TS1"=0041$24Y'+4)/5%1/ M33H@,&EN.R!0041$24Y'+4Q%1E0Z(#!I;CL@5TE$5$@Z(#$U)3L@4$%$1$E. M1RU224=(5#H@,&EN.R!"04-+1U)/54Y$.B`C8V-E969F.R!0041$24Y'+51/ M4#H@,&EN.R<@8F=C;VQO6QE M/3-$)T9/3E0M1D%-24Q9.B!4:6UEF4],T0R/C$L,#`P/"]F;VYT/CPO<#X\+W1D/@T*/'1D('-T M>6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6]R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]F8F(Y-38U9E\P8S=A7S0Y8F%?.64X,E]A9&-F8F$X M-#,Y-S`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9F)B.34V-69? M,&,W85\T.6)A7SEE.#)?861C9F)A.#0S.3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F M8F(Y-38U9E\P8S=A7S0Y8F%?.64X,E]A9&-F8F$X-#,Y-S`-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9F)B.34V-69?,&,W85\T.6)A7SEE.#)? M861C9F)A.#0S.3'0O:'1M;#L@8VAA'0^-2!Y96%R M65A'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF%T:6]N/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PY,3(\F%T:6]N(&5X<&5N'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]F8F(Y-38U9E\P8S=A7S0Y8F%?.64X,E]A9&-F8F$X-#,Y-S`- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9F)B.34V-69?,&,W85\T M.6)A7SEE.#)?861C9F)A.#0S.3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6%B;&4@+2!B86YK/&)R/CPO M=&@^#0H@("`@("`@(#QT:"!C;&%S6%B;&4@+2!B86YK/&)R/D)A M;FLG6%B;&4@+2!B86YK/&)R/D)A;FLG6%B;&4@+2!B86YK/&)R/D5U6%B;&4@+2!B86YK M/&)R/D5U&EM=6T\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^8F%S92!R871E M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M175R;V1O;&QA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^-R!Y96%R2!I;G-T86QL;65N="!I;F-L=61I;F<@ M<')I;F-I<&%L(&%N9"!I;G1E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]F8F(Y-38U9E\P8S=A7S0Y8F%?.64X,E]A9&-F8F$X-#,Y-S`-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9F)B.34V-69?,&,W85\T.6)A M7SEE.#)?861C9F)A.#0S.3'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&-E<'0@4VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'1087)T7V9B8CDU-C5F7S!C-V%?-#EB85\Y93@R7V%D8V9B83@T (,SDW,"TM#0H` ` end XML 27 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 56 166 1 false 19 0 false 5 false false R1.htm 0000 - Document - Document and Entity Information Sheet http://www.bioreference.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 0010 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.bioreference.com/role/BalanceSheet CONSOLIDATED BALANCE SHEETS false false R3.htm 0015 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.bioreference.com/role/BalanceSheetParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 0020 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.bioreference.com/role/StatementOfIncome CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 0030 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.bioreference.com/role/CashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS false false R6.htm 1010 - Disclosure - Basis of Presentation Sheet http://www.bioreference.com/role/DisclosureBasisOfPresentation Basis of Presentation false false R7.htm 1020 - Disclosure - Fair Value Measurements Sheet http://www.bioreference.com/role/DisclosureFairValueMeasurements Fair Value Measurements false false R8.htm 1030 - Disclosure - Recent Accounting Pronouncements Sheet http://www.bioreference.com/role/DisclosureRecentAccountingPronouncements Recent Accounting Pronouncements false false R9.htm 1040 - Disclosure - Accounting for Revenues Sheet http://www.bioreference.com/role/DisclosureAccountingForRevenues Accounting for Revenues false false R10.htm 1050 - Disclosure - Accounting for Accounts Receivable Sheet http://www.bioreference.com/role/DisclosureAccountingForAccountsReceivable Accounting for Accounts Receivable false false R11.htm 1060 - Disclosure - Intangible Assets Sheet http://www.bioreference.com/role/DisclosureIntangibleAssets Intangible Assets false false R12.htm 1070 - Disclosure - Revolving Note Payable - Bank Sheet http://www.bioreference.com/role/DisclosureRevolvingNotePayableBank Revolving Note Payable - Bank false false R13.htm 1080 - Disclosure - Long-Term Debt - Bank Sheet http://www.bioreference.com/role/DisclosureLongTermDebtBank Long-Term Debt - Bank false false R14.htm 1090 - Disclosure - Provision for Income Taxes Sheet http://www.bioreference.com/role/DisclosureProvisionForIncomeTaxes Provision for Income Taxes false false R15.htm 1100 - Disclosure - Acquisitions Sheet http://www.bioreference.com/role/DisclosureAcquisitions Acquisitions false false R16.htm 1110 - Disclosure - Common Stock Repurchase Sheet http://www.bioreference.com/role/DisclosureCommonStockRepurchase Common Stock Repurchase false false R17.htm 3040 - Disclosure - Accounting for Revenues (Tables) Sheet http://www.bioreference.com/role/DisclosureAccountingForRevenuesTables Accounting for Revenues (Tables) false false R18.htm 3050 - Disclosure - Accounting for Accounts Receivable (Tables) Sheet http://www.bioreference.com/role/DisclosureAccountingForAccountsReceivableTables Accounting for Accounts Receivable (Tables) false false R19.htm 3060 - Disclosure - Intangible Assets (Tables) Sheet http://www.bioreference.com/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) false false R20.htm 3100 - Disclosure - Acquisitions (Tables) Sheet http://www.bioreference.com/role/DisclosureAcquisitionsTables Acquisitions (Tables) false false R21.htm 4040 - Disclosure - Accounting for Revenues (Details) Sheet http://www.bioreference.com/role/DisclosureAccountingForRevenuesDetails Accounting for Revenues (Details) false false R22.htm 4050 - Disclosure - Accounting for Accounts Receivable (Details) Sheet http://www.bioreference.com/role/DisclosureAccountingForAccountsReceivableDetails Accounting for Accounts Receivable (Details) false false R23.htm 4060 - Disclosure - Intangible Assets (Details) Sheet http://www.bioreference.com/role/DisclosureIntangibleAssetsDetails Intangible Assets (Details) false false R24.htm 4070 - Disclosure - Revolving Note Payable - Bank (Details) Sheet http://www.bioreference.com/role/DisclosureRevolvingNotePayableBankDetails Revolving Note Payable - Bank (Details) false false R25.htm 4080 - Disclosure - Long-Term Debt - Bank (Details) Sheet http://www.bioreference.com/role/DisclosureLongTermDebtBankDetails Long-Term Debt - Bank (Details) false false R26.htm 4090 - Disclosure - Provision for Income Taxes (Details) Sheet http://www.bioreference.com/role/DisclosureProvisionForIncomeTaxesDetails Provision for Income Taxes (Details) false false R27.htm 4100 - Disclosure - Acquisitions (Details) Sheet http://www.bioreference.com/role/DisclosureAcquisitionsDetails Acquisitions (Details) false false R28.htm 4110 - Disclosure - Common Stock Repurchase (Details) Sheet http://www.bioreference.com/role/DisclosureCommonStockRepurchaseDetails Common Stock Repurchase (Details) false false All Reports Book All Reports Process Flow-Through: 0010 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Apr. 30, 2012' Process Flow-Through: Removing column 'Oct. 31, 2011' Process Flow-Through: 0015 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 0020 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 0030 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS brli-20130430.xml brli-20130430.xsd brli-20130430_cal.xml brli-20130430_def.xml brli-20130430_lab.xml brli-20130430_pre.xml true true XML 28 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)
Apr. 30, 2013
Oct. 31, 2012
Preferred Stock, Par Value (in dollars per share) $ 0.10 $ 0.10
Preferred Stock, Authorized shares, including Series A Junior Preferred Stock 1,666,667 1,666,667
Preferred Stock, Issued shares 0 0
Common Stock, Par Value (in dollars per share) $ 0.01 $ 0.01
Common Stock, Authorized shares 35,000,000 35,000,000
Common Stock, Issued shares 27,651,813 27,707,382
Common Stock, Outstanding shares 27,651,813 27,707,382
Series A Junior Preferred Stock
   
Preferred Stock, Authorized shares 3,000 3,000
XML 29 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Provision for Income Taxes
6 Months Ended
Apr. 30, 2013
Provision for Income Taxes  
Provision for Income Taxes
[9] The provision for income taxes for the three months ended April 30, 2013 consists of a current tax provision of $12,114 and a deferred tax benefit of $3,257. The provision for income taxes for the six-months ended April 30, 2013 consists of a current tax provision of $18,601 and a deferred tax benefit of $3,035.The provision for income taxes for the three months ended April 30, 2012 consists of a current tax provision of $8,398 and a deferred tax benefit of $1,302.  The provision for income taxes for the six-months ended April 30, 2012 consists of a current tax provision of $14,940 and a deferred tax benefit of $2,243.  On April 30, 2013, the Company had a current deferred tax asset of $27,446 and a long-term deferred tax asset of $2,780 included in other assets.  On April 30, 2012, the Company had a current deferred tax asset of $23,438 included in other current assets and a long-term deferred tax asset of $2,357 included in other assets.
XML 30 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
6 Months Ended
Apr. 30, 2013
Apr. 30, 2012
OPERATING ACTIVITIES:    
Net Income $ 20,003 $ 16,671
Adjustments to Reconcile Net Income to Cash Provided by (Used for) Operating Activities:    
Depreciation and Amortization 9,208 7,997
Deferred Income Tax (Benefit) Expense (3,036) (2,243)
Stock Based Compensation 290 290
(Gain) Loss on Disposal of Fixed Assets 125 343
Undistributed Equity Method (Income) Loss 225 0
Change in Assets and Liabilities, (Increase) Decrease in:    
Accounts Receivable (28,554) (2,773)
Provision for Doubtful Accounts 5,363 3,371
Inventory 434 (836)
Other Current Assets 150 (459)
Other Assets (249) (250)
Deposits (45) (60)
Increase (Decrease) in:    
Accounts Payable and Accrued Liabilities 8,918 1,599
NET CASH - OPERATING ACTIVITIES 12,832 23,650
INVESTING ACTIVITIES:    
Acquisition of Equipment and Leasehold Improvements (10,585) (9,667)
Business Acquisitions and Related Costs (6,837) (4,375)
NET CASH - INVESTING ACTIVITIES (17,422) (14,042)
FINANCING ACTIVITIES:    
Payments of Long-Term Debt (228) (631)
Payments of Capital Lease Obligations (2,223) (1,666)
Increase (Decrease) in Revolving Line of Credit 9,377 (4,469)
Common Stock Repurchase (2,030) (5,193)
Proceeds from Exercise of Options 89 64
NET CASH - FINANCING ACTIVITIES 4,985 (11,895)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 395 (2,287)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIODS 25,143 22,013
CASH AND CASH EQUIVALENTS AT END OF PERIODS 25,538 19,726
Cash paid during the period for:    
Interest 656 761
Income Taxes 16,339 20,340
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:    
Capital Leases 3,076 4,896
Write-off of property and equipment 2,501 1,478
Stock-based compensation expense $ 290 $ 290
XML 31 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Apr. 30, 2013
Oct. 31, 2012
CURRENT ASSETS:    
Cash and Cash Equivalents $ 25,538 $ 25,143
Accounts Receivable - Net 176,438 153,247
Inventory 14,468 14,902
Other Current Assets 5,223 5,373
Deferred Tax Assets 27,446 24,912
TOTAL CURRENT ASSETS 249,113 223,577
PROPERTY AND EQUIPMENT - AT COST 113,861 102,701
LESS: Accumulated Depreciation (58,727) (52,261)
PROPERTY AND EQUIPMENT - NET 55,134 50,440
OTHER ASSETS:    
Investments in Unconsolidated Affiliate 5,352 4,977
Deposits 1,001 956
Goodwill - Net 25,986 23,408
Intangible Assets - Net 10,912 6,323
Other Assets 1,115 866
Deferred Tax Asset 2,780 2,278
TOTAL OTHER ASSETS 47,146 38,808
TOTAL ASSETS 351,393 312,825
CURRENT LIABILITIES:    
Accounts Payable 46,746 41,288
Accrued Salaries and Commissions Payable 15,933 16,490
Accrued Taxes and Expenses 13,770 9,753
Other Short Term Acquisition Payable 1,296 0
Revolving Note Payable - Bank 9,377 0
Current Maturities of Long-Term Debt 479 464
Capital Lease Obligations - Short-Term Portion 4,424 3,957
TOTAL CURRENT LIABILITIES 92,025 71,952
LONG-TERM LIABILITIES    
Capital Lease Obligations - Long-Term Portion 9,849 9,463
Long - Term Debt - Net of Current Portion 3,920 4,163
TOTAL LONG-TERM LIABILITIES 13,769 13,626
SHAREHOLDERS' EQUITY    
Common Stock, $.01 Par Value; Authorized 35,000,000 shares: Issued and Outstanding 27,651,813 and 27,707,382 at April 30, 2013 and at October 31, 2012, respectively 277 277
Additional Paid-In Capital 39,256 40,907
Retained Earnings 206,066 186,063
TOTAL SHAREHOLDERS' EQUITY 245,599 227,247
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 351,393 312,825
Series A Junior Preferred Stock
   
SHAREHOLDERS' EQUITY    
Preferred Stock $.10 Par Value; Authorized 1,666,667 shares, including 3,000 shares of Series A Junior Preferred Stock None Issued $ 0 $ 0
XML 32 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6
Intangible Assets (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended 6 Months Ended 12 Months Ended 6 Months Ended 12 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2013
Apr. 30, 2012
Apr. 30, 2013
Apr. 30, 2012
Oct. 31, 2012
Apr. 30, 2013
Customer lists
Oct. 31, 2012
Customer lists
Apr. 30, 2013
Covenants Not-to-Compete
Oct. 31, 2012
Covenants Not-to-Compete
Apr. 30, 2013
Patents and Licenses
Oct. 31, 2012
Patents and Licenses
Intangible assets                      
Weighted-Average Amortization Period           20 years 20 years 5 years 5 years 17 years 17 years
Cost $ 19,131   $ 19,131   $ 14,175 $ 8,739 $ 4,573 $ 5,095 $ 4,305 $ 5,297 $ 5,297
Accumulated Amortization 8,219   8,219   7,852 2,680 2,537 4,305 4,257 1,234 1,058
Net of Accumulated Amortization 10,912   10,912   6,323 6,059 2,036 790 48 4,063 4,239
Estimated residual value 0   0   0 0 0 0 0 0 0
Amortization expenses 227 156 367 299              
Estimated amortization expense related to intangible assets                      
2013 452   452                
2014 917   917                
2015 892   892                
2016 875   875                
2017 870   870                
Thereafter 6,906   6,906                
Total $ 10,912   $ 10,912                
XML 33 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Long-Term Debt - Bank
6 Months Ended
Apr. 30, 2013
Long-Term Debt - Bank  
Long-Term Debt - Bank

[8] Long-Term Debt - Bank

 

In December 2010, the Company issued a seven-year term note for $5,408 at the rate of interest of 6.12% per annum for the financing of new equipment.  The note is payable in 84 equal monthly installments commencing on January 29, 2011 of $61 including principal and interest followed by a balloon payment of the principal and interest outstanding on the loan repayment date of  December 29, 2017.  The balance on this note as of April 30, 2013 is approximately $4,399.

XML 34 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Common Stock Repurchase
6 Months Ended
Apr. 30, 2013
Common Stock Repurchase  
Common Stock Repurchase

[11] Common Stock Repurchase

 

On November 11, 2011, the Company announced that its board of directors approved a Stock Repurchase Program authorizing the repurchase of up to 1,000,000 shares of its Common Stock at prevailing market prices over the period ending October 31, 2012.  That period was subsequently extended to the period ending October 31, 2013.  During the six-month period ended April 30, 2013, the Company repurchased 81,600 shares of its common stock at a cost of $2,030.  These repurchased shares have been recorded as canceled.

XML 35 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Revolving Note Payable - Bank
6 Months Ended
Apr. 30, 2013
Revolving Note Payable - Bank  
Revolving Note Payable - Bank

[7] Revolving Note Payable - Bank

 

In October 2011, the Company entered into an amended revolving note payable loan agreement with PNC Bank, N.A.  The maximum amount of the credit line available to the Company pursuant to the loan agreement is the lesser of (i) $45,000 or (ii) 50% of the Company’s qualified accounts receivable, as defined in the agreement.  The amendment to the Loan and Security Agreement provides for an interest rate on advances to be subject, at the election of the Company, to either the bank’s base rate or the Eurodollar rate of interest plus, in certain instances, an additional interest percentage.  The additional interest percentage charge on bank’s base rate borrowings and on Eurodollar rate borrowings ranges from 1% to 4% and is determined based upon certain financial ratios achieved by the Company.  On April 30, 2013, the Company had elected to have all of the total advances outstanding to be subject to the bank’s base rate of interest of 3.5%.  The credit line is collateralized by substantially all of the Company’s assets. The line of credit is available through October 2016 and may be extended for annual periods by mutual consent thereafter.  The terms of this agreement contain, among other provisions, requirements for maintaining defined levels of capital expenditures and fixed charge coverage, and the prohibition of the payment of cash dividends by the Company. As of April 30, 2013, the Company utilized $9,377 of the available credit under this revolving note payable loan agreement.

XML 36 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measurements
6 Months Ended
Apr. 30, 2013
Fair Value Measurements  
Fair Value Measurements

[2] Fair Value Measurements.

 

As of April 30, 2013, the Company’s financial instruments primarily consist of cash, short-term trade receivables and payables for which their carrying amounts approximate fair values, and long term debt, for which based on the borrowing rates currently available to the Company for bank loans with similar terms and average maturities, its carrying amount approximates its fair value.

 

The Company has evaluated subsequent events through the date the financial statements are issued as evidenced by the date of filing of this report with the Securities and Exchange Commission. No such reportable events have occurred.

XML 37 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 38 0001104659-13-047737-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-13-047737-xbrl.zip M4$L#!!0````(`/J#QT(QWND%\V4``&C=!@`1`!P`8G)L:2TR,#$S,#0S,"YX M;6Q55`D``S=#LE$W0[)1=7@+``$$)0X```0Y`0``[%U[<]LVMO]_9_8[X+JW MG:0CR:(DOY/NR*_44SMV;6?;O3N=#$1"$A*24`'2CWSZ>PX`4I0L.U8B62]T MTD02\3@XYW>>`,DW_[J+0G+#I.(B?KOF5:IKA,6^"'C<>;N6JC)5/N=K__KE MG_]X\S_E,CF0C"8L(*U[Y:,N2[^#VNK]_>WE;P MEXJ0G?5:M5I?YS$,%?MLS;9_T+S%A61M)F%!K.*+"+IY]6JC7LUZA#S^_,0$ M>+E%53Y!P/KCZY:*^96.N%F'"SAVK5SURG5OK4!_,-3#CKVY;B[F3=4@Y;?U MK*6W_N?9Z97?91$M#R^8*]&H>5M/LB&N M3__6!>F]74.QEC/)5>Y4L$;6S4`&,;X`5-TEA`=OUPZQW>^U_UP?FKGR1BQ. M>')O?\M_Y0'^WN9,$DT/&Z`_D^[!R6]KOU3AOZV=VF;#>[,^W#F;:GW$7':F M'I-&.K$XR+K4R]5&N5[M3QP4.F2_%J;. M?K(L>XJ+M07EHC<^%VO3XR)@0!7)?63E(;@S0-PS(=<^2*-$W7&HA:3,V!WGXNL$\&U_&=[(0`R[GHA M]WEB:"0!AW8F:+'.:_??-$QU&)*O5C7CX)(I)F^8N@8'T[SC:NT7/=%8''FS M/I*(/O'KHZ@?'T/&P2?6&U3!#><$,XU"H,4U`.-,X=Z9QNM)?-.,X)6[HL/OC0:H2$3%YRM6B M0_^8QSQAI_R&!2T`TYS MHNG8Q_[3$. M.'C8$JWS,'/B8>:K\FS!X=S,/+J9N82*\S5SY6OF!R,G+I&9K9MYJ8*V2N#.Y,_:Y+],/C MCME'/*8^#X'(Q1;XX%H&%?G)!2^/?`M9^"%K)2LTF%A+"P\APA-_=/\+UB=YPIJQ8L'SX+V42I%(,*0RF4$]Z1P-L=(SDO,?+*(CS'W/B/Z:IIB^21=^E.!5Q)X&EH$@?WO0Q#95)N6]IU0IV!;L]7%711GC`P<.)FBG&9=GIU[^-Q*"0/Z$$( M69I/PU/:PL?\"'E_$ON+K2?[J>(Q4ZKI_YURQ?5-D?U@Y^OKGLT9J]K4SEAI MB=?@;^@?$P4G4D^)F&0YK M3=LBC$/+A10@Q.3^(@3I-N/@"$CJX,5]&.J>:&?#RI9<)4(__-BB_^M3QN=MO:1!H3ZQZMEH[31O&W$BGKV(I[M_='6^:'4;X,=FN5J?!C^\ M1>.%-TWU'R-\;*:)B$2+AXM>_5W8`/*!!)8MA!P#C0KRG@/J;('ZA$R6$JGC[:6M2@@Z MP=VUY8]%I[K/-R8^5R(8701TSDDT.D_87+6P=$8P79+X=)Z0NW*!ZB)!=PXC MUFEAM[8\\>?"A7I3OL%FR:J)"UK!F[:0E\^/+(')GN;Q!1UN>`NYY8=_)L&3 M%`"B&?+A:O@ME1&C*I7L%_ORTUUHD0V472H.CB.-'/FJ2R53CPQN\:*;?-/H M%]#RR;%[\/&;1CY)6/3(R/H+7O^F@8&1%TQJM@R-'_`;0,JPY+'C^S1B.L8; MM@//EE,1&Z-'+$QWR&(1\?CI";\FN^$9'PZ:72VL^R'W,KMT+CLTYE^T33H` MLR1"'I@7,<7!!9``JJ2_GK?![-'8YS3,#WKH%VZ%`DF[!@W8#X7_6@[VUH5E;\"]OUJI5J+]G3/[1IQ,/[W6LP MOXJ\9[?D4D0TWEO[J9/L_?,?.$0O&^"L>?GNY/TNJ?+8_`]CZ';8"@?+&AZ? MO[\N'S?/3D[_LTN&1R;ZZM7)_QWM$D\/09"HMVLU/=9_O;_(/E5<$=$F1<;@ M).LX2S;C>N]Y-))J98/;%?U$H][>#]YF=:P1)K_*ZRXCU,>TF,;W/.Z0-*9I MP/%-V7X.#OC2SK``DV9@(%UZPTB+L9CT).L!?@,"=.)P,L!7=9%;GG3U]Q3L M,PS>DQP&Z4&(2SKZC=QA>(_762\Q?1,@YT.LI]>@T\QO@H9!@D;P%=W8@.M; M?WWM5$DBR+&049^?7K7\.S8M85O)VD*R$@D$B068C=@/TP!6'(;P&2Y%YD7A M.');B"3&.]%(S'Q(&JF\A]\D0=Z$+(%.EB^C6%$AOXI;=L-D*5N%Z$'0`$,# M_?@51$$[NFWVRX'A>4D30X-/$"X8K@Y.3TF;R&/FDX("?+@(S7B@VL0;\0G4=Y/Y"H9EM&$>@G=`Q`%@G$0DA&UM)2FL)2 M[AF5%7*9O>F<@`)%%'@.@D*BS_U$0*S3EU?=*Q&,(LCS<0<3[W-1[L^1I^Z< MJ5)_Z)/8KVBC1'ELULRA=S..4QCODD&.#]*('^+G-[T>I!870UB,''N4\,K2 M&82O2P!Q9I1%*QG(5G5%&@:`,L`$U;R&43ZEL5938PB0H<\7C`SYM&=W\5'6Z`"1EQAI)_IK%5),^HV!`%[ST)+A5SQ3@QA MJ0_AXX"Y$QC=ZQ7@VPN!J-9]<2*M8)!%X`J!6*`";X4EM4Q71M&C%_D3,Q'3&UBZ5 MS6@:-PW>/2QH9%5K9+WT*)3[:L_SAWDHC!$BXVK01G"E':9/5;>$-D8F9;RE MG"02?8H$Q\1O\.$?1K=[]-Y\09-QV^6^M@`@`9]*J<,;&NDWAA+:ZTEQ!S.! MOFD'>X,R4B4]3"B@I9XF8*VD5!BM115HL3#F`GR.%+?:T>I0!RZP,(N6'AVH]\>"Z)0:4NQOU.,JR#\0LDF72G2CC']Z%Z&0J6B MAY$8G:@4AM%C8G7![QMIW1FP!^X$>:Z#+@AFI#&Z8[B7"IAU(!3@8_IJ8%AJ M=6@F?`V=8%R;_:15'33`P.IF[I@NI(CAHV_X``;^0).L3N)BFRQ4?V"GZ\MF MI^M_D0,F,4I$ZP,JJB.-S%3THVI>\^I#_LW;>PVH*@RLZUE;N^17 M1D-`Y@&"^PBK8@C,5]>0COAD9Z/QFN0FN+8WD-9J]/:!I+->N(`+NF+RAD.8 M?8F@32&=`@#=R(G];LVZ0O:\Y6ZBQSQG+1U(,61>` MTT>6Y)J6\;<-1%*3:)2L=DMEV:[53&5,U.KZ=\HQ,\VB2,O\89EH6>3)%71, MC0`"KL-0@P**)AE2)'19,(J?9*[@:?=6R+&6RBPW06[6UA88)C"%GAC'T#13 M\+XB9.@$,WFBG:=@A9E-G8E('R;)^%L^DO[!I,98-Z#:R6ML&9TWA5Z5#9+E MR'V+#UH>`5XU9G7!1-*6?@Q:$4I-G1'9O#C'DG4)VK[T22QI`@L*_AY2`:MC MJJ#II6*;=U(HA0K8YIJ7(]J;*L#@T.],N45?:@81CR&PDB:-/[KKZ9=]%$>X MUYU6&$SQ5P1ZC%]?TH(4FH]#HB,H8AE(H!*(KN@/$\#`$ MCB+S-7,5C=BP^@Z('CAN4&'5GA(48`$4A:DSXY6QH3BQAAA'--]:$!A4X!!% M62%&'0 MR':!&C2ZZ&]<-(6%V3LY6\M&;24RS)4P/DPF9(QP? MYP;Y*3AI\PG")FUY=2`GLRP_E3HHU.Q%,VEIQA+XL)TV<.SJX!`')LSZJ3U; M4/\DI.5"#G([KD[AGE\A+L;8^Y>G)P-!-LZLJ=1,QL`4DO/;S9B,CDX/.:F-18!$,E$=2=EF%J\.;%^B4T%*8T:WQ&51Y0W!& M'*Z)XL!MIG-4B@+H5P#)JTRNO2Y8*!!?##1WA>KQA(8VT/?UP3GUVM9&).-1 M*Y6*$60BX!K,4Q+>[V40,QX-I^%=B*T$4=&UZT8NRS0J9K MA&I[/=S5+-H8Q*RZ`BP(N`D"+2$/98A*9*"7*U"&645"_MFL<4!C*;#`C*=& MC(B;(/?`DS8`4LM4Q.!MM%9)UL%F^HQ'PO6!BD#Z\CM_X"K@6;@!;CJHG)E13"*S.%FDZ[+ M.UU=L\/=LCNDPVH;T'49'N&MW%1MI MZN3.%F2,L"(&EC(P$R6@[@'XRS^T$>;@!S!8`]_LI_88CB$0,I&JOIR+E(R2B/4WX'\P?001 M`+P2\,[:UW+M'0T3M4/#.C!Z0"W\/9-S:00"YXO)0(Y1`JXJ=2]F=&GM='?UZ7FZ#\]+1Y<06!)UH'VE,L(Z1\>G1\O9O%P[B/`-A[NU:% MA(M!E-:C6/?*O_=H$&3?;WF0=-^N;6_^:-,H2YW,2+.-=ZO%/"L)LLL7SR3[T5*%/]D5->J5!JXH:W%Y\N[7ZZ%>U^<7YIA/23"!-=4J]>]>46WD@B:-O"?6;"&6+1F\42!N M]:E,#Q(MO7F;X]"P(-*/6X;0(V;]E3Z391OU2G7[$:;9233/!N:P%VS;D=-_ MG=$;`!U4']`)N+@U<:[#0*WORBFW863S_8\CL]*6"(,\R_3T-*_^]_5#V]4: MM&*3`[A7\;Y?9[V71KCY*`OK=S9MI6W:*&/R_::LME%IS,22U3:*EJR^H);L MNBL9Z\OU#&-VU?]^A(>SOL?4O0P&'M66(@2>]*G?B8554;7Z5<=.&BBQ6(+B87)ZR:^7EXKO,%SUQ*ML/`:#Z=HV;PJZ M]3+V#,]#NUJW4Z0'BO2<:'B*'%]HC:JY&'@9X.W\A/,3SD\X/[$4?L*ED-^< M0NXW#WY[=WG^X?WA+OG!]QEKMT MO8>9R_I&KU%\M+>`?1="1]Q%9N[)';I+7CU$Z(O%+Q-G^VCK/*G\_D4\W),I M[BA^32B>>3:/GV&/)=X%\14+H=M,'.+;FUYIH[KI,#UWF'XTBG"8_@JFMS;K MI>W:B-C<8=IA>D$Q[94V-ZNEFN_ M%=9SD>]]]Y;A-R1R"[J7.*/-T:?2H(G6CL:T%DZ*DW(G3HI.BDZ*3HK37?3T M:N(+'0"M1L'[H/"LF.;0DVL.LR?7[+H4=`8QW.2SE,4R3*N,B;$*#`X3#A,. M$PX3#A.N^+>XQ;\)!K79$VS7\P?87I@G.BXP31,OV9JE1G^7> M\0)#8QZK)9.$AE>J>]L.&@X:#S)VI=NE M+]TVPY"8IL9OU\S1F9Q@WMZJES4;#P7&>W/D*P[%:+37J&PZ. M#H[S`$>O5-O9*&UMS#(KMW?E]JXF_K;V[`D[T%._ M(W3>KC\[@M%2]5-^>Y4DZ!VX'[BF!N[[9 M*#5F>A30@=N!>UK@]L!R5Z=_*L'M;*WRSM8%33@D>L-/7B474MQPQ45,VD*2 M?0I9(&LEZN=9GF]::?A=K<<&N<"C;7- MTM;&+`]K.S0Z-/;16"]5MZ:/1K>OMY^$`_B2`KQ>WRIM5:?_A`(' M<`?PV61[.]52K3[]<[5+L6UE/E+`[_>._^R^$Q3USV3TDS#,F4')_,0^%(/X M(E9<)0I/&M(P$BHA#-%'NFD<2!:0`*[R&#KT=(<2@2]ABADR](TB)GU.0])E M-$RZ<$VEDDES.)$&$8^AMZ0)SD05N65`%?S;DZ+-%.YAT3"\)RT>AC`3]\5A^%CF+4K5(\G-(2/?@C#^F8.H9<8F"4-C5-Y!.E?%PBI5C80 MAW,ETI\AB^Y)IO3A3U@VH1$N$P67;0*2H[L>BQ6#RS0A7(%%NR62_9URE&0B M2(L1.P3R"5A(`A:D?J)W$Z6(0,AFTU'934=I-QU?Q>8PJE\XC`JR$[JE4*85A8,KFU0?R7E3Z;*Q5/:^\M5S"^:/+8A)#ZU:J>`S01N8# M)AF_`4:W[LG^Y>E):9BK()\17!TZXINSE5#)B$]#/PUI8D:5*#S4Q(Y^1^># MX:$)`H6!!D>ZSTCQ58`117\MUIIT`FF3GH.>EEVFX,!AM]H&7:YJXL>43)J?>O M/VN1DBS'CNO$NME>#P%B6Z(6%S]^ZR)R,3"@L8>`-F02KHSF<(D/5^*]`5P( M4J[&6LD;\!D#'H#.;SQ0R'64SX'[4#(?VH+'PBWQE?)^HQM-[=?.?65L-!-P M/6:@`8T*-"Q23[F-41OQD`=`G?C0,?QKA.PK/DQX<'M,;DHY#`A/`*O#UV`N M7:1`4)MBS[BQTYIE.(E0?_[$@V]'&=S!?,..#R5P':(*0>./I(+L!EN]6$TI MT-S6J?-R-80SMC2F;`&#RF&.Z]D)S_87.#`@@&0SGCX/P`%3C6.[B,X0_F`2 MXZ!%@!@$AHLB0%OA'5>4$:[&7=E,+6SR7<-XRSPVX4@'(`7.NH7@=TG?MW4I MHY_M.L''#+DKX!%R387:/H@94D4`1KUA7!E>-!M"1Z%?8+/GO@0#K)3J\HF0 M@&GD!?@8\$D4?T**$3B3=7/@12@#+9U(&7SC;BH`GR"L.])Z50PU'BOTCI7` M(9@.H3R#E."2\K7PC9@-P;QPS9`HB_8'0&LN&_K*V1#0,_@!!B#PXP8<]&SD ME`7X08GF\3$Z%WAQ`S@-)JIR:A3UH$P>"\&709GBWOG!$L<'.@%.$'A+WM*, M>P.$`W,4X>'ID4$E<$V'&4UMN8V-_#G`R51W7?NS.?P<*V=%?6"F)3B_`N1% MHSKB3L`9\IRW`H^BDE1+*$=2Z-?<5#DSDC$&`0#(>N#V_C.#[G\ M'+`1O_)&RAO^N&+?+4T88@3!&IMTGND1_!9^Y.-?G]V`R]+ZL_GWYYMGKU$Z M$"ZA,^S`!7+4I6TUD+'4%V,V$^[R\CZ]/2Y4R9$X_]WY8KQ1#F&XG.-4<;5C M`#9KCOY_;$>0O>#;Q#3C*`/YJ>F>S*QERI3H;",_X;R"R%\LQ"A"=A`:0?^" M<0(*^A0"T&2,.I@?DX!K,KL3$"XPN!2#D[D*3E2`D3K_"9;-%,@XI3,AAXHU M%)O&@D*W\!)FS'5EZ[@_(HBC$S4S$LO_$A^]X<7,V'^@AGY$;VASYZ`7Z8=)>YE?AP4-G MBCA>)EK53L](,[(B&OTD91E%1BK\+:M;'"WM0Z2-FD8$3KJ*OQ(TC'F@^#$- MO$S%))+SKW*E"F2:^^UKFE??@N^BC0Q,H9'04S^6=G.T4:]Q[)@`*^X#1(RN M^,ICY?[.`!6Z%;FE':G,]$@`B05*G;X'_5(8`_)F@?:\$(HFN.@A#*7T[__\ MD.!)O_4O0'5@CY6E`J\6*1ENA/BYH<<@\".P?ER9+K34,M9LQF@!O%Q0;FSP MLP9:/RB103ET"$,E=ZIVZ+[NIYJBRSE/A`0M--8V"^Z.)-!/"$;:L0V2(/!A MCRAV3S`$B25;Z%XB9K1GRV1J^[;$&$H]>@J$VI?*!J9:&D41J=0(>K;IP:P[ MTSIJ2#NC;IG#94%RM39$=TRN;!Y#@3Q#OF/IR5_Q1;")Q0,Q]XS`_T M/$\F$;0L?0]&6>ED[&,G+Z*Y,G0+``Z7:TF2="#!Q@*SQ($<8"QRXL#"@V=* MR8)EK*:[0(1J7,=KX0*;P.0'NEWS_=04PDQK.([<53?N,"*%"Y?J:2-D70BK MO$0::*]A_*&=)U1MW#5SU0#>AG*`05>"J`:1`M'W\+4?L*5O.'M7OA^0.?8, M)&ND`6;R!/1+`,5K)@1 MCT`%*_2BR05BEYGYLB9#1I=`,)ZSC!\_Y/C$C%B-.*.7I='=HZ9@P+\Y/#8, M<`\/=%#7;]J]EU(%+2#@6"A\NV(FD-&NDE977E/B(":!C)QRKC--.I.!O^D) M@0TED87RTC.TX*#SF+#2?>@^=+):7C&K2NHFK:"/=Z%2RYQ_GOFW]5&.(%!3\^LP"[Y&#ISG+V&Q\0^8;&+D#I6'BNP.E:AKY,>N[`JCRZUO_NZQL'L3_"=]S7ZHOHO M@VRW&U8URR#;H&FX_(>X,$??>"?UADIQ3F+/+Q!P9-C)L1TDS)6\G MIMCSTA*L3P_66S9]DH$^00/]A&WTQVJY"]HB=H:9X$=N]R+`$&#J M`Y@"K4WM"[?L,B6Y;V/,S^(\U=G9LFHXNY;P6J_8>5'>@0.[WO_D7C>G3@'Y M3G;*??]L[H24(P!;K:[9;1=?4X6@=O90:W9[YJ!91BFT!RWJ\>R-/Z\8+D>4 MW21K79.5M5526TU=_G/.<57'?QVPM"64!B$X$ASW@J-M-GO%GY!+\>TYQ[?Z MZ/"K9",5A1EUKOSUV$BE],I?=:;3UJ`%?%K\46.$<$)X541/X754-DM2=TE'8^ MK=*4UDW(5">X5XED;;>J2/5I,*50W$/MCXW-Y9H&ZL_X.=WV\(O: MV6RHLGE;F@]XO`^7S7#+\7\S!8!$D*FO%4F.X;TK%EAI@$E5_L'1Y;HX*,#4 M10<\/W,/Z$#7AX!Y=TC%ID-J-1E6H[?:.@L71WD#X8&QV>QME'>_]]GOVW_, M?M]$5T_8\-LO:<-OL]OH''X`2+=.N>I6PVX>W*4=YR/4B,`M:Q MN:6LKOI+U2+EHXM-GBALB14!K59`*YI4:*AIJ&FH3]-\O./A2L'^N$0C8C<. MMR&GNTR7W%/BEU/@ERM=#9""_7%8AI!'2R"\F MOY@<%N*6P[E%OR53+_+(.3Y7K)%S?#9#?>JT0E`CJ)%[G+M[7.Y:^QW>=;%+ M[1_MD9>#\=6RM-4`JP5JY++5>\_(#FXN>,_(T?+Y!W48#`&;@'UBP+[V9>8= M=[D'%)R$8TP0KSO$"=0$:@(UQ95/CBN+J2)6MW"R;N4)"_2`CZO:7)W9L4[5 MY@@P!)B:N&J$%\(+X>7<\5*1A#'D M@7$K9`E%VG8X/KF7S2B6O_)DHMS+(1:3*\BM`J5%.#L7G%57)Z5O]EJ#,H!& M.#MKG#7-;K\40B.=\SFH!1L$[0)VN5"VS:;K>(/XR%H$[0KB+^M[I8B]/3^H#[AV/ZA M*"V,KV&`4VUN_]P'DA:4UFE!:?WSL(07P@OAY5CQ0OG\,\WGJZ-,*8-/&?RZ M^<%'!HL*COVD],TAF-L)S*L/>!3S)BCH8.!\PN3FX9EZ.F*B\IC+/OQU&311Q$JQ MX4%D\;AC@>D`MG,&&[$*#30-]"D-=#GFH])C@7-8)W$\A3C).R5Z.3MZH=// MSAYHQ"AG,M`E,4I5IP(3S@AGY!3G[!27?NK9@^JE8\_HV+/C.66DFM,6CI?- MZA_@$`'85V^FM,Z1RT4T?%&1QU1;@X,EPT.Y7ZQX2+>N*B7Z4[2_GLT\YG MTPEHM>"J<\MJT_%G1[A^LQ9U_.ILJDL[^XR`3<`N$]BV:76*=T,)V`3L\H/N M5O&%A>EU05&O"VC=>\T#FVI3^><^BK1FM#9K1@DMA!9""Z&%\O>4O\\Q@*$3 MSRAC7S__]\@P4<%Y.92R>7(NLFW:O4H7T!"Z"=U%H;MG]CO%GP1%X"9P5P#N MKMEJ%K_1Z"2R[?K?_<\Y,ZS&ZJBR)YUV5D!L,N4&FTP"/F$A-T1:;]1@F8I' M!O\VQU5'QM@/C!#N"*D6:;1M.R66K2$AZ09 M=TP:SYO-GOKFN=WIFD;`Y9P[H5AP=]E8W6L\32@IOET\0:16-Q:I.1CL%HG+ M4,RPX/":2%B.=;=@8R$=YAI+S@*4#.)J8]NA_DYL_-5<#L;++0+8 M;!S^%K=)-0#WI^U*`H9L2OL!:J\VI8VN2N%!0J%O#?9B^:-Z#_IKG:S?U!^0WU1OICMROZGX,E'D M-QT=Z92PLH3\IC/VFXIWR\EO.G._J5=\Q6#RF\[5;_H\Y0%GXY`'Y#W1Z]/J MV:YK#JSB'7ERV4KR)W*CO$(]C=-QL>CE80'T5BCVR/4Z-M;V:^"SZ7_7E_>_&(D%?GKU(I(7 M$\;FEV_2I>!7N!)^9X8#:X>N/?/SKLQM<;O5G\^_/-\]>HQ0@1-)/')T+'+E+ MVVI@)]478S83[O+R_J`_>HEP7G#Z=^^+D=+L1[[PW06N@G_GA]SXP)9JI?F% M\1OSOM[COZAT7`!F@9;,.&JQD&"K&CS*)`1@YOB[^\]6TC]+8;7A3%DP43W?(?/0#P(?S/5$%RJ&B^^+G[DB M`,Y$!0?^S+!_0L6T?U*W"1Q3D&"FAA5;'QG1W%]U$\8;>BE`T@!WV\##G*G@ M"[QXF=5VMHOOO8?V`JW/ORD;Z<&#UD"D*5N`:EPW&<<0_;;5X/M1B!I7^WG6 M@)!@;-<`9T82_F^!';P_)MEI"5I1FVK@#I@1_]6=Q8U!\/P0=.$NLW)NFTIJ MFY)LJ)95DW!M_`3<3[2:]M/`CR;3K6S552,T8TOL*]@F34YZDG@P51$RPA]) M%&X6A?@-6#&I9EV:DKS?31QKJ25'0=))B/8/QMM$L@(%^VK:J)DI`:@2=VK] M$XE`7:QGZHP)=0N.1\(++B##588Z,+3'<]"T+A2C]X+>U$H],@^'YBM M7B]YUFIDXM&*0.F!5M9>9J&QTXZN_)E]W!/MR"2>SRV,RV<8O1L^##<\F/ZI M>3#]C`>#/;_`KAO8]Y/W7&[`YL[NDX&U#E\A981VVI`PX[P+M=<1I[:&)D[/ MYQVS;?43&[F-!;NXXQU)1/')++-_4E$^LL#8\$!PG/GS;69>/0QF1C(50"G] M-EX.$U]M#06B5';2=35O./X,_M%M>\;_,J"Q8)GIYT!-51L?_+QKP[V.&RG" MARD-M\W1'GBC52_TKDS-SPSX'CY!NQG"T)2R]=ZL/?&]E9<5\.3^D59:IM-; MAD:+W+NO&I`%S99N&52D5,5V\9,R#'/@OV]JURNH[GG;;`T&^S+*3IY8IY(W M'@P$_\R^[8B)!H4S2FY<,?BB5)Y:*X5DH?IHA.Q;[%D^<@3.VF:=MM!2V&=I`'&%+@=4/N@5E4,'S>PI-L&ON*N??6ZKV% M[)M=R_Z^D%:KT\A;EP#W/O?$](V6U;S_FS+3Z?[2VNWS4';^IZX3;/9 M;CW5.5X]?JU]O0=>M=XSV^UN+(.+9E(9@8>N-GM]*R95'<1I-R]V5O<1LOD4 M(5MFN]7?\MSD/OW\_7O1ZO1V]"++E@]GD1XFP'6J_"V2X*1)"3T>@EU$OW0' M:=K6J?EAMO7%^()XV&+Z[`02=WPSE[(*[S.IC+NI<*9XN?I917WP,P0#-G(PG3FM;+M]>WZ2?[Y2\0A!A_N/#<$4`:KO95Q.MEY\5;/T`O!SAE MIFM/P).BT("&T@!FU?$XS= MWL"Q>;M;<=6J!ZX2*.R&%3`)H"H#JC_R`M4?!X#JCJ^PM.%EM[6Y.2TDH1<` MXX39F21[B<,96W^`07@'^'$@DI$JN:#JNGC^'88D'O&%C=7H/;6>3?^I]6P>^7ZMW6ZT M#G_AVV[7:@EQ<66W3[:H2\=N-/N5O.7NV#^A!XJ3`G[LY*YU]P1KO,!@M0LJ M%5[+(B]$:D1J)W7N0$U9#".!`UBLG'6H.ZK>9H9U)[0.7)=%LZA,=1_O='I[ MV'0B"U$"MAO6/FQ"1F*%:GU8R9:RLN3NGJ"[6[==.W2F5MU]VSKMLR&T$%H( M+2?E%=4),`4Z)K7?H+?+Z\A]$V-^SDF.+_"NDBT''],M!P^\H2J%HH[LS)_< M+%@%1_A5N.W.M*P^H8Q05BC*FBTZO:Q`C.WPKLX*9K;9;!=?YFJ'DW8\)XF= M5P8I3RTPACYXVQXH\`/&.$41HI M(;+BO79*(IUS$@EWNT:XFZT6WMG1AHFG'2,V;0(%@>(>*-(2:\V7A`[*+%7" M&I18.N?$TBUGDD]]=V2\F>'&?UT/D>(RBOP+Y;4.A?X$L;/PK4X=:Y1F*HW1 M*,MTSEFF]ZHHX#O?N[B.RPSJ`R,H<*2T0IW>JQ`F:HF)FKA#1XN.DT\U5>J_ M4*;IY#--RG/Q9W,>\M59.12941:@4%;KM2M=R$T8.P.,M2F920FFXIEL0)OA M:N[('7F&Z8;/?2DHHT39`\H>$#H>LTJ%,$$9I2I@01FE<\XH74<29.2!\9&[ M^@R0J9CCV2/&!Y+V2BYM"VY9'9Z ME6[LIP33R2>8TA+>']B2ZG=3K%^\%V13]6["6+$8Z]-J)4HG%>^>6956+J!D MTLDGDVY];V)\YL',N.'#T/@92WE?W/K,DUO.VJ:(\`LF:' M,$:IIA+(;"^@9;P;_:^RM&FG7HS$`C^]>A')BPEC\\O?(BD\+N6U/QL*3RTP MOA'2<7T9!?PS_Q;^YOK.U]<__F`8KX:!*RX_.5,^BES^?OR.AY]XL!`._\@7 MW(NX_(Q/2V\RQ`BTQR:V_?8:A0*9$@UA MWRZPVY>VU4`EJ"_&;";5]C1V,TQT#[7"0-_C.2.N+OM.\&H'D$:B#"W7W MIM0T/# M@SB^C[&8^OS7[[JG0]\=_3][U_K;-H[MOR^P_X,1[`5F!TI&I%Y6[TR!-&T7 M6;1-IDEG,5@L"L6B$]V1+8\>:;-__27EMY[4@Y)LG_DP=1)+/(?\\;QYN)'Z M*![FA[]EA'D?@NW/[^8VL9N(NFXPD+M;=B%0J%,;8N%4MIK" M8S6(G.BCV'1WSG>!6PZL"[`N3L"Z:,]..#7Q<[GP'7<[VXHL=2AN3A1[N8H3 MP`>Z#G0=Z+H!10?!I6XDX?[]96Y%MA,2^S^@5P>.@"RVWRE&H;$,"]E8W\HS5/T"L&S92:B/Q6,,"9_R@=U1&'TZP@0\/WJ`G M0$^`G@`]<11Z`ES(VBYD^R>DLCW-GGL%^EX0C%95U*-U&74:H9W9+ZU/>[9T M;LN_[T3#%;JX6?/5DCW#?W"A7$3TV(E%1Y(FZX#IP6&Z4EL1P/3N+56Z(HVQ M^!9#@&G`=%>81I*NRQ)&(*D!U<>$:E4U)%TQA:.ZP->#/ET=I`QK.'('FDOL MZRQV@1O4:NRHHK2`56Q+G<`JPBK"*L(JBF5:7$S\H`V@TPAX7]'W^-8DC"QW M=&G_7Q2$,\)ZSUMS>\3ZCL2=Z%^!"]J##=>^EW)8@NF4,=%=AVG`!&`",`&8 M."Y,0/#OX()_+1JU'XGM3"R?_+3\X-BC6\]GG?1ZM&,/V"4>8I"Q1;2,=4E5 M^LP='S`TAA@M:1,:2%(ZN!P+H'%XT$#Z6,*Z^%;#@(T#Q(:F2[+6:XH;0K=' M'[J]=-W13?A$_-']D^-3&]?RPQ=VF8/G!S]"Q':XIT6@=KDNY+6Q*F$D_HX_ M`#>4QG4/;F1*"!D`;@#W\8$;20@;DFI"-3/`^PCA;1IC"1OB@XB0USCEO,:] M%UKNB*MD!^)20W+L^NZGT9]@U`U9TE45X#@D=7["<)1E254T@"/`<0AP1!(V M-:+##GTR''G3P?LV$$*"W)8H MT6O*TE@7+W@!W!`?[:%:2I&4<9^5=`!N`+<@<"NZ*JF]E@("N`'//1U/-';RSJ!9*',/BQS_K&TPV8 M07XK;=A2U8_@%,"@=/H)HQ%)I@K9+4#C(-"(=@9_T# MW*Q/.=PG`0`_4H`KBB$9LO@.!0!P`'@_WIXI2U@17U=[%&FKY4>+XK?I^[F? M;7&I?QQE=\)8U@SZ9!*NFF*,)MX\<((P8)6&ECOS@G!$&/I&3]'<]HD]LNE? MG3E]8!$_((WH#V[$/&3Z[&Q&_(ECN:,G8KGA$_U;$/G$7Q8G6O;,F=.G?2MD M(UG!Z!NA5-%_%[XW)0'+85FN^S)Z<%R7CF1-EK6,HR":/,5?>WH)'/KZ.1WU MR0L63FBY]./$I:^=+,?P8A;M)4N)]USD(+U\04;RA<9P.*@E_9%ZT0N?!''Q M)V5[9,T8FVSAUDG`T;OO"S(/"/VS%8Z<@$JT;R.?_!DY;"5#;_1`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`-HA7>)1E%O&(ZGVC;^)Y]&-J=YGR6,=]4\ZC"=,VL**, MQ^U0GO7GFVG6&SU#K> M)D*FJM4GM:R`CE2-G)K>(39EK)2'"BJ34\>_0X:N M:KAU6M0Z+AK2*.++0Q8;6A)AP-\L-[*8BT;U_Z_4(G"F+\[\\7(5^-T/"6[H M1+D8>LUBCK;SO([3LK#D.0N^OD+R!0O%QK^86C/'?7F5C-M6#.J*3R?P1:_C MW,;Z+6Q2SN,,RRN73,/_W4U8Q;]8YW84%2^^;])G5SWE'>)I[K6HN` MK!-;J[006E(R>O!\F_B_G%&H3(CK!@MK0M=K\_.JY"[^>978H0.MIBJ_/B^5 MEV*D)?)2N[]:9Z)V?[=,.M'?M%'LI\EM5#IJ\I#N)E#;8$DM38M.6$["+\F+ M+K\T_')C5;V0^RDW5NE,L\U(=QC]H]+ZK-,7/33*;(U9\6G\\[_>+3E]\%Q[ MD^M"\3`__.WOZ?30PWZBJ,U\M=["Y1M=(YRK@ADD)$C(>A(R2S2U4,!C7I@] MG<,PVY_@;H3AO[_,K!5`[>:AAW9!,W$7/QUSU?#A- M0(Y$B_?A7;8(V;=>]!!.(W>TKN_N4TX.U!DYY5!>?\)4HVJ[@X9*`$>`(Q<< MD80-\?>*@^<-GG=+B+WW0G:KZ;J1%#A`0VZ^6-6'ZKSYXI!ELV(J5#B+O^T1 M$`X([^M6/%-"IOB;=HXBLK#\N&XO&O^4U_*PREGG_8/;VRG*S&=%81ZYN^2AL@!'SD>[I8M+-V"V5A8TOKI?'[9MA2%%T M7<7=O+!>2;V M]3RTYH\.E5^704!RVS:,3Z1M0\.6#\:VYP/]`"K6&>EE$O MS!;N5A-0F>QV4B_[K[A9/;'/TX)(6-$L`&U00!,M5&"I8:EAJ8]3?7PBX7:" MO6F'2@1=--SU,JK`5!=[>*JR>=_-AMG6H6W1$E>D@?TW[%.`!8)>\"G`@U4. MM\1WO(Z#?0!L`+9P8%]YP4XJO]L+A(["R@:(#QWB`&H`-8`:G-1A.*EBVE\. MS3<=6E]=@>;T8;5)';*H'5*;5``,`&8@=A_@!?`">#EUO(@SP4^K>5B1I=RX M#4KH+018QG4=R:R6W5%``4'\T0Z)&OBY5F^5W$X/0&/ MP_DH\.*&[U5XSV1NS4/ZB!>>A][YE3=;D%!\7^(#B-*V*`![SVNVUG`=@#%< M8/38AU^2.^B#._S`*R`CB0Q54F1`!B`CC0S#%.^,0>@=0N_-D7IKA829R-;< M'GUPJ&45$`C`GTP@H4]S&QF`LT,L?1W$U1E#5OZ:A,U.L`W0!FAW"VTD847\ ME70`;8!V#\Z\K&=<@`"9C2/U[?B=9#A,,$!OJ=^LPZDO)!3A#JD(=_@18L`+ MX`7P"06X#B+]S2S:2 MMC]@.0L40[DN6U:[NBY;5E=@.BP_'#?/*\#U)KT[=:AY:"!1 M3F2A.Y(H?=V5#3@#G(&%/60+N_/K^W+7"N[O@_O[#N>ZG'YN^CAQ.&<;S\2IZ/`?1N^ M-P%W^AU_72Y&"ZSU:FP#+H:)BW&?MC%$VB'2#E?Y'9;@ M.[5X.]SC=X`UKX-H^SADO=_9)7X`;`!VE\!&DJR)MVD!V`#L[CUX17P?:DAD M#,>GX_>.X:S`T+RD?I,,I[Z*4&<[F#I;0`N@!=`":(',PH%:H2>068"K^R"7 M,#QC^L`PT1F^MZ9.R'YX#P3>]NK M-.Y0&MRS=]Q37+QQO[G9?>?5^P0I[]-X\< MF\ZV]:B:9Z,)99+^_C.9_G+V%LM(^17_?O_V[#5C@W*QGE$V%^=LFEXA^8)- M6OR+J35SW)=7R1ENO)>:/UMX\=UJDZCR__!?`*S(0DKL M.L!XM_WX\$7S?!X>9#L^'ODM)I1=*+9[L?9VXY$YHKW?>"0SP@>"X>`[[%RJ0-G/%]RMP[F;`$O-&'41HZG2`X7:+=#$)9JG\*R MJ:W;URV#>?*L5:NR/Z%C=G!N0YRY>-#2I-V,\5"%COCLR?%8:$)MK:.UF\8F MV$W#EG0';C>)[XL$=M/!"9T.R@+`;CIANTF\60YVTXG;38;X%KE@-YVJW73_ M1'QB34/B@_4$Z=/^I9TNF;)X0QY,MH[LB=9$GE!+XWA,+$@>"A!O0K$'IM>A MF5Z;>IVHN?(KJ!C:.;H0^R(.YP*[W!9,LX?2-+)N*([>\(C.7'=0WW MDJO\*NXVBK#WR[OSW_!,R;IL6Y/39=OXZ_JBI/B>I(]D]D#\L]>W M6/Y]2S[/(`W(0EED??+FDV6/]7EW%XWO-R0 MAHSN:%/RRO`'L*AJ+FU#65DME\(^EC?XA^\%P88X_6QDDXDSL]S@E[/SQ$)? MYV[<443?'W_GR]W;L]>J9BBR+/-0O!R_)K5&.;4%JYXD6I&U+H@>EQ.="X0$ MR1HVC2Y(-DM)3E*&5&1T,9NZ7$8:W5L\D!T;BMD%O8B'7G[0:K+9R31C'K(' M!EM=X2`Z!5P3*4@,<9>3232+7#I)]JZUM2%7;47V8DWAGMPS8!D;3P4MLKU:9)Z8ZSAH5!?JE@Y50'6V8(,@Z=2S5M-752Q<02S M9G!I;NY=A!5U*(SQJ/B4^8$1M_G1E/Y/)-S06JK7^7:,K.B\U-/1:U%:JLPK M[0-ND5N77`YESHMM%?.;IG7)+=?42:IT!7/[>'6I*E6SG!)=ES7A,UBJ.ZM) M:L/DUD%U*>;2E]P@E77A<.!1AFGSRD3<%DJ*L,O)GY'C$SO_F<\D<.S(B$[ZV)XSKA MRT?KNS.+9F\\W_>^.?/'*XLUE@M?-GQP^<.?R;/G/K/']U^>DU66Y7TD5B%L M9[6J/'89W!*?-5^R'NDSEY.)%U'S[3.9$.M^,X5NZ2M0\ MN=#6:]HFS?NK^Y8\A-?S(/0CYB:\)<'$=Q9+!?Z;Y3OL@<\4$V^LP-G8"V9N M)\:O^Z]+O"'^=\ELR52\?J#?'OGTZ]OEKD)I=C M<_M]0/ALSC M#IE?[M=\YM6NF5<:,5\-ZP-<>[53]D6M?JP?]I^@+R8^F4\2_.Y93#DJN27Y MG<&?HJUT60&M:<,C6&N]J\BG7PNWW'!E!RI9&*9B&"D#(TE`[J1_M*AM1=]] M3_S9EDHCK430K^CK1X2_?HQKF=G7/WGA3K$?J_4K>7\1\*_G$PH5:JS:E&BJ M,"QW8R'L*+?26$0QE3ZGQDU3,"K6W21`R:-R%S#+=6C9;5DPNTZN, MCPU.=83S^*[6[H+`Q45R%[Z9Z@`10D2$K+"FS^RE[-'ML1QA?ZY M*%.51*QK=\!]4E:"XIK%X,F]]7WE8KTAK/ MW?K+]&N;Q'G2/,-U`MC84-7L?9`Q5`V:RLN=,FA25"5IVS2@B:5FDV35"2YC M(U&E6#Q8/<+*JYBRYBM'#?`0MC9/WD0!,[T#$JSS/L MT[/^>_S7(+9=J9TX>:*V[*WO3,@J8DI_O0+`DL-MK&UKX&$.?R6VN!7T];WK M^8YM7;G499Y8[@?KP?.MT/-?Z/;,*R-.&.#-*1RY M"9BC>(L?_5\_,&_RR7/MZ]G"]YX+C\@H-2'R8TLYKJLA6N?X'YYG?W-<]W+&4E-;-CD,H08JTI3K+OD^O6US MS9&4;T$=ZD9=62"6^SII?*P9=;'<#C,K!?K!L1Y8/-EA]N,RS7IKO>SFA9$B MUNQ##:V^?`XZF)IN[,!Q7=P/88KJ&(8X$>D2QO&5%3Q1=<#^82KAV7+CVM;P MRO+]%V?^N%>>B93JQ\BQAA)Q"JXAD^6DR0*(C-"`6FIYI>UO3<%JHC*S8*A] MHJ[GS_1W%+X[!QR06EYOGQ%G2D3!=M^\/^9-^$3\I\?7D5K]4!:2L9'8 M_,6#I7;*^F3A6[+PZ=BQ5*"?7<(^T,=W2\?*[5:U_*!TNCD`3B2!VJ**=%(7'BLI0/HKD!*8T3N34:=\U>:AA(G<_FG@_V%I>K#)\]F M4BT(]U.F6G69K9J);9HS1E)R+3RJ-X.5-$D'2K7J@MO4DH'N[#'V*5E;K]N1 MJPMN=E1ZWVIC9:U*=4$^UO4\ MG=8PEJY5E^88&^6)ASRR\F>ENDQ6QN,$8HJG9/]P">+HTY0:$>%Q(D"3>;HE M,5`=2:E0"65F24K>^:PC%E4#)1)=)3.Z;X8G541Y&Z0T!72&QYG&Z_X8"9$\ M6[C>"R&?2:R/=QR%%$DU;%E=39QZ+ATN-4M^M)/#S*"JNK@TC400-7>4"L5K MM7H352A/RRI22=%073RJ^KXNSWA]TD-<."'UUEG$^N;!=1YC$RV]+-6%HV(F MTHS%0R77)A^WU<6C@D91D%.;.5(=_*^^JDR5'U MI-=>,EH^:K,HJAY(4%&"HNPAH!X?$Y?N9UQG$D_7V!_0]"9F>P"[0S>G])IAMPXJ0WV'2<23+7-WB0&NFL`U0>Q;TLP<5&MX-$3[KJ% M36L5[%+(<>`RN:1NDZCP?6!Q@,YU6\MR)`LV=)L=1M\5 M&!>NWFH;,J\,2\..$0.@93<"S>G80X$'%J4<52\;(H1E0? M00AB-T#/>`L_]),4I:0]`4R_JS*/+M4N MAT*P+2A)2H(5M%_)"9("\^ MA5/5.I91O/QC(,07J[0$Z-OP(;]_NZQE3*G]M>@DJ3$MJZF*""0&8.!4RG#= M#&,8C+(;06MM>/2QKN!IA(W!&2GS>J_8"E")9W[)511&)7]:*'AT[$A7V]X/ M@+1KB,-ZP-()\8'C%,%CTR2"\V(K=I>YW&T.(4$ M_7`%?U+LORA,3L`\BD'MPO^3'T:H%4LIIU!U-4?I25U3FL6063Q]8Y&M8%="#U#4'G/:28)F8NUX)?7BV7%P08 MR(8M51G86[^;T&H]S8AT!D$Q^Z&TV%5'8\IKH9GXP:K6J55MEK$/9HW6#::@ M-!".O47V$!%]!NAUR,`;/T&U^0#*G@JMH#>VC`W31WHW<-=MA*U;BE%A'$2> M"7DQR\X[`K59GST`NVU94"WV8N\"L`F^-\NKR=B;\E&[XK!-Z,GNEO4J/WP' M:GO3V1#W.V*/]-KECI99C@'E8JVX([UXN(.L+9L8V5;\;WA$@%[(VX'$NEM!R)5MK!`='\X@.UP0R]W[8`S,I2>@^">G6SH%:N=3%>(/NP.7'1> M;XY>W=K5S4_1L-Y2:[ER':J)7MM*[9FG8#><0]43O:*50MI0#*SOW`94%+W* ME8(&PM'D;:DI>LTK[;4P.G:NW92FHE?`4MH8VEBZX;XK*WJ)+87UAH$E4+\Y M?44OS>V>.HJ2:IM36=6\\C%*9E0XN:RF(NO8\I#)=%\M=I475\`X8Y66X^#] M\?JI8HG"Q8D5>*?H+6]A@B'C?IM3,\!+)H,I?=#>L#P4:7IF'Z=`.]II>B!/'.4GQQPJQ?]@3D_[T(N]\\HM)+@.D9 M'SC07JJMNO$G/X%"<1[%DVAUG\Y70?F;"A]+B(ZD9#6KUO51J?<#R+)MZ/[X*'\L]%@&?;K1L4R]1)I@O_@4.E/.2"T]9 M8R/;![5\(VE945_!9+GV(MXN]<'$2;+NYJ+4%BG[O*BT5C!2P>;-2\"+/_AP MM-P-U'LGVXH>\$Z>?TM054.U1#/H`^=EAP0?J)H3KXG23$QFU@.TE]G[!VP"J]HINB)#7L[7Q#J#.)36[=!X@-IYT<*;JL,\D-(Z+MS([W3*E8 MNKJ]V=V`9;'NTSGI%1(JO32]>U5,K>F\=!'JA]-1/%TAY+2^J&ZM%V('\7:K M`_SE=+BQR4,!H,983FNLZZW:97;J9(4#_4DX]Z(E'ARJ.KA6:#F-L*%@):'] M-%LN]@P`+SL[9%]/L[?`)6=?03SSD[HFY+2I9JL_$YT@DWHX]T,WG+&K!WHU M/4WY*386.EX/T79FQWF6U!W[U>=&GPBGM86'8BQ#:P!U,^,MH-=1-()UD+PGV,_ MA1IL7@5A2+T`57K!/^U-*E8MNYI.;`,"SA)N)`4KV)10MWA[P#\Z@U^FSS?@ M(;M,"-,K=U&%>5`+@`XL'TXNIM+-V?G9S=G5Z9ET.3Z9WHSOIC<79[?2Q=7I M+S]W#8Z3/H4\C-W@(O3`UW^!YXIVY_M>#SX@(;81>]WD#26F#@23N_<#T!\"H$\1'$E M4*BFO(O,>#8#`=H<4*UEOZX3;0S7%H)J^N?PD]JT3+H8-`4`&Z6+3"XG&"'" M^QY+0K^J)#*U45IKQ5"WK++5=]].R3E5IJ:6L^^GB=U"S!Z!M\J"[^1NTG?9 M/1`$+_"8X4^5!>IL?9!W-WX0?/ M1W?^`B32%?@BW40+-SP^GU[=C<['GRXN?S^2\"^E[-O;B_\Y.Y(4--+!3P_I M\5__@@@N2W*?QC_WG)]EM)/C3\L&^$ M-`OF%Z,@IHQ<:&W#HP#,T^.[L_^^&XTO+S["D;,/I,\7D[M_'DFFK"V_'DM0 MT4_.;D:GT\O+\?4MG-L,O9!VF8!C*0F-X^/#R[Z7K>>6_O_A>^OC^`%(J>%7@C4NPQ<-'\O'U>#*YN/HX.IG>W4T_ M07((6_EA@:#^TB6M%@4X&YP"^JA@CZX?:N:/;8+U M7^4$,ZX\92Q_?W`?I6FT>)FZKO^XMIAD?Z7>!N:D'2KJVE/2B#.JBQEZG2F( M2_G!9BD5H^8/\4RZD-ARSE_\T(N^(+&7%+ACDBCPO1>QSGFPR%[/*851"*J9 M,O+,4`Y5NX-I!9&,9PT:Q1?%LT3R_8PVE!^1FD,[#'YI;)SK<*#[\@^D%/YG7)N_T)!"0[X5#:D8.U&/D.P;58GGIY?KJ$1L=4F<77]1*1NAOJQ4 MT5IO?<4N>E5VO]WM]&F][20LQ"O(]J',HDV$D:BD.LL03XZ$[RQ\YZ&^<\;M MBZO)V14<HFK%G2V;/"&D1TB*D92^E M98]=K'T2F"UZ.;P"\^VY,"?CTW]]O)G^=C4YDGZ8S0"8SXGLO7^814$4OS_X MX?3T[.S\_!4\'5ZG/1^B<-'5;*R7.I6JN*7MKK^>OMLXT[>K%C=F#C<][C%%]*S)1WJBYO7=`H'M_FV2TFSW`?MNG5U410B&$`A.*G'NVJJC' M0CI$S&LG6D.$O$3(:T/2FO4L0BW'I8O%,HZ>0-9P39P814QBJTK2$$$)(6+? MA:/VK/PKZ_$K747AJ.A,)^5-QL615@0\]NGZ2,C$ M7LK$GOA6;U8ZOOD@V$Z=(1$#$S&P(<*:N4'HK6TID,8/,0"[O@_\UL^,XL`( MQ[+TG6;2"QG[#F1,%V%6$?K:OB9S1&GC]^05OO'85_GB27%R%7$-$=<0TL&> MV2-D0L2Z=B$6(M8E8EV;2GPOWKXMW8`@?Z7:H[],)$CS.G!GHJN7B$AL^6+@ MG:J)DDI0Z,@[=VTYX,(?8G0%U<3^VOW672P M%U&([;M4BNA?+V1LNS)FBPPO$>C:OJ\G[[2IA0ASB3#7H*864?@@W8%X(4W` M?2K]'36S'UU&;IC\0YQE182CI=QV>EDDI&(OI4+(A(AZ[4A9B)B7B'EM2%QO M'Z,XS5VA\>P_*S_Q4Q/P/C((AF M68+V'?K]'?B:GL!/_OWAKW^1I%_*'X\7T+S[?V;/3><78>J&#SY\/&_F)/D> MY)W[H#KR@>2!F;]P@^3]P4@[D&9P!G#(&S!_?S!1947]53V05J&??_+;[>3@ M@V*84'E70.FT^'`I?;BT-BY5M;AQ7<=@#N(8>+N@_J%$^W+6H.^PX M/77C^!DZ_1A4G0%J:SD-0[,;"\I$="V<1N]*$[:#8ZGF*^,T^W`J[4*$6,!%!8.VH:J-J6L30#7<-$2Q.GS=0!7%(KCRVLW M/L91DE1@J`:ABQ&*9IM*`PZ=7$M05HM5X")!`\L84L^D"?X=`/0'_'G=Q'0. M74VBUY"0.&I;N%W;$*[F;-''Z?,GD#Y&'I*7),T:?E?@6-1#DNK@6:7@K< ML&=?9\$*!=+:2'K-`)$-CJ)BVJ&?9J?6(*T.5=-W[E7%Z%(<74M3*MPFV M.!6O`-QQLV@![MRO;5P*C[97-,N2<6:1"37QH'M8%'M$M[`M)#RJ7K>P]-A7O/:`L.CLG5=U3%7BT:,"1AAGRD\&MFQ=8<%6]>> MJS.6A(E',VN.*G>N7B<0/P3)='X*#RE^6X;Z'7G*Z8U#F:;P MJ&35:AIX?'1L+WM>%JMW@VO7ASNM6,`*`H_ZA4N`G^K)9)I8;D#J0F9Y9VX< M0FN1-%R3N3_S:TO"HXU5V93-)JY^DIB0E.>?47'@MJ"4?5Q1Z1! M5VQLAY.I#$*B]L9B-.(!R59L6QL,YC1*TNG\%L1/_@PD$Q^ZD>DG^'3L0_(5 M)IXXC*99)B[0%&)9:T8BI6SB3!T/TV-4RU#HVX;=+*U`QB(X5&X19I'^^J:CI_N MZH,S4N;4KQ9V3*$2S[0,=.]0>`+*0?C00L&C5$>89>ZB,A0+IW(=&0X'G"HT MDI^D2CY6<'J5*R%2C44$202&PN#4J"-5-3!!V0P>SB`S!Y+B@%LLWPE4;?.: MMZNQ*,V6QK0-"^,*D3Z2I-4C=$(3<,94,3RWT,RT=#UL=T;$4W*X2#R&\$N=:/O,G?"KPE6VI] ML=<`CZ_,Q`]6<*0*IKXMB2PH#81C;%$JB8@Z>%L\VV)QA=3DE$S;NEE^3/V&JWWM9G!Z\",%1PM^B[9 MC%Z/G\%_82#8PABC\.\$Y/^]"-O7UA5$SJ.!:AL&?C+I)]NZ+'[R$R@/YU$\ MB5;WZ7P5O!3OOP!D.340`!J:V3R\T*CU,;"\5"[F76E&2P1&^)&,>0>@&VJ3#BGY2D)1\IY[E"QRP\VLGU0R]:IY85R!9,E MK$-<2=4,7EYA(T^+)*T!52`M!=^G2>95KEWU2.GLEIE4Q; ML^A@*=3QVYME\=OIO'[E5F%D"4"1MIG:E(,N0OUP.FXG*X2\U@C/4QI`O'T/ M6=X5GKLS),//N-SG01]08RRGC1HY&G9_,80\66JA=8.3+U*,X5#5Y6,%E]-R MJ;(F$V6UFV;+X,\`\#)7)OMZNLR6X.PKB&=^4M].G+;+=G";3R=(CI^B*](* M"J=Q,@T\W%(-WA'R`4F3,J>]44Q-:QG&.@6F%(6+_**^!H?3CFBRA2?44@G6 M@OB?8S^%`C6OG'-B)I[)>UHQBAPR!F(;2YV%^GY#9ZMU4V=+RU*K&.RH3>A/ MAK08TGR4/SXIJJ;\<1Y`U]9S3P,_]&=0#M#]MHOR6:$$Y+GL?Z!.#HL(NA`@ M(6>W*YC9W,!]-DA29;.*TF4:6V54PQ)64.DJ3A[-%X406:5IF*9!3OEU564 M@MK)@^CR6@S9O>R\:CM$,B<[*-CK=]C,XQ5G\=JQ*VN#4U"HV,&0S\;/#D4N M^+%1\%M4RPRI=1DW5/C_T+1ZOANVV7$:Q4OT)R3):KQT>U\T,P.3&!+]>)C4 M8[RT?>$0DT9FR`+GX1&[$=-Y^=6KEP?NY5;0S&;(1.?@#4D5#U8\Y'#;9F7# M9G6,!\K&`+/M:+QF:D=6VV;UE]>3F;=DN6U6]WC-;62\*0MNL]0G,!PF;5ZW M=@<&V68I6'M[9\0RDVY&O,NR>0HQ>&TB$0(ZVS-86_MCO`5S>R MK\:=I?QOB*G6%?.-G;#I/4J.[A7[B,W]J1H+GE975D4)Y*[7,9P0$]R M6RR4H(OT$+L+R5VECW##_(GR%1&%N'H$CK5:2FDD90WTT/^D),LO1-\@DHWE M@3"6,7ARH5*`0RW<^-\`?9)5C4$0<3;Z,KL#DD">'SF%,!N3U?+)JH?51](= MFF#QNR]N(B6K^P3\9P4W7/`LP5T"QT)LB`:,K]7'SR^GLE\G_M<1G%#Z6!L' MCCV&LPAJ@\CY(,T5J?CF2;;RSFPQ:Y8S*RF9Y<)/DA1]^S?UG:S)S3F#!#2& M+,9Z=)^`=`]`"+^<13%"!UDR+VJN<3:ZN#HGM3]"*EUIM!T5-+M7C*DI_4IG'[0NTNO!=?IWW?;` M8N7/_46T.KTM5$?EF:9BIQ1FNFO#YEW[%N%RIK)9 MFF)N`G&?JM+[FT71"B4I*NJ7G[]FYS3T__"?_P]02P,$%`````@`^H/'0AH2 M]\HE#P``PM@``!4`'`!B_[>\/3@4E*0T' MD]?!%16"1='@E(LY%R25`@;[^R7A5QI349)>9+^S-,D&EW$J6TK)`QU\^P^) MP\')P>%//_UV=7"XXJPQ7MY>W@V^G=R.2WFJD?/X@<5TP1"Q^(]/ZH\)2>C@ M)6&?DN"1SLB8!SGQE[W'-)U_&@Z?GY\_O$Q$](&+A^'1P<'Q<,EEI%#_VR_) M]M5/^X='^\>''UZ2<&\@'1=N`1DIRJ6&-^OFXI#TF\P6/A/\(C>TNE`_?WK[66-<<*XH%,J M)"CHAX#/AHIH>$J2QXN(/R>RQ5Q$^CJG7_82-IM'M/SM43)^V5.J2]\='A_\ M>'R@//=#A7FXEA8G)%)6WSU2FG91I,Z_GBYWJ<3LC,;I]?12]I\9[:*01LAZ M6IVQ)(AXD@DJNQZ1_682T5&2T#0YHREA4:?X`81N2NM1$/`L3F4RNN#BEC[1 M.*.;4=TN>/R51<+05UQ>2J_H'\JP*4DF>5Z2`\T#(7.9S0Z/AC1*D_(79?[1_L%A MD75_*'[^[1>:*B5N!']B4O^3UU\3&E[&IUR%-)-1O9X7P\42)Q&9T.C+7@?. ME*7*+5Z<0V2>*72+'T9!RIY8RFC2W5F>PNS^`PNKN[0"ZY&H>Y>(H&Q:_K.% MZ?K865`,DVPVRZ7M,YF#2_ZIX+-NF.$;]E[%WD\##X4&*3>1@Q7)$JD`GZO_ MD6AOP$5(13%9?*;LX3&5_^D7\HOA?&>G_+9C,=W*0_^>.21 MU#DY(0D+VACOPKT"M1\W.A3[PI&OZS((DH%*%>#V4P8YFL_H7-"`Y0;*?T\-"/NP%$&`L>P"6#LX9\,(A6F@A^41'EC*::!0EJN^=D]> MSE_F-$[HB5R83UG:0B2(>@E&!_5NX-#')1N'H*-Q/?J.L:#O[I$(*O,W#65: M5YKKTJ"=J'"LB6@7(`9RP(:196I3#Z@?L0#J*V&QFC!4:1<`V,E!&P8D5`<]0/]>!>A^GPA=36HO9)24 MXNGK%4T?N73'$TU2945SO>[%4[@?R+,+\.SBG@VC$ZB"'IP_80*GH#+IG]'% MWY=Q45!-;FE`V9-:@K6Q"69901/`LB/(]'7.YH$)T$"/RW^@P67N`/4N\X*+ M,YY-TFD6E78T\`@A+5QM)]T%_'DX8\.XL[>LQ]L_LJJK-:W'W$C$GIG%"$$= MRVXBT>F+:8?A:7?0VP"TI8,!HH>((7J: M):E&91^]K0[B1/ M8?;=26!AZ'I"Q]U)W;RWA=U)8$60OSB7'38OZM[S4?!GQ@25AH:9LHEJ)\1@ M^K(XY:9'ATU?D'%_MT`0"50C+U.YFP?L*^JW-MHTX21+6$RE]HGTS_54>:AX M$KHP"6`UP=/*NI-(A3MKVZ"U:@+(H[WBU^"/"Q:3.-C0W,%3F'WN`!:&#O4= MYP[=O+>%N0-8$>3;GF[IO.C"U],QCQ_NJ9B=T4ES7XJ+K'"TF0P=`'V1Q,%. M@*`-V+H"H+E5[-,!G>:G9,Y2$HW5DO-Z$K$';>[LP&E!H)%S5T$)<]4;X-2H M"/:9P%A.8N3L1&U63/("]2^TF2J[L!81\6/=!?2NX:P-P]=/ M$\"HCF(EEA\]G6%3J3RLG5@SK+S=#8]5E8]@%A'H[9L.XA+0/V`G=]YZI M@-(PWY"8JWR=ZYJAW`HJ>;MDT$MW-`W8\+W'X>=@, MA4S!?VSW6'GM/H:^>H.V)JNM,.JKJV^N:K%+1*MQXUE-\>6S_CI?PZW]FK08+A60%":!$;%!I;[A6PX*^>P-(R]YN)46(!P_;[#"P"\+VGK#< M@_K:7K3J'BTW;E0?(8RF17=[].J,V"JS^6+3-@";"0KK=00(X^>TPQY%'3NV MLZ#EX>A[\K+0U)AV`92-(^U:2H1AAEMFC[=5CG7%T<_*=W4T5$X8EJ=#VRD8 M0KI:[UI(^XY]8\D*-=WB$'.\!N$^+P'1U*.M`SO$&)+41(_%+Q,!`SX M=FF`F[?ZW?JX/.TI5Y/5VXT7\]@&/*#DRRV.+G(,ANMK\V:"MG$(*O'@R'"` M:374NR0O]E.V)6);X#1./-M?A.N)&J_`FT0HHF]Y`VXURA1SS0OPIAQLD3Z? MS2/^2NDMS>MJSJX.IB\+&VYZK%#P-16`"H!(;(O=XJJ#Y>W5)F`XZ58)P42' M%0A0TV!IP20*V[(YG\&/.8GMHX"+K+H"TI)AC3K0,$#0S9*0+W_'ZL1R>?;# M-/4SDU0.[[1)L(8=8!`@Y'HIV):[U5.3AO":*:[H M->^KTM MAJ*_H-O#[#:G%F=]9+5"L"7ORNEW[>E&P^-R!&\]QAI1AR&`<+8E8$O,HS!D MB\K0#6'J(J[%7*)9=[53E557$Q76`,/,`L39*`A;5KY5GY&/:7A.1,SBAZ2V MVWG*@M:'/N$,RRN@W`Q8\>!M+``:$)G6DFP?-S7KIXB]#;=0WO M^-O?O7U+4'>%R`F=RD!77@E=L9B+_):E5$8_46<7UO\BX9NTK/VNX99;[O4" MFTX0;GT.\2UCT[S[QL>"]E<4MZPYMNGU\C,"*_V;KT/-%.6;4!U%?R#N`XD< MXJ<:4-]0R_R-K4X[;&#,SW#>"-[^!+SF27D8H?JD/]#9HL]M^M=`H9&2'TRH M++G9JA]M2"6Y&4U]5, M$K`%^)0GJMBJO^@>+JLO]8?HHFC5WA:\)B.ZX[=U!:N'BQMGBJWQ!/!I M0VWEZP\%AG"W@``WNX:1NI`V3*QBD1\0'9,)%U+I8I_G^ MDN@KC>6Z(E)C3CAC,4M2M`+&@G9UUL%BR+(-)A;=U!$^683/ MDY!."+T"SWT,KN$#TDQQ?X19/+89H5]2\>M=B%.)+V362"M0V'1*,1L=94Y( MJ#:%Z4.O?U@8W'SX?@)K-:M3')L244[_?N$QKP]W^JC#B*N30@OQ]_'IZD*<^M,>)[0P?'"72?5IK%5H<05.71BZ#]&U;`!F M)V!>>E>A!QKIB0&S5'0KF56N6EA1PK?5Z^UDE=OQ]63O`0Q`([T3@DDJMLG+ MV8'56TWD(;J'>_<<=F\F5TVFE;L6:./#8EG+`DBGF1JDE2_ M\NU,[:^,DMXV*%[(A4-*QW+9$&INHVM@&49S#&;@Z*Q/:_O M#_<[W!17;,F)5OX)T'QK4.]C3@_[N]8I11J:6!0]\D]B)C)VTK]%M:TY@'3F MMYMHX^_QA(HC:N:-;F!_U$^MZ(59ML/9VD$^[.@LTDU9G'069/4^2>D.#P.V MG!,6[Q9-Z-KVY,60H%1)5I`@S4@T"G_/BEKJ*`[5.)#?L-C:70-E6&ZQ<3.\ M4\1X^V)]Z$":])ICO`V(KFC(`B+HXF\6WJ@YD6:[YYIRP)`SRNES[P\83"#H MP5S5V#7D$@J#H+%I?-EM%$5Y7?'^D8GPAJC/&9%7+ORSGDL0&)IF0;N#3:"S MM@).<]M;VP-K0*#3P#M:TQM* MR*>RS:,.:WH#L"V%D8LL5:6%2DVDJ,#GVU)DWU3-K`QTE[P\!;I+8&"!*"N( M;;5OZ8PP"1IQ/;V0."#1?RD18S M```.Q`,`%0`<`&)R;&DM,C`Q,S`T,S!?9&5F+GAM;%54"0`#-T.R43=#LE%U M>`L``00E#@``!#D!``#M75MWV[:6?I^UYC]X,L]IG*3M.>TZG5GRK<>SG-AC MN^V9IRY:@B4V%*&"I!/UUP]`D1(ON&R`(`$J?&D=$=@7[`\;&QNW?_SWEW5T M\H)($N+XIU=OOSE]=8+B.5Z$\?*G5UGR.DCF8?CJO__KW__M'__Q^O7).4%! MBA8G3]N3#XB0,(I.SC'98!*DE,#)Z]=EP9]1C$A9]"K[(TR3[.0Z3BFG-%BB MDW_]%L2+D[/3M]]___N'T[>'FK6*U_?7#R?_.KN_*>DQ)I?Q,HS1KD(4QI]^ M9/]Y"A)T\B4)?TSF*[0.;O`\+_S3JU6:;GY\\^;SY\_??'DBT3>8+-^\.SU] M_V9?2UB"_>MU6>PU^^GUVW>OW[_]YDNR>'5"&RY.8A%_YU&--&BN>'6I3F(MU7K++X[LWN8[5H*!&H1;JE0"'2VQ]^^.%- M_O45;>B3DUU3$QRA>_1\PO[_R_UUK>)3B`EZ1H3B!WTSQ^LWK-";BS"91SC) M"+I<;R*\7:,X/<=Q2H)YFLSB!?T[R:*4XFVV)`BQS\D%2H,P2JB,.=-TNT$_ MO4I"6A^5OZTHJY]>,66I8=Z^/_WV_2DSRW]V8O?&DJ;G>+T.TYSVCB7C1PN' MR(YJ$/JV='G(UNN`;&^?'\)E'#Z'\R!.9_,YSG*F=S@*K:FERTGLJ*2B;\]>L'1"T7F1YRBNV`;/$7H+(@_66ET)7%KOBK8A&D0A7^A MQ0VB(]7M4Q0N@VJ3=?15`/JV=+DC>(-(NJ4HO:26WS`/:44)*6$GGO;=@*[V MG3T=:008T/"-@GF6),B2@Q(2=6*9CCY+EY]0$Q. MV8F-OAW01M_:TY&U8NXZJ1_ZWXPZU>S1' MX0L;\:RH!.71))KL./2KB]N*SB.41[@(Z<#]2'@F=`EH+ M:Y3$>XR*.QJ`3]&>'WY*T)\9]?&7+]:&$"%16U+?X'CYB,CZ`CVEUF)X(5&; M>08KU[6"=9X6B!2,(FA^G61%(% MP:JT`9F7`A=_5F7>IWO#.'VS"-=OBC)O@@C0A(*\<9EE9DGP[W)YX'40QA9%;).V(6].ZO4:K9\0L2ELG:X%25=4*#+/GM#K?4-8E)=+ MW2X>T'.010!_9`*(DG958OIC&.=^]8;^L\86?4E1O$"+DC$3M>>UCURP4K0( MSVOR1&QY"Q.54V&__`YG3=5&U]0+[0>H*'A"T4^O.E!(PY2UE!&%-]::@"VK M+;((W3[#!"U]T,C^TU MUT'+'T\,1#I)\4D'4;*$BH#S^2J+&S"AXW*Q4KYS,#^R/HX6/[U*288./U+J MU&U<1CDQZKG0DOUA!.NJX9Z#Y"FW7I:\7@;!AKJZM^_>H"A-RE]8!WCW^O1M ML5+]G\7/O]\'\1+-OH3-[MWZO6CVRN]]HDXR3NU0V!U&6*QD%5O&C!C"*@PD MB'%K_`^UJ*5J_OJ7*@`^U"*2?B`@"@)W]F^;#LNDKEIT7W5OH;**CS;Z0.5> M9VNNE;C?"HT;WWJU%"_\K9BI(1^6"]XRU:X4,U:CFI?F"KZ(S<7[5IJK_LTS M(^KD.@!K55#B;-*C6."F:@A>D-9A2$?9.\]!=D5SDBZTD)9NXH2 M9M4JQX0S85/T!K0J1S[2OO45:>&S+M":-=0X.]0X*I@)&J(_E!T8\D'VG7\@ M@\`*`J2C@&L*N\^KQ&8ZI4+NOZW68)/D&S^0.D3G]'"S1[?,YCB(T3]'B'KV@.&LN MKP["2WM%VHC7./-W0QK`0K:O9W'M3F(Z]Z_98A'N9/F8,NQ=0Z-)!^T#9.R!)/K=RKXD1]\7>S;>L!W8OC)V)[:=>SV3S;BC M5BMK]ZU=Y6/O#IPF&A3!._Z0JMU%P1Y8>8/H.(38D,32 M=.P>IN4N45] M_+*AXR_ZB)IGLD!EN3/E5EGO`:6CJQYT%)1]W,K=$/DJ2S."BKS=79`O121L MSQ3_*)]A;3Z0U+7'!BW-]N@$-C4O'_=W`Y4XSPC)4R(FZ&M4U@/?OK(7V(,C M"@Y&?O.(L:B400.<>]X^!N-`':[CQ\^8[225IY\UZNLAM%K_:$$J;*1A<%IE M/X)03Z(&Y8JZ@;5%01NN%0K'#%A10PT&V8H`(PX]=X?4.F&V14`7LA4"1XQ8 M43,-!=@*_Q''JNRXVTLW']LBH(W7`X%CQJN@F0;#ZX&_C\<:@7H\KA!!`3L3 M90;7=GT]M%;K'RU8A8TT#%:K['T\8@E4PPR@9K`\8C`Z@:`(>'_S8Z>RWH-Y MTZ;E:=/RM&EYVK0\;5J>-BV/=K^@#RTP;6[[RC:WV<%3'FJR=UVNUQN"7W;[ M,[CN$%!ROWM&4G(<>ZG@RAKLJY(2]Q$D0KUN!.=%X!54+N?&JW,C8@-+SX[` MJK7.CZBJ#7J&1,.DV%AW4&>ZX9\G43$ZTC,EP/;5/ED+-6JH1H1J#=^"":XOU-==WPV">/@(I0NT(6@>\J[# MX7TJ&JC^:10HD&BC;^XZ,>66!)?IX%NR#.+PKUS4(%Z<90E5))GROU/^=\K_ M3OE?U^9ZV$7S]VB#"5N>NHZ?,5D'A2ODSFUUJI13.E`5#^:W$D'/ML5'^517 MFT)KUJM!8=`)L);=L8TVJHRS"CT3#@C/:ALB4YY M64_FN/HXPWK-P)_H@MGF^)2S\WB,X"ZN<+_5O;[[!1.8B;%[&+:ED'W3VCX2'CQAPDIO'U'"7$PI''^A"E:Z7*Q2E784 MBO/[(M95CQ-#5!:B5*3\S^L:C7EZF7"M\4V9%+?<->XJM\7O)&22%%(5-_K@ M1YP&T>X?S;RL8?4R2:M=W6UO`@?O'=O%)'+79^D>8,6S!(5<_`E7+M_Z`!-4AT",V[U8P"9NEVL0XS+4GE, MS>F6]A3//]WFPK';MW\+V%TVZ;2&,:UA3&L8%8V_VC4,MTOHTQYVS3WLCA-/ MJX"@,W85T3E>LRNM@ETK[Z]'HY/*?9'BV-?LS;(;VZST,5AS MS]]P/I43KMHG7_*)EN"'I:H+$HW=>.<3KQI/'X>_4D+^627NQP9>W"^H<2V+ M%>+7=OE5"%3--N@UV+LGLA"B4W"*H_"E.LUE`KT[/7W/OSU9NV+MZ3-815>; M.ODFQ!VTYAF^%(]EN8 MKJ[C1?@2+K(@:@UJ=*![9*UT^WPHQ`DN^F6RWVO>#Y/C"W@&,4=OH5-?TOO8 M.UNB,NWN490KG:S"S2.^I%XGW7*C-,/:A0&U:[N+\WH&-.[:E-6^T(^LK&-H MR^CCM&-0Q+=V6/F*>=ZF,N]`+]VOYCWL+6_'R%5@=P<@PN0IEB<>-F@>/H=4 MK\K":QXQ%-/BRTU5Q6TFK+D:4=#&4:P@\]>`*JYKZ][ MS*C<[>?V7FCCC/?'C*&G:*)DEJ4K3,*_#CLHNJX\J>AW78@2TW>U9\?N:DG/ M[=[#JHE]B7V<5^6N=^>E$W9R.]U^Q.DN=?.PB<+T', MGU'2K'T<7:%3F_4`=%UYO!TWGM1-\=1LBKN,S%?TQSL2SND(2VNO<9PK7P0H MO`&D5T;5D:0G1L?1CX:R1$]C2T^BVWT]03:G,U&@.0MH:T`G!+:ZG!:SKMT. MR.SK[GHF%O&H^P'%M_L@A*P+<%BVWAEU\V(E5O M;>Y@AJ0KK]W7*:SWF]ER2=`R2-%5$)(/`?F$TE^#**N/P[N\6$(]1/J(?UN% M\U5Y"H.@RR_4280)2\5<8?*X0E8*(!J&A'@Q8Z_],)\:QCD=]@H0OD=I2-!:,*4=FG?7?*D9 M[Z_#._1H+X_RK&;:\'OSWT?7FR^8MPJC,-W>D@L4I*OA.[50A.'Z-D>$J8O; ML=XH>SI'*7Z'_\&3#E]=!=_KMTON[;2FX4@>J]S@(+XE/V]_1!LSV@Y M_!(N["UQVI2EJPNP(\O7[0MZL*='3L&.=H+-)J?N%[,Z.,K;+$W2(%Z$\?(> M1Q%M"/;1?3)1K#\EUO)M16)]!"SE8FR!S M.$S=T]@>X^B@7#V\W5IXG2096EQDA+VDG0N;*Y=4+R@KP_=6#S0F4-U@J$G@ M>/M/U]8_C/!"?6;E%2<[`T0'$Y'&\'Z]T>XQB@ MN'H(UEU.3X\FU?(;"I>K%"UF+X@$2U3+2;$6?NX[#:,I@/T9(EB`L;F`OM,W M9I;S.K4#5DDPN70W[V?#N@8NQW@!>9MFZM\).1T>>QH"Y/3^CQ7SR,D-; M^"A\C);ZH\QDJMJ@GA`:TKWH<[;E6W0X3XYE4-L>@5?1T?U(,Z^SQ2+:V3[B`>%E*IRAXCD;_G0*>G0"T_!>I\:CD]+ZGY MO*1SBQVN.-[=0/D!I2N\N(Y?4)+F^9#6-++UQB&T8NL10W5%?YM%_NPCI!*T M.9P\V*AO7&RH/_^^;17;^NN*XZ2Y$*Q10^A2 M.35<98B-YD?Z;6`^.0+Q&L1O"B19XXS^-\HIH<45)H=4\J$4#$1:I.3H`I(Z M!MB9M)IU/`*%&.1I!8&('('8W;9AFK:.S7>@((>EG,(QH%&CC:R#4,Y;F+BU M_98Z6#ACU!F#[6@QY@!:$D1YLEIYCUYP],*N(<(IN@NV+"@]"^)/QMW)YN?[-L^5E MB>"RY>5Z-1_[U;0;0',W@-O>Q>*9V^=S@FC,WK*\L)]'3Q>(]S#88KE@5UE+B#.@2HN-=>:^KPPE!Q06*-N05<)KA5AL? M`]1206.?T.91\G',JLO)71J4%>%:V_UZL\2.+2LKUX[;Q-H&]GD=V-#$K3C: MJ9%Y,P%]*TOG!MWM[#:>V:(6B)2`5_!_&M=4&#^L0 MRH.L,LH%X3IYG2H@.+@?YS4,K82%,@Y0,U,CI)\X85B,M`91KU#""Q3LPT0: M2/0/E$&="?L_-XC0K0:"2[6:H]!"RT\H`2-L!SAD#E$(G)5C#W.9$;S`4100 M3>B(*BK!TZXX>O@HVL(N@-K,P+['QQ@0LC]1&NHIMR2ZO2>#)WN1=#_#A.#/ M;*H2;.B7=`M(\*JJ2G*^XJJ..J`T9ZM*"`,;HG..6,RGGS%>1X994GWS<#:? MLUUKR3V:H_`%N�E;0!WM2DCPF/F@W9&U[5O#X`5*YB3,);Q];HR= MBIP*K"HW>%%5]1VM'1I""XUZ?.QNG>T#;;F@#QN"@L5M7-5`"C1E+2[&)+7& M!2^H^AV0)6'!!]5W?4ZF[LL=BTID<$MRT=`H.2X$R-3L8/4&6;ZEOW<>ZB>E M2N<9(>T]T;(BE5"J7<1W#``4TPYMVO3X5O^;NPC\CH28/.(91>B"LP7>!BF# M"+M-:@SPL=10O470;;Z>WIW#4VIWHJER.3$`J<(Z$DARZHP1>RK5.X.,PP!R MH,?E\0O:#\(TB,*_T.(&!0FZ?8K"95"].\[9"8P[@C>(T"X:!7$ZBQ?LU,LF MCQ6WCY0W9\5=HT9A*!V3C;N$J%%#U0+5&NX6F75,BDWTKW9Z`#/6 M]4%,?-R,MA>4NRPD^%HYOU?[ZF@$T+$P5BD%,OZ!<'GVKD;01T//LA2O\5,8 MH81K:N'WHETXW\=A;I5B!@;GD!QD7\!51JBD=(B^"K^D^4VW\>+V^3F<(_H' MN]\V2Q&1]^@N)(H&,R,Q#K!8:!X#/)EQ]7164H2/>>BXF"4)$M_A"2E:;G:6 M%O7@2L2F@$Q"^26=RAJM"PXE-08]X0.R&S;1M;;S5\*E?A6AA'J_EV\ZNQ5* MW9ZRR%K%?YJ%HQL7\JBKG:CP_LHT#]=#JF MF*2/QS2JTB8WB(J+S@(*YCEZ6"&4[N0_VWX(_L#D/`J29#:?9^LL8A<&7:`- M0?,\-R*!C06J')1UHCHB4-IK/5,,=Y+`Q]T6->7D:GU$S;4.L\H\``,JCPFG MNFUA#$<`(^6N"Y<)YC)DJ$8+4V9YRBQ/F>4ILSQEED>76Z@[G3#7^E0,3K2Y0Y@^UI<\Y!SM+?PX3(/\Y"MUP'9WCX_ MA,LXI$,\4V1W8"R,EWTN([3(%Z&U`+RA66= M*F4D":KB@7N6""IWT-"*+1>MKCBHD]8R+N[0`E7/`&%:=]5J9D?S,*1$U=H2 M23N):E!3W5_;-3T9QL#XPUU:AC^@J7CGVP1;E90HET]Y)1PE'$S1 M@"&*`L'"8Y0OE_(8^`B*Z_4F"`D;OF^?F\KM](Z8W@V@:-8J'X"$UO(/4-RX MSJP53((Z,"?(EER7,[ZF\*Y7W:>IW32U.\JIW327F^9RTUQNFLM-<[EI+C?- MY;Z.N=Q''-.0>X-2-%L2)-D&I2Y8M)RLX/B0`E:[(V!D?`;9&G47I(SG+%[< MA'/JN@4GKE7%RET#PF+C@P!0Y8X`$'/Q<9N26,%?$O2<13?A[>%(>0:R.X;D9R)]]4G5 MQUO,CJ?9)WM'?\V`G7)IL?CE70$+2.$8!VMJT#2X59S M:SPN8X'-6S!LWH)A\_:(8,/7VC9LWLIAX_SZ8Y[,[\'(>0]&SOLC0@Y?:]O( M>:]$CN,;^G?G"=IJS9Z2E`3SYNH&N'R9B%:7=QT7V4[%Z#91KRD6@#`^[B4X M#Y+50_XP&Q5&U/.:NQ]UZNRO!@75<011.)*PF?I5Z"F9[:X$!3'Q^@8*[H3$ M^:&D:0%D6@"9%D"F!9!I`61:`)D60*8%D&D!9%H`\1&'O[\;!1+1RH<]E6L#,ELZ=D]MB3V:/9 MC/VMLUPD:]S\-`XUR/]F010^;YEU=H(F!W5$^4;C^@6&#.H[]1@L@+2@1OD>E5 M:N%67LEISLT,@]BP24Q0N\^=03GZF+.0R\Y-5>A4`2'.?8),$S-*E"GS8C"& M:G#UDPX37&^RE^`*DW/J/UFT1_O'.8T@PSRT9'TC[R3$T*9PFA=.D<)H43I/":5(X30H'G11Z#:W6NK]7X.)MA.@' M7=+]#\/@R_*=JE/284HZ^+2O9DHZ'$_2P>U0^`&_Y/.,ZUBNZ3V.(JK:YX`T MGX/J0*%H;R,*SL%G,'OMWE2=Y[!&(OCH`A4=$RVR.?NJ-RUM5X-%/[I-A>."?]; M0$@0%V_ONLLP/*P"@LX".E,Z9\\?QLFNF9ELRWR.=+8]%+D+MNRG&4L"B5(. M]@B6[XY;(.C!,^U*-1*1'O)7W"W1;3WRWIGNH(D.BZC#_;5N[6'NSA+7GY?O M+.G1['N[HZ,!>]N3DS?A?2I?3*U]\N2]>%OPPU+5^>_%=^2=OZE:X^EC0%A* MR,UX\#\V\.(^B\&U+%:(7[5YE4#5;#YG&30,U]K7Y,ATO)U<,-M)=V:96<_R MS/YRO8GP%J%K&OS&:?A2C7:90.].3_F7@.A7+-]NT*CH:)XEZ("X@]8\PU=> M7M`@.\BI/X!`IZ:P.#6%Q>F88<'7NC,L3OO)`PXSB:K-K.=4P3#=YC'((PU, MSZA@GS1G3W""P&D3A*`C-`X[<])NV>&G3!`11]E+V*_)+$M7F(1_H<4O[`KP MAB>@(?WE%SHY"1-T1\(YNFY.KM@;N7OV_45*[ MJVK]C@='EOVVW#R<)'J/'+I[9C$'KU/ZEGHD'L(Z.LL%W?3*.WX?^OB8T;;J M.[EI\1XY]!%2N5]9Z;,O=>NJ0'M8&IM%RG3LGV(EIOYIB4-KY6C,/92W@#:^ M+BI=S!M_)[6]L-AB?QL+WH%7ERS7B&0EO4H`VAD+L$[C]#:=JZQ'R8099EVR M'6]^QD!4M4H*454I^;6@2M0X3E!5$<:1KWJDY:'>BE-6C*QJV:\&6\(&PJ@C#1]7WO:,* MO:`8BJMV63&RJF6_&FP)&\@-NJKB\/'UM^-)#M[@SX@42Z#KL/GHW1"L>MDA MT61U#'V)O_P^G(4&6GSO52$O-U/:U/B7S6:H_BQ@U4=_;K&:^G-W"XVP/[<4 MLIL+\;`_?\P8"F^?;[,T28-X$<;+8J-FGUU;S;6/7B[C.G5XJW8;8=^7Z68W M;V71#3Q94KZM]&\H7*Y2M)B](!(LT3UB&*:?*[?E/"*R?L=S$_Y(574C/DAU MW&[&AQ9VY89\T-UN#G2,;JI6Y0PMPSC.7V_/+U5ZZ]17P41SXK!4HDU>:W@$ M'*/K4C6`W6R[Q[.MX@O;%S[@;$O,M<_9%H_K<3N4P>TVXMD63S=O%T5L.OG7`1RM?!<."UH\0)VZN(>G$P7F>9L6_LB/7!N0*-UCER+QJ#'P\%6 MQW;:I.JM5+SK)[&U>([W1#5,3C)L683_.$.3<0_A*PA!8.R M#G2>*!07X"#-_7E;`S1@@)(`#\=AT02(SV=3#8#0.H;H$`J\@YVV ML"`];MD7&MQN7OH0Q,'NJBWN=EC1Y_)9U]9G1W-&2;_&2BU$5C[L,FT3&.3H M89G$^2>=7D7;_=0-+1Y03*O;U&< MS?_,PB2L9G_<79UXEB6TY9.D(I0H]0,I6AA<7M2#E`]'0!I@5?XES_;H56\E M>J#5!\WQ@,R+.[="U1?(6-;3.E!61W-E'D=A3C9'44K<&[W*TVCB"$/UYN=C M8-P8_(19"L[H)PH1Y6(+7%@XR\MC^@XL;*W5I#)U36YC3([4!`J69K M]M#N/W&T.`M:3WITHJ&'JR:-XT"7M&5ZP%B3G_+0E=,G+;*G!/V9L8SH"SJ\ M9>%3/J;O>=\T29DF*5.<^17&F8[OKJY[7E'6656L3*X*B_FB(#>C+"G"5\S) MXS`J$V"0)K5TG(!DGO7EDAIO*K>I#^7'>\%$7DJ`AGTIMZE4-$:41>#@F+/^.?54YL?'=1S4JV_+-KWX9@D]6@`&?]\%U1D'[O03G.."^ M>M`!"/+W!RQ"P?$-7G5QN=&OM`P?`*XO@E1V[[;IU=E!D< M@Y02`V(?*O*I^#B!;DK*C5+DA02V=A^/2&W)L;4R`N$1Y)G;YXQ)!X.W$@F. M3^!&G*.$?$Y25*<\*\LLXBE,5'1C#=)+9 MNG)ZD$]ID*5=QO4&!_S'3O@?"]V:'[TUE%0+F(6:)'0F#GX%(?HY*T$<8IZR ML@';NE`?@C0C8;IE9I+.)7@%N5.*>D%'T-:>8TC4,YIJU.GY./C4Y:53>X*" M!,T6BW`GYADF!'\.XZ5\]@RIR,6)O.)8<*.AOA&.Y/1]?..A*3\=%E"2W@DCS\ZK4"=,/P5*>NX!4%.!*5G$\N`*K;X@K&?U!'KNL"[2_5?//+(BH+"%> MA/.[8,N^R3T0J"87*HJ:8\&*3@,8@47!P,>[V^L*-&26PDE0E@N@5MFQ0$:N MI!%(6B1]O!*[NN[*R:XT/U4R*H=/_MI8H@+0I'4*/MYF7!?^*IBCW>$+:9]N M%^-VYVHQ?ZT,5,VH$U>I>;K$-QW6LX(B>^?T)."R=$2/8LYM>K[124B^$6F^ MO7W6"2S4U?A.25+-7W@9JF[FM"34A8#R*?G2D/J.A/$\W`21%$ZJ2I"`M5)I M+%`"JFTCA*W0%L+(DPNV'K+U.B"T`SR$RSA\#N=!G,[F2U/%_0.D*+Z[C%Y2D^62R!8#6/530BJT;J-05/;BD2R"D M_&HN2"5HL-;>L+YSMA7L_-6H45@35,.9YQ9*)]P@J5%# MU0)^[)75,2DVT;_:GP',6*<&,?$Q$N@%3ZT]JCXABK<5USZDI-MT^P>5VT3> M7E!NB"#X6@D@:U\=A0Y1L@.269;B-7X*(\%F?N'WHHTXW\A7#&]T$WX@A;7<1K$R_`I0K,D06ERMOT0_(')>10D M"6>>;E"S:$VMFCZVS$%&80K6L+:ZA?BUWGF`8>$IS!VX`ZG::>9XE-.Q%Y"9,!--+28DRC.25HSRLY#'PT6M]Q/& MAJDEQO/'(MFZUBKF/6#F9TA0'*]I$_3'-W,S M%];;K.,SL]K,1Y)`%.@E[+S&T%92U,:VA.+1@!O::OV@6\)]W([[-ETAPI:/ MJMW7&-I2:MJP%E`[&DA#6JL?.`LX^[AS&:[4;(U)&O[%1IUF9&L,:`!-;5A+ M:1X-N.$MUP_$I?SM7@PI2$K`9;U`&TP+F,.T24`;DP<"1P-`09OT@[8#,Q\O MEX3K\3/&B\]A%'&O+NQ*1AN533)'@TUI^_2#T"9+'Z_0U)YMWH3!4QC1@B@I M+I5*[H(M9Q-$#Y1-,Q`RRD<#<-U6[#4G(9-"L#MN)-T@?UNFT(7.2B67"%NE MJ0U]*KLD=U@WFO2KX+XO;Y(<7S3[R+1%7EFD9OEW.[@X)O<0S7C`N+PWV= M8BI^C-A5N;B;1\4%RM-&G`(.K]94F@T#=.(:M4DQ/S+$H>1E9/:`")OWW^7# M(QV^-CXZL*1^NI1JHA^MF=<$&'1],6.XJDEE24*9FT%891W856`[#=*F: MMD[I8-86!3]Z)'M)9Q8OV/_8WIF7(&)GE&?I>4#(-HR7OP91UHRFM>J4@S*L MCE/SBXR,S51NHZ+!(!^O883]`$N9I3]L(_R(TD*II@L`%"T]@;2HKXC04!`$ M!#D]/WP_N[0[9J_,^[:\UKW[RU9X2!4#VJ]^G:PF<<-J MX@*%ZKP"OEI0J0S(CCPJY88[M]:\*.+ZQ^#+3CZA\P64W#_V)2GIJZ'AZH$L M+B57;D'S*.B6!=NR(-M?@W;NM/S^^KU;HPGWIO],<`)^BZ%66'5E?%'8NTF4 MEG;RV92*E!^1$HWFLG46T5G^X@)M")J'Y7;$".66B!?E1MA\R15XF,4VV4,$ M;HFL=\CKJ<44,WYK3/V((X4"MN:12!T M.(DB2_2)B]7"$%XQ[ZP,U`B2\>,1\2.<%#SJUS"NHI3P4;NBE%/32@S(?::. MIUG;QFVJ_+?G"FI>KKN5)R*:&K6FD/)B^_FCJ)C'Y@?J!K6_F)R7"SCE@8.& MP9L_%XUP^-EC@PIDAQKP4%UP9MAUUK5^3(Z&"9=?YE&V"..EP)@Z5?996D@5 MCT%@H#,4(##2@E.ZWJ2`A;Y>6J:="!Z)EX=H!06`@);@N*KK`;Z=SI0,\Y#" MDF3Q2,"@I2=\X)<3%1PY]6MFIYC1*69R7AO=4N>']ON_^6!8KCFY1O1V\FTP MU?:EHUSTO*]5_Q"C5U7S4+N\0#8="75 M3&!]R9ZK)CD_;'VYWD1XBU#^^@=:M%5IYFNAY."P!E/W)Y M%,`D8Q?&SO$:T6F("!K*<@>G("KG-12@^FFY!A%%/Z*$/"51/8$MV>$G*59- M[W"+>6UWH'9PLXL)^I'.8W%N%R]ZP;W\ZP MPOOS-?+"7EM?2U,X$%1D_-Z96`[NLC=8J@NB(T-88#@X(:3]6 M\=IZ*.,Z93SGN=V5&L'MS"/ER=J=(M(4S]NEQ8';/4<5R6OJ;B']*V#CAT=@ M(4RX.S?*;H/#<4H]&(KG8>NI7D#)2C@H+#DBJ,`U-D6)E(.'=\;?!2R]L4(I M>Z-]ND!^ND!^ND!^ND!^ND"^&$JG"^1M7R#OAV&G&^-'=6.\X"FR.K.'%0UE MDEF6KC`)_\KW6^^.U1>B_4\6A[AIWBXDN!EP*`DOC]%9:`UU(&#&Q,O[3^2J M:$%-"U2CA(]EH'BZT,X3^CI),A`"%.5:.]-B>NX24R]'550P1$T\O;52J2*X8.0,DV-D8R M:,!UT\("=+AP?8JC*3%WK%"4$MG>ZU$"II.!S>7C@^,3&BUI;[,T28.81;PJ MHW.*BBQ?*SH.\XNU,\!`C9AH9YY'<2(P5M"KQ(T?1Q8Q&&FL&U?JQ@VNUV_V M.A59F/HRI/.L>,N0TQK.M(8SK>%,:SC3&LZTAN/4L+^_\\>TZ#G(HM2*;5MJ MV;"N<6I=L%A3Y/,?$,OGPQ?>U.7KRV^R\CXOPH'U!"_%R2AZTH,/TS8N!(3? MV]->KTVLTD-M4@X%/U;`!+OHN>8$E96?4?#:S#KZJ4VNH.;':E=SGSS7[O)" M@M,(7EL:I)':Q"(R79>R!"-P><6-*K M[PA>I@#"W1NIBCY-,?8GH_38>[E%2Z#';IFH`U@!!.1HE1)P>?[."'-BP,(; MJG5L3T<2"6:E$GCYL)Y4>Z;-&>W$M1T0"Z$`\K-^8;8#\)2>5A>W^K*H?:T6=CUVMK,Y[;9)WE#MA4&]:@#' M6J]V7.Y4TB0].M$Z5R]W#$L[DC[^Q/4@;M(+!&K#2.42@=B#\E6Z/PCJ?'!Z MM5ZU4Z#9_WB@TZ@FO&)$5&VD3D^_26PX/1!7+W<_2KL/'(EF%"".T#-\:H-, MY1*U,0J50.D<]7!J^\AH2[3'%:I*=\7N\`L``00E#@``!#D!``#L_6USY+B5+HI^OQ'W/^#Z['/<':%J=W7UV,?>>^>) M+$EE:Q^5I)'4[7%4[)B@,I$2IYEDFF2J2O[U%P#?20`$B`4"F5+$C+N4Q%H+ M))YGK87W__'_?-M&Z!FG69C$__-W[W_X\7<(QZMD'<:/__-W^^Q=D*W"\'?_ MS^+_^__Y'_^_=^_0:8J#'*_1PPOZC-,TC")TFJ2[)`URH@"]>U<5_"N.<5H5 M_;3_KS#/]N@BSHFE/'C$Z#_^'L1K]/'']W_\XW]^_O%](]D1O+B]N$/_\?'V MLM)'C9S'CV&,"X$HC'_["_V?AR##Z%L6_B5;/>%M<)FL6.'_^;NG/-_]Y0]_ M^/KUZP_?'M+HAR1]_,-//_[XX0^UE+`$_>M=5>P=_>G=^Y_>?7C_P[=L_3M$ M/ER<,=L*1JKBI(:=TE\_5&7?_^$_/E_>L)5(T5TAA(K@_*#6I5V MWO_YSW_^`WOZ._+U$"J^7YI$^!9O$/WO+[<70D-__@,M\8<8/]+VN0P><$0L M,A7YRP[_S]]EX787X>JWIQ1O^+JB-.VHHM_VS_3;OO\C_;;_1]?"'XRK>D]0 MA^W7MVT&H-))'D0S5+IEIEWIB/YT2?[5,8Z_Y3A>XW5EGAJ0`)/9;^!6ZTY6 M':T196N2=M^)8I[4^?V''W_^\".K,?WE/S_N,\+^+%NN_KD/LY"2_&:?KIX( MR6[2<(67451R_W2?ICC.+\/@(8Q(09Q=)D&_W/T. MA6MP(XM*$VJI0I4NQ)2A1ALJU:&6/L04HE+C__A#TT##1EVF76X$Z:KZB.2? M(Q^^+/&'54*BP2Y_UVF#39IL+0`]L06R-F;^@J"THSQ!T/7=9Z2>R8X6#2)/ MJ/J?/^F0-1]&R(-E+'GSQ=U3DN:(!.1ME[5O#-3#SAL'C;[C!QT.KI/5?DN4 M,<5'0,,/OUO1,=F@H$7*59(5OZ&'*M*NDNU#&!?Q M-"CLD0XA00W5LBH#+.EUL@)$-&+Q=5>BB_S`K%$;*9$CA9C*O$M*V[/D%72\-] M??N0D5W7.F@6[13P-"ON0CZH6X8`+DNB<,VB;/`J82Y*>5\-T(%35;=8_]#' M>MJX]ZQT[PW\<^;>B[\=9XD.@"_(^OP!OJTL[A8_XWB/R[J4?^GD<5(%*IF< M0($]XDMK/`/Q1?8G4I^O;ISZ:5&RX7[Y@\_DEX--C?XJ@%6A/U>/H@,0U&&V MV,>UKY?F3>S2S`'^89;'Z=BT&JSHV90_O$;T3\K[C@__6MF?23=G%A(,TK\8 M=YQ^I[_3>N9SK\<>`Z8D@+,SP%82>!&ODFU5E^(/G110(JZ2`'+%[7%?4EN+ M<8]O=2+A>LUV&*S6NCR-3A><<+8HLY]J?+94BO2X.B:]_\YG/OW@X!IF1V MLQ+`(*N[>PI2_#'(\/HTV>YPG#'@+M.4X`W3ZGQ\:8KS M3';N*HL]Y+PU63!=B"E#;8.H99%NR6B7*ZTB9A:5=E%E&!6644!-HY9MM"[Z MBHUYMY[9#9T3IRSI1H19J]"$DYG?'#(9F[7JH%V75^KARDX3=4A?P_PIC-'7 MIW#UA)+2:VWW&?%O&.%2*=M_1I<1%@4P+OU8WO)C)`M]"C.$M[LH*3QAZ=G2 M-\_FD"1OONV0?!MP+_6UNK?A:NN=@;=#^WA-G1WY)7Z_0,!_G3_&,/PBK,-P3!J8+O(4WX MU;P?D.#5W&E8&U;(Q?!$4PN4I(C5X^@#F)CZ<\:Q,06 MYP_>X-"&,OSWC98&-H:)_+KC#]=O_M`'%KUYQ(/WB(5E*_$ST(X'I3O.FG)/T[)2S=_'^=_G4? M$)7YR^?@Y2,IESR'K1/)3(=)(.MB.EX"4QAT6A8U0B1*M'`6U7J0.,CJ-,P#Y06?)AI MO(2H$D#@A/DR7G0Y(%[%C]&8X_:SP]7Z52\#[2H_F31^LNB8T(['QX2ZV._( M;P&Z8YV0TIV2E]B&>8[Q]Z1;@D+2O\E(\]#^QHI.MB;Q"5H%!*/%:5GDC8/X MA7$'QVNT36+,.B2/E0NF3Y.'*'QD7^7-`_OB@<$'>=Y\L)<^V)?QGR-WP]P1 M(:E7IJFJ/<>,V:F$/;],_A*[YK).Q3`3QJQ6[#WVZ2[)BI>(`U(\?D39GE2V M+DG4UJ]'1Z]8\OY(;8P.=1WJD-4Q!@3H0:Q7%!`,AK4Z5;JE+W,=X\]X^X#3 M7C11*%FVG+2D42Q3J`-`KB^W(@X!,KG%?_OIAS_]D>*)_<.MWU%IRD3CFW<9 M*Q%H^"35"IG^2`SI=1#'DQ,+N*']JU9@[X5QYGP0B:V.XQ@4GD2=@L-!E%:Z M*Q[5M8$DDB+VQC!9`41*H"]%F?]])#`2I!*V800:AN^_)HIA>%!2&(9;)8$9 M,*B#+8_:-J3#@T9NU)_F7Q/O_.FPC25$$`%"2(-:0$:#EE:[WK0V!#J`:P%* M-#C_MP\__/%'EM;1?QP';-3#L*_`L1:&S3$C"L.DA+=A>"*,E,,P+(Q@PS`I MK]H?YI05A^)V66@>#.L!SH.."2TFM"0%3*`E_.4"IY%E;!!B0LR&1D3*A[9F MRXZU,64[)D/@BL7E/_[P;W]B<9G^XWA`I!&;O881\+R0+21]4.@NT.+^=1BF M(TP];(,C3"5TE]^)?:,,KWYX3)[_L,8A^5;O?Z+_H&']IW<_OB_O,OX_R$__ MN23H65,$G>%LE8:[-HY*T,J*E!^"7\2()#*K9C%;H%E,!*[`HOX5M7YV"W9I M2R4J7[8+;%[)!L]\/3-FH)\(>A03T&%18?[9+@KLYH>U@,X^.Q9T7'M+D)][ MT@+>IIZN_E"8\ERU@F`)Y9S_NF'G_Z-Y9ST'\>" M'O6,TV/\6$\W(2"DD&QN2&GOR1_NU)VMCY_L-\D=,\_421%N%DB(7DG*EA^*PZ-CDL M*DX-6T6A/?*@%N"I8=N"EA]N!`6I(5TTZ&UJ.&Q>F0L6@4'L@&L)J0-NZ;4< MVFM+ME-#'/[\O4\(_>#4=.18]&:N@O?NRGA@`04DD-26G_4L.IR%)/ M#8&1!1J@[\)OBO%Y4%(8GELE@4DQJ`-T<&X;T"%"(\
2YMY%YV+`2`HA0 M($1_+2`#?TNK7:]:&[(0?'XX#-NH!V5?@6(_&YMA1 MB,59^,V[4#P14H"'XXX)+3*T)`4A MF9;P-RAS&EG&!B$FQ&QH1*1\:&NV[&,;4[;#,P2N6(A^_ZS0_;%,1_P+W=)2I!V]PE!D%\!7.,KK?G-JGU^UE>])` M*[Q_%B((?K?XCR!0AA%3-HUUP'0F4"BI.\GIFMLNQ&3 M>L'&LNDU@=\L["&9.MN-&5V"6FB42ZVS-K"$DD%S9H+S4.L+_<3IX!L!ZV\$ MMJG+1^)]J.-8HP#5&E"C`E4Z$%6"2BWH\BV<<;%R:'PR3IM_V3ZD.(J"IE)Q MO&\JQ&K!39)U!#LIL9H@@-_0J2&$CU"T-^81E-14[*\*M[G/BC>\9P(^,%T+ M,6,)X'T%X"I=?`U(E>=O1X=5\%&_ MN>'Z8=#-*7QLW<5A/1K2ORF/@2LO%<(]B/O;J;$.>&F"Y0KP!LG3:<(.ADP9 M2F_#[+?3%)-DCO[KEYBU,UXOM\D^[B=/^H+E%],1-"*V?@W-DBV(Z:ZA9 M=,HB6N0$%<79'Z@60(6$6XI.@$PRO3&[!%67;PBJ8Q,R(JG;!9L%_TZI_PZR M+"&`IP$^S=!.Z2I(C_D$M+:@Z5.A#A<*6MZ$J3U"IM+Z8BAZ*7^I% MI6)4::;W5:%"M^-3[:UP(;$*P=Z9\Y`F6F?(P]8<])(0R*K!7KQTF/2F.7W% MWC)3:=V+L0M>,D;F54GF;4EF7)%Y1\B\*_"#@]43>L%!^D9K?02^$1ORLT+? MYG.@W!YV5L(^U0,`OK<6U+"..Y'+R'N\VQ0YPU.1,S2#T#[<:'-(3D)TX\P1 M.`E;W:3[IS!=WP1I_E+_7(W03^H:Z>A3Z0ZIZ;/G477>QW9RI%B7B4Y32?OB M<_`MW.ZWE5]LO-Q)[0K+@9>SNLY$WOW"%'";<74+&X###,]CH8Q'8DE MN5`Q\+J*@G#+"(O767O$ME)Z9-F-(^9/ZNJ\U-Z$)YQST%/8?GXF.+'(._3&TR?84^AI<^)HQJ\CQLWU:X& MO)MJM`,XJ5K98?JH(8"-?92($X8>JE9K[J%:-?0A.ZBK,]_LA7ONT6Y!KXM. MLGB6JU=%7F%'W28=H=/UUT#(.6<=/.#D<'9A.T91N`Y[]M9CM^X"@'L-+ER` MK5Y#_Z<4;\/]MIK^T.DOJ&E2Z2F,:;+G'=7>P6+O8+0"$_W@B%Z5'L'PYT)) MO1[*8\>CB$TUEZ,%=!57(U>HZ&3&:C5;AB&OR'S)OALJT03_;X.X7#(%OS&% M"X4WKO`_T)QYN".Z#'/O9IO!,+_M\>C8\N,YR3D5F9ZU/C[ZJQ%!;[N_-B^,5_NTU:LN%_6M M]VD8/[)?4KQ+TIS^M<-IF*S9,-B^WG2*2\N98[8K8RC1;>D&FJ.ZX<, M?F/6]+)!<9_**EYI2M?L9ZX*#;:#'!O21.G9P6)-*YL:Z7G8!=R'-N`J7S9P MDT<'.$%*,A_@;`VR5=4Y3>(\#1_VG-NP)\NK#*CQY>UU:V3UM3AX)C`[L>/" MU:8R4%9'B+:DQ[T.*;K4^AH*`%7I7_#4*/8J^#68K2//,S_?4)=]X+/SQBI< MKUH/BETV5>^;V^-^?="?-+)U9."?<^QJ!OP+QZEJ,A3=U2!N$K96?[7LI1[9 M>)4M^DP9FYJ9/@:IXAG>A#%>MZW16BP?\?6FJDI6;D?KD7&*:/D-]42-G,64 M6IJEA9H6Q8Y!2]&B+-U)],HD1)^$I-V[3)81T-#7CV[ MD&%/QS)HNN<$T#3)H[A-\3_W88KK`U#JT53:)'1M4[@*=W3Y2[DNZL9YDCGTV[T@'S*U&3D@R,_< M5S$QH4IOL`DVR MW*P60:4,*H2\Y.\(B,8(K(1!.7_Y*D8)++(\0Q3CFYXC0;.-ZV);>07?K(3O M[I7!5S,).QH`SY.'6<8O]DAD%X&-RN!X'.X.IA)6!YS.P8$D;LB M'<6C#DJOEC/$?9T*S9'.^D1%=FE#FX0/+TUXIXG$=T&&`II`T-+?OW%-#IHW MMNE]N'ER;Z\()]X779*L'$!]3),LHT>NMHYAK1#0,G#WI-7+ MUKTEK5EFC^F.@(MXE6SQ??"M7-+Y$<>DWODRBI*O=#K_4Y*>)?N'?+./EJL5 M7:#1W]8!H*G)Y*=K,O5GIN]@G+D;5$#JM2;K753"J)!&1+Q:G(]*!:C6P"8V M*QVH4N+<_QA#,P'$R,#;3%78\3+3:P6<$DRMB&+B_>>"1#$[WF$M3;U]XQ)- MM:]PCAY*UH0Q"CK$>0CHW4\/;X3I(^*-,OP/!)\]>\<9V4[F=16:PB(TY20T ME=MXT']7>3&.3;+I)`W2%[0.-T01CNF]A*P4,].A MYKJ*:4%9,?=)M1\<%2?17G-4)6DNVX>U3897/SPFSW]8XY"TT?N?Z#]H0OW3 MNQ_?O_OPGJ74Y*?_/*4[;./\4YBM@N@?.$C/X_79\(C0L6+5W;K"8F87,HY8 M-\MB)=HE5RR*A!;E$U0\0O09(@_1F?-C,D<;,5']X+V;"06E6_<0"O6YZBJ> M41]-K[8DAI$`>@8YL6P>U"N:E+K&^[29(?3_.6$S:WD)XR< M=$G.CGY!O[N%A*,P>`BC,`\'AV)-EE><,^'(6QVS M$M9WEJ%=GO7I@U-#;76@I@=/$U<0T(')0U%3"[W!JA4=39SV.B4E`%YNY9M`' MQ=GS$O/V::RNH2(\SJH^Z MH/Z6K;(.5GFVC.ER[&P?T8/.EX\I9D?R9/>TL]ICBK&>ZAC9Z7K,SA8KT\4DI9J@VK!2O0U:I M,P)OMHKT,]X^X+3G)J:*E]]67]S(G4VM+8P/FV!=[+JTE0WF+^HEW3BCO&G5H5>A#2>'G?%CM/1ERB2D,N@Y!5TOC!_3M0\9T7>M0%^@XA3\; MT>EL8FA)H5*,!<-:$'TI1!VGN?/#710!7PW@(6_Q<8OZ#^5Y%EV<_Z$N]NJ@ M+1C@\0?:!JG<35K.\=WER>JWNZ>`L&*YSY^2-/P7F_@KNA)W.`W)@_^UC\.D MG\Z9J"B_Z#051@0WJ;4*Q9]Q^I#(2#ZQ`F*B3U*XJ*501L5.4,8$45!+NN6[ M$;H2B-;NLGZ*IH;YT^H!&=BFU`!Z8,8+Z+/AF-;9,?&>.>ED@^(D)JI(7YKU MQ'<-00IF?$<:=-=E#6J5S\@WB%Y0>>!,T6I4*_TKS+(]3K^GY]1LP[P(F"KT6R68_OH.)]T!*5,&NXS+Z#XSZ7.^:* MDM%7R5V@F4<_./NA';#NBH!5B*)&]@1=B"CR:ADAR&%?)2-^!NRJ^4&+GSFT M:(3*P'6B'CE>+4U^/A2:&'3Y/@;K,_R0EVLY>[3B/RR_1O^A$77YE@`H.5`L M)ENOZ(+\C>@/U0ICMSP0M$4B_X)=Y';+-)CLRT(ZY:YNJ*'@R$U6N.Z;`^+4(DZ$Y'$AN+H_X= M=YXT(2)([V`@8A!K[I,\B/Z*8YP&$=U-NJ:+#;(\)1AXQOP(I"-2OJV:B!'P M=6JE%,.H/G$,4S0GYH>2@L7]]?WR$OWU_.K\EOQW>76&EF>?+ZXN[NYOE_<7 MOYZC\_^X.;^Z.[]S2P8M2"13FJQ+&Q7)ADQJ=B"]L(I%J+`["Q+96!PMA\J" MQ?$VG:)^A&Y[4!2%^:,`(W"B,`\H1Y(*YL+18PNP01>PU5;V5K^[O2WDI',B M33'*V\M.'"/F1L"K='#]'CZFC"P6.S(PD% MU@`ZU!S5DG,(^X47]!>T(S]Q+IXGV?=?')]!*&JE9.S+]LX<[)5JG34XD(=T MOWWM4''?J-'9G2BTV>F/Z$OUL^-54?I-+8K)<(UMX'[^GH8YOMYLKC>?]FD< MTK75P-B/$\)KM@!1`I0<<4ZC(LAM>E MW()=M;T3S4;I$F%$J.'%J'9(GSAB#/2&*HLPHUZ4%7F7%$#;=("&CQ-H(I][ MF%`#[OC81-M(=^T"0RI#(\A?-UV_#G/%E3GRAJRZI2ARDUOVMCR+C6%P-9XOG`PZ+*6 M+$"C;'AT<)T=\)W9P24'(,@<30UL(M/6!2UG)>Z*6]/YM[-(RU1'J_'+F!W) M([-K>/*.0+7DB!VNQ*+Z&96WU?MQ%8N\Q1*E#]P[_X97M'70#5^3O3WK7X-T MG=TG-\1<>OTU)JG?14Q'ZWI`&BU7[4(7ES/;>#AF'V)_H<2&9".A4*HUQ$_: MESU'10''>P5'VS)1_NR]O7^BXJU-?F*-H!M516:@-^T`@Z;8?B,>;EBU(;5C MD$J8.$TRZ)S?V3<4;-CVF-53B)_IQ%)UEG@>I(_8_9D#`.@3;JL^`/P!;3R! MQAW)78N'?5]%3Z.G)8X`-:(=RQ91`SH.-3KV-#K>!-Y1LSJNI-D7$XP?^=9W M4NDOJ?:09+TBVWUT>Z,^FNTN'-TYQ)97'[=QVO;6QV1T,:`Z35-Z!;K-ZU`' M7Y1@I#S(8@(CD.AV08`1/])+/(H#78513E1P$.V&!8'@+ZH!E`/DZ%)"V@2"#H'T1AWD81*=) MEE]O1$LBY(7*-Q45,D*[W#(`SH4&Q!@7B"R:B:VO8?Y$#[@)BY)H18JZ1?=( M"R9JW[N+:7[9!L\B79#>D&\#JA\+!@X:?$R3+&OMYVY6&`19=(Y,F;4N8V+S M9BT@D[\3AN7VW4QEUZ(Y,6J5;'=!_.+^O%U[P!:?'SH[L`TRFEN\BH(L"S?A MJJC#AJUS^0<.TN+JUJQ)L$09CI&.\NM-U&'$<*-ZFX6AJ:;%O)^F<=$7*]90 MT"5@5!*5HJB1]2ANF>$N`8%!E_R35#7.8&)-(*/>I"J`;A_WA!HT@U,CQ^LE M@2BY>ZTT`$X&?6&"5K*80*->("%0S9Z,Z"H:%LL5NU2+]MCHJ;^EE/.( MIH."9%(C]:FG(-JFFI(EV'BD8!)Z;=E,,!Q;<=:/+TPEC3.53N?!Q!Y>Q1G6 M<2`6:$?47$AE,^\%_EHE?>T=6X2E,(>9'Y8&.0J)P$E*2[]38'H9)<:MK$DP&V^FI/Q^4Y484=2LYF:,G6Q;3.&)*A>-'&H$V6$=M2C: M8-=9D2',$IA&[])]FJZ&_U/K8K'3LME3^RLA!E2)4:J*\*'6AA"A#*H[I MDW/'!`SOQ`ZX^GD*A.YV(@-35]@$'*).P$/[!\)1VB5=UBMJTX*O:<77E&IE MQ[8G50>U(6W4D#;LDC;U*)OPF[3B7N\;;16_(/A4Q*$P=W@07R`D,N4"NL)? MT3^2]#=T1Q?&HS.\"]*\6A__-QQ$^5.'\1VVUPOJ?Y\I,]_Y<)77U!>.+!PB M]0VZ(N5E+444NHA7>WI=ZODW>FT.7G\B+=E]@YXOF2A=?G-M:2./-[&N9MT% M?:-BSZ6K:U%=VU.F&)4(JF0*Q]3K)KCU&E,!E1BVWBX85V,,8[?9IM@_;H7D5!>'V=2%=E.R^#JP#YZDNX2[+/-L7 MW_'@7ZR>;BC@.$>XI:3]%W MI->8,9GOW7H."!`F@&CH^@\#A8T/,:H59/`UJ`CTUBH/&3.V#2O>;Q]P2L=8 M"N*@D)E!:V:'%=D5]_<%&0J(=+:/BC,F&R(R210T1AW';5_8)TIZW_A7?2"@ MC6(^\HXDP$P<%?(GJ-!PPBA5*#DI0EAV@OI1+6N'M343[<;IT6U,K$6J<0N@<6C,''BV9Q=RLLPMJ\"8%6#.[[H?;\Q$ M_;/W;KT7EF\0+],)Z6+%=J#.EP;'"PWN7,1XXD-AH".*U@<"'N#I.7@0#5=; MM8]O#AZ2?8[6%[#">!T^A^M]$"&\W47)B_MY M/2!P"U("N^`VV7O&/C]MFM,D9F=N9,N85"&F0[IA_+A\3'&!B-'3<2!45;O2 MC%29[6H`>`O#_6IF-9#LBMAS(3+.F8_%S?2D,3HT\SLA:4R.5 M9C['T@([HZK`[KSUDUJT/WGL4=L6B81;==]H9'.UJJ],(IWJ5MRARU5Q0ZQ5 MAUBKAEA!K?,'=-\]WG@;O*!=FI!.,$;T%)JP.+&DEF"JB-O95CN=ZB>N]PO[ M1%+17N(#(*G)MJPP#Q]';N,L*:Y2M-I@)2UJMA1>H1:&6Z7D%B1+V66"B^:I MXT7G*LV8Z'SNWN)QB41KA;A4KS6X%P=S71#6I0'Y0C>D)4=QKR53?@M%&2,F M:-7+C!*JIL3<4-.P*`].J\LA6M`M7_2:/YG4.ET&*8DV5%*TY(93HL$8/2$5 M5D$-K^C5S"*OU')1115\9ODY`**)#37*C0QIJ,DJDLY2[TK-)NAHQ&P`I>,+ MA^;\C:$H&A@X(C`"]^GGPV.WEQ[&=&<*WL9CC;OZ+D9Y-]/ M!7C#&KP[ZE\'-QS3_:KY"^OUAZ23[\N,M66<"_K6;G!NLLRM!"CINI^SAFQ= MNRSH/>B(5$O?E$3,%J5HU,IP99.:)WPE)NA54`GG3N9B`FF1Z>_86 MTPS$[A&G'HPWBUBYCM`W6F+;$8YID;$\,@W9:09O. ML:1I^(Q1D+-CZ*HGKP'APHTRQXEQX'[,_#"GY^4$#_LH2'LWHT(`WO5&L'D0 M+]JBXQ3Q!IE7-1.Y#Z+6?F.2!M).%;O[6]"GT1`VY%R91;Y%H-+9_Q.EP%*2[^&ZYOZ`!IDRTI1YH1/A%F74>8M+D[N[@[ M(D,/8105OVRK\$-EMJ5%QT,<7O!,,`#B,\_L#H]$T37!7'K_%*;KFR#-7VZ" MER3MGQALKDA]^$2HR':O=.0-K`^OB.T;=5=%:A4S62*/F`+$-""F`A4Z?'BJ`5R]VRO0I]4-%M9IY@$=03V@CY/SCD0TK86/WCDC6K4/*F'DRY^" MF!_63^B9(^LPI2N["AW>!_HY>&DP(/4:F*F559L/O?I%#Y.99T.N^:.,IHCETD>1";1Q!!\[-1@ M6@?T:D$X/3GR&H:S#Q6:(G$X^,?(H=B)($WQ@,LK8DG/@0*&O^[)^P[!)`Q/ M3F`@,6R0D)`<*/E*=X%\2M)614Y3TK$K#E$HAPTYAQ!/DBV_DZ:L$6DGU=,L M>=$U*2:PGJ9%79SMC6K'EE*BO:C)BR-LIZ$H,6K<+EFU5#2\U;0,&8:T3(-. MZ3H"=G^=4UGJ#YXD2'-B6)0V'3N*@?,J5T`>9EM![;);`[+MY&M5>NY.XN4X MG9H5\8(DRP?$&Z1>-Z2MBT3ODJ3)<8;Y6=98L?*;B(L9<73,NEF:)-$NYIM0 M:%$^842IGGF2Y8RV8J+ZQ;L<$)5NX"[6!^G+159`DP]0N-"4@@>80\>)*#_P M'BG``1X6+,.PC;^MHGU&=W%%^)%$Z31\?,K18QK$-(0_O+!"C\DS3F.VHY[- MJ6*4?(V+>US9E:W,''V$O^VBA%[9$*,P?B8_TG4]I`<7T",I5SC+6'\NJ"YY MI?+A%B-ZED:X"0N#4?"5(3F(LH1H(=5;$__'ZI4A>KP&51`5[]6^6<)Q*@$` M>4&"8`_R*F&__";L>VR"[(%]E'WV[C$(=N3CO/_I#S@B79CR%YH@_/3NQ_?O M/KQG*4+Y\W\N]WFR31["2)`>")]7`RW#YV9)N\B>X8`)1ZTDY1Z47K1^\B3D MBULF&?V8O42W7ZR5S`XU@';1^NIA!Q/,&IU&Y(!Q3'8?Q(6C))J9*7BWC%]4;Z@M51MQJ"9@??:M?0\!A<'7N2 M0W'5U2S*LN6VGPC5I5%3')'RGOC)"9A)IK=F[Y1=9?G6F;L:-B%]L;I=4"<] M.X"I6R]+OP9@BD+!D4(3N)T/Z.M3N'I"7X,,!:M_[L.T MZ25B=EZ8XV[83&@7=-7K,L&_F<->Z2 M+;#^6Q*M/P:#(]B,=)3?<:(.(]H;U1N&_U.K('8%TS0.)G788SI.LR.?[RG( M,-JE=#7,$XX([XE(E_P4U>S04UR(KU;[-%B]5`-%&8XBG/X^:RZ7#YI+/XGH M+DURNO8^S.EAJL4JG"!^0:LH"+<9*B[\I#O%Z`C4#J>E=*D]:M)"4LF$48P> M;43(Y-@IF3$C`0%JUU%-4M7XK(DU@0S6DZH`=4.S)WRE.68EB%J2B(I26E3" MU2&HA3BB\H@J>+VT$.6KKY48D)M8?&$'R7%O>F&+/'KW\+J!+TA=?03^C/,3 M*[9<@J0*IT]T0HG.I9RG*5U:D=+M@#3/$!T]/$FVFM?0DS4;!9]23XCQ<4V[ MDK%S+4V+ICBZRTF*2:^11[_LUD&.'8^U3T),8M20O1%Z'16MT7L]RZ!S.#JF MH?(\1]!E4T(->$N)XC1[*H-:0AY=U3,GK(533QX`VV`H.*)1W-%8^V7*'[L+O0%A1N0"[5! M^FF!$=#)'$"84%?[U].+P\:#R!GZC0C@.11(4'1G1\+F"A2Z2H']H"TL&P?(>I]O+)(BY,9+_L'RG_D,C?/,M`;BY@6(Q MD'M%%_1O%"6N;\P3-$(B_W1=X'7+-'CKRT*ZK*YNZ+.7)K*T:)\]KI+?ZAY#+]R9/L5;-Q!?$$IG%-KN_# M#_E%G.4I8^NO01K2JS9N@QQ_##*\_!;V#[%1%ZBN[E,0,+NX3[E&9O!5LB.Y MM&]/@4;D'YRW!YT MU+0.0G:8#=O)2H)J3"KR3/>R;G"*V:Y64I*&W"!'V^"%GA:RS\I-KD&TVM,M MKRP@/U>X#6D:C+.<259K%-84YF%=#<=AV@Z81>%\7CA;BPQGR99T`+5B0U=$ M*3I4(A9)VJV5S0A16YI*SU*!6I0H"GL=)WJ`4"07%T9*Y"HD5>E5V9DO7A06 MYXT80*"D4>-B39>_;<)5,494W_/=CAU%Z"`^[MC#A@FVIX4.&^BV$C[.]VFR M3J(H2+E#5OJ"HZ%D*&B)Q:(:`@R#:1F=0N:!FD7S"Z.AKW03PD*!=".0&B5> M7UZ%?D.;\X28OMWY`HTEA'(&`GN0'0LSAQA=(.&N'VD.&O!`XYCS`_W#:-+? M`KX?XZ,S`5@PKNH6P&!IT^<@WZ=A_D*'@Z5I$J\@-RWJ%@0D'J\&D#3KZ5>E M54=L2*+J,1N(]XDPW`85$$32^%PZM,N+X-_5:<]?M^V`KHX!1P\;&*5?C.0+ M-%,ISCN$L$^9YQ3D:44D"&1A18P+W:T_A^O3G_YSZ( M;MCY7.'J)GAAQWA+(["2)#ICI!!>\R@*JGD>OIA'17%*\O-6PQ?9@%QS3!:)"+&7*W29P_12\L M2@11](K`JY::'!-\K68S\R!XF._$/4#O*E>\JQJ)_(,-8_AT?LIL(%?*EN8' MN4$^=1=$.+L/OMWBS3Y>G](S*VX)0Z)GO.XQ1*%D^56D)8WXJ5`'LWQ(;D#, M.IG<@CU$Y"DJ'B/V'%4%W')'I5D3C>_?989$H&&"5"ND>Y<8`LU&+*"(9AL% MCG*"H[3`$3MB!J5'A2-1(G$X2`).#&R`B7,31GUH4L9'6;9?T;.P-_N(Y+<5 MY-#7,']"5_@K^E^4$2_H+'P.LW(Y";%=+"WQ*54`@ZD@%;`-4Y/[QE@37V\N MRL4Z%\4QY>N+6#T),-)1'1\Q38?91GR3>AMNQY]H6K(M?Y+&Q;*F>"6(*DG2 M845>9REFN$M`8-#;LS]%56OO_K2:@!Y.,:4*L(>0^T$-MAJRHD09",,6,P01 MT8^\RR4SA.=9O%)N0-^3Y@D]9-EBO?)7@S"N[T]SR1C1?6H>,L8@U3S_MF,W MNIQ_*^KQB7QX]21SHG3Y1;6EC1S%Q+J:I93Z1L4N05?7HA)`E42QB=OK]'$J MHA+#9NZ27%-)0V]MZY"A4-,X:(+H$.@T*:RACCM0]SH?G!OJHASP=8`=..-S MB7=9EH(7S(OM4GRX?"VW'W(1Q4!N!%(!H?AZ\EE0;D6W9FFD"J+4Q3Z.K/;%J"KD'"4BVG.@NS/(Q7^4WPDJ19,RRVC*)K@H'T_BE, MUS=!FK\LX_592$]-+HKVV`&FK_RF`/J,>`[V/F9)$D0UQ'[!7'MK@6^E!!6/ M.E.G1!%BFA!3A9@N=O)YH:V4<>LQX""<@*.HZVF,U39N"*"&D.'5N#J@*:'G M[.LNL%]7_-L53=R>;PH(_Q+&OYSQ;]?CWQOQQ#AZHY[J)P-.>WUGGVQS@#X9 MRX*4D^LB)A:_.$ZCO>2F(`$_)&X:I.ZW^!G'>WQ;=,.H_ANI7T18K$,A*[ M_A'82.,MP6L/F=<`5PZT@W'`7*>=CU+!&ZUGHK6H4_)&;(B/"]Q].61N#[LV MNTX07[78'O38OFZS_9&Q/2WU.N[+'!S=!?V<8Z&[MI9V2XG2(>_L7[X?]RA`BN*)V$*,E=Q6E58]%[MM;[Z3 MWQNK%@^QL0Q9FN#22[=^GZ$'"DZ?CXR&PN2TD]H/$)56SZ:Q#RPH'$)O:Z/@W20N/W8.L-&?\A M:P9]G<1!\KJZ/:\[_$./8`LW(4DQ@HJQ:0LG]$JD#*?/.*,4#U`4;D.V\I&F M&]O2'SS4_F!5^8-]O&:3XABM"B>R*6OO."2#O%R M2W)'=7LE`8*O_5&F^@B<[U@Z6$:*[X\#4&I#ICY#RNI8*`RJ M2`*RS*H!RX>`:"!.*7O".$=K\ORD.#YSL\$KSOW>:).DASG\:8!*I4%.>%0: MA/@+8B**SKZ1_W+G;H7/RS?D/#>BC-">6>CFJ1638EAZ4?U$-UCY,5GY" M__7#"0IB>OD$'3';XOPIH9M*GDEZA>N8AGTX2'H25`1A"Q(J)J?VL:_^F7WT M"_;-*0R6ZW58V&I^.TVVVS#/AR?W3==0G=XW18/9D4_3ZVQXBM\DPY(#GR;H M6Q1"J)!"39$3U`BV?D:UJ..SG0R`E@"T?.^$)WU%K5.>IM0"],PS_0K`'O+G MG@8GG-&.E<[\NF>Z-H3.O+;L")["E)<+`K^&J1IX/RN M+U>D$!X!^.IH`7TZQ]_RCT3[;STZFBFISA:< MJ,3L-"VCF@.=KC6U#I+SMJ:I7)"_]U&0LBTT49+MT\(WQ"_TS(#D*QOUI'Z! M.IOT&=>SK*Z/VC+#7P*#AMYA7)-TM8[GFE@7T+/F)M4!]E!$7\C!KG=?,>FY"R?:!$_+;S)X:L1< M@2TS0@Z5BIG6+[LH?J`CSI[L1!0U1S+R#;L8[A5JP#F0AG3,/>702ZH-&IKF M$ZUN>QB31&);.,L=3O,@I(?:LO,JB-S9?Q13+X<%!%'$]P,*D*MJ37#PH:!\ M-;MV8$TLB%A036P08S[C-%R'07Q*BH:K("*MEZ14^N4T27?TG\0D-_Y,D"S? M7DO2",T3ZF@6T_0,BN&OHV=1%495:=041ZWRGD3**`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` ML33G]AAN:;"CXR5U,>/%N!&UD]UYLOV;6)HRZ(LW&SU56YQ[POHX1$J2C`CQ M3T'G:K=U.0''&.BXA46@%3OHGI/HF?9`KNADU$WPPOH<[Q"]..^X$*9RM<;A M8`QX*,`FS#[0&VC"#.$(L^Y[6O7VZ:T30E_GT94Q(.A3N!3")OKLYLV_)M&> MP"M]^11&Q)]Q\V5!F4Z>/"@#D!\+[$+DQ4/58_EP7Z+*@^O?4?'`A^Q7U&") MTO?E9;N]HOTL=Z#)BUL7;](P2>^3)?%=:\ZB,0A5$VY5'*J:[;XET5O`9=03 M:@!SD=)`L>A6Q!/9M8A,"P5WK<>?6#89HI.N2AH!/"<&ZFJ<=A'2L%ZN+B_K MU\1:Y\$;3K'=O-W+R,I[R(K[1G<5>X(W]HBP\<8?X3>RV#'RAT+"M78D4DGN MYQQ22WQE)_H:YD_)GDV99B$I5,\ETN,L5_LT+?IR69Z&;$(U0TG\WNB\J*=#JFH*$"_5%X+B.ZIT,)8+U4@6'56R\>H?HZ* M`CYT6D?:-M%I`UX7EB_1[\F*]/JW._#TB0"!S$WJGIX3DQ?J8\?V"ZJ*# M'80JHD!["M5K";7+4,FBRKY#!46+UI;#.QH]@W2=H5]V:^?W?4[""6(DI=8#L(.O;UQM6$D-B MSPES#4VG(IQO4#/9;#L#;0UV!X32W: MX[JGYW30H>QB!I`.*#0L0P\X_XIQ,?F'*VMTJR0QA_+@&TJ)P?)"KRW.\G"% M-IC.*$8HHP/C["S60?$\3\.'?<[6(^?M/9Q]?B<,:L'ZO_;%6199.7V(XV#% M;HXD*J/@J^L-C_Z17GC"SAOM^=\+Z+XQO^E..I>U#E0H040+HFI05P]J@NX9 M+^B^$4X$H$,EG-U.ZLW^(0I7GZ(D&!S-*'K>Z:!VG@-T3SGV(#JG7;5C7=-V MZ:IC6OR&V(\^=$MY#9.,?DM>E[15K-\A[6BPUAT]98=+W.7)ZK=JC.?7),<9 M8Z+;-EU6C$DU)!G7#YE+C5D#7<=L%7#=&:5G!C+2V2@.(&2G%#XET9IN M5R&/BZ-GZ"$S*\?;(^$!*.H.'"P$@9<"VT7A<$EOW`,EF\*/RK-B<;!Z*B': M@Z7C;JX%7`JRYOEP:3?KO<6/(5U1%.=7P;8/=5F13N[;+P*0_O*M0F3``\UC M27!/H,J#FY\1_=V'5%C05(G*I^4EQ-V2_9RXK\?>+,TWTDO,*)%PN@KIT;'9 M/J6GC9TFSS@-'C'A$NESAFL\/%9_@F@%;2U1,\A/J*4A%?0L2BBBHVA1E$9- M<5271Y4`R[(K$<>LFH*>Q*15>RS4T-!BIY9=T$%.#7,J"'W!"N`:@F:HUZXA M1'*F8U1"$G4U"_IO1']T3!5]0"33FZI'*F7Y%M,T;(*F6,IVP5<_S8W-XN!# MA2/G:<+$8%PMGZ>KE`KEQ5@K*CX^VA']KI.H67`N[%`<)]*A%OS,CG"ZB*?" M;%V\F%)%A0!SS06Z_;AR9R8`BWH`3@%L-U/Z<6JF]./43.G'N3*E'_4S)2.: M_@A#TTJ-,DE_/!R2]D&C0U(^X-0I^N,$BO[H*,;\:.&6J]D13%,I!L^#2/0! MH&F0`!TB.*''4F?'I^KM4F6J_^.1I/H02)^>*5E$ND&FQ)9Z%&NY_A[F3Y]) MVV_WV[L=7H6;$*]OBJUAP2.^WK#J<;,F,R7EEYRJQ(CU9C4WRZPFVQ;[@(DJ M%RTY=L0A*B51+8H:6;JVJLC'_$B_#-&7P&"AZP^FZ6I\P]2Z0$;$:74`3=V\ MH0A-Z?Y6\(.@__V/_R<]LG.;%`L-:9AL']3ISWI8M]00I86OF!S`J:,__-!) M*9^F$,FK,[L<\TJ0A/K)*]/D]"'(\+H^2X;86#9K-#Z^-$5N@A?ZT_)KD*[[ M56^M=6[>@I?$6C?63G8M&C/W;=:_!$#R;+..(Q[2GNDB&4=,&K4MH)8)NG*I M7:XT@Y@=3O;>WC[62N4]\*+V&9?,BVN.3[9FL^>[+;X;>.YDK:[P'9!C=#/L MPI'2362UF]AU.OG"5&Q3WE?0)')?G\+54Y&??:/K_C),[U588;3=9SF]ZB#( M480#\N_W+.?;H$T0TL/XTM]PCIZ#:/_FBZQPX,T;.?9&-GI\1^F0AGL]MW/Z MIU%KQ<4K/:?E0S_T>+R6K%][]%[+\F+WIDKL';+KACS\E>\*`MUE\%(!B#7Q M"C4"62`OMS.Z6EXF7B^=[QSG491#K8)>K*1704!_6;TZ:JJ9TU&YP8)[J0V[ M@U$?)=XA*]W#Q[Y[**9TL_-ON["X,.P>IUO>Z!.\]O9P$Z1V\XP+_ET!!I1` M*S6220':*H>,/DJ'C+)FS.@C9\RHU(P:U8CJ]B"_L<"*Q#(4.?D+G)%>P@)9 M>_!^%5SEX(=U#I/L=."F7`>;O_%S,HC>&`K_<6T,=1PH23^4QT/C-$S6;/0@ MW.(31%G#!A(>V?$\]$(Z1&]6B]B/M`P=*&T&*S)J\ETQQ5,NM0Q8M,;4''9] M>O/!T5\VP'`$]'?2NUD^/J;XD2#Y4Q"FG]G8V*]T:.QZT^JHT?4$MY@.K>7W MR=\IOLL77*;XO!B1HV>:?TI20IM/89KE]^'@V"^OZVC8/5+^M&9L/B*G@P:O,6*;ILL&E<_ MF%&MIEH[$[K,W:=]=Y^TW#WFN/L-<_>L5U4>],6Z71BC[\(8K9,H"M+,\:U7 M7C;1@80"^-&=%+M?Q[L>O;K M+GDO&_A0H@GXX.!;-+$P4$GR\R2EI5_NZ:V)\>/'?1;&.,NX.],52Y>H=LBD:\08 M:%_8(LQH_[`%M+P$VD-9Z+CP)>K"'";"@!-LFR`;)IV1&',G*"#I);WKER60 M&7YDP]8^97[@P!1D0W,!TR1#($8POL0!L??83H2N=YC.I<:/]!G.;G&,OP81 M9S&F@88JDYBBP8R;T^MLF'%,,BQA[@1]BT((E5*=2:<35`NB0O($E;(>K'`T M@5H"T/8]=NLK:C%^2BU`PY-^!6"3(O=,H,G33;WH*"UA7HZ$O$ZD"U.L5X=U MZ/3,`[C3=7:T8_?7[_X>SW-/UK)XM%-DBOG0Q6+!%,8HQ> M<)`2#?1TQ&T2YT\T;XS7I'Q(BN(8K8,7UROVG)%0E$YZ1D*#M/.&2EC3R'PIU,$L+Y0;$7D`FMZC^B9JG)ZA^[I9:*JV: M:'S^+E$D`@TAI%HAHX_$$&A&90%$Q3T7CS0@9/O=+@KI)<+?Z,#YL0!(E/`< M#H2`$Q4;*.),6FZ3?3$HE.*`BZ\U6N]3MJ&UV1I03C6B7>79DMJ8XU0!#(Z" MT&\;CB:A/$WHJ84OW"DE_L,J8/<>FE&$:\DP+/=U2N#?+;JH_O9DJD?0#HG\ MZ_4PV"G3@EU/%M3Q=73#ALNIC@(]ZI$8%@@,*<(=!S"P2$H"/)S0=`@ M#3C#&TQLKQ7S`-7BY7<8+VY$)M7:F*4""E;$)!H57E0EO,X&E-L]T6V;+F/& MI!K*C.N'=-MCUD!3`JN`HTD!!W*NLP)X@(GR@H.%&'!J8!=EBLG!ND*B1]F! M!2@*\H/YH&B0(5SG3S@M[,IS@_&"Y=O+"AI1:+P&9IF`5+^8+!*Q!7M6^6'O MPKY"DR;J'[\+?G'Y!O8RG9"^5VP'-+"#XX<=T-="T#&@112W#P0OP%$:'C** MD9GM2&70*D-SBE?)8QS^BP3K<@MKL1D!Q4E>E/Q*C[IOCK0/8U:J%,_(2V(/ MAN^!0"J(Z'9!:A#%_YHDZZ]A%"T?LCP-5GD/UJ+'Y=L-'QO11V3-+#ISM(H) M,BB\J'Y!7ZK?'`=?89LD8]^QB\E^J0:)0WE()]G7#AI*C1J;ALWJMT-K8U%X MA&MEDY,=@PAGI'=RBS?[>/W7-,GZZU$E):I3#7DES$X($=LT/-&/JUAR)@:G M_(+]R$;]BI\1^]WQV0Z25DH4/FOO5(-AP=:9`CPMH.?##`W`'M5E#@)V3%6] MI"]C@,@)(-("$*LH"+0)-$S2;+8<217^"OZ7[26+^@L M?`XS>F`(442,L,3R,+$D/'').S1!G_4#`"C9DM$^ON@FE6J131"_D+\(XC$] MKH;DJ9A`Z6&?M]?AE`N8J=2^'+NC2TJS?5BHWZ^>.LAU?4[-5/R)SF@!QA_, MT-PMW?B<[]FJU>+P6KS!=>"4>IE,0&@[9286@>M4*-0,;RI/;4NICRU1T MA_A:):LC:3-4E?6F9ZP"#%XO61U0P_ZR1);;=Y;:LC38([%I:Z#0+CI;F<4@T'$T(Y$CV.& ML,+(Y*&#V-[HI644,$PW6Q^*E(N_P9_+3!C_%!T1GY`3:, M<5'FPX6?E(YG\(MR!S;Z10%[)?Q:0`YU#"RH]DYZ@L/!CZH`*DKXU'40-*Z@ M#R&%`KNUU;KN6+(Z9`*&)YC(U?))XT,\]%BRI#8QXCB:K8R90 M@)(E%:$$:5Z->!A!36D,Q`;4P*+W+8Z"'*_/RU$K:?@6E.7&[T%90*X(Z@$9 MP8L.`M0H9&<4U2H1U>G#JDUPK">V<-;U1E#:&_<%5U_(8`Q5*]`!G(,B;7&@ M*J-M/7]/L<]6P/XC27\K67N&=T&:5Q>G_`T'4?YT@A[P)F'W\Q5)P`G145.? MYAGKDOX)I3_]@>U9^GVFY`0VV/5`I__T%^7*;PY`\SL"I^^'Y0/D2WU*YZ!& M[*@A=M@E=MHA=N4ZUGB]7^55;T.I-^%#-^(`/(.@HW*XGL%M5T@^ZVG/`%SW M"'9^U=X;^Y&"Z4R#6#`W.E?7'E-I>^>WE&MT$L8Z6>%):8&4VR MSY*BN?411==->7[5T'VH)G:'GY@Y\!\6NW%O'F3BN@FKH[*./<<'Z+%:OQ:H M':@3L-=C\\@)J/3BRK9G[9[AU0^/R?,?UC@D[?_^)_H/VL/[Z=V/[]]]>,_Z M>.2G_SPK`_ZG,%L%T3]PD'XBO_3[:2.EJD-V1:7,CJ.4VS8\4E>H7'+DI$!F M43U`Q1-$'R'VS/$YDB.MERA^ZMZ9D?S"K:,B1=I\'J\8KL""50HW+F&^O@OV MS9PG!V/K/(!,`*<`SM<=`>,;,M(+%[[!Z`:-Y^`KIF#JY-L4[3PDI7W\[G)0 MS?F85S/J9Y&Z%GOGKX6\_DVOSL1?!U.K)X>\/M-S3V"OB^[`$\S3%;]A5^6. M=\8YY;C=\4XYP`XYQSYDE[RK7K53WI8:=,N+A_YUS'DM*>B:BQN=VSEO%1=U MSSL:K770EVO"Q3S,POCQ-,GR3'`(]%BQ\EW%Q8SP/6;=#-X2[6)T"X46K2>( M/?+FU.C11DQ4/W@7VJ+2#;+%^B!3/)$5T!X7*%K8&6M]O!PZ2$2]#'LP,?!_ MY]M=E+#3HTZ3F!G+2`)"_IWM([J:;UF=Z95=AC&^R/&V'_P--)3?9Y(&(Z88 MU-G,UTXS+";6%'V+1@C54JS[TS%-);^C8J\)V^;A[K35[`Y;`04/\P^\6]Z4+ MYWGJ5X5EP3R&'UB>)2'[F,2D%L73[3;,Z!4_V3*[P80S)!]YQ->;TR2*\"K' MZUO\C.-]GTJSV-).]R;9FLF9&'R'N>+JM"I"^*@IEG5C=FFC+%%;04&&&CO4 M0=:64&GJ4+RC"=4F.%-S9FM[W@DFISCJ26_F)D>94%5'8U('Y5UHGZ#M,%8M MA_$09,0WT-L_.FYC5;N-M-"1H>^(;PFJ8M^_N1%X!+\Y$I>.!'AEV['ZDN$Z MN*[G>!AS-!S70E>_%3>M9\42N/(8X21%&4Z?PU7K5&'V MX_18!_0.P(<9=T,/UX?-TLE=KM=A8?]JOWW`Z?6F>3:Y-ZNB5+O;*E;.Y.J(C=8'PXU(3NEW+1ADJM%&OWCP_%*>I!.X)WE&#--I.4*9[BK>3U]5- M:B:KDZ/.G&.&LJU!-=."AGY!_NYK&$7MM.;@5R:XH*5Y#^O5$]-9Y\@U-X?= MG9A'516*GK2O17D*LLXMJ0?3&7%"8./NA4\$GJ?#$,?[(/HOEW9WB]4`E55`K3J@NA+E\%:K9]92$"&V3!M;#O$$?7T*5T_H M*7C&)#EDNQTJ"JR)#"E0N,QF-.+WF=(`!F'0(Z;7QQ77N%)YCB-NC5^VACZ* M.AW%`,AQ.V[SH997Z;A-!G7^N2>$^$R8E:POXF>O8S4(`-($$2L_-&6AL^2FC>H%FB`8U@>W9^L@HUKDI<,$AZ+V!"J6KE9Y/TR>M'M*S3?(Z4?`E+;%4;9$\8YZ[>X M[B#X0SY1BNX]^0R29';K=KDB\ZY8$TQ/1OS(+A^\29/GD"[E)/7Z&*S/\,-@ M5>1D^?(;3Y`WOYU^2GW-$M\I9D?NL=?2MF`BU5XU5`G1,\E1(89J.>9*B"1B MHA[<1C\)7HEQBW/NK]=1T[O97J\&D,%6V[QF@IKD021.4!TCGZ:B9<$*_07J MV1[.8K"##OTMU_^US\H!-SI0=Q9FQ<:)UX=_41+ZFA@`G&.Z)@$GFZR'NLO= M0FB]3^FP=+GSB)Z;RZXYSZI0D6(ZM%>6!Q)8UK9?CU-,)N01)ID_D,D@G>>:N-[P:]HBJ+UA^/QU!(R>B M7T.SE%'+GMA9:*A9"%)`2FY^_NB6OQ,PDTQOS2Y?U>4;HNK8A`Q_ZG9!AR9G M!S#-]6Y($*;][E[.YV?O9AX`B_*Y(X4P<.HV/XIE-Z*PM0'TFA+R9YFEE1>8 MH-53D#Z2]"QX#,(X(Z7)<_9:Y0:)9+/)2+^G6#`09N@1QZ1`%+U4]ZK0D<6O M;'"PDZ2QOUA6N$]W29'JI32SJ[+%%*]P^!P\1,[O-IZ)3X(4SBV?#)*V3V$< MYO@R?,;K"T*%^#$D;;G,"%JR3_M\G^+E-DGS\%\,3>4UIO>TUU^/6_8X"Z>P M_,(0"HW\#]P;F26%(/40>RD`]8M"!V)*4*,%%6I0H0>U%567(B.FJIEL=^M, M`$&,Y!FP>R7-_K(H/!&((VO!IQ3^\\A M>A1N9Y049WFX9>TMH;"TR?L`X;LWWTY+Q0!-Z3)/]SG'B[2G9!8GZ89'=(+'_6([(+U?_W)-> M!C5P0]S$4Y#AFY1T*LHZD)_/,.G:A8/9_>D*RB\^18&1LYM>8[/$?))=L0N; MH&Y1R:"6$*JD$!-#C1RJ!-UZ#@.$)>9MWO4+^GH:/S"E#I!!7M\^Z%BO<_C3 MK/24T/QFDY]E62%;_5\^YTT]A#M;>GDS:NJZ:E M9QID>!>DY$GT0F_27D5)AM>.TT='E!&DAWY1QO8=U/=$;8]]O$>]FZ:+1R"7 M2[>MP-PG76H']SX4<+-PV0?;` M7G&?O7L,@EV!.1SE6?5+'WSES_^Y+$\FOJVGCZYP?EK,;?4`HU*TNBE:6M3L M&F"%6D!6>EU^HYW/[ MA4"(PK<,Z&<'!L;YT1-I>%$^\(,&@C8;$$#:MCW@=\L.(=_79<-U=FU`.TUC M.'0<9?G(,PLJK(:Z(DS_L8S7[>G0 MFY2N4<4[?@5;;^&D@M:8\!7T[*=#_7)`Z9HL:UE):0U5* MZ@5@C"PNS^_N&(DJ?:BMT+G;@$5O8@LY`Y<$HKWCP8#J"QPG06H%'58/AW\T M:%\6"P_>"&@&G3<*&GU'K>E?:5?H@-CW@:7,7.*=H%H=2Z3;"D]0I9+\BRH] M*7+M2N\;:57!=BRDG;.C0.J4XK5X]>0MSL+U/HA^#:)]WVE,E*[3?DUI0]E:5`+E,MMW$7UYO"D@K,#^_/C"+LU<_X#QC6*O/[KL)0E+GTV`7YD'4 M#U_R4E68$I4R(ZO.V372>HGBI^YQA5^X MQ0F1-E!7SC<"Z[+A0,(F"[HP>7=Q)#`1.E5+0''N)#]C>M^CFJOLEI4[S*JL M#6)TZV&/'+4=;8J4D@.:>.Y->PT\1A8N'N2$*41&:5-IGL'+%J;`EK/801+/ MY3980E^*4O_[>$"EZ8=!836G3ZY//[TBWS7(GBYRO,WNDUM,OW/(5C`6,\^7 M249^/R5%V-DU:[S^^/)+1C/TZ^+`H?AQN$$E380,W)"V5S;86<'ERN:OJ.VOJ>/J3E4 MV:,'\W]'39(^R_>HMHH:L^A+9=BYIYR)B,G<8.][:[M6VP[?]OO!IB)V:PO< MYN_O/D86ZA^K5YFSLST&:=YF)%JEJM`![FD MJ$"=_0T+&#I-D440)\=1+G-+@^*+UF_H-,EQ,Y.5 M'GHV?FDHO,OJ`NOS!):4R,"5]=@;2EN81Q$%2`S9PA/B4H>OW9('Y1FSX$ZA MX=1WM*S,"2I*H2_E?VEQQ,H[[][#@DW!.5N%VXQNNSH^Y^XI2/''@"3,I\F6 MQI;V07Y][ZTE5#EQ12$SYFG5#,*EJQJ44%%-Q:+]8W$J4DHZ08]Q^"_2*?XN MC-$ZB:(@S;YWS$4]<"33FJ['2R79%CT5;8$&!26;8+%A+ERR2%&?P<6*OGN@ M95$'KWYDZE:A*0P:3L`Y;PAAUVE\2M*S9/^0;_91M16>O]A!6:`5.L8$C+FI M5B.@D#%J3$[+$?%%78:=R5R5J@\P<,]"Q>9/]!MHR#VY7)=W8S:@`X+<'F0P ML(JX*@A(,.?+D@DKX).Y_@.&G]8N,]+A>4B<^CVZ0>Q5^#KACJQ9X39CAM': M]'6]Z1\_W\\NE`I7F<5(83.&*=7$T+6/V9`02BZZZ-Q^0QO<)J2+BN[ MI5'NG`5EN;YY4!:01()Z@#-H:$>50'W)@7.N"G1&77QBDZBM!6220X/+I)Z( MB$@#S?:<<\\46'?.#J@&3KD#JZ+,\2!*S3O;P=2,OIG%BO+\--$B=5F9RA?S MRYAQ16;7D"$"U1)F<"46Q<_U88[^K&>6MEFB](E[N.<5;>&=KPG4=_),P.:S M,+"@CO+TE]O;\ZM[M+R[.[^_<[WRU``-0C]H`0]S^SVIPY-Z.E`79\.W::"W M[\T\%5Q6R)\VG14%CW4A,9ER1OS18?4IG+G8]JJ<[L;ND*=?Z"VX''' MY;0?`\!S:`W"[72TCF&S5;A.I)K??,`IITF2L<_(0VI3JH_5MCR\#VJT@U[] M;=36[%KNZ_OE);J^_]OY+?+'*^FTMMPS0;2WHTZ@K/,GZ_1!)O<6.GGJ6?R@ M4^<#-,4'K$O:AY>I"S)TBSTU"YY'NTT;G]/MEQU.TRIUPR8V[MR>ANMBN+X% M!(>0WD0!1\UVVCN1G^*0A3 M=B3A67&Q[C[%TK$6A?(=OR`M#X!/A?I`>!.YF3$XRZ3K'(86*@Z614TQST9X M5%H_T6X@'F\D8GU*22W`>T2).0L#2-:`QX:96"$OAKQAD27WR?-@R]V8E=2! MBXL)QK!`W;78.NR8E@9'.$*<,2[/'+&D%84#(2IN=UA:/"QBT\D.K5CPK4!P MH9ZT/4#FA3\U`8CJB!D<1.;SE1_W61CC+&,'=F?LH,,;@L6G(,,W:;C"Y98M M\G/9);\,@X MQ")JNHX)T$#CRT!K#1DA`2L&M8[Q`!E(HW:E#K7TG:!*(V(J4:.S63S64GN" MWIAL!KWCXK+35&;Y+>R/V8^4$J<812EH3]6V#>YS2N5:_H/)<#T!Z?*19XZ[ M>V/-)Z,FIYW%)*.%I80IM'D,?GH\S_6FNHGG/":O_,(.D0S"]3@I5*3%9)%+ M0Y-(I:[@Y!HQJD4ZJ2Y!6*8R="-#?5E;(792'BY+)+UCJA*F9`S6`*68V3(E M4L;+K5M.:67&]=+6T>WL#L%>[M0A^07]GNS**`*Q&*]8`/H:YD]H5Z6C!/M) M?59RX,',]=R(UT@9CQ#S6D0^^0-C' M@=B_)LGZ:QA%A9^#JH`,4[34UK?U$01_E@^ MHU>5[B,6]BAK4=!H]ORKIY^>X-_M<'J10^.S9!N$ ML<+`.K>\9(B]5QY\L)U;'_AA][X9O0'XKK0@QE6ET)>BG(?#\OS&EP[0R_`B M&:KOB,D'[7L6?"/;:;)]"&/F%T1[_%6*]BC&+PK"+EDM8(@EL##.*:[@H@4& M3X8+I0TYH(M"L_>8PI,8DH2OUS=^C(?3ZOBBAPB/'*<)JE-[W$2J9/F87U;%@[`5N\0J'S_35IJ<68PJG+GGG*)QW MD:WPC5PL<.=5!G!5[5!]LYR]^?50O-8H)*J# M^CA;I#XWBXR6I%=;%EOZW@@H`],A4]!IJG!)?F!WMX\G`8.BXO#>*@KM;P:U M`/P=65$%6%!3,!:0DJMEE[+<:NV!+H7V0J< MV+I2[T9^S;&CX;Z!T>/=UH9.2!EWQXBR/@'+>@:M32(U^B>UO;5@MQL=\2,(/=QK/XJR7&U M2WT9KR^3^/$>I]LS_#!]TX2"3NT1>ZG.F<8:)76PW;F;]*4AAAWE[[R@?R/Z M`Z*_H.^6^SQY=YD$4W+`\@MKO,GG+;.]3-;7RC5IIU/ M"+3-Y-VD[S)K!B&J"81;X^M>L)_I*:GONM.0A^*7Y$"W%,S\?R-B6J0.FPN.MW& MVUR4I.OI&;@VWWYMK0V_O)4-+ZC5;!SQQ0M MBUAA3Q89*D)#MEEX'%(]=LMEI1N(N;9LQ$NY32LS5];QZ>=213L('(LP\V)P MOCAQ&NQ"N@H#DRB7?=KGI):?PSC<[K7\3W7Y-_X"#M#RQ/E"X_ ML;:T$5,GUM4LEN@;%9-65]>B%$"%Q`DJ9%`IA"HI1,3H\;9$$#%)MSR?BJG$ ML*&[O-=4TC@`;>N0T4C3.&A8<@AU&JB(?_OY=0%7%+)\@:YW0>Q3^(P-HMA` M7"^,M<3GX/B@MK,$LK958WHWRG1#&94\H%@V1):N3Q!A4\\EU%JT?4++OH-X M5EMW$=#L0+X,:7]Z;?@U#&HS(-BGL'9#V$/^R^Y!OMY%>IAXCU&U:N&4#H_P525-]XG&T2T#8KY[I>4@:SAJ33)H>RY MQO3J^++Q.LX;G\?JHQFQY3N&O&H>["/RDS[30[]/!'*4'GP,"&A7^.X) MXW)-T\>7S\%_)>EI%&09>0U9*J`LS`O["L)P/D:YIH#A7,6FHM,85S4(TZ4( M8C(GY>I"]/""F!QB@BJ7LS6CZS5=V[@F1_LL;]0QQ!H-\_V0(:9Y/TE4I\$3Z-;,6_'6K`K5_TE.R MT,C>S<6+%7NE#M0HH6L/"C5^[HGRB5E*\=Y3;KF)[2T'?5&457&'S;+6IO+UW%X(SCJO=5KSB M&+/6"04&V3"T'!>D5)R\35"Y<=3KH@_YUS3)9`M:><4XKKE;#(PU/.MPSKBG M78T@':$N+];UI53LJ3\LX38BEQZ2YN:PHEV:3X>N/EO.M6W%FE;9PM\V:[VQMM&EOXZ:B M![3YC8,O[1VQ(HCJ3**WU>COB6W5P,6&[MJ\DRW=EJ!?[H'[M]<'8].MW7,` MV;-`5QYS/"7&]41UPELM:I_EO5K.$-0:BX:DKA3IA#*ZIOU;CNZ_XNB9E$CB M_.D0XED?2WH^@(]$'?)7IWWK\;ZV.WOL*BW/'[:@P5T&JP^O!:-&(T9LF&"6AMR53:2JY*]D>>+=CPEYSV#DIQ24__5OAC#+?"7ZI+JO0A;4S,4*?VY5YE[A/S-9]%?X M8WS8*_SG8);I"G^7W/)I)*,X[94PV^0H\+ZXYE'@C?@LQR/W:SO/4>`MJ^;G M(M?*M(\")Y('M!IJB"SMHY0%V-1;0E)KT3](N;'OXBCPRKJ3H\"M0+Z<6?[C M:\.OZ5'@]A'L=#_$91CC"Q*:%?9$#(J*]T6TBD(O>A_4`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`,WCQ:$XHAP'$C_H('&'TS!9W^5!FKO' MXP>"Q^7=W]#RZ@RQ?YS_^R\7ORXOSZ_N[]#R'GT\_^O%U=7%U5_1]2=T0>DY^?U5X/-G?_#I.M>^2:)P]2+>YZ(A M(\VU!S(6>"JHE[6\9FA/EZ%]#8>5U8AP,,)&.7RD7.R)CG%Q8,E^K.B9A-OS M,0L`I8GU"2I*HR_E?SW:L&$/GGI)MUV`N@X6O=@F//UA@JS.0`W8&0X3ZCE7 M)UEQO[:.IL,*+F-XT4OYQDXXT%"AF0#:.J=`P[3=(&0=N"-!:3`0Z=&A'_,! MVVALR#*TYPU;=VQUPAJGK(Z?@K#X1[-_D1.NE&5:84I!QICBRO4""DLJ]N2L M'M=0<#FKRJ'GZEB?9+,)5SC]?8:B<$-W\9$R[)+>'O\B2@H-M]\?\1(EDQ(S(WD>9.A3U'R ME:[8)/^\B)]QEI/1UY3D/Y-^K/'P.!OS MD&98"[D_,5)>.!JJHEBL3_^JM;#>6*T'-8HZ9[IXU!,#P6X"C9^A0S+1VO55 M9O6##L@FM0%?I.(MZ6CV>??+S?SJ_OE);H[_=OYV2^7YW1F]NKZZAV; MN+VX^O7\[IZN)Z!SN9\NKI97I^ROT_N+7R_N+\[O_O)&.!&$#I5R,V8.49!E MUYN[/%G]=I9L@S#NYP+"`E5TYQ0P\R!"BX81F*=70N]A\07[C6;3[%?TI?C= M=<03MU`R_DU[%!F4:X&>H\,;&"?;;9@7QY'&Z],DIFS$\:K#/N'2ATG"%?PU MAQ;)1.,V4V1UXAC4B,R4>LY`?K5NGY:F M@P]?DFZ:`=ITR,WI?NE9/@!JJQ-9G;;V2&J=DE,).$*W'[SEFQ:[M+FDQ)S9 M4CS8$3YX$+%T[?KSYXO[S\5V";J'XOJ*CL&=7YU>G+O>+@&$H@D)%PB.YO6W M2 MNM[NKN2!N_T5XI@9@34PMZJPV[Q?N(?V9ET:N)$.=4$0HH3/TGBYW7*;E]<,V=^@U-69['/'),8 M^D^Q!!17QNH$YE`D;*%'_:&5J-0X%%,$3]# MLHD$N<036['DKD4&;;EN6T@[PW'& M;CI9QNM;G(\^`P<*OM\HQ'/JZ#]$6&,4!8&XXSAH:LB0*UZRV(U<"*!1M M0H&DJ"GW1FL!X_IE9J1T$PLN;M(P7H6["+-C(SIEG;-JO'$3G488<$@HT>&. M1"^P"Q=:`G3=\!@J777SW./#^<$P)?',EE$UJR=F@RK[(&HN73[;XXOX#I./ MO/X'#H;C&>HBC6=6$#&EEG*M8#RUBCDIV\85+$BK_>R<3NJMG4QIC0&Y1B4[ M)%.P`^S"1RT"NG+[("M=>U6N=7?]"2)%Z3W416%$2Q\K&"6^?F8X^N#[/X6; M_$G+]0\D1CU_2\(2(0=ULNKWV]:F,+*1IU[_3[X2;=C0"CP3H6.49+6@"L=: M5N;Q^+5!^PX?#%T*[IZ5]=K;FX%0W]?;@:%C3_\IS%9!1"OZ. M\'H?X?O@(9*-T9OKDD4'=5WPM-9]#UL11:,>FMY`6?.B^IV.&06/CRDF"C#: MAG&XW6_IN?[EX1MHSZX%P&P=!/MA51HNIA0"(LJF\K,3A+^MHCW;>,7DLXS4 M**,KG8E(MM\2-;LT7%$OM,;?R/^N4AQD'DQ$`"!>[J$F$DCFN515CO@T]9I9 M#[JJ5;$:CMU34Q;""QTL>*-*"ZJ9_(4I\FJLSAMF:64%GG'+BSXC(;-NIW$@ M,MYK;(G8RNH'M;+;;VR;FY3:-PIHS_&/'E):U-HJ6;L((^-)>RVIE+6W[,S4 M>ZPMSM!]A`.92@>2%?:[!VD(Q@E]2$MP],'W7Y%`=?\51\_X,RGS-#Q)5%=P M-`X,!2VQ5%1#JS&!8W0*:0=J:'SXX"LEA5A0(.8(CD;)V9=7H>C0YCQQHV_7 M?O2P!$>%2$)%4"&#"J'7@%[]X#('?GT(-/=/8:JW)F$@,1I:6A*6&#RHD]5@ MTK8VA;:-/`T?_^8K`8<-K<`\$3I&"5<+JC"M966>$%$;M!\;P-"E$`U86:^[ M%68@U/?[=F#HWM,O-\3=Z:Y"X`N-^/N^D!5&\FMFT>L/#.I3LZ=BKKJ,Q3JZW*R?90'<>YC;U\!.;H3 MDF/G*6@IT9YRM'0%MY[QF:?L;UK>F]OJ9X:YX4S[@0/]@P[0GW'ZD'CJ MMLF;+);CZ\+R)YSAM]5A<.SYX#=['*>%*LF?2HIGPRO83M?TV4VZ]4D>1!XR M2)$G&EP80?P,4<%JDJ/?^.*$Y7#QH)5;>(`(K6P@IURU[A-H7#]PKZ`5(PU1 M,&>\R_+KS1U.GTD2E)WA78I7(:OC,EXOMTF:A__BQT!-N3HN*LL9,D/1#O#) MK.I?1<8@];HOVH]9\MLNX)IMNAA)#)JOSTI%!6VF*E<7UH=K?B73.#\K1&DV MD.5TNT]5^`2])(\QK`BJRWC%&D$;BX@CA02?.5T1(7GZFBTZWZXIF]T[*%A15WR+ M@T7Z/3Z[AY=?T)WY[>_7IR> MWQU2&ZOYIJFM[,K["->PR0IQO1'8BC2994COI+A&@2LR\%8>+:Z1MIP`W&,K MPGAE15"WM>R%9\-B"F<`#]9_[KFZOQPR+-1\'Q0P9O2%*5Z'^:=@%49A_G*6 M;(-P,/8H*5+Y06X1,[1+K!KZ0+YF"<1Y`HOB5U3]C+X4#UP[/UEC)2H?MX=O M3LD6NKEZ_,3V\ELXZ&D("W!Q710`1'7;(B2F2[VJB&;%AWBF/WN%YDX#";#, M:40NDFDY$8X+'=Z@>)^F.,[91<;+>'U)+$7WP;?S;_3V/EQ>@=@'MHY,A74U M&3/XZ]0+(I]1M"=ABI*&!7N._J]@N_OOB)5QS!NM]D\F-4^/72JB+<*I60)- MGU5,@DU(S0,\EF87!5$!039`2LLB4AB5I=%W97G7-\=;A*4P07<`S-F#PT6\ M2K9X4$^ZNBZ,]V'\>+W#Q455PN$.8T7=,#))$02_#=X`A/+3[(_Z@2EJ:]=0 M"/,]P@EJ=*!&B3^C.>;`[#L2EUL"*O)S" M/%5VS1E-@'M9\%AJ]ZMDR=,Q@6N:8X>"U^P.^A->DR"B.I(V5KKKHL6E(4@U M5A<03DF,C))**%MSJBSA,:E&&[S/*D6$=$DE$AJP2JS=@M<6&;.1Z-O`&?7> MY;/CPM*(B[:.ICF==):3,))>AEF>?<;;!SPXDE![Q5$Q=/$4[N2>35*RY^&X)4'@SM$,G`7(WG6<`_SZ M-5SH/*<'&M]$P0K[P0E9^PZX(6T(/D9CSW##_E%G.7IGAYO=H:S51HR%%]O?@W2D%[P=AOD^&.0#9:"31$M MOYN>J!&9IM32C%V:%L5TTU*TH*514YQNO:T%Z*+S2@11&<2$W')R$GX2DW;M MLE9'0T-C/;N084'',FC&X030-">I(9M2R#Z\)LB*,A7WH'45FR[#&%_D>"L/ M0X-2W(C3*@5(R8%MR#C25J[*L$:F'QW0%_H,L8>.4[.Q]A/01]307)[4A464 M:&FSY[)K(WK>>?1X74"@%`>`/>2'#0DUY^D;*/1.6=0)V6:0^/"[Q642/[XC M)K=H??C@$!R[:`L.3]$R*^^D]RI2=EM/@'I>$W/QS@J*L%YJ\1/GGU+\SSV.5R_7FQN7:+@WC5;@+(K0KGGO5 MLU,`AX!PRK#BLE`L+:*FS)Z]I$5L%6J&;U9L5EEO9_BL`]=*`)42QPY6M0QZ M3KC.&U[.PFP5)=D^Q8+-/_)"K=#!*V3,1+%E<]9Q=5"'%C4U"85%H MDEBSET@)C=K)HZS"DIM%%1,117&4Q-U9R.-&J5H.-1].7<43SBDRX@+<*`%P MBHS8(B2_1D^1X10?3LUX<(J,I($$-!"?(C,L)X*V7Z?(]'HNP0HOM\E^;%AI M4(P_C-0J!MDO'UB''R9JFU#N>C="!=S#!NX!^]TGN'/:4-2!%K4VO[MU%8LC=:8080_&D,>H^510$5Q;`40+*Y\YE6PQ=SS$<>*<7UFNQ@@ M&X;6(;G0T:[*A9;0D`GTH267@11Q/*+,*[N:V[FG.B17SX.E6B.WT^885(< MIY]Q+FF6"20PC'&3$Y]GA\P@I9:KV`&5*U]]45[9OJR'53\F:9I\)2Y$/HZA M(LCUXG)!0*ZIU!"2=B/V5#DH53.D8U7\!#4"J)'PB9U*D!%050-N7-;*Y$44 MEMNT%R1D=BWN=9@!OW5`";-LC]>O`9QJ065N>'K2-;BIDE2=/L)`2*6ST!*R ME\X-:F:[^]`V.#'':U34'0J_EZN-HD$MV1.A2"7GJV45D[^6K=FZ%K7-6?H8 MD$!4ZG607ZKRQPS.25T2:_!TUTDI1B_HQ.^RK/UYO![IGTAE!%T3@0QHM MEX6L3F1//:'C:U@0W&S+[:K?!1D*T*Y8J>/XA#8]'`A3.A7X"'(YKJ@XC1-8 MLMG!X)JT$RFL`9`;)ZJRQ<;_("\#!R+ECQ>5JGV,.7#I0XQ@MS.LFW6#RH%" M)#@:+8:"EN@JJJ'5N,$Q.H6[`S6#Y1'5-,4A!14A9A0X/(*W41KWY56X/+0Y M3Z#IV[4?;2S!=CSNG!27[:Q1(_0:T*L?AN;`[YP!:8/3%*_O@V_++,-Y=I,F MQ'OE+S<$<_DR7I__PRKP39)\_!?[(?7`%=Q"'()V/E#T&FRI0=WLW9?IBG!%J85_7N8/UW$ MZ_`Y7.^#Z.XI2.DQ6"2:EN/\'U_NZ6>[WC2%N!L:;!KIA39H(R"^Q,Z;PX1, M\+J-.R=@DPOV,]WLUSSP9*.(5>`/_)U5@O4\(ZRMH1>%?A??/&YY9X+:O5YZ M0CV/."8$XN'4:@;CL49MC7N@$15-`B3O0E\B: MZ&TBU"%?Q@P!SX%/`;N.V4#AT/\"=)Z@5@OV-KU!+,$31,J*P8_KXFL3=9)=%2FW*RA9LYP8H*S=EAH(ZU& M6(6YXT+:1-?O*=:T#HY7N$W`'MH^M-#6N7(>??=PE"Y-?-C\/$#S)E>8UGF? MUE&?IU,^:P<FQNJ:.6-!TNTD>1.-N MUP@DG?Y>#1/TCL+D4/&@O,#-&!%NG>!("BTK*G&*P,FRK!;P3E(KU^`*BIVF M;^FOM'VE!%%+='D2C+C8@XA'5\+"R*WOO=T3WX9 MWZ0R+"GQO'5)<+KTZ@#O=QL#>BRIY'13U1-42OK'HWY[2VG$!X>$0Z6`G$*U M5MMNN#1DW0L;PHOO@YV?V`.#'1T/["=Z[$Q70.+GP^\6U:?KC#P%M."1P&AD M8L)_&/VL`Z-=DH5Y^(SOYW=&/S=@.IR>]R1(_>P&4O-GAFR_]3)>7Q)3FML; M=$1[N:.:*`C?=&H)DUTJ6ARGH)*B)CU@Q=F^4"9P`*MMM!`TX.T$_/5HK*)A MR&LUNS9BAXIE*QGMK)"F.6\/RZ\%KF,9L3O`.ARS(/^H?BOK?(LSG#[CC+S3 M!*^(\')J/HN3= MV(XDYP=X!ZN]3^/ZV1TY.S1'0'.6C\&:'8;E[;*$@^"N\J#@0;/7^W2*_A>O M+\/@(8S"/,1`2910K5GJQ%'KPET*W\Y)FL2K#;A/'!J!2(D*K:BE]B!=J1CM MI@YTC$=F3G.@W=A5L"?PJE8X-O`=&Y/B!C)Y%XC M(Y_?:^NV/6O@4$=OPU+,>$)YV%+)XCROZ*%AA,??C=XC*)']\14&\/ M8F6+`;HTUK=XCJZY%KK`8.SG`F/HGF+L?!B2222TV(.*X:(>/*I:``\"X2;C+86;! M8IG`TH*H79)!D![:1R^&J4L?+R8E:>[LJ)PS6+!$)"LCFGB,0EZL#@FB8H:T MDULWY9E0NXQ:`J%%]:09@?!FE&&D#1/5[]TG"+]TFQ,B?;#.F6\%>!P!$"SE MM2?LV:%C0^P^;:%C5B=97TU#1Z!;%],,_>18R<95BDN:\F"L#L8.4V)`2@.A M7.?ZGQ.*F@C7-P&U2S)_NDN3]7[EP\5`X\V=:+3+@#HB@0Y[Q%J!W:O($+2' MA487]WJII4?72\&@2.*"K>+(C2.N782Z1QX3X;AFL0@8F<9J!>>L)9;4>"54 MH.R^_6':*!BXE%.$$(=Y(DD^!<5V;/ETD45KSMT:&@_(W<."4"4`S`-#-R%! MXOHE+AZ00Y:8HLR('NZQ'T="*!SH,T#N/'[`:GK+IG8;3/!ZOV1DJ5GUA8RL@9 MC-@V8[E8N9B^(IE%]0"1)T7*?8+*AVZ).=9\B>*W[E))4+CAB%`;9/XJ,`*: MEP*BA-U?.F2))E!KZC26MW1R*Z^TA,?6AN!.G/*F.>A\2DK9) MW'-"QXDHP;8.OQ&EM8-C='\0))9^'F")/::.Z9A1)-BR80M%[A(\TB4.5SVL M2LL(DKNR#"@[.G9A$[M*M3HA"@EN4L<>^07X;I,)X2HIF^^8&>.Q&TJAL:2MN(;'AV"%-,U7Q!D M-U&;BAUQDG:DJ%%,SR!0XRXU$\WJCY83I&A0,_&C]BU$9K5)/;$4)V_S"_Z2 MZ3?5]A:0@#-A)M%HTX5.G"56S^H-44+SN"%./%H8`0$:U9P-$C;N?.A-$H6K M%U5/*B@M\*>#TJ!D$=3%@F\=6E+G3E_6>S\K:F(A<>28$)"G)R2FT$"[3?_; M,V;+"P/BB>^13U!1#'TI_^NM@S9%FZJSMH4W=XY;L*AEK)C`50,M1!FS#LLC MI<4C0B'O/;%XH8=B(PNX,%R<(=;G#?HW&[RB@TWU/3*W08[I61YAO"=5OR:] M=K:>)"L?T2,]XE48E?LF!62!U5IQ"TJK&15AW\V0N6"5D1`=R,:B5M2^RHP* MG*!&&VK4G=0%4%>E-Q>@0^,\L02RGM^"4=YR2MTFME_RZW;'9Z2!G1[O]\L/=#VB#UZ1`A+(\R/$8=K3]$R2(N^T5T-J\=!>!_3H,F9SN1D9C8_.'=* M`N3&]!.+0_$B)H["U!-,(;NK`*X9HY,\B"!B-!!^BZLZ\CV)C2S7_2[(4$!G M2U]D M(\+I5D37=>CI%\?$7E_ZA";II2Y4*^L+^>B%IJ%YQ#V94$3JM;04C[DSS5K: MC\I:%9JA2^T5&6F`9UW@(BN`OV?Q**O@WR0\N!X50I9%&B%59 M]UQC;V$_<9#4P,Q)"15KI`I,!]OHS;2TRKN^71`$HEH.2Q'P&GY*I%'/08GK M-7<:(*K)[/%_=DX5A[1TN<(>U+?S=?(!RK>/.,:;,#^X9&`>4IF$?[>TFC'@ M;W=1\H)Q>?)#ZYK04^X-%\KEJ]`]7M[,I:C6QS`(*YB1>(51Z455Y%U:GGW6 M*G2"3GVX&$.]Z1/MUND1=$RLQ<)Q"Z`1;,P<;)BRB[KV=<]W012D87D).]W* M%689&R.]"5Z"A\CU6(X%Z`FCPXS@F]_/W^'T.5SA:D,1/>NG.?Z'Q*8RH_A$ M/GO[27F_M"`8P"CM10Q3I2`\AWDS0%=@7*%Q?V%H8M'^$:V2+#]!55"C*S(> MJIRUV>7G.F.%A?'`!8'2H^>ES'0/79EI76T$6[,Z@>T;.!0&LET(I294JNJ< MH=N6.>GT(]GRK`Y_SWTX&]UO@HXE$H=%4<]2DN7C8XH?2?!HCBP4G2`*ID\G M$9'KL^_^5-YGKO1CI"Z&?D^J?9AT'(#'4L*BGK/2@+>.EY*IU710\AK.GC[( MJC-KYN"./)KY0JVJ=1IMYL_F"@^)9Y0@>$*]&=."?^[#'3UO^#/>/N"T'^3Y M3ZN0W7]JYD#XMB#"Z4"SA-^]LHO/>!W2N:'Z@6/&"5HD&?F,/2YT"[60W9<& M#1%=Y6`.?WKS,F=<_82^%#^Z]JF:+2ST=T!M/*\ORE\^X_PI65_$SSC+V4'H MC?\4'M6A+=CR8*J"QM#7JZ$Y)Y3MR>FBJ&91E$5%8=0JS28Y_E<2$H;]2OYF M"4SK.B*/3M#1AU$RO8&';%63[Q)9U2:T'U>S"SL_-S>F:71H2J`PIHNI3 MI&Q3,3MQL@@37\O+:=".O/43[5)Y235E7FE1:)0OL[CQ.7SV%/ATO7%&W?$O M,6FZ+(G"-9OO7&XV;"F8Z_D30\QH.EY/4*-U?+)VXCH),!\D2>F!0T1T,K(E MB+B.NO58&KTK2RD"Q"L&FH>HP_?8F*+_7OZ$OQQ(N1-%&3)4I? MF$>!7M$^Z`>:_()YFY,87P5;+,'[6&%A+M,M#!Q?>#6!#BP]&SHQI2/*#288 MGR!:QBNBC+:U)(A(L"&,'FT96>#HZO:73,5]N?&:33)46)I M&WWML;I:Z8%+C&KWS(6Z#FFX?10Q8YUX1Y>&69*S7 MFT]!F/X:1'M<_Z.9.>"O6YD@6C%<2]2,WA-J"3%J:;8R9/ M@45BTEP]#FMH:!%8RR[H^(*&9;"!!A?H9$,/97FZ]9\61*SD2>O?G54+?JP5 MF@W0PJ$)YY">+R#55?SX4O_S;R%.24,]O5SB9]+>W\+^!+&>4/EQ586,V*U7 M,S-6*]L2\UE1Q:+-W?HY^D(?.F:K)A22:0W5Y:>:;,-,55O>HC8TA435#UN3HF MSJ'KN$7(Q%#9+%16.#,T:3[(!Z>_UXO-@5M1%N@2N0YB#5O'1D=06F>0E*^Q MOHYO\6J?IF'\2`I<)7%:_4EO%,[NZ?$NHE@$I;+TI7VKU MSWU(7D/DX$3E^@YK6`[&`8GL0R;/'!L*7F(@M;@I5T#3\:@8?T78CPV(XVTY MY.A(L_C&-EP M_(6[7&22K&0T0R(+WF<BXGS(3J#2A))9U&YFZLO/HX=`6!*Q%74@(LO![CY,T"SN.$^MI)3\VJ!'H M-L.#X"6[<6#UA-?[B.7H&\K29Y8*;/V;_?".:J,]@(,AVV&-6%^&,;[(\5:X ML`%2-^#(=4NW\]'KP7NZ'\%N5\GN*'9CB9>8L-M7&IV:B0K5C9AROU(4(#:` M#G>+R`8XY%V;@!WV;M7<8AIC5C6;^9&%F'EP"%?Q+M]GK%E]Q^X&QT52O:=,:\D#('$=0`B#]>``G4XIM.V0-:-`Z#-F*,#A"T^K%2<\-&2G8PT')3:L'S[&X29< M!7&.?HF3APRGSVP*K8>LXP#4J!.V!"FW#OB]L@-^K^R`WUMSP.]M.^#W$UGS M?MP!O_?8`??;5LH7/A`D;'FOPI;W[R*$:Z_M"Y]+F$WG$@3L=#0V+.K8?^2=E# M_Z3LH7^RYJ%_TO?0$[CUTT1N57*=U.8Z?R)`N1:E-S_Y1YY^0TO)PT>%A#H_ MJ5#GI[G<]4^P!W%80%-WN*(?]G_R..Q/P9&.$X9$THQ..(S#'%^20+N^B'," MAY`X!19_JNXMO,&IV'B>F>(#AJ2*:W5HYZ"9(N#2G9`W;J"13#_ M/@<(F<=GY=ZQ@J@I663A)Z@HC&CI8P6C,!+,#D$QTXWK)0_ M050#HBI>,S_T,V67#/$BA/XU3;+!WAS%XN-AL2QNRS5T:F,WU%6F)C&^$%ZX MOWI(N655B,C#PCCAF)02M4K],X499FV&@&(.))4@P0H>&]8FN'=@M'GALB]% M6RHU1,9=]R74!DB-6EDCW:7:;B85!2/4\VE3H0X>5$@H0M$X#2\Y&X>4[,SD M_"_M[,.;`Y#%Q<8U"@/V]%B!-R$"'`[TM.Y`'KUZ?1[P??C=HEC6$;X:"`HN M3YX?@EXD(X+^[STQ;SX&V]$R>1"VU#+S^%2G[DZ&8:L:0`Y2%3KI0.R_>4MP M)3`9C#3Q4#EYH(DI,QEI*FOC=C"65<+=:*PUI!N.QS(=KYLG<$.R\S#%BZ#Z M:4\O5>2\AN@(`@!5X^%5094MMZ/\%M8\CTH-)KF?<<6C'NB*+H3BNZ%/84:W M+#!O]#D@ENB5QE\JU?X.4*C#5L5!Z9)@W$>-:E1R5`KUFBFNC]9DKH$1=SQK MW^*X1D&;3K@HB5(D;0^GOSLSE28$?$_(Y$7H__C2K,;BW0>I+SD>V(>2 MMMR,J([6PC;'X"3O,=`S-@WP\-)9Q^C%!9(3L*/B$D:`-\[_O@(EN@^M'@"[ MEZO5?KMG0:3MJ#0&RN0*%,;(1`JLC1C(:VQY9$QH?-I0@4#=HO6@DXA[2_@Q M'"EU^Y6PJ-#?Y^M1Z^J+ZC#7>!C?_AQ#8;-`6VD`[`W\G(;W&?Y^Q$).IKXA MKAYD!3]7TZ09I)ZF&0?6N>\P^TQ2OQ908^Q=O8O[)YSB@/[FK]M0A=G$,7,9 M9B>-FG<43ATY[]7*W3Q3IR)NYIIFX<+T.2=&G\/<"6"/2#`34/-3R=<8S>I/ M.&V\N*.M9/H&.Z9D[JU'K9J[V6!75`!T]Q%52==U_/&0W,8`1R8;B(9XG#Q7 M3749;1]B=7&\P8XH<[C!S@[$33?8$16OF1^`&^QF8(C/(?3^:V*^/++1,7UQ M)-4Q]VJQIMZSKQ1CID'7B1&-1FO$OB:'YE':N#-9'S:`[_2U85\3HY5AM":. M5U!^3>9:8C$G-6B\)3[SY]<+<<`%D-9![FO`O,7T2)HU3J\WQ8(V^CY&X5.J M<5(P%6BNGSL;U.?F`0)SH>E30/D".V'/],YQK8[>3-U:<_S&1#FD#IN+7J0+5UAC-T2K\'B09X5MN9]6 M3>R&YL+0)+]!11?D?RBI#VZ11[NI5<@[A,8X*^FW42$Z#6$RH_H*J0$='T:F9&-V5;8MHI MJEC0JK:@@P":C85 MT0+4YB>A=DNR4C/E?5AO]%IB&"M& MC4CX-R*[*`N@("8,ZQ2I!I0<,TZQM1/-)NDQ3"[4HM:8=E"G+S<&.D5I$634 MNX_#S+5G!\:9T)?/A#1OO+?@E!1-*35O#G3VB6;=K'IWI9,65'4HT-";\TAT M`:)*3/DI(XK"RC2UHN75&5J>?;ZXNKB[OUW> M7_QZCL[_X^;\ZN[\[B_'#=")$<0:1&>,*$FR_AI&M,;]\:_^WS=)%*Y>^K%E MJGP59?3ES>@\M;X0M)Y@6T)P;6WEB;6#06''W)Z,H,2X47MLUU73XKU^#4"# ME*YYJ,4=CB'-HER];Z4_[W'WW+TD3C9WUSG80ZH(`Q]'I%A M_G`HB'*"X`7$7EA**C&MH8\?R!<#6H[2(?CL.%C8-%^GI3JN[IW[:=SQ%AOS M+/IMYD5:7#W238?YB:#QT M=\650G;?XDQY:]?L#/FJ#2RJY*?5\X-,2\&0/"$-M8YE+\+-69BMHB2C)[P* M1O>GR(Z''9ZL+:Z+ZVF-[5R3DQC/T;08T-Q;`DL@HD+B482-TWBH0HG*/,N^ MT?EBNPO"%*];RWR+G^B:D,OA_;/:% MNX<\-N79VBD_2*T.E@&A=7'6(_.H^)#("A9MY)>C9JWTZV?";3?);,$U\&9' MP1Q8'[/;Z[@[=W%Y_NKA'UU?H M]OS7\ZM?SN\.HT&%3LA9DVKM61H+;!.:],,A\E*TJ\BT&>>+!TV([GGJP4=3JOPXRE)&H-:LFUG\43$.$Y9X^5MPM@70! MDDQLO2[M%(4;2BI;@_2ZBD9!NQHSXI0&Y]-@%Y*@'_Z+?.Q5DN49^IJ&>8YC M`MS-<2-3%-E=8=-)*$FKK6+7F\LD?F3;9JN%':MHOP[C1_X*C^)_Z8P&F]`0 MAQUH"\,0!6PM+B0)4!:'FQX^`]S1/:=,\[>QO M'M":+A`MU1_24M%#]0<*:=11>(09T[-XE6SQ71[DF+ZA8)7`2*DJ31*5,O-W MN;<[HGBA1P M3/R1ADP4OWJ/?OS"+0J)M/E%@_O@6[,P0-C=4"C:(82H*``KY+6`H(;0PA@_ M!(*+XBDBCU'S''WQ)S2J-&^BTPP\KO`E^H01Z05-)R668`>;;.")IFLW:?(< M9O1@U4V2H@9?K@\J@$.2,.VQCB6G'EB:C$A+BOTO:%(BK0.X]]5(3OARA\24 MLTDX:(RB$B5ET?W.V\9$X@7<:W$Y\I[:ZW4Z MKG+D*=GME+QTCHS2)!=4/4@8VN$)T[!?XC4]WBI\V-.]!MTDZ[M"Q_<>;),! M\3@&Z8DFQQVD!&;!O(O+>Y411.O@I''T[BE(V>'K^PY.HZ,&I%KP.EQ(`EW` M,1<,/W`[J\+^Z!'C4K">_EAP^3/X+(M]?3K##3YHV5885)(0U][HKXZ`3OK!MR18;C*("S(D7LT=SHSU$?7 M)'@"=N=!4BT0J@4[.U2V&K2F<%$>?+SDFS*GM%@SRHQ97+V%B1D0F!S$XJ^) M,-%TKYX`!?*X`$B@?#ABH$@'1^"!XB">XNPF"`>'#?"?]N-G]10&[EU;0/&R M5JJ`Z[+LHHU?1'_R!,2]QAB"E]M:?<@6A3A0K:2M^+)"N9V^BWX;L]E\_[R4 M8@./AB_#)I[5"Z4XR/`9+OY[$9_NLYS4-3W#NR0+>9/)B@*-KQH5,$6X8HV, M/=JX'2D!QL0751GT757J>](71U5!5)5TSA95""3ZC31@U(A>T:,N?3M[/2&TWV:TEV*;/_NJ'<7BPC].T\$F&CB6D'[ M>*XE'99Q%(C\?'&X1EG6CY,U=/`@H>(HBH14'$K*R,BS8]?E#RU.6ANDX_8M M0)*Z_M>$/O508!M_+L/!W>(5#I^#AZ@/>AT183C@B0"34%PKZ'#` MM:3#/8X"43BHBJ*FK&]\E,!!PL=1$`G9.)24L9%GQVXT&%JT'@TL())&@U<$ M/O5@8!M^/@2#F^"%5I7>TKQ:I7L"QK`X)"[$X[T%'26C`4.NQ!)S56IN*ZB, MV)Y":JG*T,6/Y7'1X@7%FH+BX3BA(/10R$@-P8?FQ/:T M1D-$:H3#=)4`*B5\6ABLBQK9L(D:XL1#)P)YZ0"*T*;E83R!7L`VI);HKE:3X7UX#E#7&`6<$L_,IHKKB.I-$`B'Y--%` MR,;PO*!F5J:*AK:T1^;[*N3314TT\GC(7H2-L4%[.:;D@_8]V=%A^X&M&2:. M>C;GF3J"AV@S?73\&-2<.K*,0I>A@N[EC(DUE8%!3EEA8.B4!68=IQ[08:!K M0H=:;4F1TV^5\8UEO#:6D$L,"2&C6B(R(G4TV_7B+5/6G3<(L(J%M\6?+\># M('6O#(\A+X:36CTZ_2$EB?#XL!)7V%;W7%)3:\-+?)N3^N<\5>/#3.VAT0,8 M:I*A2:6//H[&\5XZ1X=23YUK>Z:A)X[MN8:?[$*\W.S!`;F_@TP60#QAL&E& M&+N,8G=YLOKM*8G6!,#%:3&W211]2M*O0 M%2>_Q.N_!VD:<,_Q-=74CH)3-9G["K-W@/(:DVLQXD$FZEV<;S9XQ:[>/0NC M?1X^8W2'5_N497%_057!/Y2RZ#OB:#*FW_V9,<:X3``!PO$XTQ3VO,_46H'' MVFD5`;L&US_RU*&X$$>%/"H4H+8&VJ14!ZI81%=#5&K>:-3%R6$1:3`WPIGM@3/^YX5;'Y*8`^(#(I# M\/W2WCE*V<"YO,7Z(.8-?@\T^`/7G#192'3'GSNU?X?S\VRK:K\/X\:])LOX:1M&(WY>)"!P_7P24>+):P;I^ M@25USG$5#"EW@DA!]%U=%%5EG8^D:N!!R$8%%`G(R),4LY%OQV8(X%FT&@.L M`)(;!=`[BLECA9]J-+`/P%GC`;MDM#R`>NCZ>4\;+]]]:DHCGBUCW]U3*F5% MI^RB^J&Z_L`Y[KEMD8Q\P`&6VX4ZL.U*`[O(MG)H;SBUB4L?=\"-+'%9(,T\ MOR/B'C,_?-1S02`'S`^MP#@?A6/'6P4;1/IPICSGRP^P*#M-OBDQQ*"-<^0; MS5:"2J>HB_E?ST: ML3;%C-@OVD*-`W])NJHB']EZU/>+[!$,Y%M6@$!>:%0`-BW8AK('XQR<3S_$ MZ;!A^LBDHXA#-#(Y*WZ+:`;.O2:TI5<[B%4;9U)<7?V!;M.J$H1 M.8Y%5JSE9/C%C+$JLV[N?`3:Y>#E"BV:)^7532?(EU[%2!LFJM]["'=>Z2[T M^?J@/1K/"O@9"H!P:0ZY^:YX\+TO`UNF6)$Y1SMHF<]I7B;Q(ZG3]@P_Y/?$ MV%FR#<*X!TIYH?*CB`H9$4%NVO@W0[CP8.&BJ M>[[=1D2Z)9[NA;_8[M+DF>VPRS[C[0-.^VYQ MO&3E&V4ES:@P7@=#+RDU(&&Y1/T3MI^A+\=QU>J#0K(G&]^_10RS0XHA, M*Z@G%1N"=:?P***.M<%1V'I^'/`1^E?+`)K9TV;RRSND9=K>=5C&G!@BNP`> ME:-ZA`4#B47Y0_@O>GD..SKG^B$*'P.VV]L#$@B;+5'ZRAS8]XOV`#_4Y`_4 M'X/HW2)Y>":)ML2I9@$Q4%DU"+3V9"7)'!D(*H+,E&$#IE/=I/ M:1.5XEQG?ES.&!2:DT7+>Z[[$4!8H'+WG`)F-!-:-&043Z^$/L/BB\X]2^6O MCADA;IYD_(/VD#XHUX(U1P>H;QWHU^S[)23GDL1OT[:G?O+^^GYYB4Y_N;T] MO[I'EQ?+CQ>7%_<7YW>'"`&ANP,%@1-'MLRR_1:OWXL]6;_$T)4U):!@W;<) MD95RM2O!NBZ_J"-4CJ+RN>-E8+*&XB%:T)I#0%<%N8ANM%CR:Y4!L`S1O/59 M]M>ZC:#\_3";7\&C@0#`B4^[(M]K+#\;EAGZM789*&`/[8(!NZ-:"=HMB6ZZ MUCSP!MZKC M)I"X<=SG&/>LXK*R/@B\?Q77PT*?1)L<2!([$4M:'1Y@-+D9U8[7PRN2QAVSDAAG_%LN!C8FJE([ MN&'2$6MJ8Z=2)9WA5#J57EV.YY\[5T,&=\15`U.<05B9-']D5F[/UGB]S*JM M*&`?HBPV-!$!+:_.T-W?EK?G?[N^/#N_O?L].O_W7R[N_W'L.%69+I@7J?Z$ M%G*9X'>:?@A5;O?$Y^!9N]]N/29HF7\/X\338D2<4\QVVK@F]01L)29MWJ>ZNH8V[77LPH8>=PVI"V9/[S>YUE.LF52;858)I21 M!#&.##BOA?6R%+9X]O3(/-2PN,7/2?1,*1HG.>G#[((7%I22IE`9Q/RCKA@8 M4LZ.X4E"U8&HG*,<2[:#S<"DS2AC`9'2N%*41JWBQPM*G0AB&Y9N8P:[FSK( M\!DN_LL.^QL>W#M%5!)!Q*+@G!VK)3QQ)1;U^"M4)"9Q)8*^JX2^/T%,SH,C MB">!2$IL10A*V"W2(">YV*[M$"2R#'R(J!-<%X+'&\')SVJE)4$J%99<`H/Z@$?@MHF]+C92(J"#/K"'K!"SN?I M55I92C@1*"3\JD7DA&IIMAT4:E/`$^Y6@$6]?+=C7/>+WZ&/0?S;\6!*QVM# MH\JM7[ZG[:G@DSOE)/ZX+`?.G(Y]>#]C2B$E]K_LN8>NM]N84HKPVEU" M#E9<3HQ2HT^DR*HZB@X-$1=I46%8Q)@%(JOF!.!HEF-_(-"#O3[38(V7\9J-*]SB M%0Z?*9&SLS!;14FV3['P>$43'?6U#I-T&-[[8%!O"!<\T;[L^H@I&A?+U8I2 ME?KP39*B\L\,-7*NKYDP`5@"TM[]BRHFJ&K?9#&I)J"19$H5P*93_4`^FVZE M@BC&2ZKF-"010[0 MOE_M4!I2''X=-J7>B5@CFXLFM2<]_XKJ=7UO@WH[BH85C-O136SX^/(YR/A;L@0BG>!2_LWFC:B\?! MZJG:>K,)GS'*]JL5QFR!Y(8DT$3@!0?E4?DTP<;!AKR%/ZR10(/+HU$H<7@U ME.$SC:?;E@\=VK(1($%1.`RB)^A3@;%_$(RAJKP_!TB`XDPE$MM#FALO+QX, MEI3A^'2XP5R)76`/KCHDQ9/PO9PHR?)ILMV%.$ZXQ9Z@@T7.-4@D08BC4"=!MRJV- M\T8FO[A;/>'U/F*K4K9AS';?[DH!M*HE/.D1JH!A0"]U!/6H)A$<$D]JQ89W MEAB$]M46$=CUXU5!U)0LEP0B[YP[-!;''/]<:'23$Y>9>XBSVZHKGEUOZ@[Z M14P[0_?$^F#EK9$23E:MHP0LS=*O.7!>KE4!M5Q-0^6"(.3?_*#U1!QQD[K) M>.3D?.JZ^$FA3EUL=2;4ZV"CM^$4XKQAGD;Z!#7R-!-K!B;#N!@&8DI>,T-4 M^D7^<,3G(/HU,0ZAC8K)`92JF-FQ-+5V$CR9>4B_0A32P/GSH;F%%GH,G,(` M@Y,=PM?$Q!W0>K@-F%\3=^'2`JB-0^77Y+4R`BY(VN:$QP'R$^&F:81LZY@: M(@L=\_J2=KU=!,G2/J!#81IIF/SC@3F%#H2F>P4.$J8.J9QZ`+F?@68:8C\KXB04 MS\<)@]!,5:%"%RJ4O5%KB)K#(Y>G,9RE(.&S\=QJ6\?D;B_3,7._H%5O)]W> MPCYDUX!JI#'Y3P?D.`80,DCNATBIQ-I,H3J#ZAUM$T:4^O5Q]&0"CNLPDK(;0JR[MEO2Y"DHG-UV6THG!# M8&5KD#%.T2A42)L1GC1@M8JBNNP)*DJCJCABY8\;HZ*XXPJE;J/*Y^`;/?2E MJO$-3B](9%P/9P&F"4MBC$P8G,CC-;44<:2&]9@M4:4>?]".Y*#)JAAB67D8 MCA0P)66\,B8EM!?KD+-?9MMVJ!+;MAFQ9H&W)'Z50DT`(V*HDGM-X-:):O/# M>\X8%Y.JT6[>9[Q]P/V=G*+'=9SJ/S;D*=\:2*P9J);1K5=X\3G]`=V&JZ<@ M7:-/P1-.\Q?7;!$T3#+V,?MX[Y9J([HO#^N2N]KAG*Y!.Q>.L_H-?2E^=7R` MFGY+BWT;5%O/Z9^8#Q4X)\ZSVC-UGAEBE6,'Q"=U]UT^D M'ZV/QU:1-A@[DK!>IZ4:SN5,:L;"V13IF"^>1KU%Q3[&O$UG]"YX'>ZW=.R; MW0+&]S*R,I6WX9B7P)$!L1F>F#QT#&1IDR5* M7[@':U[1%KSYFD!=%\\$F`N#P0)S:>Q!,=?''OGBW`PP(71V%E`QH_,KSJ_F M.SW>L\K9=9^9H9IG!\*Y]?1*@-PIN2C_=(Q5[M=/I!^MA\QVD18BNY*@_JFM M&LPO36M&YH?*T]D]\3X:+2KT-@!M.J-W29Y9A_(B_C6(]@&MSS**DJ]T8"Q; MQNM;G.'T&6>W211]2M*O0;KN^Z#I&BI/-46#&0NFUQG"ZTVR+B'5!'V+NBB[ M[NN?^R`*-R]T9/J06HS]>O`%AD<`]U%F5* M,;I1N@%^(\DX4,FB+U0:E>*N(Y(C'@BCFV=,F"]27M$E=_AZ<[W#*:MZ_TPP M<8'R$_(*&!%;;!$@2G&5BYG)*;ZX3A^#./Q7$V8^[K,PQIGCV")IJ&3\TW;Y M,"S7P)VG`]*O#_5#N6WCMJ=.M_B5+A9N?1Q_KC.;A@*17X3%P8Q>#>>G0?9T MDR;/X1JO/[[\DN'U1?PIC(E3)NG@4] M@92:40[TS2"\-%2%).R&,;'X='&UO#J]N/HK6I[>7_QZ<7]Q?O<7QSX`%JB) M'9CT/`V([I9W`JHK:&0#J1-8-#P4CK&HBW-$5:%*%WIX0=]1=:3S\SVJ-:)& MY0EJE'9BM2=W,_O-4F%&<)`\=9YYE%4>>Q^UC$-3F3S34%9FP_5IOHE29I'D M0:2=6:A71-O;J:I>7)W?H]/EW=_0.W1]8/H@PWXB!Z?"`MI."ZM`(^OQR9W,XO12C M+HEQ%W]25\-9Y]V\ISYMD,LFE%GD/+]'%U>GM^?+NW/TW=EY\:_OR6_%N-;R MZJSXQ_F__W+QZ_+R_.K>SU$M<#!KAKC9X.P\6%W$SSB#&A?75"8/:QYS+4*Z+M1515M\?%+ZY^/;\[A'%Q72B..95IT)9[&46=HXY'N6XSA%;% MNECNV+IGC4)'MM9TH./BCBBF&KWYZ2:(W3[&.0A:MAA)\BW81T/6E35S2EKL:>1].HU-5HZ6*>I9!` MWU&9[U$M18%HD;>OQ[E'@8`BT$8!&]L#H+8%^+1MQX_M.A99`[L]YXUBDX<:/2.9 M\X"O.&2JMP1WHE*0N4:[2W`GOIF]);CZ%;(UF](LP>5-0/JY!'$SL0"0OO\R5MQV7@"U/`+/1<^Z8D==P;FN@4IS MW]52ZCQLIV"ESJ=C"[UEI+AK=&B[+=X_;Z? M9EA17B44_K<[VYQ;N$)(@/$;[#CZRF_:`\6K`*RI*"9@P9K0%$4)89 MD;!#++8HGM$4<RU159N.ZQ";RLN&#/R_(*@E!$7`-`+\LU M,LX2CEB+(P_U4Q24C_W@B*11!QP9!4"/(ZCP$Y8][5#G;F\Z[UT:67."`5_+2G-[*55S+?!"\L%ISM\?T33G&PR0?C M39/ER\\Y0=Z(9Y/K"^"YI]@6$U-?VZ+YMUMJ3@=-8MR.71IKJVG8/:$&D`%# MVSQ4''&,8AIUF@.T"ZD35,A55\RC2O($$5GTFF$OBE\^`=^[:"=86#]16B_2 M`2V8GUC7^:*-CBA^#'*--X1&VI4=(2=$@0KM2Z"`<@7BUNQD2 M]5S`>Y.*>'F53 MQ1]W`BL'GKHY/TWDGXJV\ M.L\W)-.S;MR![>A;$#S\FR2C& M)IHG3$*$,6+R;%#F,,8?P8E@.!(S&Q5\C(9?$[-8V)/7CH2U_$QNHU??6:-@ M8QO":U3::`3\^5"(WX?+!-KS$:=-^5+-%,+7-7`3^4KS\\<]*_B=&/.^)H<5 M\>"`;Q[M[$/?NTAWND_I4/FT,-<3UHMQM?`Z/XKCIY)B23.GPXC MD`$AW3"$6<:Z=\'K(OY$N&;43QLHT.VHM13,D^8.:CQG5ZUM'"#7;=31H/;' M@Z`Z#S/Z2:L(=[HY:ZUG0M+:JH.3#EMM?_8>FRT83^NS4?&#ZK2!$L"XVS8+ M!7R,?>&SV7S=0(%V[&L4S.0Q^C6>-?:UC$,XC5H=C7U_.A3J#S`S@?H"W&D3 MO](SA?A-'=S$OLK^_+'/$HPGQCXB?EBQ#Y(`YK%O#@JXBGWKXL"XRS#&%SG> MRN.5!/P6,4QI$KH@>B`NC[14=BV`NJ-8(%+LKZ,B%!#W?;B M1]^6G5@!""-.#%A7Y_%^H:40*^;5AAA3<*GY<%OP\JY?,JTS,JT',D^R9F/% M[:A%X\RLW`CCE1\?;W[=7,HH?=+.F9ST%6;N($!@3WO>Y[A!:ICE@\-TQIB1 M/@9Q^*^`5N0TB;,D"M?LCV6\OB'D(!5F?UYORAN,@^B._%+>HB$X%0!29Q5O M8'2:N0/(]S)T%4!5D3@2$`N+CT$69O0TK+:,8V<""L_$"CIZ;@A"=G8^3O*U#=\>OE27/QS.V:&MD=RHW.ME. M][96ZBMKO:A1C!K-'ETQ9HT<,&YUG'X0'I9C!-M72,.^# M;];^6OYX;IVJ6_?LZI59W.VW6WK/(?'\+9'.?;&ET%$$`WT^0@>+J1X!-I0H MUP(\U&B\OX?9HW+MP0;:7[-[8D/_P!U2*C/BZ8ZOTWI`;L]R#GT$CF_&'#Q_ MPFFQAD"PM5-8H,IC.07,_+C0HJ&?Y>F5>,)A\07[K5R@0CQ5\;-C]R%NGV3\ MB_8(."C7H@A'!VCT'NB'';TQ;7P6J%CS5Y]FZ<%MP]-:7^B`0=M_9B=6'*9& M7'!Y7J1P/EBI<-NY20J;0WZT)@!.3V9CA`-BT9(-10$/6##>I(G>A^=P0RC3 MXXE$MX^<&2?*.#O@*6'AZ@.N=C4&>`Y[):PK`UR*:CO7!@P-@/6OS5N]"?[E MT;7>G-4_$0+2#``0!$XZ,O1NXK&^S+#,L#O3+@.5VP[M@G5J.JJ54MN61*]K MTSSQ`-_"%N.EN,*&'>:X35%NFMO69*FGTYBPU=DQ`47C]3SKZFA#0:'#`P:& MF5W>:9+EUYL[G#Z'*SS8\B8NT79W_1+F\.;;!'!U`\4CF.Z5K[KPY%`[[J^Q( M*RR0G2++'>T9E04<_%&L)^18T+A)U:&A,4W=KA.=G2M^*$4\74LZ"4>"(28] M&')'G$94B`:@1BW;ZL2/FH8/"_-#NS\N\'H@JS*`X`JT,P/25ICNYQND7+U3_W81:RM7)E80]H(6O1 M1/7K?'7&B_G,B'-N5@"=&W#\R'EGH-0M12?#[0Q^^(*]]Z-A[D]VUH=-^ZHKP.?W4]=%G&]0W1:BTM[MS)D"'JX'5D)-V\GFZK M(P(=6XK^^,\%LF+\&.1X?3]RVITME%$'?7]]O[Q$U_=_.[]%WQ574'^/SO_C MYOSJ[OP.O4-7Y_?'A#/EH00K2//%:CLJJLM/B"MU1FW;'BVTAE&7PW-#PEV,&X[0@80N.\P6- MZNS+3TEZBW<$\4]!AJ\WI\EVF\1W^7!1B;I`^2%5!(S8J%XCC?Q,S$0E(/9'/GQ=]\_OZ^X0-R:7XXSX+8YQE.+O".:ETD#V53]8"KZ\C MVO/_:J(@U-2I)0Q%%2V.DU5)44-:@L/R5]0(T*M@V6)>*E0]7_O!8"T`#;@\ M`7X]3JMH&+);S:Z-**-B>=(`U'B",RNFV:F,Y>/VC$'&%LG>XHC6F:U2=[PT M?3X@CX4G=U!V&+(NXIR`+7R(<+$9:2Q.B?0P]^DR7J_RL-G10\O*B_R\,/RL(03U0>8;APS&G0;2'/)UI3RDVS" MIA>3;00M(JKUQ214&UJPZM_[YFQW!F!Q1]U\+ZDX)W_MJ!3+_-EU34])M$87 MVUV:/!?G#!X?#I6=OD4DSNCT<9P51TJR^9(;TJU+<4ZJ3%_@(X[Q)E2Y`<94 M314B)JLQH[)A[0%F%0VJ("']5*6+\^TN2EXP1F4I=$-,..:Z*<02J.;N^86) MVEKN8G)]0./9Q%J`=6-\8@#K]!2RK;WA7?&*&Y[>.^2>+\)(ZBUC9HR[!+!7 MP1:?)=L@C/O1E/NPBI&]AV:DYUHR)')?IX2>W:(+^C>B/Z`OQ4^N.<1OB$3^ M^7IH[Y1I8;@GZQLRE]_"08^?\ZB'RN(1"";;5F`066HQ M!*:<\HOZQV*9R`EBOY^@BRS;.Y]SEK16HO!Y>T@>%FP!FJ<%-$\>&@!=7PH` M!I:]=N&`_ML/[W]$-T%:P.*_H^4^?TK2\%^DP/N3/_[QC^3__X2RIR"EJQ;" M>!7MUW1%](>3'W_\L?R]/)6,WE2R1/]K'X=)BOIFKI(8'S3DA$DK,.A<.=,[ MUI1-ZTO]JJ@PU\4."P/R3%032,?+L:%*NX'HT!T715J\\XD?PH864&4$&%S. M]&5$]!GJMN>^^[8L>G)`=''\^TG;H1?N^ICPI>:5#P)A'W00]HS3A\0-QCZT M,985&"OS@.`H?5C3,BXPYC8?*#(VA5R@6U"2!U0%P:G4K0%\_*_UZS&G%!/& M??]R8FZ#2KG";7P)2XKRL7WN"455OJ:\>$N'Y7+`1(IK&:0?ICB2U5=@E5#'E&QT:2 MM+B]=5V,DJ`;=HP=*>\3[T;!(>"@(JBX;!3)BI@IMF7/SXML6O3Y%A'*C07U M^!WZ+HS1.HFB(,W0CJ"4A0?'A]+8A:E:V#AHH-KL&MJ$*J^KN"-0?7ZM4%7J M2,2=`KPA MEY6T<.FM:!\VP=.S#K9HUB6*:1>E7Y#T49(H7+V@+^5__5D/.SO$Q3T67T`^ M9UA+5ABOLT^D+5@V>\WJE)U_P^DJS#AS#XKEZ\`U6MZ0X(KU,>7SN!D9@<>D M%U411$E1KMDI2Z&ZF&NBJC9]HMTZ?2*.B+69-VH!-IZ,F`,>U+**NF(HJXV[ MZA'ML)2ECP]S8O<_'^IF=?`[G.8O=$%QOHS7]>;17S*\V4>7X68XY:$LT3CY M<0E3WJG6"89W"M:DS!N57YQG>;AE*P3I9XV#$T@8 M+!VBGE7KO2(;D%3H'_D[@6(;M]H=)^O(]2#`7&'EO*U5="R0L*)V:-JJA25B M%A8FD)$*CM&/E/&49^WF'>?6$`QC;*)GU8\SB.F=Q=\32YK3'/*K_*S@B3GT MV^N;\]O[?Z#EU1DZ__=?+FX^GU_=^W!_'QR6M'VSCVC26F`[-9,U0M.'5X(F MX0I9VVCR(*)?AC&^R/%V<+R2LL!8=&\)V"'3H$8V"=4V-H%6C7BW.X@][PX. M6WV<6B*DC-&KEE,@6]PP<%M-%.'OI"RR)6V-=>G1'\M+,%*P#T MP-?_-4TR93_?*3SFX\O"=CC7J8DEME4V)C"M$!WKR;%2GK*KV]3CS.)!8XQ3 M3$:!3Z7N69PYLP6]>,T.OJ0]N^4].KV^\S4?GX0N;9\-BB\/?+7V)([V](WU MB9M9IVP,1\9;TS1W^^TV2%_H\=?J$F.!H"UAAXC# M.EGB8]H+8S) M*K,@):=8<%$_19LD1=5S5!5P3KKQMDUTVF!`*:%$AT(2OO`6'DRE M9W\-<)+X:,N`FM$'$Y@^!1F^?HC"1W;6Q=D>7\17)%K657*C%YZ=8/@F;)%">44=2Q(.WYP3##-QD\FMDR/=&K"+?ZI6@/U[6I& MP7+[^9#'_'Y9%#5E3Q`IC<(8T?*H$$"%Q'&C5!@<'.'49<@8C0ZC@0"<=EKN M?61E,T^Y#I]^M[BG%KPCA`KV54$NP[-M%VO/FVHVM,!''F*[J[LWDY9WGN?> M8?+EUO1`5[4,=UA>GMNVR]M(+(;UL9?/=FQIYQ,M:9K#_NP;*43-.Y87"!$A MSP<:L=%,H&UAAERU,6*Ð(?:G$7*].F0W.ZO%H;D`[[FLL M-\0'?PHWZKT-OH2LO]&7@$\/^76RD!X.#&DFB#UY<8(8T(*(E?0U110`09XD M2M$C2Q*[@B-I8M^*UQ2\B.^?PE1CS'907-[9;Q6WT3$;U,9>5[]M2KMGU@C3 MCOZ_>4@H7LN.=;E$6)#WMVJIT>Y62_\,G?S:FN4^/@R0QGKXK*"OWML(;)K= M>PMP<^ZSM7(F3O&1`5J;V1*G-A:'9ZT?N&:@%42Z"S(`_0 MEU_B8+\.21G'PU6:`$FF-5^7G6JR#4=5;4$&!C6;4.%A-FS24,$#9:NL1SO] M[()3%#S(>PSWC[@_D`2YTD;9=43>2Z!;751K8R_(7"I=M#$J7!-TQPB:^QY.ANT]QCX10N2$NQQ>IC&N M?X80<0E]DXM5>$DC@$O3:>X[NY]\KS"H"QIVL1CBVU M7C5^E,5[?/!D@$?<0%S$3:CKLU&*-)]%WNYD$9-M&.9LN[%,B1$"S8Y2G'L_B`@*`". M1;R)B):'0U6EH]%2O78SY&ZJE;&((J-8ABN3MJ\)5H0AW1-Y[Q MP7.83',>\,53/VK%1\:^P2:%U&IC9]!0<;IH1/C@AK)E$TA:X!@9[.--+8WI M]YU5'U_:3WC+1[0%1YC&$[3".7$-[;"/:T^?AQPU_37\XNPM>V$D>UYO+)'Z\Q^GV##\,(Z"\6,U'43%#]LFMFW)-J%W& M+('0HGE"+V2DS]Z1KNT6T:>N^332B(GJ!^]SA5^ZS0R1/MB^%]^*8J?JSP50 M8OQ(N2H;B0#$"]M_UV&Q03VBB?0(?74I@)A$:UND\\Z)/G"D'%5#G82T`@5R'@NMV@X& M`L,SQ`?+2.Y'D5>.7YVP,R>"YPQ.>1#&>'T>I'$8/V;+U6J_W;-.R!G>A*MP MF."K"M2A:%S`D,"J-3(-/`IV9"P=%5]495!5"'W7*H;*Z!UNUN%7S+?T`'B,4!-[_3G!YL['\W=-20L)?#G,7BJI M90O,4=EFQ1?QG1_"_58Q#6AWA3.Y8P=HEB@L:Q(]$X]RFN)UF'\*5F$4YB^"CJ!"V<:OR\J: MTFV\'L9$DYJ0DDPBN:@?H^(YJ@IXTSE0:>-$JRD&/!*+=#@DTPSLOL6F@$?J MK,"J]-LEL.(DQV@7O-"C)-`[]!#$OQT/IB3>V3JJ9O3*8?9;MHS7OY!OFM)^ M(TZA1U3 M2*F1$ZVVZ!%()M(BD%RS+P2Z>PI2_!!D>'V:;.G6`C:[NDQ3>G`4G8G]^-(4 M*:>]EU^#=%T=R'R3ABM\O2'2VR2^RTG.=H,)\N,^^^P;*IO)IB$CWMO_`F9. MPVK]Q!['HMD%$WS')%%;.VJI1P\OJ%VN-(&8C9/ZB'+$S+`%'\P08I;(\\*6 M6Z\W`[F2^6#<];?V[#7.VN8[02;@]NH)FKT?G2>A_8;S;^3?(7$$.^8(`I+Z MH%WQ.'ADCF$3A"EZ#J(]^VM5N(F,JGGS#I`(?4W^P74FR'[-EOO\*4G#?V&2 MSJYQRE[@FE7YAG`QJZC!WI(=.7J]S[.<=`U(![(HE_T=AX]/.5XOGW%*^-(1 M^8@?PYA.=GX,B+H5?J^4.[JMFC3;=%4U"\'%[5>V%HR5^G5)U2,C5ZX,6DL=5/#L>CKZKO9 MS^?=O!G4U*M/[W0P_I9V,$2#%2<%+3/45`KM::V*(0A4V$.L8@,OS2IW@EK5 M*\N3HGT7WY-]<^6'XQ$2HU:V0I-&I_%V_[-9IO MXF4_YEA5E)OI:W?9CI+^5E=^:XO:8?DS&-GV[5#]$*OOELGWVV M'],QQ^.U9^PA_A9/.)U#3'E^$S7E_$Y+4>0]+36V89SK-/^WR?XN4V M2?/P7^R+E5H&BWOPW553<%5+59R+3PEA`=!MAJ2>(7I*%%I8TN)L99 M'F[9`79!2Q#A0A*EY7GRA-MI'3;"VC`*F&7'<<,&!1*;T.OY;T`++2<,6F_0 M_!>P9F!)["$RF:63+2X7&M\QE:C1B0JE)ZA0B]IZJYN:T!>FVI]S)0Z'U,*T M[.!I/6."%$0X*\_LN,/I,TG^LBL\V.DI+U6E+:)29DY+;MO0^PB52QR)0&;! M'J#R">E5EL].$'GJF-,C[9S_B%6Y01:0,-:GPCL+O?X&!"0\?5^3VZ M/?_U_.J7\[N_'#8RA#[8:VQ\T,$&Z>P^)'.AXP-!!_E,?AP2:`R.#X<(CI^U M'$="#[*?!1H_'Q4T?IX7&FXSJK^F2=:_QF:TG"2K*LN!P[]CWU+'M\1ZC1'TX40U#LU(E= M$A>W*EW$JV2+[X-OY5#31QSC39@K35X9:.K-54W2!#*:;?`.,$/7TRHP/E(] M16]G6+H1IW\5"A#14(\]?UG9I\AQF=/J&'D(?%HS*@V_.^R">T&5L2L97PKB(X6Q9SL?! M8IUF74ZV7.7A)NO]T&Z0M; M5++=1"\@/@Q#N(MW?H9@615<6OU<':"*G4>I]H^D7`\DS@$&KK(*ZI; MYFYP6KU6N%K&Z[,PVN=XK9A,3-(RR"`TM0`YL4EUA_);NL95G)6>SHY_JB]@ MO*$;&JCP"6+B[)C_4H''/FD:#CF.R`30`]^CI8SG<#1K8R?8:U7"4E??.5WZ M`9WT)G?[O%BC2?Y\J+FR+KD2XQSABE7T.)CJ6&AJZG739CQH^T4<%^'Y'7*]N4SB1[ICY@P_J([7ZXD/`K*J.)"'T:LMJ&-1-JWB4125]<8*22<\ MW`412O&NO(&"CAKB8/5$G^=/&&U8#WV_6F',]@YNPFQ%!%XP/6J*.ATZ58V# M3>Y\PGHJ`#DN91*$!YY$30O/A:C:MQ-TU:S#]Z<=\*$?6ALI^A>5>T>`O454 MTN,4="[$CT=/UYAW$2^++16?PSC<[K>7F-Z\4#C3[%.2G@:[D"[`I#]GBA'4 M5.$@IDY7".123-\(-.X:5$;%\TQ6W_%$P>-CBA^#G$3@8FO6ME!(0G5,%&3E M`0"K0A^*F$)?_)$Q@#D>"H@4`X\U52_/ATVOHYU(/K4^\+'=4\X-MDD67"L5 M(2927<`@L=+*,KE7=]3)C6SA5U\TIBPX7RBF( M0BWH4:XE[/H=%;-*"W;&%77C.BO!C=[T9(4P+4Y1J/K9!"!_\L6C:`"*MU)' M%X[#A3FC&K@K<13L6EJK-FH9/L[.B.M^[.Q$QG5YLH#'`=(VG!56FCD"M),Y MW\T&TPEJ7*^&NR6=FUM,FRJ,0C:;H3KQ.UG5TX"9['#*RF7E[!@]M"AG`]B__'#W`]I@ M$FZ);\KR(-\3K+\P+2GM7A.&T6)T5440O_R>1.&JXFV#M*@OCLL`_[SI,U,V M#6?0M#5RI]$FU,O2)+1V3>#CND5U<4'(Z?CPI"#=@IUA!L6&[>IE,^E:VKT\:TVK3WLC>AK5T? M[?DU30LZT]IH5\VUD?Y"3/Y_1>],C1C#DLI*-5S^'?ZVBO89[7D0S1E^9EW\ M;1+G3Y2.Q3^*LJZO0@2EQ-C$G!'3Y#-S>JI')^=T:SK#++E>E2Q/E/O&Y9'I M\D)9=[Z\UG=@,^9><%-SWMQK=KI(:FX(^Y^"\LJ(9<1LJL\S:$D/$A5%:2`? MIE57T.1#U;**:U+3Q3_O@B8/I3A=V+["**@5>+,P3@]2'& M%*W;"=-*QN$#\NSX[@?92JB\SZD1\SB4SH/S\?#H%NDN0MZ_[X.4^.[HY5,8 MD[Y3&$07,!\[Y M>3$>1/UAAHN`>H8W.$WIONUOQ0S(,EY?AL%#&+'-:HHA=9*605#5U`+D5R;5 M'32PZM9`Q;WHZ>RX%WJ^PKH49ZO#V*)N]"4JQ5^\<2?38,=Q*";X'3@4+64\ MEZ)9&SOA5JL2\`'7.2?Z0;<29NN_RLEB>D!`2X''@=<-4\:#KU]<\7&YE\(\ MM*X&[05@%N:8=>L\UY(P[>DF97WZB\1\="3Z8)NP<$Q]]E95T92E9/9G9E4K M8.GH+V=JXD!^0J^V4)%2V:J*:U!4UO$*E0QJ"YV@AY?V#[XMV-1$ M%L<_3,+FP#6H:>'Y!57[_CF%[@*.MB7&1`?EE(D"$'Z\5%,FEEE2(+5'0 M(7-OH92OZZT5\,"AK#**!C052_*H*;/C'QW/B'(2J*B*&J5]8V<2MC@[5A4Q]2` MH#)9[AY$J:V#(>DE20$N@46>Q"'"J3*[E-=C?@MUXY&**L4()5=EE?@J;V$WBHW48+I7D"I>\*(; MQB>(ED!?:!G/0YL2_I1=B`::%5V*3*.ZDY'7RS^W([AMBOZ:+??D+=+P7WC] M"SW$L'4%U0V!>/;QY?P;3E=AN7;ZEJ!>88K6MD'5FR,!#-J]YP[LB\QQ\R1$ M90VNRC,W;W1S)1V(QZ7R ME4LZAMQ5.AMCTYCUG!5T]L?FE_`U?FC,-EDQ/7O4.-I0,39#-@//K0<(T8R< MG7?S,##@1SH6'M=#4,7KJX!RB_KUAG,V6H85O*@ MROJZ;K%X@FJY]DY0YN^J$KZY.&VP\?S61,0.G9&J(JZ'4:^%AVZ#ZQZ7*1O+ M83-(Y!WJ,N5Q2DCIJZU7,$C7T6DT(M=_/;NZG4YWI:9ZZ%:6,#K7U M,0_6*ECJ1$RI=SX-"//*&=I4.BDF8\KJU?,NC1K[YRMO<13DM*YI_G+?&@K_ M^-)Y(O6+$W0,?*"6#B!_-Z'>4+Y-S[2*']/1V/%9Y6/$GJ.V*,NUNH\]\TY3 MD,?Q1-,!//`Z&JIX'D:K)OYYDYN4GOF;O]"N9KZ,UW06?3?>2U,3&Q[8."(& M=8R=4NW`3J\;LZ9T;)U<2?>TNK+L"1M0RMD)`'5YWPBOB!3>^70Z&!O06B[- M/8]NQ)Y_Y/TUB/9%0A.O_WT?1.'FA?3\EJM5LB>9S5F8K:(DVZ<*:T,F:QI0 M?((F(-9/?@?091I3:J'B(/3U+NY._W9^]LOE.;JX0._0K\O+7Y;W%]=7:'EU MAO[]E^7EQ:=_7%S]%2U/3Z]_N;J_\\5C3,@ M71'X!0?>$*:_1*!6P`)LHP)5.E"CA$1=_^;ZW1)I?';>3RK-&,C%0[:7HJU/ M&B)5:%82,?,G&K6""+9JYB1.0D7!XCI]#.+P7XT+J#:E.^:W#@22*4W4XZN" M9(N82G9`@YF"1;"H-0?R6!R2S:CYM*O.&AB%X6-V.,X>$,Z2;1#&?,_??=9U M\=4S"#IU[8"PIE8Y2H^R9,V"+\4/?F"]UP)]4',;J(O=HL@`I)6D/VA,0YPM M;]+R=$.V,.4SWC[@=(#-T9(U4B4E#7$[6@>0U$-F109LL=RB>(B6Z'_MXS!) M45VJ6#WF&O7C;9MH-$*?$4*!-C\D6F%3":$AN`P"'$!%OE!"J(<=]*4HX]QU MPH!(G!38A=&,3I<[8=WWM])"E:L5%#)CB-2R(35$NB6LX(LL1*LZ'+-`WFR) MVD?N(9];M@5Z@2Y0M\FU`7L\!!0VF+-DGO'C4:%#Z!FMX,.U/VPMX!&MWRE6 M4&?7^SS+@WA-^GY_Q^'C4X[72WJ)[2/NKJI.HHCT#*F@DJ^=HP)2/VZW`A;< MP1Q?S$;\L5QO7?]EM3K"N-E>#2E=#'E2;G7)R#\:^R>HJ@$JJ]#?`/.%5@-] M*NKA.EEUQ_@1)S^CUY&&#YOU&`M-=K^!_;3(9OUG2+E>D3NDJ6+?;[UY)I>H M?O--QY"2_Y44S+.+^`:G8;+^:YID@UEN>Q:`DFJN!:?10O+.;M-B?L7L.7J> M/=#$MC"`PA@5)N@OB?-5`18I`^;[QWD)Y-HYAN!\-_+#R#%NA2M&P13:)I`74*M.01[(T?IT:7: M@C%S]>;)CT\+SN"`;.X21>0P]7^7G(5L`'7T(D>YG+8FTU9*,A<+V7'S\M-- M#[4'8959X+F%$VYYE#D(#SS@YD6RP2G=%`/>LFHN`FG9KM>$_T:6LQO0"ALX M8,!Z*.5+\C-AI*-%(W.AGD MGU/KCW>MDR@*T@SM<%J,??D^]'4D;F=R.GODCN>`$N3S;[LP94).LN2)YJ%2 M96WS;B/,Q*_E.&G6K[7%(*-;&=CTN67]]>304SD.%]',O`Q44-.L!6!DTWY_ MK_)JS=K[E5P?LO-CH[Q4Y%C3[(/S3-82[J/Q30>5>A?OY2CQGF`<+NW6,NXZ M_$SX4LY3;KTZ6XTY.E6!3K=+VZ\IV9[":\B`-MVOP`4SC3J`AC*M=_3Z"/R11XFUVFO38ZXA,VI8JT`[=Y2M.EW" MK_EMW.[P4:^LO37^JG4`W0G4,GKH63(P5\&V&TQS$D`;$!2-PVU*4'Y;+Y;R MZE7:C_6^A^>R:-+;VBY<+18^03@*'T-ZE\4F21$N14[0U\H/!:4?JAZA'0/K M0:;-!^Z>;.V0.E0'=4BI\6"P'3P-%EH`2WDY%AR'#.$[NTYE>16S&0.&]H!3 M5,[ZB4-W]F+"`#KV,5:"N?"!(4AWS7D+OW+'0045\\0_%ZX@QH_TDCV;F:)S MC]!?5<`RMD/?K.Z*Q?92,;]X?#@IUG*]#HN7:&[KR98/69X&JQPXV5*R!91V MC=ARZG>5OH,'_?2Q>MKSPW++8WMYT8Y4ZP0%M1*T;K0NA=;N>(A M.)C#R1];8Y)7>][M1+;TP\](5_I]F<_IOJ_KH;EAM6:9G"FMV9LY+@P+C^Q]'7EK2;4L M.&JA-0@/7?:WD@TJ<[A&_X%ZYE&.F#ME11J:>F.1&0!'+'X#+Y(U4?7\&/CR M@_XT1?LO,@@;PARL\[.AEOZ*:K7;0WZE1FG4@)FS:HT+;-@ MU8+3MO9MK#ER&S76=>_P=5AT9BC+G*W5G_+1G]OCU8B7MTUHJ><'-SX6#RR\ MK?UD$+S2=H?RCM*IR`;[3H;]PC*#9!;+$3[$;)[T;X]G=MM]S)9MGZ<)CL=A MZ26KQ^^R#B*Q_?@R?.7EMQ`PB1VS8)ZPBBVX"B)C[^PL7$@J9B4T".TM>.X; M?:'/O)RF@8$ZA$M6Y).Y\Q49`G&TXKJ-;.J(\I+QYRP$X:+.*:C9SW4O6Z2O-W\;83?CGM MRMB9^MPNZ6VW1^W]M<^'XB=FZ1U[XRD.-$T[2[9!&-O,T;H6;"1HE05_?'?W MG3URVW7%9O+9I3VK[KJP<4RNND<9.WZ:RTL;+KHP9,D_5V_AMW.>M'ASQD.I M-:W";TSQ^%!JS6_CS1)W9R>\JM;!UA+X(S^46I>K-E;)SW\HM:)Q*ZOH#^=0 M:L5*ZXTH[-C):^>QQ>,&#\AM]7=$!SE;[8GC-9V"9PL_BV/PCO'$:=]]SPQ; M=MZ\CW$C?=#W/G=YD.9O_J?X>CS_\X`?PSAF1S2\>2'77NC#FQ?RJ?<]<6BA M6@?5^@HSKG<76[6YWIUGU9]AU?%OX]LLN+3&,R]-Y=1AT>\IOY)%[Q)RV5U# M.LIJFRM(A\8MKR#EO:VW\^WB2GLY`>^W9YEOT7L[%SZ^Q3T>.JQ9%[T?@,LZ MT.SV,OF*TW*)PS94NW$`UI25M9I]4_[$%\%7\"UC'59SKN5=/OGB!K^T M\/Q1\K4:;&6_'-`(!S!]+"W?DI+5RA*NKD5;"[GZ[^5M(MJKJ9?9IR]>PG:> MR_`HWJU^997.>+DX9_K5PQ(-0/O[[(BRL&A._KS9JA&8X8'UJS MMP[H&*X8$)/$QK26S2L&!F:L3%3Y>,7`H'I3%N#,-P7NP@L(EM7(IK591^_0 M+QIP0>\95LF\>H)/6.,RUPH[)_3FKUKAKYI[([8QZHZ7V*Z[3Q,[B;_L=G,- MMPM,V1AN'YCR9Q1-\!5\&VX?5G.F@;2^8<%P^U/X^/3*QMM%_+$S+B9GJXU1 ML9Y%2Z-B@_?R=KR]5U,OQ]M]<1.VQ]N9N2,=;W?J5V89;_?2L\R<,&876;;G MWTG2>]1.R.I'YFZQ9P5V@*E1/N)_JH*+CP$IMO+M:LA^4R2R3\AA3%FBA_!: M#CS6E9KM;-S3;50:!`ZX6:6NT%7#:HT7C20=VNWYH;IC\`05OQQ,4\H&/(R: M$!DM6<<424E#T([6P13!,@,R0(OE%K?X M.8F>Z<#C59)C.GG(#LE^ASX&\6^NP3[>J(G&U^\302C0YH5$JS MTZ;K,X/[L")#[Z$9_KF6#"'?URE!>;?HHOX;?6&_N#X%B=\.B?SK]2#;*=-" M:4_6.V#>K7`-L;7WISAJBX M@89P%C5B'\N7G%,W.3I`>TL#_;#7%9JV/AL9K7X]Q"87=HO]:G2MCO(S3A\2 MN\U.^LZGQ5V0Q2CW+=Z1UWD*,M?'C$T#@:A##0H"!_'K>L.:YRF)UL01G/]S M'^8OHFZVCDP_RLEE8,B@4B^@6#AB2H$I4@V+T^NKN^O+B[/E_?D9NKLG__E\ M?G5_AZX_H;N_+6_/_W9]>79^>_=[=/[OOUS<_\,32BD!8\@R#3SU:2<3Y3!1 M;LE#I,3P,J320X#*(H]<[XGS<9R3F9MD=?J1_9K*A!UG9/G7X96&X M(ZL'$'D$)A38PY5<5+^BZF>_QBJD+3NDC`(0^ISAB7!(P]?L'6N*>$A7(B3Q M&&MD9?NLX9>%88VL'D"L$9A08`U793&`?Q*@RBFR0+V3+OT61M5&28M$E$H)*WT5J!)7$R2TK)G%A!-ZG[ MN+Q<7IV>DU[3^?F]/ZG<>/OS4CI5U`Q3.Z$D-\63V/&.?J=1D&5EOTX6L$3E M^D0;EH-AE\@^$*4XZA5X-)!:L%_HHO9BU,ZKR"1LPB%71EJ[3Y!^<0XKAAK] MH0*I4K%ZYVR?AO'C3;%LD:WJ*?Y]$:]2'&3X#!?_'9!DLH::/A,T&!)K]07UA1D28"FX8ET'ZI:-,?;%FOKZ;]6Q2QSQB)B6$3$ M39(BS*ZZ9JM.R%^$N=D^RFF+)WT0#_[A7B>U(4G`WA,\>^9JG->AFO;W$>IMW7^#6(]MP^ MH)YD.^JI2IIS7Z^.`+17-CC">44]B_YZJ34*XC4JR_?YSV0\8+HF_[_V_O6IH:UY7P7U&=U5DPJV%SSR)5(8295&4( M0Y*9.L7*@`'7#3$3.S#S[Z_E1_Q2R]VR)"MP-YPY6-TMHN_K;K4[TN;#(!AL MA!T6P8.E6%>[\''G/1?W9#3/;EB%9W[E+Y0G76JZQ&D859=.CZ#V=VA-UMH'Q"0*HCD,.\3 MZG+F:JJB^9E^B]"PJ5A,K6FI5U%YG;3RV*'C>LA0P55,)2C#E$JKXL@J:=VB MM5<`5;-6JO_ZL8JM^5=EWC]JE4K\AG$[>.A)]\:5HP$/QP(*=YHJ\O)0)),W MP?'N^9H+35+;9-I+M)5'#O-[7//K/3^Q:?I"VW?TQ1X"25V<1X-1SGQ83:<' MD,W`0@2#S1N.9+:@W1794LF3VKFXT>%$7!>V:Y9Q3XQY@R#?C1A(WWV!8HB( M9W[O!<[.<'SKF\VVE4@W7NY26BEK[<(4@KZDC%5@SU:8LKC/,@-,9"QR?I.E M$:TJX<8L7BT'ER\[;QN+`B/?&=XVSVD7Q1DU#=600]70G^%J<]85B,C6.ZA/ MU)?Y@/S:AKOJ+9O^;_YO%YJK%$$5:EAE@2.@*6KX!.HLM(_"#>+]SHA(Q`#>D8=(A=KC6=IS55Y7ZCNNBI,;C M0M1"RUM]EC9:CP\6^_:ZY8IHS<>9D`-.@(H?8N>;$'WB-^12#=3.M\*N_>;- MS/(`+QATC`GE+JPWA\K#)1/!B7'Y_][?O'ZNHSRP1/!+(N]]-_21Z1O M>K6$,/62BI"Y'6-K9@:WB%5;BKO"4@5J&Y@,ST:X&;T@<.#V=1"H,!NY@RQR M[U:Q9:V8<;"I_V64#82F*5A66#BUDT1$!3U3% M4:0'6W`4S\%>-5YDWTXQW@+:#_%-4#]@X]TNL9/=_'S[IU9GN/*RHWG';]XN M2=5RM2>'+WM%+"%)9OTCT^]FXWZ5F65XES23*9FT)P\.NR=$!*FH`8 M`]60WK;3RW9Z5^T+*3Z52(Z_1F?>AK>8NH9Q#+:QB)8AV;1; MI+G#;-&GVZZDM\^2F.FB- M!:64YZ"2+N)+K)M-K:3&];>6#`/ULM\WXD_9[N.A&+_=&P;'0T>T\R"ZVX31 M?N>O_-_Q66+_OZA8)I&31C&AG`%N2^9GC--BFU0VB[0<4UXI0T8'B[M!)66O M0+R+MT*+YB./P*RY]QY&H0F^%>'C62G`;K@(2V6<>R&B'[:TL&,'N$.&FNR] M.W3A/1AIY&)@H('$-#-9/CO=-`:M45@,*!%2^"3OMV+%!"@PH%*!(" MHR`&LEYSJ&\9#"*6AYT5G\][!R(^D-B"HL4PLK^-_%][ M?QM/7Y,?$;A#Z1I7!`IX7#^Z==G7L>.0V)#0"90:+==GR^GW]?1RQ:8_DI_+ M@9G4N88A^N-N,`4:7J$&K%&K6X;,:,O]]8(DS>T/#UGVU*5$7@-F0/]J$#7# M>5#H]5_',,!_ZGKEUV%=+R=PK_D@(=?=IN2E'FZ-`?@+7N2!^AP%_RJQ=QX^ M>T'K@)ZN<6+X5\?IQ'_;OE8"U-2C&5"1:H4$QA^RF^RQ6R%!L)80(U2E&=:P_F*!C8`-D MZT)1.'4'+)DL?0A-FBJ#&`*>L#QRPK)1[";_K[/5$IVPQ%91;`!ST`WF^'?0 MD4LW1\&;RVR4[JUEU;;VC66NG+2M3&6@325_Z!9O6NLGVU`*%AK>3O+!TLUD MILU5]/.O@'1`OSH$P'TV1"OHJU;U(C[7C(=[*B#8,J8/',-Y;;%`D`N6%$!X M\14AF1Y'L?W-YS<&R<%='R-&=S%&)[SK=O6G[0?]:)3G$HYO=!OK!0%UK>$T=?_KJZOY]-OTDA\A<#Y; M3N:+Y?IZNF2+"S89+[^RB_GB)YM=7BRNOXU7L\7E/^\;KG#L&`:P]N++BO^] MBX?9]CYX#>[WWN9G$#]=^YMTNM%3\+(*I]OD0_DC?%.O*)U_R&3I7K16G&N_ M^$,W"O.;JFN4"O`S;DL1]I;(L*H0QVXFYDC'@"JFPIX+76<^44GI`'V_O%_&3OQO?W87[9(=X[=_YP2NO!61%WR;_*3(%ZW$R_;A.F9>&\(VU M)R$W2L,H?\(O44B""O]"?!I/.+,G._\^B*/TDMGS<'\;/^PWK-`T,*5),`F5 M5K%!7XQHA;0X2SJS3)1)794#2_A,OP3"!Z8@3(<>$,C*P>Z^DC,)5"C''`*J M5J/*-GH)=W$:__C77%Z>H0(N:FP9161C^U*S>QYZHH;4CI2-$LG1>!^'S^%M ML/&S<#`.$NA[#P,?`X9;WI"T"BTJP2(U"LDT:_;RL"F-WMT$CG)O7AG`#B,< MJ1?KA)3$/QL'E3U_O(Z2S]>"&VI,&GMA3#X&\, M':VS"V$.OQD6VL!:A/)/L`[=^I@2JTU9G1ZOKEN7BU->5N[$F@OK;OY)6W3( M8^E9=GL^B=\VF95'M_??DZUL\/`GV>`6N6WE8`U!1XN2;/YQ$65[T4)IGOTX M0S4)4XJF:708GB:?I4"Y%ZP=0^-`JXT:BL)>BUOG+$E%26FB9?<8O]F$;_SD M\BCY`Z[]R-^]^I'P50-%I,5OF8@F6G?/2A>;I98P))8HJ'"W');2N!CHR%L" M$AP$1$6#J,5/6%)$2YF=XV#CY,G;/?KWJW`21G'R^^EO?G\<'(<5=*#X"NHP M2.".>6O8KZC:5^4YI'&4/^`8YH]2SNC< MI2E-0==FSA',\ZUA9[@[81)B?%Q>0%M/%YGA2B#-[^@A!HC& MO##^`'$5$M:FJB,H-!37)3$O9O&3SY))\0*1Y\1]MC1`(&DLQA&*M,5GA23I MP9*]<)6;M!.>M*$0&7ZD?1W,P1LF3S M6K^&/S#RZSDIQ_ZO$ON>8WLF>QCOSDS?/\II5>0P"N+@U5^YC?;/?XW*'<(' MA'5G=?G]PYI4@7[U=[>ARX`^_>"`[BQ7#P]H5\K8P-FT-"%4"5O3R;6TF9DL M!*+.M46J0/0[.W/N+1$;R`*@_%1F;D__*?@;N-'PN^CBQ\6I&L\ M[$D'CT^Q?S].DEGOT;_<\^DM'I9/7@*GQ3Z. MXB3X)"G.F1<%=PUD*;9CQA4DS!O:)I&Q7"6CV>9`.^/RD18 M189W\R52P_).#45AK\6M;SX.9U]^;J:GK/Q MC^GU^,N47:Z_G4VO^1FARZ]C?EKH)W8V7LXF_["_@RV+4D4#7T1O$]Q02'(! MWH,'M/-@LT]^VYH]+J1U2#\E M[]MS51\,Y\#[O(%Q7EV$>?*OY)?%KY(?MU[D)[_Y'U!+`P04````"`#Z@\=" M;DVBJRYJ``#0HP<`%0`<`&)R;&DM,C`Q,S`T,S!?<')E+GAM;%54"0`#-T.R M43=#LE%U>`L``00E#@``!#D!``#MO=ER)#>R)GS_F_WO4--SK59)ZN7HV.D9 M2VYJSK"*;)*23E^U!3.1271%!JA86$P]_0"Q9,:"Q8%`)!!@FLE4),/A<'=\ M<``.P/%?__MM&W]X16F&2?*W/WSWQX]_^("2)5GA9/.W/Q39-U&VQ/@/__M_ M_?__WW_]CV^^^7">HBA'JP]/NP^?4)KB./YP3M(7DD8Y9?#AFV\:PI]0@M*& M]*KX-\ZSXL-UDM.:\FB#/OSWKU&R^G#V\;N__.5?GSY^=RC9*7A]?_WPX;_/ M[F\:?JR2RV2#$U05B''RY3_9_YZB#'UXR_!_9LMGM(UNR+(D_ML?GO/\Y3^_ M_?;KUZ]_?'M*XS^2=//M]Q\__O#MOI20@OWV34/V#?O3-]]]_\T/W_WQ+5O] MX0,U7)*5=0,J:OL2H^=MSBM9\7G&:=E@QV_[(;/O=7YAM_V>WAF]'B_I( M\BB>7MYV-5"AGS"AU:*4=CKTQR795O583CD6*K>$]@ M;2MR3RGK0['=1NGN=OV`-PE>XV64Y(OEDA1ES[DC,69]I_EWG!ZZ=1U71QL= M0Z\F>YZHJ8$"^QZ]HJ2PHXZ4L2WI;TBR>43I]@(]Y6=1\L6&X"*>=N<=")W1 M>?<:YW=QE%CIZ3*^]KP3_3^;#UOR37UNUFP- M=$GG5R]L:F@#23*^]GHJ7;=N,&6ZR#)D9PTCXFFM!Z`8+>EJ[Q]%E.8HC7=7 M.*&-BZ/X(LHC*V,LJ`9;^MSFSZB>+%K!/(^?M9$T>F*A)I+N:)]ZH4:B4UV* MS_NFS!I9\D!:%4TRRZE_R>[1$N%7UN;6YSOB*B:=MUEI(#GGXT=?+$Z.M*H[ M0M3"BFH0_L==#=F9J>A59SEG)VWT MIR.VT9_LZ[]CBJ%[-6FDL8!5'6OG;7S%+ZCC._'ZLXU8Q MMS=CCMG1CKN(3J4>:1U9M+0WVU$RGW">-K(!^!SM>;&G#/U64`]Y^6K-`0N9 M3K7/9R<2*6)J,_)#DK)#W:.7(ET^TR6/M9B/F/-4NVAV(G$BII;7L-9=BHSO M\:.BQPJ''B6V,%E0X2A1W,G"M].,4O9&I\E/;DUR9.O8*X)CK`0FWE>:8$-I MNKF!W4G!I.=^K!_XF>"DCZ4C/M/-2NQ.1XYWGF?:@SR3GN"Q?G1GVJB__7#_ M=/%*NX'*8YW-F?)4SM%B09,&@2;?H9YD:]J>U&=1AK/;]5V*,MI_RGK&22KD7BM MPO:LMT2=E5A*$OKCT@9X5;Q'ZD"6!6/$YC.4?;Z[3M8DW9J[9"D_:ZL\G-=! MG9'KNQ:?2>.\$P1XQTK\0(?)$D.WZRH>8B(CA\DXJ$59N?5PG=#>A.+XXFUL_(''T>*<*XZRK`Q[E6U*5W^TR#]1E"ZV M%F;>$/YM75Y:^+JA?^A4CMYRE*S0JJF>Z3)M?HI2LD:VF"P[XL0L;0M)5<9@ M?_F7QF6)`UR?LI*RJ2!FR3K^]@<;K.B,ZH3%]ZUK3"JS;G2%Y=>[9[PB+MVC9*ETW5],=! M-^CFVZDIOGTIYTO?+)]QO.]!ZY1L+2&*V+5E6_W__#!&P@\Y^3!2LB*C$I$R MS,2FFB2E4[DZ_]1+Z7#2.O^/I!G*-F`9I5`WZHSC7CJI>7XF2U M?`)?**6ID22@<>:]&I#=KFN92@%7B^QP`5CDK$R*UE;0*^K,%E M<&MBOD*OA@E=@U-L7A74):)/.,';8EM:X"XJ'7!V1=*V8:"('O%Y^3_@^B$%2F<;,W518?%-9M9`P*KN?ZFJ5]*&-VG9Z6:!)GJ"M26#.#YA#?7;UQHD4.H5NG!B`DL[@)QY@=XZ4+^6*+5M_UARLQ13,\\2B\1Y5:+SWDL-99K>@SV;Z0A,WZFV-AU!R7;R\HR9K[2=#- M`E-.P[T#?4[S`?U8,QEBWJ#:"4.M3B%_4G>>7D&R9%FI9GZ;B.MK]#`B)NMD04Q+Y[ M""UEM1R!BO/,IVR-=X-A"DA=VUE)[3NJ]-35@I62M?F\Z!6E3\0?9.W'S<\H MKSN3`%42RAZBN)1S09-:32,D<=F:3S\\1M%GNJ`&`VE(+,%2FWB.4&Z)-$M&M4(!R=RC=1FQ[Z`*OZRDX"Y^7EZ\-.@F$G49'D;-[;YU%P[A. M.XQ$:@G5[?\6V@MG)W>#S\ MX?S4.\HFO6.N:^S:$G5<`7B@047=Q;F8VMU=K/%H)+K6Z%W*,I:@A5]QS4&" MM+-.!T(55J8+6%69,&"K99D)P*NJ/ZQ9B.*PB<8TQ`(GV.&@,"= MHCU4PXJ&@FT#0TV"<)@<87KL]BDUQ:Q%1BHY%1C.O`-@`*L3"WY]]J+57N*0 MQ4/KO]56NZD.(I7Q=Q_[T0$7JM52#" MO(4*G'MX*=1Y7<*V5?F.GB<6M\=8$"?,>0LU#;.S!N)SWOINH_R@+BOJ% MI.#\\`ZUPD@<2ZH)?#X"Z\'L7]2^4&K'^PO9CO/Y'+;S0[X="Q[%OW.$".N$ M"\]N@-D[8-8^1V0.-1N)LI+A$4Z'S'LI=*PED*@I_CK3@SJ*Z(79'H+9?H%/ M:_11EXIM'+P!5^'+6"(X8JS20W\-/8(3$(=^KXJAH`/@=.Q*6"$*!,<&JU^= MU<6/%;83M&%/F!X;W1>(BKFLSX72*>&6I'G](K,>N`&,8-B6,@H(VG"#385L MJ03CG;9;8(.7O-KE@2[:QT6L1<=LMG"UX([!BU6=I8<$JZXS!SP4VVV4[F[7 M#WB3E*\$=EYI)C%F:A-29VP`T%='2L^L4Q.SK!^DD;,/:=6!/Q;.'"^@_+'+]&L742ID" M7CIE&IS!RO@..`/-M9`'XQ_6Q@)[1#=A]^WEJ%.1[2\VB<@\QQ90/QTXB5GZ M$ABQ@R#A'IP<4;K%ZA:`%_,<<8;ZZR`07D58AV9^(F3U%<?P8-G_71>>\O)JF(K*SQ>N M((M8@JVH+CY\_S)3^%Y%./TEB@OT"44L0'$82.0#O7:YNG$TRGD.4U,+Z,!3 MHPY[V\0^P/(>T6EV4::ZV"18'9X!T]>-`*#W''ZZ&NO`#L!;\`+63.'VF$8K MU&0$:O8#J?H(O[*W&K@#MU:9NA&`93R'GHGF.O`#\N=#\$=?3B+T+QTK`H`P M:D%&CKDY+SUMM<)]*LZ"6+.5A_LFV0F5XP9*+MKGG!MR-/75@8Z:M0`[<]VH MN(S2A-HBNT/IPS-M%SG2@-1-4C@5M>,/728Y7@; MY8-S&_R/M57['SV'C%07'83T&0D`,=>MA>OM"UW6LJ7L;7J!LQ>21?'MFCWB M?H-?T:J)OBSC8D4-Q`_#*/:UIJNAV1*;H@;/\3V]5;4VXJ:01M#3YKIELEB] MHC3'&37`.;"M;>O7O(LM9)[U`V3+%+YRCR*;%]UO'NL4]!^9(>^AM)>M6)8#N\7<_ M!*OG,F14+>#DSDY-6-M31N@YDL`ZZF!&QE2`CKEN0CP43QGZK:"6N7P]'!J3 MXTJK3/,(,ZR,YV@ST5P'>$#^`@Q:V9F8Q^GQ\GGIT]GQ8VV<5PN*>H-V=9O0 MD;1(4RKL(EE])DG:_'H695C^I+M-EOWM]E$L/?<\$]C-:)-^5/43GH%W[;8. MYKLB:;VW[-I+#;>X!5Y*32@\4C#*2PDFN`_+9[0J8G2[_HSR!Y2^XB7JF%0X M,=$NV,Q.-`HZGM$Z?8"/>5G4?+%<0=O MBR/HVC*2NN'Y).Y6)'ML?8KR(BUO3%9!ST9(H`_0*S[P!-#BSOR!M&G):$MT M_0&OLJXG@%82\"3@:2/ML!BPW8:ZY;)SLDK;;]53U>3HH?3)AI% MW3U38=":9)1A>L]3P.NOSZEHU.O+W5H]8-ZCWPJ%ML5TD21'%[8_L4$_3!>F/2\3++&N+HQS) M>AP#P?<(,TZ!>CUQPKI`+#`)VQ&O%\Z_0Z<:_#)R^/?+!`)PJ2FF@'"_P@GO M%+M>H5PG]/\L-YSK=$.%3M8+O^WP-@^_.W,"G*'YA(M`Q_R!6[0_I##7: MH!N\';PJHUFJUAMQ6PK@UF[,M:83KHU2-RH_==>90! MKX;S-+/"$B#*"L\'CV`3&,)2QM_SM<+EVQ)E=-V]W=()'69O*M4ZJ<%F4K2Y M9Z%5U$^@C5`?`#,][KY,PG5!MEBM<"5TH]8M_>S`2.G>^U0L((^P\]`=3#88+PG3-;C M>KW7OXCG>,.Z+XY@\:-@.[0O'#D0M%\GJ`L=%SMZ_`.UA&W$9 M;&5K9U_8TTP_4](TCW#"#@"X M#BYQA1*=?8/0-L??Y+06\VJ0A,7+J_=S6*WG%"RX-/;/%(/EVQ%T"5X= MJB,L6F5J!`#+6#SMBN+U5<'LSZGZFIV]C.*[:,=V-:Y(6I]Y^$1AMHSB^J4! M-B31_[+!O<-)>#?3"[N\G3D5/9"0:8W:]3\@T*'F354Q)/A\8:JINB#5U+;ZD]#=QE(U2[9-O.NY15A[B M%/GEYX/!L<:9P@'RJYTP<[_K*%/S*$S[/1C'^UG"=VH$`2DPO>K-(`^VNH2R M:;^;I/UBD@][5?"FE#V9!-N?4M8E?3/I?>Q)];,?.O8,DD=7E&%KH[+JIW(L MA;%M;Y1?X03GJ$QHR6U#]2:Y-H?!!KD&!V<.QPP5Q(:ANMY(2Y#N%KJ&`#,_ MF-WH3&0Z7Q4Y,U7K&?-ZN0$"ODW6O1YAA_5\N\H$IK74A^Q(9C.V[7K@IXLD MM,S1ZA]%E%+IXATU$%TCX2B^B/+(\31@*-1ULB;IMK2%R8J^O2-(7I3@RTA`AX%=/*/.OZ$%U+%+:: MK..@`D\%(QZF&^826PR*1C%+2/9VC]9%LCJ/([R]1QF)7P?7L@&4C9.043IS M!<`&(#J:=ONWO(:R.\LX^W:(I#J6=[NFD:!S:G@H!G%HTG\:L9C M!D"S81U="!K6Z=M9CT:UR[=*_"MJ>C@L#4OO[Q5IEIX!%,=91!>$VK5Y=^A" M+.QGE',/GNL440^DK2(S0)>![A:'UE85(64JH<*0E"&6G5YZH2O\)L5+76:- MQMPS$0!?5>D5JU2U:A_'I$G*:LC$GA.HH%8]28OHOW'$+CD1]@Y5D9 M]+N*\V=INJ6[LS1XZ1F#>YRE;*%86PK?%A7[B<+MNA*U!TCA]]J0G.\S!I5* M6UNPX=1C<[KO>IK6>?=B^(Z]\Q`^@.-Z M#\/[%W`L[9^RZ$`M69U\.OLI)=G@"HR*KAV9X=/Y_OH-4$.MQV[$/#V_*%L> M#:=:4$=T>.LT*U.69)5'$K[]H%OPD$8"7-!S*!G;0`=;.I5X?C]5K4IUI2:M MK];@U1T[IS2XB#*:#QB*0CX.$VEK8PZ$5)C%^KFUH;+`@"R48?Y.-([+"/[A MPNU=M"-I?_0=SPCN9(6,@H,VT&;38ELLQ.R=MC:(M<$:("B/"CZ;=_A)'L73 M;"?W)M"?47Z&UJ2\U?>*,RHY73:>12OV8AQDV0(J+UG.*,I[/C<=:Y&QRQ]% M79[CD2?T[9JG9P^(^@4/-QG!!3V'GK$-=#"G4XDOB1ZF"^70W@;SB#"_YSW$ M8-I9\&$VDSI,XJD^%]LGE-ZNZ5B?XV295[/*PZ'&X;RSG!BDJ"'M;_'9XM=L M"8[GYSD6;5M,![46ZIXP'82=,T9]_>N7XM@;`&OUU/>1E('89KM!&=2WPEVX M$S"2N^<]85IKZO0+ZY+P>\E_?/SX,82=N2I1#+-"8QIF#?IS5L1LOVZQ25'Y M:)[]\Y0:5:M.5=I@U9R=&L5JBJU_N$3E%K)P]]^0S_#!`%T^[IX,L`$+8L^& MO8<%1DC7>WQ`5RI)5-W9XN8^2C9H\88'`W7_[\T0>_B[,X"-!P81*]A%BW%5 MY:!XJ,+;IO^$V(26U_C=+^WF;[ZXFQT-VH[(A.Y-9)K"^R9J"OG82)]PPEXF MY#83]UOS%F3WF]NFZDE(Y*)SFJNB*U]O[!;T9:/2UM.A;^+&YGW;/_SYYG5C M2T27-W:WH.<;=_`1@BXHT'6.MH.W$) MM1;[MT\QWI1FO:)SZ2C^)XK23U%>I#C?J8^YZ90>[FS#2L]@D31$+1EK)M,5 MT5Z4WBXX3`1K8_4K2I^(IT"_*-!U\AF]Y8]?4?R*/E&:9\F!#6!!&;P%!7TX MP*$%31&J(881GN:`2"`$LZ#FL.:<8LT?T)(D*V8Q,'Z'193(;1<)"[-"8TR( MUG:=[V!:4>I<[K5IP7100HG25HFP0"HRQ808;57IRTLW4T/TBA1I_JR%T6$1 M)4C;1<)"J=`8$\*T76=8!YHD.N.U+DS[)=0H/90(#*0"4TR)T4.5OKR%,R%$ M(:"$P#`@X!T%:C;/+(T[DS>M_UNL*?9U72"_D,(+]@L%@T>502;SA?U:IST_ M=-SM@C.2%"SY'/NZW>*,G<+.%EGWA%54;K%"6]% MX($D^IW2OB3OH"=/W'S'[O[VU?$E8C7:9S"MC+MYN[!VSZP*A]^9.$8Z,OXK M"<*^\M'JUI45F`DH,?8@)9NM,^"GP\NGP\NGP\NGP\NGP\O^'EZ>^*7QL]TC MK9LSF&B44+TUWB[AGP68;!=D&^'^ZE2CA/*U]58)_YY;Y[2H],%UD?K=[@6H M3O[F>JL:NX.E.*=-*0G7(_(_]MK=N4_4:3.B4`K8F@?.[=8,<\C<*\V%B.!K MLX[M?YT+2.1J&:%DP#*LP5:V=%3=T3 ML>^91:?(X"J^K(C#G7R3AB9&INCOXFO4W+U"+ZL1/$8[N;`&L)7!)7,Q5]/[ MY!X;1W]%8&8V4#V2$<.97^.J-0CVUAX-1MP\]ZP@G@V&M+0V@X^J"L]W9V\0 M%1@QV5G(/4V9#RE]=5>O[!XEZ&L4<[9;1G!H7DXTX>#NE5$8IH@-RW0A*:^9 M@=&HQK`634--\_H=N&%23A`MUR<.:&<`1QUM=8&GX!W6@JNG[%61TQEL';R_ MBW95=JA"M.0R+,V'H;KT_("I:9&14%77YLL(?E3PGK/',@=OAIL5UH/NOK`G MR(7C$0YEOH%D2%9*H0'M?>U!C_PB[:^3QZ^$W0*0+Y$TRNOANUT^8(@+S70L ME+<%>)?S#W:5.D5H'-0''+3!WN(0-MQ%ICHBX%LBO,M92W4M>Q3B!PQT`=]B M$#3>188Z'MQ;$OARGOG8:,>OX_S[@($VV@\,PD:[P%!'1/M!@K`N\P,M\/B, M4A2Q>[QF8!^6U\-ZNWS`4!>:Z5A(;PO@RV,H1P6Z&;S-0!TTE!T!6`3;O\XT M'\9=D2Z?J<(&Z5I-BC:''+6*SN]Z0C*R:I80(]BT7 MJQ$&N=C5S\*J4S\B_ZI`;6'R53"]'*1>I%VU#$]@PE5+P`PWU:I`85&> M52BY')`^9%BUC$=8;E5+<`PVJZI`7V%*53"]'(]>)%.U#$A@&E5+B`PW@:I( M84'J0"BY`I`>I`NTC4=0ED!;<`PU5^I07R7^E(@+`F,3H\J?M*BB"Z@#D9N_ MJ->_`THA5%J4(01I1(I;C\FT*IIPPN8Z[YV_8`W"5[C);N#LRP? M?:86NR,Q/F7`.67`.67`Z>E\RH`SPXG8*0/.*0/.*0/.*0/.^\N`8P=0Y:[[ M,XE7U]N7E+Q6%QNYWA1`N;]Z*J'T#SC\E"EP=8W2ITC9AS5$#Y<>@H,-:L+: MXC)"=QECHNR9K4OI/ZS-7Z.X7*GFYU&:[JBHOT2Q\/JB4=DF8XQ>66?]#]"Z M9)PENAU17%_YIHE>/6'UR$,:!K&WDB;P@14;)/%1%?,8J3 M3")``QFDZY%SGE7*'KB1[*7M49MOMJE[A(+?"-+WP`NH5D8W7J7QL8`KD04F M@-6-?VE])L;CSQE:%_$-7O<'6(T2*D2V2_BWY!K"2P9&H?;`E==-.U,%J):P MIGL7B`J]Q+QM:MZGVKC=3S/!D$0?$[!TV4T83'6]97B;;J($_UYRCY+569%1 M,V2G/<+3'N%IC["M\VF/<(;C7]NYL:>0Z+I[5352LKIK6>5V?86I]Z/^/GZ@ M?ZG?"1,D'+/)L[E>:(>G,SLW[RC>HQ>2YFSB_X`VI7`]XZD):XO("-W=L;3: M]$3#'+W+EC;D8)U?5K^/SONP[*SEK`3'R>8Z69-T6VI]MJL_RB.9VAP&04T- M#N%`=KP!)\*RD6`^1K/VZC5S\:9/B80!;'`%9=` MDU?HI=^L).0>$^%^:R#3_>8.(J`V)G)E>HTO8UDV^;:;EN0L5LR,L?>;C574WY[0\J'*? MSO$`+-9E$'KL.E%0D:YO5129*WX,#&)G<`;5Z\MVD^@J$4J7S!(;Q%F:U0]F MD$=VBZGZI;^99%B\V5G2+NYZY("AC(RV#'>$D59>[CMI5^I+$,X$GO?H%24% MJC6J?],!J)0!!*("!F&`%&*="6`JJ-:72P8F0+U.EF3;:%3]H@-327$(2+G% MPX"HVC(3`)1;:<@W/7.R_');JL;NQ/X:L=>)\M.V[6G;]K1MV];Y76_;SO6V MW^EJI\'5SKGNT;>.(JW/R9:]:6H7%URA=*39/[?`=;JF.Y>NLSUM" M'IG.RET7,T[>WH;K6#E]G'&P\Z&?HRWW;CGG4[/HZWSR(7IK"4-$JK8P=CNN M]G+9UZG59Z3P;^%S/_;0XGR#E=NT1"%][UQUBT6[W8ZZ@7JY?8G)#J'KA(4* M\&M[GO,;_[#=JL/8EPFM.:@^FH+JHRFH M/LX;5'R]+8#J8YA+XHM:8L$P^BO.GZ^3%7[%JR**!R,J'64?F85OUPQZ/PS?GDDE]1;Y3ON!-&P M=-V$VJ7=+9"G1309:\G>\G@2:5G/T);R*!/G4@66E0BE3)XZO/SP@I9XC:E> MK;VW\.X]C'*\2.O M\G#E#VX/5ZHT%"EX(SIZ:8UAVP&-9!@6BJV;>$+XVY`UK/SUI3+\$6K[734?+/JI_BF7V)7QHZ_H? MG6)5L[&,Y2;)=Y])7@6Z'EYBG)^3Y)5^8EMUS'3]SFA6>G]%4+-T*!UIE-4F MZ2:Z$H45[CSL/,N-^-0W8O/.QUV*E]7.]I8DI=GJ90QO\)JTHO8H-E%%H?3" M8[7%9./:1,)[?EW)6/5^I&&H>[09G$$Z2F5C.RVPLO?><4W:Q*O."U3`EP6E MK`,;+;OK&PB7;R\X+0L]HG2KNSXTXPY='>IR#ZE/3F9U)RM#78E]>7C2>J]; M;#8IVD0YNHIP^BE*OZ"\S%K?F3U4J;\D?SZC)?/S76A%%V^4>>$,Q8S MNR+IXS.ZPFF6/^+!%3BO91SM`2:5\=W[D>,AP"]O-*G>]AY!=>/3E"Z\5!W1 MR1,FJ\6:2LE\.4Y*/A?L!O(]RG%:\K(5AQY3]]@8M5G=[\6W3-AB7L6VS?3A M^X*_OB-?<,&\)(YQOKM-+U"4/Q_?)0A%.)YGX(AP,E4PM;(7G425,ZP;$B6WZ4]%Q%(E[#Y%NS-*1U[QRMZ6MDU9QCH0 M.[*\=T\R08MZY5+LZ,?W+3_.>?=QA'^^+?(LCY(53C;W)(ZI!=E'RW,3>266 M9A^B2MZ[5]!I`Z^ZNT)PP5&:CZ>.7!T_FJX/=_G;[[X-__GU7%A?L]N;N:UA MJ2-+];'RF7'`]YE.:GSJW)_U_?G[JW3]U[T![!=7"#$P95![], M5G/OWH?=X.PZJ2(EUJ.#PAJL!?\X-9RZ^(@6F4L7YVHR_HSOCU4G3\K]2?== MG.V$7F=9@58711J]F%\PP63O#:1.8&/1@8P;M`^^:#$+N?V/M>;3N92#H M^%.TGO6>D=;]B07R]M[EIY1DUJY6JFNP-$!R:PBY@T[>(G,9(+F:"+:X/GX\ M!;`VOR*\>:9N:_&*TFB#.K%^UC;KJ:/4F@+87R.#!9B?`YDZNFW6=IY'OL%* M":)GL[UA>AP3NO$D;MS'''W&^%Y^/!]SK$D*T`)'=$2GV/WL7-"4,M5BM<6>/P5)KHV<&CU&4IF*2H:WZ>9I*]+YT6\7&;2R&_ M(*8<[/H(-GEC&3 MZ!O\O<9;Z^_.''0I`_=A*,Z7MMS.GW`:6I7(A.YV[GWA_>L[\@>2FC6ULW;Z M%+VQI+7@6#BX2<%1E=6F89'1J>ZAQ! MHD`&A+0VJ9S4W2QQ_YA0]6S")Y0_D]5U\HJRO(R9=5XW:B9Y6H6:.1JPD+-^ M`FI,8JA]MT?)JBKG)\`J?'S>727[\*\(]=]2!^(,P@J(/CDK#]XG`V$-@$X- MFXF>'9.)`D&O7`0O0"P2D?LD+8RX>:M<0>PMU$#`(9K6T(.83(3RO7-%U=.\ M!5X_CBS?Z+W>.*/Q>VX#SW1D(@(U'U%IU6U;.E[4=AU\P+Z1"?;=HM6KJ MB%O\O'CY6RGY8&\*.N$<;FH!)YVM@C,"BK$]IAK2VQ7._'`.7\%]EOISDO57 M@1HEA),`3@E_\3A$%W?<5UE!$XPW[0U?4&V^;.@()@X"';:DH/^/2TYH=472 M0SC[0`6#H!8K.3:!K,(`K8G=)D`S4`Q?#D?JP9RC"GOP`^?Y(&_-"`YR4,LY MA(%E#2M-`&%Y[<+8L>\^VM@C&_O?@+VM$]^JX4DI'H/8L;U'KR1^95D028[N MHAV;W)]%R9=Z]_:T>7O:O+6]>>LVBEL_-\K?N>5]:W9NN]^\V[F5B"[?N>T6 M]&5Y=-JF=[9-/]\3S"3-V2,^9R1-R5O)*NUE)"Y_!PH[J-"%S%_F%"(7/6321,?1S2NH)R)DUB@MHZ M/`)G+:]N4@)0J=O@0IZLN7F\/&Q8[CZSC(3;N,[WE"4M-VA7P/[PD-VP22WM M]5I:)30KKJZ,_'4#A+992GQL2T9X?D=;-_N6.%;C$0.MK%/$7(<$0QM(0.3@Z##;RR M^8P[ET5*5B2.HU03::*"2JP-"P:`-H4U;.-M6-T4`1W?9@:P\W'2"4"+A63; MW*MHSXW@4!R(5A+UN?'@Z!NHV744U8""@JUYQDXO(J0\[>J0\#X0=AZ]T"_Y M#@`L55$)SL1%O8+=$%$"Z`%-H4;B37N;6J\FW^87.M(OLO8CVHOEDIURRN[1 M$N%78&![+&L#M*I9AX5F35-.B':U)#/?S.I.\RY0MDQQ.2VY7??FAHKP$*PH M=X*N*NH_N$>80A.\>C7-_#A\5]E2IP>J1K2Z3=K*2G&I+,6%I*34W-`(-<`H M($HJ<3:7!84C[IM#:TH@<2FYX.E1S@TP,D5'@:3'N`;&GV?JG)BB6:/]>9&F MPW.X,I+6-'!(XC]D`*H93,N&'&N0_$4?)*\H?2*.EQMW*2;I(UE0]*\XY[1M ML#)83@Q9S0-OEDPUX7)A6'-P&6IXYJ@N"[4R)P-P+BPC`32GS#R1JU+>`D0Y M54Q[X\7U#0/:!W$>Q?AWJ@&*,G3[%.--U$X1Y^R202E/5@LH."LJI6GZ!)_& M@SOUM4RE@*M%EF5(E;U)66)PBUY2PIT7D+8:,5&XU_=Y%71OQ4L8^WB*]"XE M+RBE8V4<)?DB6;$[4B]5WLM'6C?G'))&B=J&H!(>7&!38X*8J"^ZLB:LC@$* M5,VL`,7$YAYNTBBA`E2[A#-`Z2!$!BBA^EU``:J3`JI=C8^`V@O*/94B^-JZ M0=OYZA\H.*U,5&H!`7!@W=Q^[;`,Z]+7HLC)ECSA&&5HV7B/[`LGL7M%ZY-QG#HC:V M&8NY0,V"@8S0:%9O<.&>_I01B1.E04B;JT)2TKE,S#44-IJ1R_G[XALGP]E/ M*$\DKSL]VGZ-\D/8^C+%LLE\6VB%F*JPM$%5Z6!I6`S@)7#D9'<9T5I.W9 MS[P'C)(A7+>;R0WR&?5#UF:%>?`'%)X7RG6M,0+,@*KL)>DCK%K[)W)8_\*E M\O>H['*/I%+EYX2*VE9W<$1'O^C^S(Y.47]W&$:8`+C5H%=#P`[RJF`KP3J3 M4?TT5W97&?&7*"[HA)[VM]YWP7Z??<8\QSJ2L;^HG\Q\P#YALWY?J\=< M%(A_7LZD*!CU[:)>3"8LP1;4&81V$T\\QHD'ZR-ML0)>B8ITOTX>OY)_HBB5 MA3DT2NOTA7;I]]@=A-9SWB/:DKVWR52E/JT3C>D6@_*:':-5_IUV#9$%?>@< M+=G>X,N284@.J/7\>,&X/B MFCWC4/R=]@R!_7SH&0?1^#UCKK?00/J;=`>3/O`^@>\;VD40-[A#-S+>?RR( M7R>T+Z(LOTZ6<;%"J^ND^:*-?#4K<(>0L7IW_01L5[?=1R8FOU?]-=B!0V59 MZQL:UCWEGTP0*G2W:G2W:G2W:G2W93IDYX M)O'J>ON2DE=4CH= MG53,CE=\3*,D>R%I93PYE$&T=9,H:.<"3AV5C5"HJ""LS=?#;46Q=:2I?F#% M!OE^5,4\N"8*U,QJ$A=YG6%F\+H M]?0!:B_@]`MZQDN1\^%_K*W:_S@7S$B5,H)*GV-PF07/BHR]^)+1/O&$DRI1 MOR"N`B&M;2TG=:;LYX*UXNVZ$0]EY>H_/80/:E75A+6B,D)GO0;44$1#RV[7 MD;%G?4;&-JP!^Q`&:W1M1Y/.=JW?Y'LS>L4'>S30XMXCS< M@;>DY<0)%50]MSV@\F`S1A,0!*JS:"<&5A_#D;`>'S?W>,)6WID?7@732R#4 MHW?NA42`$&!&IB[?X_0J$(&DQW@D/D3'L&*2XE5T3BGQLKQ\05)6>'>=+/F' MKL`%FB-6@`)>M3F_08F!ZNKF[]15'IT"U.'++$D`J4^(:H"C9*C#.4E?V(]4 M<"ZV#$K6EM8J.0^TF1O#`'9:E845ZK^B&N?H!K^RBZ1YE&PP';@YJ8:'LR:# MDHU/U"DYR]F5N6W&S[BTZO9BEBZ1N)4E.-KR)V&&I=58Y)=VAD<33,FA"#!/ M%XX:(BB0R*_:BT7`9Y(LR?8%Y6BQH:.$>.]33=C$P22$/L))B@NBH3@8/;P: MRVB9I"9KX[`G!^;/BRPG6Y26Z:N9>W_&+WS@`2B;C2X9Y1RA!U=]-/:D5AAJT,Q9TR)5;6&I4X5Q]DNF\F,V=[E`_A,&51GNZ?[%)B\ M$=PW@)"*PY$MTEG"2$/[26+;KPN8UQ63O]O M/.`]6B+\RBP$`*8A0S%\M1GZ%`P;`I4/Z'%64X;']F(((*Y=O2\!VV/W"^'P M8MPQE!RU>X:$8T!=`VJWJ?J&I/ZPHLEPD]SFSRAER_NVVS#N&%)NVIU"P"V@ M#@&QUU2=05!W6,=+X>98;$F:X]_96-E?31IW!P!/[4XAY1E0UX#;;JH.(I7` MEUL@@MUON)87Z(50`G.0]QEH(_K`("#X"JPR%58/U865LQYN@9\(67W%<4Q[ M;3%B:L]GHXWI/IN`D"VUT%3X[E=J+6V])YM.VNO[&QP]X9@2LH/K2V:4["[: M<6IAYOF,\E18X5%LKHAR>81I=L+]&0^ M<@!X:G<<*<^`N@S<=E-U%JD$(W+).Y[=#WW`#8F2"88*'EL+XT27;4"(U[+@ M\4:(KA`U[G\,9SPX)UE^NVZN^ETFU,"[CG'470+,0@Q_`(LY0EW7,J-A#:C0 MZN&.P<,@KO."/>1D^>6VU(YEM_TU2M.(SN\>JQT_5_WN(-_MFJ4Q0$E6ZE^> MX$(KUFK9PS-%X!-MIY7H)8ZZ!]IA5B-N+#,/+O&6XITQ\=H*+%C#;ZJ#F6>[ M`TVMPN)KE*[DMWLM\1U<^QW-UYDGM(0\,IV5NPYTG+S=R\:CY?3Q6BG;]F7G M`7DI"CF?FDQ\G4\>G,:RA2$B55MT+&MD[>5YOTZM/B.%G\R1^[&'%N?75+A- M2Q32]]+/M%BTVVV:MV($:]W+[4M,=@A=TRD0G>"]MN<\3"!F#GX61>V"38)% MC8+.FY>39M%4;W[CMY(M:C#VY:R9.:@^FH+JHRFH/LX;5'R]+8#J8Y@W?I4# MJ6@<'2S'F[F\-8;-)-X"P[#F2]9-/.$LRX:L@?4XA7D[T90E=48XWY7F?$1O M^1D5[(OFZAG.$+ALAC!TU^/L=0[`FEG;MKVN-EI8R((9(J0O4Z4C]3'VUVQ1 MY,\DQ;^CU<\)5;)/@-5ZRJQ?5.12<;.Y(C)<8-8^:_-G9GL6AE=FE MD'SW"='V7%TGKRC+R_F6/'H.*33P'_)"'KAPOH##OR(D"*O:8`4TFYR5!\L0 M$$2(59N)5ALY%AFQM\@#X8AH6D,/<3(1FN== M9%4?)0#-(E-Q?/$F2D4I_%Z;A//=&2:`;4G46G4;6LZ7-26'7Z@+'X%W%8;M MM`M")Q)^A>%LC7]">TPUVK4KG'D$;#CQ%IRZ41,V[_](".WYX,7J%:4YSF@U MY3$&D=0*LD9F(9FS;@*P-P'KU^T(8M;E>T5"EF&YYY:>EV]L[=Y?RXD)AJC9 M$[C#BPH)!*!1#R<"ECV4[%D=`1_>=4"C!;].=X16X$6^V#*#P#7+#(D$#EE" M41N'2^$Y"M1:Z30YEYM'3S@)AN26V/<4G#@ORF!G?:JP2CPT>+)(K]`0(M)" MSE`CPP,Q5+J+($X-/>A(.?N/IH*=_:K]7E+V@9=ELC+[>I[Y" M*./-,6RSK5O#'EM?43F1X4`PME>W$/?'SYXT'>[E`^IT%=CK"[,9NB,IQ3V&5JKT=X/6.9Q&C'0KY\/F0E4=*L#NA][^R`WLP>R//# M,J=GV_9>ZAT\V^;CP;O3"THAEG\.4+ZWHLPD)TH]_U]B5BF:RH-8IM44Y;JS^Q_;R;8;Q*NUP/2X!RSD`FA`\Q MU[N+N7X-;:0!.(<%P\5;5KO]WMX[1;HL"-X!RZ3A'UZN_&J[/GEA`GLL-$4+N9(!&#)_GN M#X/I[;JO=F61F'-\3+-440:($:#2 MHX$BKF?F+ZN>`H;O*\KEQ6SJ%-8**ZPU\UF76,F?,[0NXAN\[GL_G2)*.+:+ M^#@(_=VCKI&+U,J%8S7N4X541Q;]$<3'(2&16>G^F4;/T;'`YSBYF M0-6NLT;N\6\.VCV1N$@&=CGLB:H.LNJ4[9]RA95U?SI12T=[1\6TZK=S>LQM MY*<]^1@>1.A[3A!QXR@5Q//#F);Z(W&EJBNL%V0D?>>JR)EI6N:HK\L*O*0- M5NH9)X#5_/!MT70CT3].$G[?"'!%Q;'"/6([9%1A-B!ERRC^)XKZ&Y,6.0*" M!V"./DZ4X;A71!G,[`J>5"OE5(4CP/*%&]?EV("I_/B5C.H_/1Y&/6;/XYWU M$;[M7/:*O43ASKA$6M/JX;MN("[F?:'B\AY[`\=^SOM#)=.[FF&4J29 M!^WUU%ZLJ=!6>@27DU&WZ'%Z9WU#9D>7':0G5]U+O$GU9V*,1Y)'\2(NJQE< M,[7'<$2`ML\PY+Y@9M6C=0FP>'7/,$D+R#AY=>%5*RW@#\[NP7J?#,K2T![A MM#Q94#MI=ITD>L(QSC&[41*Q%EO=)O=H6:0I%9T2?"9)VOQZ%F68>QG#.M_& MX]GCZWGNEZDLJ),:QJ(,/N[][]4[V^U__#M&*6W"Y]T->D4Q[YJ[5J$^;!6% MW`W&UM%&#$W5&WUMR=6!LT(>K[%:*UU>,AYJP<\]8%*VCUQ86?<`AF&-C+.* M`*32NCL(A-7I(Q`OLQQOZ;3T=KV7>__#89;'O1!L4K1Y#5VKJ'L4:F&*C#*- M`(L0"93N'F@WP1?1T;L+0YWZ M.HZ15T_XH/L.#+KOP*#[+BC0\?6V#[KOY*!S\K;E=+C[`8R['\"X^R$HW/'U MMH^['Y2XF[V_&[&$NQ$E89B"M\50TXT':1VF7=I/8/AC1`#LB!W6)81Z4V+H MN421;RA]$P!7T\^ZDPSQ3/2-9!_\-YW[AFIQPIIMGT?9\P.U!MNT$@[-/6!K ME6F2W,'*N-MT`..0F!F@MZ^@JJY,=@>KQAH@>3FJ76^'HJ)GF*BIYBH7Z#FJ"HZW0XA[0\&7%+W*)9I<+3S MUC)ICGWBVG7H4^LFR)].-T&F59.AKNJ/R>H?113C]8[AJQ*UE::*%]`"Z.R=>(.@GF[NZI#=)7E#W2ZCD!;[U"`XC) M"SG#EAEJB*$YNCC3JKL+/7F=/@:NY;)SX]4Z14!XL<92_A1@5-BS>3!.WBG@)J< M:1D=:!U"B/J5AK7H:^M_08JG?%W$C9=7XE=>@(-848%98A2D_7A4BJH)[8UV MZ(Q#%-$V+J^YXO`A,FUA9FAF)&N31'#UUF#^0C*+A]."];1@/2U83PO6TX+UM&#U:L$ZVZWWTX(UJ`7K7`,GI^7J:;DZY7+5 M"Y!_(J_E*].S3(Z_QG4(+B*[R#:5+G*&[%"_1?91LN$')XU16-\G4E3ES;Y:`2X[<'EW7 M.4X)YF6G%M['8[66->6$QR>LH>F74]3@K#,>J0N18[1,MX=.JUG9@Z?0*+!N M.U23N^4P80WCNZVX!G?==L+.-*ZO`INCUU?MJS.R@XK5.,J5@F'UMXG@<3\U M9?.6GXQRCDA60HWHF,<:(D5BE:_^R<3QY8P?&)./7PD0DP-*(29;E.\'DR+S M.,)D2QQ?CEO#,4GIH9Z20RO&99OV'2%3:")7V&P+-/Y$Z9'1>46*%`C.(:D0 MFVW2]P--H8$<(;,M#Q^8?_(8F/@5ZC6'I&)@MDC?$3!%!G(%S)8\?&#^V5]@ M/N`W("X'E$)8MBC?#RI%YG$$RI8X?$S^Q6-,HE>40%$YI!7CLDW[CI`I-)$K M;+8%XJ/SKS,]+6'5AC>"LVW35C)%0/?&@U-RL]B*@;?/C'9CI$KY$@'QL?^3 MKRBM[;7%_0,JQZAJ$E_0KRJ,D7C83ZU[`FD;33B6W[1//4ZKDB\Q>@^]P<\O M+\?R!H*JIO`&@ZI.WL!&&\W2&PQ4.LT-A+;Z7+#ET^WZMLBS/$I6.-G4)W*G M=`SJ6J?P$;):3^["/.YV3\D:KMA'R0*G0GY8.-W3DQ'[3W94-TCDZN4^0,;7"2 ME&\.EO?WOG/JZ6"B.7%W*M%./L\%!L)T?"H3^++K[O$ZL?["HOE'7">*:YUR MG=+\?*^.2=FBU]SEFP\OP#R`=BV MJNTK_Q;D"VO'B24F6C+C\4UQ^<9^[&?AT"O42O,'*>2L%]C#+C$T41?MH^5I M4@)"Y`CK5`7(=(_1VQE*T!KG5[3]U:BWRU1GV``P#:/73&+B"7J5+3DG'$M< M9P"KQ^2[*,UWCRF=T4;5(Q2N4^*+Y!)FKH.1[]/8J<@]R-,E$O)LU_DB3;]E MP&.054N+A\-<@$`$$#OVZ2<(E-?>S6.E5:N/>6Y@"G"R3ND75/187D$/+B:8 MX(J,,(_H#H&&'`RB.O7[CDMN^B0Q`0=GSI,7&<"!`'2$N:YA)7V$3)/HQ])[ M@5$2;+=?4*+5`TKH:NS0WYKE M:1^"Y@SJEC!AX(6#DZ*,6+`,:.CK;`Z95/DN'&@='OQI0>;!DT$0`@>HL6B3`ZF/`$=;C+3[8CRGBY_,&TTLP MTZ-W[F=$"!"`1*8NWZ?T*A"AHL=XF@34-RA!.4O1M<++*'Y8T@K9D78Z1R$I M8[*[3I;<$)1^P=HF.@6]P@*_H0L2]1I\G&*5%$%$(J'IW\BH1:F=;H!D!'S6U:E84' M.784]'9==\+594(-N3N/LN>["*_4*(24%@-37MHG+\B-"8VSA](Q=N(_VG7Y MXBL%XRA0G\66O>/X=Q*OSJ+E%S,\\GGHH;+/(Q1L2FTS"4+[-4Z84<1U7/*A M>,K0;P7;F'A%AS<]G8F)53"9IY M3^5+2P^S@H/TDC;T(1FWB)>O[?L:#5+4U7 M)FEW[MQ&2L-O;^?S&G5##EL;\MZ&B"VGK:>T_GJ5>M)XS!BI0SC+QV&O=::8>BE[7@%81<927," MATOB3"DFQG5"Q2BV@FB+A*)6B4OA#/?2-B`0?;IPY_%C".?R\?$Z(U,@KQ40 M1%MD)"W<#DG2HXQ_&UE&TUQ)YM-XT[Z0-W+JDS.?E MVP%-)N`-B?A/WO(_UH;H?_2X7:5Z0!NTSV2BJ:4_HYE)0$PPH/D=#^L*+0J' M*:BXLU(?@F&*5H:I!6IE(2MG[QX)G%Y7T$]17J0XW[$.+FUS'B&WV;N$GK3\ ML&D'K2]14`:`/>%EDQ=;BC-022[0%"7G@S0=$QA" M35%%6$^V=57O:2L%HX"6"[\![7P`)U?3$&(#IF&]A-4.P$OV6R3[+'XC1*($ M&!!='C-_M:BKYU6T1-7=&ZD#&9)Q?4>;S&=0`)4S]!AM?GQG,>-]VM-=44L8 MM'E-5`)-[6H.$#4(6+RB](FX!VFO/Z;EN;7E[G:M,VE2%^/[0$DQG_%HJ+RI MCY3P/R`PC%A%3\&[%"=+_,*&`_B4?5`(,G=O%9H/\H"*VYG-M[@+1^KCAR;L MS^S/=DV$&G"V2DS,F?WSB+T]G:2E)>R@DHIERM"'N4'=[[L7 M_!-%Z>-7,@;\/18FF-^S"`WJ?-M,BO!]E4)@SW6W5]\,M/;^EMLX)L;@KI@$ M"6^.?:8'>%6I$.)S79UI&^**%(,59U!+_M@=L"O MH_UWFX0:)[:)WIT5W6*43W7/?`->RP6%.)QP.ML4>3/),6_H]4C.4,'XOYV MJ!5>;8.9\W*7Q`*&"F+76KV<%U(9RNP7X^J>^1'PGO:K1;*Z1SG;/;Z@_CG9 M5+LJE17D$`<5Y2-:471^`-:QQ4B\*JJ:^=%PF+*_1'$Q2':H7U(+G'7)8+#) ML\0TT*QK"BFWT&64L@=-,JI@V?%<3][Z\@BF;2JR&@9B,F=^H;P/PQ8-45S/ MGJMQ.L]3_%3D[#[?(SF/XOBV7#1D%(F_1FD:#<_V6^!4FVD4)V=^1(D!8M-& M78\BJIOYDE%U!IQC_CQZP=0F[;<_77N;62T5!9>#6FOP9NK_"\MZT$"SIP64 MO-9#33Z#>82FSKJ3!S5[7^Z76>PUUUE6\";NU=^O2/J`TE>\Y*^]M`NW>Y5& MX1E@?4,HM-BE!U9<^: MJX;7V7HQ6C`!ML"JF22/8F5O(#.1XY'BX(Q6TG]OR0JO$?9I\7(W/[8!$6+7 MEKU9]`@)F3L;*9D@)8:5XW^NW5L]V6:!WQN6?N'V*<:;ZEUM9[/M4I"LEDQT MYEM&LW_2EDOC;#Y42U*)=9U[ M[6`I!HA=(_6V@GE5EW/\<55.Z6H\1CQ)[2%>RDL3\0)>\T<\Q$B6$2^H>Z)EEAJ;Z)72&P`O[P'J#&)H?;\%REX5;4S3*BJ"-D7W*7DE?H"DEP1]APJ MV:+'Z,WA_&0O@W(V`J`\[%R+*5WN\?>E$GD""*E85Q]Z/:2QB):BW:XNX5_O MMDOXAMR_'XKM-DIWM^L'O$GP&B^C)%\LERS'$]O9(3%VNAP9BB+H[6K"&ARPM* MLF;:5-T981,DR(Z+;LG#;@*\I+.N?4=%K`2\S9]1>D>H1'M)ZZ8#[+N,95/; MS)R-R[T8;8`0:P8;[,E`96%.R5R&D/W6=4+_3]=1R&$$MI9`&'<5?-]'(`?? M'<98:UD@,58U:5]#OWR!N&&(EGK]R&J/:Q5/E7$+N7_V[W2=[D`>2T'A*6X5 MG4!%'[HLY'8B5#_XW4,)QY"[;BL`>8^S+^PS&L-H@2!6J&H)^L5@JCF0V_6:R]B M:(9NOP;5R?HWM*Z0>_A=2EZH]]M1/\ANO;Z4#[8X"WO5PK"6R-L2";P!F+X) M9*GIW87\1+(!PGP&1546\Q*KBGG9(.?8K3( M,F1T]=M.5_J)D-57',>T-?HR*2<81F5K]&B6=1C]$PDG#@*"2^QC@8`2SOR) M62L3$T-T78I6Q55$$5!AR%[E`<5HF:/5/XHHI=+%N_UYJHLHCYSYF*$XU\F: MI-O>:7F!ES$L74-*N[0S3R.55.1L]`I!;.*#RS%M1YHK2$[ MG\ZYQ/J7[!XM$7YEF>@[ M):1ZEC**Q_XPE!$/AV<=Q>U,[)BD?^AQ4&%UE,JHHI"=1_N(>)2LFEMUSIS& MJ"/K`C=CE:>-:Q$>N++/[(T+=+N^?4%IG32H:S0Q06T!'H$S#V.WB0E`_:[# ML5(_D/V/V=1ALO'50Z5G'Q/X+['TK6DB2_,37PASH=YF76O.;'I)_*Y M]J4.V6.7&68YB9/67';=/L5\CV+:1JMSDN59>5+JB3W[<%>_YR5PUW:8 MU7`=R\R9@P8+?M867.2/+7'3-:J(FS-O:PE;Q+9%NUYUG)3,G8Z6+F3O>8]> M2?R*DPT+0U#=6=3!Z:W#AV>2YNQ^V1E)4_*5'2T5O8Z@IFR2N,LH[1UAHJW# M($;!@`$'$(#438A-1>TN\3R@&8BNNET?(*FB#*.I6(?<@:\BG):O1'U"$?O= M-(&\G=Z[E^8@H*C[0DAK-,A)G4U+>&*)>CN(5J*N#ST=U&)$3]=N1Y?5P'JZ M@G/(_9RIW2P"_U%$,5[O6+[Y>GO-68>7BR7H^GJ%:J1`"[E[I&;YC%9%3(9Y4.2:.N M\)S(>90]7\7DJ\OG&NNX.EU?-L*(PA$`TOVCHU=2K9(V&9'),ECE'' M0NPU:I#=10FO3T:O!=P/=S=0$7B`J]Q*4EZ<\Q MJD,@BRU)\_HT2W\G7J-(L]T.*N(N9?>QP$^,K-=+UCVQL.7F.TC(P$;#BUKB M_4L1EV_LU$&3/W30"T#4^PZ@H'XGV->QF0O8*^0+S/D?SL^T3]@,#FS(B/9G M-?A$[P+6(`L='\TBL?@@_F&N(/XIP@FST6WR$+&-G$Z6BD.BERZH]0HU20^` MA=X%Z(TL>/Q.`!63WRG^I-,I?JPZ18(V+/KONEL<['9%L<$TS7>?4/Y,J,U> M46WV7J_0*M-Y;4Q9YEWT"1/[';]+`*7D]X@_S[='M!=59B"[Z-?]HO[-\08JG?%W$^Y/`76!"2`]I+26D,P.BAMYC`"BO)K`@W]`T M;)J?T-KP8-H+HA5ZP@[MS)"GH[E=W]>IQ\*8[)?3XUB')4LZ+U+6?G7V5.4D M5%A$//WD%)D]))5VL(M,7G4AQLEX:A_FWAH0%122@W10*`R8RFTQ`5`'%087 MP!HJ?EYD.=FB]`*]D`P#8"HJ((3HL,#LX:FP@5UH#BOCP_(OX4PO]P:ZP=$3 MCF4G`LT*JV-.W,*S!ZZ&;2S[5VG%?$#_-1Q`-TO#.M$&.P>U7*8%5>I@#G!D M"<)$&6N2,_$1Z#+(2B-0&O8"@YXCC#PN)1Y28^/,FK8RBO47U8J4`.*BO`M+1HRU.$V.QKJI2)9<.1^=8!QAK0ZW[$Z MSPFJVUBUZU0=::R0%H\\^;"@&/B5P;N4BN%$1"\:0X;T`?4`7>L<;;08RF'E MQ.HL!HDZ5[[=Q;$A4_F@HQ.1^>;=3:%'P+8`.75-,:J<<*+J@UOO\E2MMQEOV+;*[5., M-]RYO4%)"82%)0-'-^$V* MYT,+7;$J%5>5.Z_639Y1M*ES@;!NRA](?;.RKZD+"L:9W) MH*R6P\+A89\6C.-L9S6J8C6:$E3WL&K7J?K.6"$M'G_V(00O,(=Y+S+O,I[U MCY%11FV(&X82W\7)LW*#.5FQ?UB^E]8--%=#XW`&NQ-0RBX,5E1L=(\6#3^Z_OWC,>!]D=$I,GX72'R,G&^R'LH M7E[BTC11W)CF.EF3=%MA0/!RB%ZI)E$FM)3WF#337P^3X#J\N8,D>&2VG'E$ M>"7`DNASRXUU/[M#AV:K$Z5R/43`^#<.J\LWL(LXUPD5`V4Y4[('&-ZG_:VQ M]B=G0!&V.I%*WT5#GTEU2ZM=.+@FKS-/HXS;ZMROG4RMKU,!TCS]\H' M=N^A<7I-,L3]^;%DQ8FQ')Z4DXPL-MBU1J)Q[+R?UUBVF/XD?%SEHJ.!L^T. MW*,#U`NPO#1]!PFDWH-90>W4@5K!(-&UR=`!CY&C@K2B?F^&<,'<_=<4Y^AV MO3XD#Z?JBQ++PXAK8ZN(@\"?ED7LPT]5?6#3AW([\Z^S#GL'\HU8!#$%@?;SO['QRIEK((A2:GZ,&:H80P[FI4H, M*2Z=J@D'F/+HFNDTV-*Z66H78_#+I`YF>TJL715I@G.F'&0)+J4>H$Y`'1CT M(#:9$G^"^D4@-#IRY<.2H[;6;7H7I7G]2WF?.\-,R<^(_7%+$I1'Z:[JBDT* MD'9Z0CIUW:+5=_VS@Y,P;XX76F8>1`>:U.+V^YMM<47=T\&!>,$8<4V]"H[B MI`*=VQW,4!SZ]P#S'EZ*,I7^D MJ#N+A]?$;;(<;^,62X?W#^V!CDQBX/X5Q-'R5M>X;,@YY9D31VZ7+`MF!196 MH7JSI!/[4],&KE:PRI+5(G"..D5JX,"*C'1O&5K^<4->OUTA7'DV^D/?H=$_ M_:N2X!YM,*LXR3]'V_[E)!E)K1*?Q)GST&H4`M*PV]LA%;#NS&T0[[]7]3?)I/2=!I^0#.SEI?K.*;I!YQE![*.U/:-!H^4K<";M3_U MO%;U:38-+-'(K%V[#&4GB8[U*Y>FU\`]FMFUM$S'<4W>XRR[ M17^DME]0L59,M*LXVO1/T?"^-2=GNM]FT\8RG*]0'IS``!TGC4PEY0@2BV(KQ\BHF43],+?S>:>[.]YDU MMEBW,4W=X2IHZ*,&[VKO%CW7-&_]"<-"JI>O'!`-1MPP/0<%S,<\!;`X*AAPZYP55A3 M#00.'1<*';J9@D&LJPTX=+@+`-&..;H^ZG2#\SJQA;V]]@-/998?".G^&)^, MU-T)1;2)XD]1SHY3L',<95;>#34W%I\)TBK3J`\KXZQ3@EJ2F.G>[9BRFLH3 MBK`:`CQ)LS=':[IR>/+"V;G%4HYG$E,#9^P(?;[[3'*11X`1YZVD!1)BMWD; M!H(=&DCD&;3+20W!+>A)0N>O[48RR>_2*D@(]H/05+\O7TOL]74[5]&L1E;->K&H5 M`E6MVUD%;,M>*F+G3?XU2QD#RSMFC8:BM)A2HF:+6$#D,VA`BH$Q(^(66-*T MKIH7B*JPQ%6#)JO%ENU?_,Y+E:9=C@LL:3EW%ZSD0!I`#:Y][S(5MYXA^*3\ MY^ZS:/TDI5K=HYB]>G?YQE*Q]0^VR(F:]:V`R&,<@?2"@D;$+&R/A6G7R.E: M':4XBOLQ2A`MWS/U:3U&D8Z6AAZHSS.P)(GEJ[1=E7M(DE#4EN52>(P:M490 MK'`Y67Q&S`>$2,$AM>*,(&$%#3`@&&5/\>$]N9]2DF5W*5GC_L**\Z4V7>>+ MSTLHL0K@=5.'A<5APHNV1PE*HYC-P5=;G)3W]G+\BNJIEF#!K5FJP0RTE-=X M,E(=CC4H^\`&(_@R';XT]7,IK@L@HJ-R%V?`JLH->UD5@<44%6;1\W5Z/FY> MN--3W1A[RFJ\6>X+SG:<1:L+])3S\H*[)7P^@'T9%/--F_H&J8?`!)3-`$@'H7/ MLW.U2N"9.)=58"O_,LSUF22DJZM\\:=7J!U*!!3R&EPFBL/Q!N1N[\EN+R;C MS0.P_*%2\'5_S*7WU1EZ-*%!5)IU40/CWGY.5S&HS7;I-K`$'S8J,I%3FB.0 M@+J:(DK,WIM5F2U'Q!*_,J]@]^C#1/ZQAKFCC5+<_ M"JI\O<@A27:&UB1%K??8/^&$I.4-KZI7TH5SETMU./P3RI_)ZM"5^XM,!S5W M#D$?J6:?URWNF@"\^#FJB+*41S-G32;U0R!(^@WM;ZJ-%F& MI>4^3ES:9P".,\58/R>N1II`:YZW[<^B.*)_>'A&*'>8>6-_Y;]^X"V*[TCU ME*HP_P:\R#[Y!*2(PUP3C M9:NWQ;P@VP@/KKL+"9I;7AP"]PTL;$8"4$G0R'V>Y9TO#B\O&_H!I>S9T;MF M0E!*_`FQV46_@ZLIFRXNHW1WVT_`,-F)@H= M!`#8,RJ?U.DQ",P;5.K5^?ZE.!#0=.`PH'&&"D&[$Y@V76!T>1U`,>`1&#;8 M6^DL>RC]A^VNOT8QVU%?Y.=1FNYPLODEBHO!"TXZ99JI)ZR,8RR)$$/,E.9! MK%=%.3&%L0X,>?4+T!E[A9[J3,?CSRBOK=-W3@#2QD=)2?V%EX:*0%3).08V MQV&G@1+*>S?,0,G[U#K2>_CD+S@D*@#!T.7@S0U,BT=Q.ZKW("`F:!^Y[1'X M"P>E.D!0\/@$EX2BDO@Q>JL4%8XQ`,I]$@H)I;^H@2L(A(^4H<5KE3[@2.9= M9#UQ-C[%@CL!>1*C6XT^G%6[2]G]@GQW%T?58RETIO["(@EE+JD>)&#$M7E5 MQ!ZNK[7T4RVT57FQ+RF3*R9*W:X&[5"74=KNL@I"H/Z\.Z3\N_PA:`(.\J60G.-D-*/0\ER1(0 M[!:3=29O/#(/(0/4"1;UYK$);$8/N^L(NQ3GWQU")1H(5#<>8(9\RW.Z>K?S M9ANXIN,T.SB6]6TQ""C(R0XI+05D7H,'J!T.4E*:X>[(;,8GB%YP^`BX!38EY@7T)=,;"+%DRV0V M4-+25&?"(V<;6%9`A1]2=-69>1]KC@?J?M:%#-#3N`@Q:50]VH1^>;HY8WD4[=KY2?GB53]0[MMHG\@%<@%.K M4MV$4)(<6NTS#`PXE]N7F.P0JE]!'=JDOPT!I6\V)-3TGB-+5V,=D`%X!S8B MTFZ5%FC5RK4H]%5RNH.[$M%YCBNHAII.2\0SL&!V&0>[(5$B'_)49.VX(I?, M*,K0[5.,-U5::3YH M8,3[RZIR8L^AI*6K#JI4C"W&IGT`F')9IER5S'#A976E!5]:&>7<]BS>K3QW M"J(=0L>K$Z@CHXZ:!U0-`X_P\ZNS7=(+?+%P@Q5,+Q\#O=B"A>%)/!("-V:E MU4C&0_5V[6P#E^UYI1!JH`*IIXDD$<_`G!;7#I!!$C(XS@([`.5T MH<-G:3'RZ,4TJ^X@[1"9P.WP2'I.ITLR`]BH53-T.%V.^\GX;-^(`!\X`1^U M\/)0BP\BI4XZH.$QL[B)[\5J7;%F$(=\I.3`0_\S M6Y=I:F]E@T1046#I8-C\$5=9*%A^Y?(-Z@U*EM0`G$FX@K(U'Q=2S@IW<)W- M(2>M0[03;"?XY/X]M+NRN9Y1CI=4/^=O@9P>1T.GQ]%.CZ.='D>3`.#T.-KI M<;33XVBGQ]%.CZ.='D=[%X^C=1%/9^RW::GUJMQP:)XOU[4>3/),6_EY<# MJVQCM:?]/T6"27_$&L."BS(HBUE@SL@>^@B$5A.T(^P;00NH6I"<*?BLPRRX MW4F>NM=95H#`U"64`*DAG!&(N+J9`JAA%M@N8^OD!W!.IE%B>+)F=K,Q?6TA M``-Q#>R^<4MGQ:`'H!PB:S;#'5P[321!![KYWD/NZ\H=Y114(N1X/K[!M#)" MC'QDF^VEXH&>MT6>Y5'"5A@JR'!(1;CID,X%/&+]C!#486?QVK$G6\VM73O. M60[GT57+.ZVG'<33#N)I!_%][R`*(J]U8.X!L<`*SL\0D]1`-8-@@09L\"BUJQ/$5 M2;]&:3\P;5AZ__"@9FGW&./&(L=9`1*>U*XAL%54J6T5U+\H4CI2W]&%)*EV M%\MOMZ6JV>4;2IPC1`KACO<5)R;VSJR2!`OE>$].7=FAS/J/#H3\"!L'Y=XBAIG7P`@D"B]K(>_P(O$,X@'R\;X@?`5NEE]='O;XT:C^O MA?P@'?UB2=U%=6MX&([0*P9PZMUBH;ERB5$F=>#=>KV)H1[!;>NC5UP.XJ(] MP:\V"%7N&(Q<:,U*UPO![+P=;JQQ%&FWA>/8C`/$"7N';FV(JMRQ`<*A,B@=LQ[*C5ST.)2+#I3UE7I\1FV] MKEA"G%+X>@!:_;O(JBQ7*OCJ8MUE*+C>7%2YPMHQ)5J2H?.FV>BO9V26%E@R+ M9'7YQN(UM-ORL0LC;K]I+"%V^W3S7K#RMUJZ0],\TL8]HS)\D5H`6)9K$&59 M9[T9V,IDG#6ZO5Q>Y_Y9:'A=(6;4/"A*A2$IZQ^[ZR1[0>602ZURWY2Y0B@S M<"F"22"DMH-LHAOY=3?V02])XAH3JX@:Z;A0C)W*Y">2"*'HZ03 MJ.B#TU"V#H'KUUM;"#B7RPDQQ[`[[UV+>SWI6I-T6VWBVLP1)ZQ%.9/&'-HHZK50:@H0\=VK#YB)DUNEU>K^XZUQ2DSK"=PF*Y)$7Y9,$# MRR,1I:OLYY=5E+L+7!PD.G^.DDWY`L-EFI+TG%`[ES,QT7!O4K2YF*A5U-V] M3("8(H]C5%;#/#YX(",$D'&VZ?HA'0G*NZ!Z-8?MC:Z35U3M*EPGUY0FCB_> MG#FB*A+]">7/;(.O$8RUS_\A.,E_H;\4J3"D:EBZQI1V:6<>22"I.E2B7U!N M&[\"(J;-3T88INN(-"5@ODBGYL`\SSU:L@NW>(V7U81P?9?2(O]$4;K8,@?M M+M91"E+MQ1YV784+*`#M?C4AI;6W/%+;5NTM1O'8IP\PXN%P.05I3&+'./W5 ME*3J*B6!496NIB_U%_:_IRA#]"__#U!+`P04````"`#Z@\="RM9KO]88``!D M-@$`$0`<`&)R;&DM,C`Q,S`T,S`N>'-D550)``,W0[)1-T.R475X"P`!!"4. M```$.0$``.U=[7/;-I/_?C/W/_#\Y?I\<&3'2:_)-'U&UDNB&]MR)3EIY^:F M`Y&0A)8B59"TK>>OOP5(BJ0`@B`E)U0.G<[$(G>76/SPLE@L%C__\WGM6H^8 M!L3W/IQ=OKHXL[!G^P[QEA_.HN`?_.#^W>A2C$#O6?&O= M8DJ)ZUH]GVY\BD(08)V?IX0?L8=I2CJ,_B1A$%DC+X0OA6B)K=^^(,^QKB\N M?_SQC]N+RXRSP#B:C*;6;]>3FU0>^\C`6Q(/QPS/@?,^L%=XC:P0T24.[]`: M!QMDXP]GJS#7LV)3_$"4U`-O[+]=>?UQ>75Q9LKT!:%(27S*,1# MGZ[[>($B-P3-O;\CY)(%P0Y4B(O7V`L+!+G74(->\!Y*4OCDT]4KGR[A0Q>7 MG=]N;Z:\D"GQG+I$MX`Q!T`1;C7YU>7*9-+O+\* MGWF&#Z?%NNJPUW,4X)3D'?:-#E!@2NP=@^]I\/C>^1X?(W+"'5^^ M5&\[\;#?$6 M?O(('C*N]RF*$[RPN)SWK-H_G`5DO7%9D?FS%32O#V=,S_.T:?VQH?@5E"XE M836CJ`1><<`20%?@1;O)/IR*0-06I`AZ@A!_@VE(H,UF3;!S-+5LY-95"UCL MR&VU5@Y>U-4*6(A'VJR4B^9UE0(6[+ZL/DS.##2PV!\/DY%ZI.:EZOMVQ.:( MKN<,O)"$VQ%T5+KF+>K,(C`@*2EV!4B+D$'WRP7\9YU;*7_^3S:%QL*LG+2? M._LB]J5'`7;&WB_\[_T>G7`G)"K.O4ZCSUALEW*^Y&D*Q>$(72.7#>'3%<9A MC$CAB1J!2X;`%"H))Q#TQG?3\+$2P$UC@&2'RL!N:ULL=, M9_#/[>`.0!D/K?']8-*=C8#`0"*#I(>"U=#UGX(8BNRG&H*K&A#TNM-/UO!F M_,5`()_?26"[?A!1?(T"$HP7]SG%DPE>2:*"ZC*>7S(!\(/+L/R%E9=BL%%C M,T2$?D9NA&\Q8K]9NP_VT9$3J?%Y+>##I%A&KPLHH;^G2"'[$780$S.9$:JC<" M5#F,8%UCI7(,0C402GX$K-F31S1WL1(K";D:M;=5J*42K4RD`5`-X`BT]98$ M:JH;!%@<$87W:HA^%"#*!%BQ!(-(U8SUZ+N/T*3O_!#?HRUKQ=?(^TN^MYQAMD\S#V4H">_5Z/PDH,,$G#,) M%A-A4-%"!3P62B69'%1!J@J^^'O M"&J.?5]BV.7>*2&YO)!8!AFS`4$-0L]?KWUO&OKV7Q.\B:B]XKL4133D1&I8 M1"]#+,7B8JQ,CD&HP4)HQJ9IO>500JI"ZTI_463]$,LS#NW#5D<:`)8RJ:%L MLE(RJ#9<,LEA+*%2XZ:Q?#(P-3`MRGJ:0*&$I\+,,,@<,IOU<8B(JS>=I;0J MM-[4F<\2@0:YPR8T'0S+N=1H-IO2#+#-YK02),O(U-!IS6H&J8.0ZH$ZKS7A MBFDK,+NL@9GU`Q-IO3;@-?3MEG2W*G(UA#4]O:8+-O7YEJ!71J9&3=,#;-`Z MT!=<`EH%M1J[.IYA`V"3A5RIA2F2**&J7,H9<`[P'9>@I*15PZ7M23;('12[ M5H*-@X M*%1$2>T3JB$3@T9S+I*=*"N69="J,ALSCK1HS,6@T+\SBTLQ9 M*WW8DNK/SI'(7ZE!$3W'*0Z,V4!0L3Q&0.I:IP6;W,N]\ M#58EHA)7HJ[A88"N<8S/14%`%L2.5UF+>PHLOV-$NVN^[2\YRE?%H895=(#L MBXQ/RX)0BTFU$K$&RMKN_"L-?_Y5!5PRYX?$H6]=F;Y6'R`ALD!*HP9(]'3( M`3)1!'7WG^6NWQ(J-4BBYZ-D]]GX?+6@8NYRE)@6O_(,?EOB+=-0M1+31(]) M#:3H#9GV/@WZ#S<#:S2"7Y^[-P\\!8K5O>M;OSYT;T;#WT=W'ZUNKS=^,$9H MG>4"=L'"PPPJ&F+J;H?$0YY-D-M'(2I;/&@QJ3&6.%(2J=9.K+63:S'!!E7] M.+M''(1LAVODP0(:NV[_68ROD]"H,1.=*9D0BWA6*L;`4Y$KBF_\KWS7P308 M@!T1;H6\41(2-3@_U4A@-/W4G0P^C6_Z@\GT/RU8OX]FOQO0*GQ>=(D\\B]> M<%@-7T:J[:UJ!E^A"*=\N M-5!5&"+9A#\AP5\!S$H/0$JAH7LLIW;9XEJ330VDQ(62LS^X8#[!%42;;J@= M.8XV)$2NJ@?*2-28B2Z11(;I=G4L$40],*R#>TRG*T2%2#KAO1H4T>>1"K!` M@L5%&$@J1D+FRQAO>/.%X>P+HM">):%8)61J@,3`D?A812*(CW*I*`.4CA7/ MUCL]WPLIC#@,"/@[B%RV6NTN*98GGZW!J893](1DHJV=;(YJ)MW*Q!N(M68N M\B_LW&`4X/'<)4NDFL&DI$H0KT1'2$Z6Q859.6D&L^IS:H1[V9-.Q=H\$$O\ M6"I2-6;R4VJ)K+2_9=(,9A7[W/#II?3`1>Z-&A'1X9&QFNJOV@%+_`OBME?Z M0EWYHN=BQVGJ_K"%;]T5;P52HL]"8ZEK,-3L/Z7)=/;>JS$2W1&9`]`X'9K[ M:S4K%ZA6@:'DL$MEA-K_/'@H<@C0_*]!\I#HTGIAI6HDWTCB,NK%DQHL MCQ%SB5' M5D&IQE&62406AF4P.S!9IQRW"FHU=K*8$66J3@.AI@MFE\&Q+$O_/H$:*)D3 M)I_3T>#2*,!`#DX)E1HAT1DC!AL8G`Z+.BBQ293$:M1$-TUY!()![^BA""7] MKRZ_&F/1H5,O+,'@?GA\@ASH:@8ULJ*;1QFK8(`\W.M:`F0E@Q+(MY*@$[7/ MU0!Y!)=KR72JPZ.&4^+(J>-^-?`>=JZQ+*^7FEH-J>BM*3WE:'9$CNN)*TT# M5H=9C:[HPZGCBS-POP#<0NJ;FMQJP"6!-_4!-RESC@NYD(ZJ)K<:J[*M-6."'>RB4EUHJ,NFAK.VN\K<<]A\WZTT^+G6W6H__2BZILQM M:L>!IN3J4#F9&B31X20'R72DYH?DR^)MRRG5F(D>)=F1>=/!FNYME^7P*2%3 M@R4ZB&2[VP:J@[:WRQQ]:FHU.F&D(SQQTQ M3$&9#JV.`#70DA"BFH$*IO\>:QE8?P58`:[HF-%<_'W'6/[<>0Z<]VBS(=[" MY\^2)Y[GQRK$#]DSLM[X-+0\M,;!!MFX@/?SG+JO?+KL."'MA/"!CA>M,27V MF178*[Q&-WY\=88>U_GKBXMWYY>OSR]_?`7?/K,ZS^<-R^)[=\=+A#90&)!P<7E^=5E:"EX"*6,'NV&0 M/CG/1.F7A\L.L/UJZ3]V'$RTR[//P_YH5(*\8@SJX$A5PF4U*M%^8[GJ$"\( MXQP,.@V%L[!?YRD?:RI7K*G4AB:1]Y;__7O@?3`-V.0KQF`R?41C0/0A)&3-)'ZD>;E)0`R9F%X"TS$SZ< M+9`;`+U'7)?)_7`6T@A^Q\1SY#*4/IS9%#LD3!]O8+CQG1DO0(QDJ*A%6/G9 M;*Y9XO%B@AFF[$-3O&0TW2#`83#S9S"2N_&/7&W59XUK!8925DC&>^PJR>ON M1#3)_]),^0E^Q%Z$$Q627[KJES"?5`4D;KQ8A?RUN-7J2UG;ICQW>%Q#WP9S M?[W!7A`?<&6+L"6GN]YF)-"S>;-^0M1)%FV#9U"#P-#`/]M=A)BRNVZ(Q^7T M&?H3')+XJO-<,AW_EUM ML!ERO(CK:.C3+RMBK]BL.*8?(\0\&]M;M+UF6ZF/Q&'FZ^&`'*<<;1N8"II, M6!V,/7R+UW-,.O$6G2UF(=7DBGV9.OH5..ZA1T6E&L@U2! M[@3T&OH1U5`K3W8*6I%'';#R9">@U90\:RB5HSH%G9@!K:-5GJZ%>MFPN&2G M8EBYF6&`1IB-VX@N$ MLO)^C[J;?\1Q6L2K=/NI5MC55).IJYV@W2:EKCI-2JFSS9HL9,O/E.KRST?B6Y!,C/EZJ0>6PM=5"4*3'"\ M0P,6/WT$ZS]VQ54K7L9W.IK?HF>RCM:I19N]9!9("FGB%ZNNCWK2VN8HZ[/X M$&BYNX#C9,1+LO.R[;HGUO?`:.O[T3Q<1&XQP65:-1KR=0&D@J:\D)WZ^V;.". MYGCT"3@OK-'+*JE1]Y697LH6-TCXG23YI_W M&0JO&@PS+]J]OE`0/EXLQK#2HQY\G&+Q1G*N2R5E6_')"EY^Y_J>AG+"MBK( M=^Z#F7\/7'3\!-TH&'FLZ>5G@G*:MJHEPJ'$ZA04&7DP\B\)?$8(_E,1M56Q MQ)/?\X,0+"Y)CRHC.!FC]#YW0N?KN.XI-VY!Q;?."JOPS M_!Q>NV!.:>J;HR^8EV'Z_(C&E89J$VR[*`AXS@]>W`4?%'_'B,;[=T$&D$S5 MAOSM4)W'S8(&_C(^G5*EJA9]&U2[07,?B'S*=G8VV$Y<)I/TQ-,0XT#98YL* M:%O/A0)'K-@V!N/9V3D(H.B;*.0!##J:%AK!<02^Y"QVT%9`LL*(.R\L"=E1 M!&?PS):&V!E2?UVL@4)T1$W.ML[D=SB,E6"QYZS(.24E[UH+9;U.+!OR&DLX MNQ6.T3* MB_I2M'9`N6MGBIEKI^@.$OQE&K2M@F(JH=1K5.$*NFM`/$].V M:;V)-K+Q[4`YK3#U=K>&JPTZ)5G;\)6$6"BUTZ0_*35E[567H0T-L^_;$3]* MXSD##SZVS2V")1#JD;<-P6R/#0S#).HC62?&>VDR%.LPM0')W&99SIC);YC) MO/TUF-J&:G79XQ@XFL3"$>>>Q2(4@AD.D-'6=9$&I*[+_5U99.D]VOHTJ-0F^Z]7X"^^XH3$"Z@;&:1;T**I:3M$Z;&PPMBIW0XG&\ M4QML7):H+[_8MP7]ZC"U3F-)ZHUX&X8_8&XJ;G+$GIU/ONMM*SD+7@%3'B2PAY\1)4SD M!,81=A*]^TR*H7_5Q,VBMAP"$@,21R1_$U7['`QM95/R$P)T$%'?\>$3XCGG M.DPMU_@6A1&%89#UO%(-BT3Y)EL[,OX%5+B+6$WS[7GDQEY=8B>'\\J[8P57 M7DD"X^D21M2OZ_5%+EM9/L<[%CT7D?4$![Y;W+]14K5VDR/=C1FQB0H'81S% MR*(9];1NR-_:^DB/9>4WWO1JHC9G6UPRMB_-:R5?9;6V2HWL((#E'A7&R*;I\]*#JA=^Y3Z3V`O]]`&WD"K M#O+(IN>QXLB%O5,6QQ7[DBVB>EU81'>WRS\IGBE74GU;!6"DPJ[;?Y8M:27O M6M=&650H-!\R9_'MQV%Q`F_"W58?1;9)\AFY47KH[U<8 M7O:\"V0.P1Y/9=XS%68>0A[/MWX M5!Z348NK=3H/71^*C\3"RR#4(6Z=AOIC2Z,!J;V+B=WYGB%Y9O\PBVZ\6+!\ MS1Z/((I@W;B+YA?!;L3>.OCS5DY%R&`5Y8'CZ\N$!M:QXGB`^\SO`KNSU^`/ M$W-0%_B::;W39>(GLERYVUT8'7;B6,%;Y*$XL^HN"8ADC5F'^9!%Y0ME45TL M6#CL8W8=';-_V=+08["C9'6X1A[P],DB,9)Y]V;"HYD;WRU0.,R]] MCT>*IFA_]D.\NU&LL!M>1=I"[,M2).:RC@&6Q-F;#6NQ?=7!X*!,BDDW'?&, M@-",5 M>?,WA"9'+`O[CT>7?-"F9=MJ;Y?I<8@(&%_T+QPR?PEW:.\:#NNS$\Q/`,U\ MGO(^O:N0XB1/,E-A"`;M"E8Z-`AG9"VTYO:5[V0FV?D+N7N]NQ-W"'IQ>!97=\)<^ M*=R*I*(ZF=:<9JD0@RCW7K2NK28W<^U6:O>^2^RMS`]22=E*/XB08:Y@GA_Y]JMMAGCR7P M=+IXUP'E0L*6D>QLC^Q,:SE)VTPJ_<0&;,N2E340?-4UN4^W"O8\"G496^A, MT%?AVO>B`,=OUVL2!-QK5HA3[/FN"SV<9;O:OZ7XA;_3-A^UOKI9C$NZJYF] M:U1_:H$MW"/5UXS?#I'L6L2!B?SY+ATUS^.>Z9]QWOGA-)K_R9V^N2MRF]7O M\4O1DJFO.IRC)$R+V^G)I?38&?JT6;27IIB3J2V^FDF&J"1Y!S-UKO'"I_&U MOVQL`SV3_.3"FJ\>[[>)S]5SX@K%'2]D&A8=O-I,K8T(A$$"+&#FA=G/3CR, M>";PW,TDR5J")W7?=8)\?.`1A'V3BM)(W"\>FD\W*_B=JHD&\+B/-WY0O(:T M"7,[5FN%BOFYP^HEL%=XC>#G_P%02P$"'@,4````"`#Z@\=",=[I!?-E``!H MW08`$0`8```````!````I($`````8G)L:2TR,#$S,#0S,"YX;6Q55`4``S=# MLE%U>`L``00E#@``!#D!``!02P$"'@,4````"`#Z@\="&A+WRB4/``#"V``` M%0`8```````!````I($^9@``8G)L:2TR,#$S,#0S,%]C86PN>&UL550%``,W M0[)1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`^H/'0KJX<0GF,P``#L0# M`!4`&````````0```*2!LG4``&)R;&DM,C`Q,S`T,S!?9&5F+GAM;%54!0`# M-T.R475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`/J#QT(UW@XA/`$!``-U M$``5`!@```````$```"D@>>I``!B`L``00E#@``!#D!``!02P$"'@,4````"`#Z@\=";DVBJRYJ``#0 MHP<`%0`8```````!````I(%RJP$`8G)L:2TR,#$S,#0S,%]P&UL550% M``,W0[)1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`^H/'0LK6:[_6&``` M9#8!`!$`&````````0```*2![Q4"`&)R;&DM,C`Q,S`T,S`N>'-D550%``,W H0[)1=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``!`O`@`````` ` end XML 39 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Intangible Assets (Tables)
6 Months Ended
Apr. 30, 2013
Intangible Assets  
Schedule of information on intangible assets

 

 

April 30, 2013

 

 

 

Weighted-

 

 

 

 

 

Net of

 

 

 

Average

 

 

 

Accumulated

 

Accumulated

 

 

 

Amortization

 

 

 

Amortization

 

Amortization

 

Intangible Asset

 

Period

 

Cost ($)

 

($)

 

($)

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

8,739

 

2,680

 

6,059

 

Covenants Not-to-Compete

 

5

 

5,095

 

4,305

 

790

 

Patents and Licenses

 

17

 

5,297

 

1,234

 

4,063

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

19,131

 

8,219

 

10,912

 

 

October 31, 2012

 

 

 

Weighted-Average

 

 

 

 

 

Net of

 

 

 

Amortization

 

 

 

Accumulated

 

Accumulated

 

Intangible Asset

 

Period

 

Cost ($)

 

Amortization ($)

 

Amortization ($)

 

 

 

 

 

 

 

 

 

 

 

Customer Lists

 

20

 

4,573

 

2,537

 

2,036

 

Covenants Not-to-Compete

 

5

 

4,305

 

4,257

 

48

 

Patents and Licenses

 

17

 

5,297

 

1,058

 

4,239

 

 

 

 

 

 

 

 

 

 

 

Totals

 

 

 

14,175

 

7,852

 

6,323

Schedule of estimated amortization expense related to remaining intangible assets

 

 

October 31,

 

($)

 

2013

 

452

 

2014

 

917

 

2015

 

892

 

2016

 

875

 

2017

 

870

 

Thereafter

 

6,906

 

 

 

 

 

Total

 

10,912

XML 40 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Acquisitions
6 Months Ended
Apr. 30, 2013
Acquisitions  
Acquisitions

[10] ] On December 21, 2012, we entered into an agreement pursuant to which we agreed to purchase all of the authorized, issued and outstanding shares of Meridian Clinical Laboratory, Corp. ( “MCL”), a Florida corporation.  More information about MCL and the agreement may be found in the Form 8-K the Company filed on December 27, 2012.

 

On December 31, 2012, we entered into an agreement pursuant to which we agreed to purchase all of the authorized, issued and outstanding shares of Florida Clinical Laboratory, Inc. (“FCL”), a Florida corporation.  More information about FCL and the agreement may be found in the Form 8-K we filed on January 4, 2013.

 

The initial accounting for these two acquisitions is now complete. Accordingly Management updated its previously reported provisional amounts of the assets, liabilities and equity interests initially reported on its first quarter report on form 10-Q. The following table sets forth these final allocations.

 

 

 

($)

 

 

 

FCL

 

MCL

 

Totals:

 

 

 

 

 

 

 

 

 

Accounts Receivable

 

1,008

 

232

 

1,240

 

Autos

 

137

 

48

 

185

 

Medical Equipment

 

225

 

3

 

228

 

Computer Equipment

 

21

 

 

21

 

Leasehold Improvements

 

53

 

 

53

 

Other Non-Current Assets

 

3

 

 

3

 

Non-Compete Agreement

 

747

 

43

 

790

 

Deposits

 

 

2

 

2

 

Customer Relationships in Place

 

3,235

 

930

 

4,165

 

Goodwill

 

1,905

 

673

 

2,578

 

Accounts Payable

 

118

 

83

 

201

 

Long Term Debt (Auto-Loans)

 

200

 

0

 

200

 

Short Term Acquisition Payable

 

1,000

 

250

 

1,250

XML 41 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accounting for Accounts Receivable (Details) (USD $)
In Thousands, unless otherwise specified
Apr. 30, 2013
Oct. 31, 2012
Allowances    
Total Allowance $ 393,278 $ 319,195
Contractual Credits/Discounts
   
Allowances    
Total Allowance 336,642 267,921
Doubtful Accounts
   
Allowances    
Total Allowance $ 56,636 $ 51,274
XML 42 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
Acquisitions (Tables)
6 Months Ended
Apr. 30, 2013
Acquisitions  
Schedule of provisional purchase price allocations

 

 

 

 

($)

 

 

 

FCL

 

MCL

 

Totals:

 

 

 

 

 

 

 

 

 

Accounts Receivable

 

1,008

 

232

 

1,240

 

Autos

 

137

 

48

 

185

 

Medical Equipment

 

225

 

3

 

228

 

Computer Equipment

 

21

 

 

21

 

Leasehold Improvements

 

53

 

 

53

 

Other Non-Current Assets

 

3

 

 

3

 

Non-Compete Agreement

 

747

 

43

 

790

 

Deposits

 

 

2

 

2

 

Customer Relationships in Place

 

3,235

 

930

 

4,165

 

Goodwill

 

1,905

 

673

 

2,578

 

Accounts Payable

 

118

 

83

 

201

 

Long Term Debt (Auto-Loans)

 

200

 

0

 

200

 

Short Term Acquisition Payable

 

1,000

 

250

 

1,250

XML 43 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information
6 Months Ended
Apr. 30, 2013
Jun. 03, 2013
Document and Entity Information    
Entity Registrant Name BIO REFERENCE LABORATORIES INC  
Entity Central Index Key 0000792641  
Document Type 10-Q  
Document Period End Date Apr. 30, 2013  
Amendment Flag false  
Current Fiscal Year End Date --10-31  
Entity Current Reporting Status Yes  
Entity Filer Category Accelerated Filer  
Entity Common Stock, Shares Outstanding   27,663,213
Document Fiscal Year Focus 2013  
Document Fiscal Period Focus Q2  
XML 44 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accounting for Revenues (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended
Apr. 30, 2013
Apr. 30, 2012
Apr. 30, 2013
Item
Apr. 30, 2012
Accounting for Revenues        
Gross Service Revenues $ 861,506 $ 763,823 $ 1,660,216 $ 1,447,639
Contractual Adjustments and Discounts:        
Medicare/Medicaid Portion 86,433 81,318 168,260 156,059
All Other Third Party Payors 584,211 519,117 1,127,496 978,273
Total Contractual Adjustments and Discounts 670,644 600,435 1,295,756 1,134,332
Service Revenues Net of Contractual Adjustments and Discounts 190,862 163,388 364,460 313,307
Patient Service Revenue Provision for Bad Debts 14,410 11,945 26,751 23,071
Net Revenues $ 176,452 $ 151,443 $ 337,709 $ 290,236
Number of distinct payors included in all other third party and Direct     800